0001255294-13-000875.txt : 20131113 0001255294-13-000875.hdr.sgml : 20131113 20131113171042 ACCESSION NUMBER: 0001255294-13-000875 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20130930 FILED AS OF DATE: 20131113 DATE AS OF CHANGE: 20131113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SKINVISIBLE INC CENTRAL INDEX KEY: 0001085277 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880344219 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-25911 FILM NUMBER: 131215564 BUSINESS ADDRESS: STREET 1: 6320 S SANDHILL ROAD STREET 2: SUITE 10 CITY: LAS VEGAS STATE: NV ZIP: 89120 BUSINESS PHONE: 7024337154 MAIL ADDRESS: STREET 1: 6320 S SANDHILL ROAD STREET 2: SUITE 10 CITY: LAS VEGAS STATE: NV ZIP: 89120 10-Q 1 mainbody.htm MAINBODY

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

[X]	Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	For the quarterly period ended September 30, 2013

[ ]	Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934

	For the transition period from __________ to __________

	Commission File Number: 000-25911

Skinvisible, Inc.

(Exact name of Registrant as specified in its charter)

Nevada	88-0344219
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

6320 South Sandhill Road, Suite 10, Las Vegas, NV 89120

(Address of principal executive offices)

702.433.7154

(Registrant’s telephone number)

_______________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days

[X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [ ] No [X]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

[ ] Large accelerated filer Accelerated filer	[ ] Non-accelerated filer
[X] Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

[ ] Yes [X] No

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 110,729,969 common shares as of October 1, 2013

Table of Contents

	TABLE OF CONTENTS	Page
PART I – FINANCIAL INFORMATION
Item 1:	Financial Statements	3
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	10
Item 4:	Controls and Procedures	11
PART II – OTHER INFORMATION
Item 1:	Legal Proceedings	11
Item 1A:	Risk Factors	11
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	12
Item 3:	Defaults Upon Senior Securities	12
Item 4:	Mine Safety Disclosure	12
Item 5:	Other Information	12
Item 6:	Exhibits	12

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Our consolidated financial statements included in this Form 10-Q are as follows:

F-1	Consolidated Balance Sheets as of September 30, 2013 (unaudited) and December 31, 2012 (audited);

F-2	Consolidated Statements of Operations for the three and nine months ended September 30, 2013 and 2012 (unaudited);

F-3	Consolidated Statements of Cash Flow for the nine months ended September 30, 2013 and 2012 (unaudited);

F-4	Notes to Consolidated Financial Statements.

These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended September 30, 2013 are not necessarily indicative of the results that can be expected for the full year.

Table of Contents

SKINVISIBLE, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

	September 30, 2013			December 31, 2012
ASSETS
Current assets
Cash	$	674,315		$	450,507
Accounts receivable		10,000			27,299
Inventory		22,437			18,769
Due from related party		41,188			1,145
Prepaid expense and other current assets		1,015			515
Total current assets		748,955			498,235
Fixed assets, net of accumulated depreciation of $322,477 and $318,519, respectively		3,891			4,459
Intangible and other assets:
Patents and trademarks, net of accumulated amortization of $239,208
and $213,205, respectively		345,690			251,553
Total assets	$	1,098,536		$	754,247
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities
Accounts payable and accrued liabilities	$	584,536		$	636,314
Accrued interest payable		131,499			25,264
Loans from related party		134			7,661
Loans payable		1,000,000			1,991
Convertible notes payable, net of unamortized debt discount of $61,724
and $102,200, respectively		1,099,862			1,088,386
Convertible notes payable related party, net of unamortized discount of $919,956
and $1,036,956, respectively		803,905			593,227
Unearned revenue		—			19,792
Total current liabilities		3,619,936			2,372,635
Total liabilities		3,619,936			2,372,635
Stockholders' deficit
Common stock; $0.001 par value; 200,000,000 shares authorized;
110,729,969 and 109,507,409 shares issued and outstanding at September 30, 2013
and December 31, 2012, respectively		110,730			109,507
Additional paid-in capital		20,968,993			20,841,670
Stock payable		—			1,800
Accumulated deficit		(23,601,123	)		(22,571,365	)
Total stockholders' deficit		(2,521,400	)		(1,618,388	)
Total liabilities and stockholders' deficit	$	1,098,536		$	754,247

F-1

Table of Contents

SKINVISIBLE, INC. CONSOLIDATED

STATEMENTS OF OPERATIONS

(Unaudited)

	Three months ended			Three months ended			Nine months ended			Nine months ended
	September 30, 2013			September 30, 2012			September 30, 2013			September 30, 2012
Revenues	$	13,635		$	22,920		$	48,370		$	83,548
Cost of revenues		565			—			1,754			1,944
Gross profit		13,070			22,920			46,616			81,604
Operating expenses
Depreciation and amortization		9,824			8,068			27,006			43,982
Selling general and administrative		220,021			316,856			616,167			996,189
Total operating expenses		229,845			324,924			643,173			1,040,171
Loss from operations		(216,775	)		(302,004	)		(596,557	)		(958,567	)
Other income and (expense)
Other income		97			25,000			97			25,000
Interest expense		(125,825	)		(11,866	)		(436,398	)		(81,886	)
Gain on extinguishment of debt		2,400			(36	)		3,100			1,691
Total other expense		(123,328	)		13,098			(433,201	)		(55,195	)
Net loss	$	(340,103	)	$	(288,906	)	$	(1,029,758	)	$	(1,013,762	)
Basic loss per common share	$	(0.00	)	$	(0.00	)	$	(0.01	)	$	(0.01	)
Basic weighted average common
shares outstanding		110,683,012			105,073,960			110,374,484			102,694,597

F-2

Table of Contents

SKINVISIBLE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Nine months ended			Nine months ended
	September 30, 2013			September 30, 2012
Cash flows from operating activities:
Net loss	$	(1,029,758	)	$	(1,013,762	)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization		27,006			43,982
Stock-based compensation		21,200			—
Amortization of debt discount		228,244			432,602
Accrued expenses converted to notes		—			223,868
Stock issued for interest expense		422			—
Debt paid with common stock		—			78,361
Gain on extinguishment of debt		3,100			(1,691	)
Changes in operating assets and liabilities:
(Increase) decrease in inventory		(3,668	)		8,998
Decrease in accounts receivable		17,299			(8,895	)
Increase in prepaid expenses and other current assets		(500	)		(9,691	)
Increase in accounts payable and accrued liabilities		69,776			97,283
Increase in accrued interest		105,099			23,174
Decrease in unearned revenue		(19,792	)		(50,000	)
Net cash used in operating activities		(581,572	)		(175,771	)
Cash flows from investing activities:
Purchase of fixed assets and intangible assets		(120,575	)		(56,023	)
Net cash used in investing activities		(120,575	)		(56,023	)
Cash flows from financing activities:
Proceeds from, net of payments to, related parties for loans		(7,527	)		(2,681	)
Payments on related parties convertible notes payable		(12,475	)		—
Proceeds from convertible notes payable		—			312,900
Advances to related parties		(40,043	)
Payments on convertible notes payable		(14,000	)		(7,500	)
Proceeds from loans payable		1,000,000			(5,000	)
Net cash provided by (used in) financing activities		925,955			297,719
Net change in cash		223,808			65,925
Cash, beginning of period		450,507			1,218
Cash, end of period	$	674,315		$	67,143
Supplemental disclosure of cash flow information:
Cash paid for interest	$	97,194		$	—
Cash paid for tax	$	—		$	—
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Non-cash investing and financing activities:
Loan payable converted to convertible loan	$	23,554		$	(9,719	)
Common stock issued on conversion of debts	$	23,554		$	78,361
Beneficial conversion feature	$	—		$	326,510
Common stock issued for extinguishment of debts	$	16,100		$	—

F-3

Table of Contents

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES

Description of business – Skinvisible, Inc., (referred to as the “Company”) is focused on the development and manufacture of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations, offer solutions for a broad spectrum of markets women’s health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.

History – Skinvisible, Inc. (referred to as the “Company”) was incorporated in Nevada on March 6, 1998 under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.

Skinvisible, Inc. together with its subsidiary shall herein be collectively referred to as the “Company”.

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $23,601,123 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

Principles of consolidation – The consolidated financial statements include the accounts of the Company and its subsidiary. All significant intercompany balances and transactions have been eliminated.

Use of estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents.

Fair Value of Financial Instruments

The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items.

As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The three levels of the fair value hierarchy are described below:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

F-4

Table of Contents

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

Revenue recognition

Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

Royalty sales – The Company also recognizes royalty revenue from licensing its patented product formulations only when earned, when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Distribution and license rights sales – The Company also recognizes revenue from distribution and license rights only when earned (and are amortized over a five year period), when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2013, the Company had not recorded a reserve for doubtful accounts. The Company has $1,000,000 in convertible notes payable which are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®.

Inventory – Substantially all inventory consists of finished goods and are valued based upon first-in first-out ("FIFO") cost, not in excess of market. The determination of whether the carrying amount of inventory requires a write-down is based on an evaluation of inventory.

Goodwill and intangible assets – The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other”. According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.

Income taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Stock-based compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to a Employee Stock Purchase Plan based on the estimated fair values.

Stock based compensation expense recognized under ASC 718-10 for the nine months ended September 30, 2013 and 2012 totaled $21,200 and $0 respectively.

Earnings (loss) per share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

F-5

Table of Contents

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

2. FIXED ASSETS

Fixed assets consist of the following as of September 30, 2013 and December 31, 2012:

	September 30, 2013			December 31, 2012
Machinery and equipment		48,163		$	45,208
Furniture and fixtures		113,635			113,635
Computers, equipment and software		38,540			38,105
Leasehold improvements		12,569			12,569
Lab equipment		113,461			113,461
Total		326,368			322,978
Less: accumulated depreciation		(322,477	)		(318,519	)
Fixed assets, net of accumulated depreciation		3,891		$	4,459

Depreciation expense for the nine months ended September 30, 2013 and 2012 was $1,003 and $943, respectively.

3. INTANGIBLE AND OTHER ASSETS

Patents and trademarks are capitalized at its historical cost and are amortized over their useful lives. As of September 30, 2013, patents and trademarks total $584,898, net of $239,208 of accumulated amortization. Amortization expense for the nine months ended September 30, 2013 and 2012 was $26,003 and $43,039, respectively. The Company has secured $1,000,000 in notes payable with its US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods".

License and distributor rights (“agreement”) were acquired by the Company in January 1999 and provide exclusive use distribution of polymers and polymer based products. The Company has a non-expiring term on the license and distribution rights. Accordingly, the Company annually assesses this license and distribution rights for impairment and has determined that no impairment write-down is considered necessary as of September 30, 2013.

4. UNEARNED REVENUE

On January 16, 2013, the company terminated its licensing agreement with Panalab dated January 23, 2008. The agreement provided Panalab the right to distribute, market, sell and promote Skinvisible’s proprietary formulas made with Invisicare and Adapalene through-out Panalabs assigned territory. Panalab had failed to sell or sub-license the products in the territory, thereby not fulfilling the conditions as set forth in the agreement and allowing for immediate termination of the agreement. As a result of this cancelation, unearned revenue of $19,792 has been recognized as revenue during the nine months ended September 30, 2013.

F-6

Table of Contents

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

5. STOCK OPTIONS AND WARRANTS

The following is a summary of option activity during the nine months ended September 30, 2013.

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2012	9,400,000	$	0.05
Options granted and assumed	300,000	$	0.03
Options expired	400,000	$	0.05
Options canceled	—		—
Options exercised	—		—
Balance, September 30, 2013	9,300,000	$	0.05

As of September 30, 2013, 9,300,000 stock options are exercisable.

On September 23, 2013, the Company granted stock options for 300,000 shares of its common stock with a strike price of $0.03. The stock options were exercisable upon grant and have a life of 5 years. The stock options were valued at $8,400 using the Black-Scholes option pricing model based upon the following assumptions: term of 5 years, risk free interest rate of 1.33%, a dividend yield of 0% and volatility rates of 443%. The Company recorded an expense of $8,400 for the nine months ended September 30, 2013.

Stock warrants -

The following is a summary of warrants activity during the nine months ended September 30, 2013.

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2012	6,765,200	$	0.06
Warrants granted and assumed	471,280	$	0.06
Warrants expired	2,562,500	$	0.05
Warrants canceled	—		—
Warrants exercised	—		—
Balance, September 30, 2013	4,673,980	$	0.06

All warrants outstanding as of September 30, 2013 are exercisable.

271,280 warrants were issued during the three months ended March 31, 2013 as part of a series of convertible notes with attached warrants. The warrants issued allow the holder to purchase one share for every two shares issued upon conversion at an exercise price of $0.07 cents per share.

On May 22, 2013 200,000 warrants were issued as compensation for consulting services. The warrants issued allow the holder to purchase one share at an exercise price of $0.04 cents per share.

F-7

Table of Contents

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

6. RELATED PARTY TRANSACTIONS

On September 23, 2013, the Company granted stock options for 300,000 shares of its common stock to an employee. See Note 5 for additional information.

During the three months ended September 30, 2013 the Company advanced $40,143 to employees of the Company for business related expenses. The advance is non-interest bearing and due upon demand.

7. CONVERTIBLE NOTES PAYABLE

Convertible Notes Payable consists of the following:	September 30,			December 31,
	2013			2012
$52,476 face value,10% unsecured note payable to an investor, note interest and payment are due on demand. The note could be converted to option rights for Skinvisible, Inc. shares at ten cents per share ($0.10), these rights expired January 12, 2010. Note is currently in default, no penalties occur due to default. During the nine months ended September 30, 2013, the Company made $12,000 in cash payment to reduce the note balance.	$	40,476		$	52,476
$27,000 face value 10% unsecured $27,000 notes payable to investors, due October, 2012. At the investor’s written request, until the repayment date the note may be converted at the investors option to shares of the Company’s common stock at a fixed price of $0.05 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.07 per share for two years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $19,385. The aggregate beneficial conversion feature has been fully accreted and was charged to general and administrative expenses during the year ended December 31, 2012. The beneficial conversion feature is valued under the intrinsic value method. Interest due to lender can also be converted at a rate of ($0.05) per share into warrants. During the nine months ended September 30, 2013, the Company made a $2,000 cash payment to reduce the note balance and converted principal of $15,000 plus accrued interest of $1,277 to 542,560 shares of common stock and granted 271,280 warrants with the exercise price of $0.07 per shares for two years.		10,000			27,000
$1,000,000 face value 9% notes payable to investors, due two years from the anniversary date of execution. The notes mature at various times from September 2014 to December 2014. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The Notes are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company has determined the value associated with the beneficial conversion feature in connection with the notes and interest to be $111,110. The aggregate original issue discount feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of $40,476 and $8,910 during the periods ending September 30, 2013 and December 31, 2012, respectively. The original issue discount feature is valued under the intrinsic value method.		1,000,000			1,000,000
		1,050,476			1,079,476
Original issue discount		111,110			111,110
Unamortized debt discount		(61,724	)		(102,200	)
	$	1,099,862		$	1,088,386

F-8

Table of Contents

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

8. CONVERTIBLE NOTES PAYABLE RELATED PARTY

On December 31, 2011, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before December 31, 2010 and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $802,864 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $538,295 for the notes negotiated on December 31, 2010, $45,557 for the notes negotiated on July 1, 2011 and $1,123,078 for the notes negotiated December 31, 2011. The beneficial conversion feature is valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of $124,818 for the nine months ended September 30, 2013. As of September 30, 2013, the aggregate convertible notes payable are $568,638, net of unamortized beneficial conversion feature of $541,965.

On June 30, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before July 1, 2011 and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $325,023 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $209,809. The beneficial conversion feature is valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of $32,161 for the nine months ended September 30, 2013. As of September 30, 2013, the aggregate convertible notes payable are $169,080, net of unamortized beneficial conversion feature of $155,942.

On December 30 and 31, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $182,083 of related party notes accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $182,083 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $182,083. The beneficial conversion feature is valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of $27,223 for the nine months ended September 30, 2013. As of September 30, 2013, the aggregate convertible notes payable are $27,236, net of unamortized beneficial conversion feature of $154,847.

On June 30, 2013, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements, $106,153 of related party notes accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $106,153 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $70,768. The beneficial conversion feature is valued under the intrinsic value method. The aggregate beneficial conversion feature will be accreted and charged to general and administrative expenses as a financing expense As of September 30, 2013, the aggregate convertible notes payable are $38,950, net of unamortized beneficial conversion feature of $67,202.

F-9

Table of Contents

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

9. NOTES PAYABLE

On May 22, 2013 the Company approved a financing plan to offer accredited investors up to $1,000,000 in secured promissory notes. During the nine months ended September 30, 2013 the Company entered into twenty-four 9% notes payable to investors and received total proceeds of 1,000,000. The notes are due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods".

10. STOCKHOLDERS’ DEFICIT

The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. The Company has 110,729,969 and 109,507,409 issued and outstanding shares of common stock as of September 30, 2013 and December 31, 2012, respectively.

During the nine months ended September 30, 2013, the Company issued a total of 680,000 shares of common stock, with a fair value of $16,100 for the conversion of debts totaling $18,000. The Company recorded a gain of $3,100 on extinguishment of debts.

On February 11, 2013, the Company issued a total of 300,000 shares of common stock for conversion of principal on convertible notes payable of $15,000 plus $1,277 accrued interest. The Company issued an additional 242,560 shares of common stock for this conversion of convertible notes payable, which the shares were fair valued at $7,277.

11. COMMITMENTS AND CONTINGENCIES

Lease obligations – The Company has operating leases for its offices. Future minimum lease payments under the operating leases for the facilities as of September 30, 2013 are as follows:

Fiscal year ending 2013 14,050

Fiscal year ending 2014 33,156

Fiscal year ending 2015 5,526

Rental expense, resulting from operating lease agreements, approximated $14,942 and $40,434 for the nine months ended September 30, 2013 and 2012, respectively.

12. SUBSEQUENT EVENTS

The Company has evaluated events subsequent to the balance sheet through the issuance date of these financial statements in accordance with FASB ASC 855 and has determined that there are no such events that would require adjustment to, or disclosure in, the financial statements.

F-10

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Company Overview

We, through our wholly owned subsidiary Skinvisible Pharmaceuticals Inc., are a pharmaceutical research and development (“R&D”) company that has developed and patented an innovative polymer delivery system, Invisicare® and formulated over forty topical skin products, which we out-license globally. We were incorporated in 1998, and target an estimated $80 billion global skincare and dermatology market and a $30 billion global over-the-counter market as well as other healthcare / medical and consumer goods markets.

With the research and development complete on forty products and numerous patents issued (technology and product patents), we are ready to monetize our investment. Our business model is to out-license our patented prescription, over-the-counter (“OTC”) and cosmeceutical products featuring Invisicare to established manufacturers and marketers of brands internationally and to maximize profits from the products we have already out-licensed. We have also recently developed a product for Netherton syndrome, for which we are seeking “orphan drug” status in both the United States and Europe. This designation has the potential to be highly lucrative, with more global companies seeing the value of an orphan drug.

The opportunity for us to license our products has recently increased due to improving market conditions and the need for pharmaceutical companies to access external R&D companies for new products due to their own down-sizing or elimination of internal R&D departments. The demand for our products is enhanced due to the granting of key US and international patents and the completed development of a number of unique products.

Table of Contents

Our Plan for the Next Twelve Months

Our growth strategy is to:

Capitalize on the success of current licensees;

Increase the value of our current pipeline; and

Boost licensing revenues by securing additional licensees globally and develop a robust royalty revenue stream that will finance our future growth.

Capitalize On Current Licensees:

We have licensees around the globe. Three of these licensees are currently in the marketplace: Avon Products globally, Women’s Choice Pharmaceuticals in the United States and Alto Pharmaceuticals in Canada. Additionally, we have licensees that have products being prepared for launch. We work diligently with our licensees to ensure they have a smooth manufacturing process, ongoing R&D support and marketing feedback.

Avon Products, Inc:

Product: We have a long-term contract with Avon globally for over ten years to provide Invisicare polymer for their long-lasting lipsticks.

Sales: Invisicare polymers are purchased directly from Skinvisible.

Alto Pharmaceuticals:

Product: DermSafe®, long lasting hand sanitizer lotion launched in Canada in Q4 of 2011 for commercial / industrial use.

Sales and Royalties: Alto has received Health Canada marketing approval for DermSafe and is currently marketing the product directly and seeking distributors in the commercial marketplace.

Women’s Choice Pharmaceuticals:

Product: ProCort®, long lasting prescription hemorrhoid cream launched in the United States in August of 2011.

Sales and Royalties: ProCort continues to increase sales every quarter. Skinvisible receives a royalty based on net sales. This past year Women's Choice Pharmaceuticals LLC partnered with Advanced Medical Enterprises, LLC to market ProCort® in Puerto Rico. With over thirty pharmaceutical sales reps calling on OBGYNs in the US, Women’s Choice has been successfully growing their sales of ProCort® and we look forward to increased growth in 2013. Women’s Choice is seeking to form other strategic alliances in 2013 in order to increase its sales efforts by targeting new territories and targeting medical specialists which previously were not called upon.

Table of Contents

Product Launches for 2013:

We have additional products which are anticipated to be in the market in 2013.

DermSafe® Hand Sanitizer Skinvisible’s hand sanitizer formulated with Invisicare® and chlorhexidine gluconate has received registration in Belgium on behalf of Skinvisible. This registration allows Skinvisible to make DermSafe® available in most of Europe through a simple registration process. The Company is currently seeking licensees and/or distributors to begin the sale of DermSafe in the EU.
Triclosan Hand Sanitizer & First Aid Antiseptic Previously licensed as Safe4Hours® Antibacterial/Antimicrobial Hand Sanitizers (1% Triclosan) and Safe4Hours® First Aid Antiseptic & Skin Protectant for North America to Dermal Defense, Skinvisible has received the rights back for both products. Skinvisible anticipates setting up distributors for these products on an international basis.
Embil Pharmaceuticals Co. Ltd. Licensed two prescription acne products: Clindamycin and Retinoic Acid for the countries of Turkey, Azerbaijan, Kazakhstan, Kyrgyzstan, Turkmenistan, and Uzbekistan, as well as the S.E Asian countries of Indonesia, Malaysia, and the Philippines, for an upfront license fee and royalty. The launch has been delayed due to company reorganization. It is anticipated that regulatory approval will begin in the latter half of 2013.
Mayquest Pharmaceuticals PTY Licensed DermSafe chlorhexidine hand sanitizer for Singapore, Taiwan, Thailand, Indonesia and the Philippines for a license fee and royalty. Received importation approval for DermSafe from Canada to Singapore. Launch pending. Currently seeking distribution partner or sub- licensee to launch the product.

Table of Contents

Increasing The Value Of Skinvisible’s Pipeline: Clinical Enhancement Of Pipeline

We have a pipeline of over forty products which are available for licensing. Testing is conducted in-house generating proof of concept including release of the active ingredient as well as long term shelf life (stability). Additional studies conducted on specific products including skin sensitivity, toxicity and product efficacy are outsourced to FDA compliant laboratories. These studies are critical in attracting potential licensees. Our clinical strategy is to:

(1)

Add new studies for our prescription products. Our clinical strategy is to increase the amount of outsourced studies, specifically for our prescription products. Additional studies including skin penetration and skin irritation studies will add to the integrity and value of our products available for licensing.

(2)

Add new long-term efficacy studies for our DermSafe® hand sanitizer. Last year we commissioned an independent laboratory to further analyze the long-term effectiveness of DermSafe® when put in contact with two bacteria; the “super bug” MRSA and E. coli, the “restaurant bug” since it is often transmitted by food and food handlers. The long-term effectiveness of two bacteria; Methicillin-resistant Staphylococcus aureus or MRSA (ATCC #33591) and Escherichia coli or E. coli (ATCC #43888") were tested up to four hours after application. The results showed that the individual arms of subjects which had DermSafe® applied and were even rinsed prior to each bacteria challenge, showed a 95.83% reduction at the 4 hour time point for MRSA and 99.38% for E. coli.

The regulatory approval in Europe has been transferred to Skinvisible. The objective for 2013 is to make DermSafe available internationally to the general public and also for use in hospitals, schools, law enforcement and the military through independent distributors or through an EU or international licensing agreement.

(3)

Obtain orphan drug status for our Netherton syndrome product. Along with our research and development of products to treat common skin conditions, we have also developed a patent pending product to treat a rare skin condition called Netherton syndrome. This disease is caused by a genetic defect which causes the skin to continually exfoliate, never forming a skin bond. This leaves the patient highly susceptible to infection and dealing with a life-long condition that has no cure.

Our product has shown excellent results in lab studies blocking the enzyme that breaks down the skin and we are seeking “Orphan Drug” designation in both the US (FDA) and Europe (EMA).

The advantages of obtaining Orphan Drug designation is that it provides various incentives including a reduction or elimination of registration and market authorization fees, protocol assistance, and seven years of market exclusivity for the product in the US and ten years in Europe. These incentives are highly attractive to pharmaceutical companies targeting this market. We are currently in discussions with potential licensees and we are implementing a case report to study the moisturization effects of the product. This has begun and is expected to conclude in December 2013. This report, if successful, will add greatly to our request for Orphan Drug designation with both the EMA and FDA. Our lab studies have shown positive results so we are encouraged to go forward with the human study, however there can be no assurances that our project will be successful.

(4)

Seek clinical partnerships which will result in FDA approvals of our prescription products. There are three “Phases” involved in obtaining FDA approval. The completion of Phase 1 and/or Phase 2 will increase the value of the license and royalty fees of our products significantly. We are also seeking partnerships with Clinical Research Organizations (CROs) in order to define and begin the regulatory pathway for one or more of our prescription products.

Secure Additional Licensees:

We are in discussions and undergoing internal studies with various global pharmaceutical and Consumer Goods companies for licenses. These negotiations are at various stages and some are expected to close at the end of 2013.

To facilitate further expansion, we have entered discussions with potential partners that are dermatology service providers and knowledgeable and connected in the dermatology market.

New Products Available for Exclusive Licensing:

During the past few months Skinvisible has developed a new sunless tanning mousse / foam which uses a unique foam with Invisicare®, developed specifically for its foaming properties. This adds to Skinvisible’s line of sunless tanning products which includes sunless tanning lotions (light, medium and dark), pre-sun moisturizer and after-sun moisturizer along with sunless tanning spray products for commercial use. The addition of a sunless tanning mousse enhances this line of products which are available for exclusive licensing.

Skinvisible completed its first production of its patented broad spectrum sunscreen. Skinvisible’s sunscreens (SPF 15, 30 and 50) are formulated with Avobenzone, the only UVA sun filter allowed under the US FDA monograph. This UVA/UVB sunscreen was granted a patent from the United States patent office last year. Avobenzone is known for breaking down in the sun after only two hours – thus the requirement to reapply every 2 hours. Skinvisible’s patent was granted based on Invisicare's® minimum 8 hour photo stability. For countries outside the United States, Skinvisible has additionally patented UVA/UVB sunscreens formulated with Tinosorb S that are available for licensing.

Table of Contents

Patents Pending:

Skinvisible continues to expand its patent protection in the US for Invisicare®, its unique topical drug delivery technology as well as internationally for various products formulated with Invisicare®. Skinvisible Invisicare® patents protect Invisicare® in three areas: composition, manufacturing and use. Product patents include UVA stabilization in sunscreens (Invisicare® stabilizes avobenzone sunscreen for eight hours), retinoid stabilization and dermal barrier product protection. Patents pending include acne, anti-fungal, cationic actives (i.e. imiquimod), ichthyosis and others.

Skinvisible’s patent portfolio includes a total of fourteen US and international patents specifically protecting Invisicare and the products formulated with it.

Results of Operations for the Three and Nine Months Ended September 30, 2013 and 2012

Revenues

Our total revenue reported for the three months ended September 30, 2013 was $13,635, a decrease from $22,920 for the same period ended September 30, 2012. The decrease in revenues for the three months ended September, 2013 from the prior year period is a result of the cancellation of a licensing agreement during the first quarter of 2013. Our revenue for the three months ended September 30, 2013 consisted of $0 from product sales and $13,635 from royalties on patent licenses, and our revenue for the three months ended September 30, 2012 consisted of $0 from product sales, $7,920 from royalties on patent licenses and $15,000 as license fees.

Our total revenue reported for the nine months ended September 30, 2013 was $48,370, a decrease from $83,548 for the same period ended September 30, 2012. The decrease in revenues for the nine months ended September 30, 2013 from the prior year period is a result of the cancellation of a licensing agreement during the first quarter of 2013, $19,873 in deferred revenue was recognized as a result of this cancelation. Our revenue for the nine months ended September 30, 2013 consisted of $3,178from product sales and $25,400 from royalties on patent licenses and $19,873 as license fees, and our revenue for the nine months ended September 30, 2012 consisted of $5,755 from product sales, $27,793 from royalties on patent licenses and $50,000 as license fees.

We expect revenues to increase for the balance of 2013 as we are currently in discussions on license agreements for two of our products.

Cost of Revenues

Our cost of revenues for the three months ended September 30, 2013 increased to $565 from the prior year period when cost of revenues was $0. Our cost of revenues for the nine months ended September 30, 2013 decreased to $1,754 from the prior year period when cost of revenues was $1,944.

The increase in our cost of revenues for the three months ended September 30, 2013 from the prior year period is attributable to an increase in shipping and freight costs. The decrease in our cost of revenues for the nine months ended September 30, 2013 from the prior year period is attributable to a decrease in lab expenses.

Gross Profit

Gross profit for the three months ended September 30, 2013 was $13,070, or approximately 95% of sales. Gross profit for three months ended September 30, 2012 was $22,920, or approximately 100% of sales. Gross profit for the nine months ended September 30, 2013 was $46,616, or approximately 96% of sales. Gross profit for nine months ended September 30, 2012 was $81,604, or approximately 97% of sales.

Operating Expenses

Operating expenses decreased to $229,845 for the three months ended September 30, 2013 from $324,924 for the same period ended September 30, 2012. Our operating expenses for the three months ended September 30, 2013 consisted of $9,824 in depreciation and amortization and $220,021 in selling, general and administrative expenses. Our operating expenses for the three months ended September 30, 2012 consisted of $8,068 in depreciation and amortization and $316,856 in selling, general and administrative expenses.

Operating expenses decreased to $643,173 for the nine months ended September 30, 2013 from $1,040,171 for the same period ended September 30, 2012. Our operating expenses for the nine months ended September 30, 2013 consisted of $27,006 in depreciation and amortization and $616,167 in selling, general and administrative expenses. Our operating expenses for the nine months ended September 30, 2012 consisted of $43,982 in depreciation and amortization and $996,189 in selling, general and administrative expenses.

Our selling, general and administrative expenses decreased significantly in the three and nine months ended September 30, 2013 compared to the prior year periods as a result of decreased marketing expenses, accounting and audit fees, legal fees, amortization expenses.

Table of Contents

Other Expenses

We had other expenses of $123,328 for the three months ended September 30, 2013, compared with other income of $13,098 for the three months ended September 30, 2012. This was largely the result of $125,825 we paid in interest expenses for the three months ended September 30, 2013 from $11,866 in the prior period ended September 30, 2012.

We had other expenses of $433,201for the nine months ended September 30, 2013, compared with other expenses of $55,195 for the nine months ended September 30, 2012. This was largely the result of $436,398 we paid in interest expenses for the nine months ended September 30, 2013 from $81,886 in the prior period ended September 30, 2012.

Net Loss

We recorded a net loss of $340,103 for the three months ended September 30, 2013, as compared with a net loss of $288,906 for the three months ended September 30, 2012. We recorded a net loss of $1,029,758 for the nine months ended September 30, 2013, as compared with a net loss of $1,013,762 for the nine months ended September 30, 2012.

Liquidity and Capital Resources

As of September 30, 2013, we had total current assets of $748,955 and total assets in the amount of $1,098,536. Our total current liabilities as of September 30, 2013 were $3,619,936. We had a working capital deficit of $2,870,981 as of September 30, 2013.

Operating activities used $581,572 in cash for the nine months ended September 30, 2013. Our net loss of $1,029,758 was the main component of our negative operating cash flow, offset mainly by amortization of debt discount of $228,244, an increase of accrued interest of $105,099 and an increase in accounts payable and accrued liabilities of $69,766.

Cash flows used by investing activities during the nine months ended September 30, 2013 was $120,575 as a result of the purchase of fixed and intangible assets.

Cash flows used by financing activities during the nine months ended September 30, 2013 amounted to $925,955 and consisted of $1,000,000 in proceeds on loans payable, offset mainly by $40,043 in advances to related parties for business related expenses, $14,000 in payments on convertible promissory notes, and $12,475 in payments to related parties on convertible promissory notes.

During the nine months ended September 30, 2013, we executed Promissory Notes (the “Notes”) in the aggregate principal amount of $1,000,000 to several investors. The proceeds of the Notes are to be used for our general working capital purposes. The Notes bear interest at the rate of 9% per annum and mature at various times from May to August of 2015. We received net proceeds of $900,000 from the Notes. We expect to service the Notes with income derived from license fees. If we are unable to generate revenue from license fees, we would be unable to service the Notes in the long term or we would be forced to try and renegotiate terms with the lenders. There can be no assurance, however, that we would be able to renegotiate any terms with the lenders. For the short term, however, we have sufficient capital available to service the Notes.

The Notes are secured by US Patent rights granted for our Sunscreen Products: US patent number #8,128,913: “Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods.”

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

Off Balance Sheet Arrangements

As of September 30, 2013, there were no off balance sheet arrangements.

Critical Accounting Policies

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

Table of Contents

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred cumulative net losses of $23,601,123 since our inception and require capital for our contemplated operational and marketing activities to take place. Our ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of our contemplated plan of operations, and our transition, ultimately, to the attainment of profitable operations are necessary for us to continue operations. The ability to successfully resolve these factors raise substantial doubt about our ability to continue as a going concern. These consolidated financial statements do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

Royalty sales – We also recognize royalty revenue from licensing our patented product formulations only when earned, with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Distribution and license rights sales – We also recognize revenue from distribution and license rights only when earned (and are amortized over a five year period), with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2013, we had not recorded a reserve for doubtful accounts.

Recently Issued Accounting Pronouncements

We do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash flow.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Table of Contents

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2013. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2013, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of September 30, 2013, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

Our company plans to take steps to enhance and improve the design of our internal controls over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes during our fiscal year ending December 31, 2013: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the three months ended September 30, 2013 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

Item 1A: Risk Factors

A smaller reporting company is not required to provide the information required by this Item.

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The information set forth below relates to our issuances of securities without registration under the Securities Act of 1933 during the reporting period which were not previously included in a Quarterly Report on Form 10-Q or Current Report on Form 8-K.

On July 3, 2013, we issued 240,000 shares of our common stock as a result of entering into debt conversion agreements to convert a total principal balance and interest of $7,200 into equity.

On September 23, 2013, we issued a five-year option to an employee to purchase 300,000 shares of our common stock at an exercise price of $0.03 per share.

On October 2, 2013, we issued 180,000 shares of our common stock as a result of entering into debt conversion agreements to convert a total principal balance and interest of $3,600 into equity.

The Notes are secured by US Patent rights granted for our Sunscreen Products: US patent number #8,128,913: “Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods.”

These securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders represented their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.

Item 3. Defaults upon Senior Securities

None

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None

Item 6. Exhibits

Exhibit Number	Description of Exhibit
31.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101**	The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 formatted in Extensible Business Reporting Language (XBRL).
**Provided herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Skinvisible, Inc.

Date:	November __, 2013

	By: /s/ Terry Howlett Terry Howlett Title: Chief Executive Officer, Chief Financial Officer and Director

EX-31.1 2 ex31_1.htm EX31_1

CERTIFICATIONS

I, Terry Howlett, certify that;

I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2013 of Skinvisible, Inc. (the “registrant”);

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November __, 2013

/s/ Terry Howlett

By: Terry Howlett

Title: Chief Executive Officer

EX-31.2 3 ex31_2.htm EX31_2

CERTIFICATIONS

I, Terry Howlett, certify that;

I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2013 of Skinvisible, Inc. (the “registrant”);

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November __, 2013

/s/ Terry Howlett

By: Terry Howlett

Title: Chief Financial Officer

EX-32.1 4 ex32_1.htm EX32_1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND

CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly Report of Skinvisible, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2013 filed with the Securities and Exchange Commission (the “Report”), I, Terry Howlett, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

By:	/s/ Terry Howlett
Name:	Terry Howlett
Title:	Principal Executive Officer, Principal Financial Officer and Director
Date:	November __, 2013

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

GRAPHIC 5 image_001.jpg GRAPHIC begin 644 image_001.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBD)H`* M*;NYZ4Z@`HHI,^U`"T4@;-&:`N+2TT'-.H`***1CA2?2@`HJK)>00MMFFC0X MSAG`_G3?[3L_^?J#_OZ*:39#G%=2Y15/^T;/_GZA_P"_@I?[1L_^?F#_`+^B MCE8>TCW+=%4_[2LQUNX/^_@_QH_M.R_Y^X/^_@_QHY7V#VD>YY;_"BJ@U&SQ_Q]0_]_!1_:5G_P`_4'_?T4Y;HJI_:- MG_S\P?\`?T4G]I67>Z@_[^BCE8>TCW+E%5/[1L_^?F'_`+^"C^T;,=;J$?\` M;04Y;HJG_:5G_S]0?]_11_:5GVNH/^_HHY6'M(]RY^%'X54_M*S_Y^ MH/\`OZ*/[3L_^?J#_OZ*.5A[2/9D%,9SGC%5QJ5J?\`EXA_[^"BS*CR`&F_VE9]KF#_OZ*.5A[2/TCW+=%5/[1L_^?F#_OZ*/[1M/^?F#_OZ*.5A[2/< MMT55CO;>5MJ31,V,X5P35>]UFUL#&DSD22?=1`68_@.:+,?.C2HK+L-;M+^2 M2*"0F2+[Z-D,OU!YK4S2&FF+1244#"H+F3RHC)G`49)]JFJCK!QI%V?2%_Y4 MXJ[L1-VBV<+<^-M3N;G99)&JLP6,%=S-S5O[;XU_Y]@?^V:_XUSF@`_V]IXX M_P!8/Y5ZZ!A:[<3&-)I)'GX?FJW;9POVWQK_`,^H_P"_:_XTGVWQM_S[#_OV MO^-=[CVI<+7-[1=CI]@^YROAZ\\03:C(FJVYC@\K*_NP/FSZ@GM3/%^L:AI3 M6C6,J)')N#ADW9/!'TXS^E=9TKBOB%_Q[6/_`%U/\JJ@E.HHL5:\*;LS6\+Z MG=:GI23W3*9=Y0[5P/RKH.E5PB`9)/05GV_B/2;N=8+>]225NBJ"2?TJ+.QHY)'(^/U4ZI:DJ"1 M">H]ZPK+0;[4H&FM+:)T5BI)8#G_`":W?'O_`"$K7_KB?YU0TB?7[>S(TRW= MH&8MD(#ST_I7KTO=PR:L>+5]ZLTS$D@$:_E1Y M:?\`/-?RK170]689&FW&/]VE&A:QG_D&W'Y"CV^&78?)6[&;Y3LK$N-9;D(B3/W! M^5+Y2?W1^57FTC4HH3-)83K$HR6*]!5(\@$54/8S^&Q,O:1W$\N/^XGY4&./ M'W%_*E!IU:^QI]B?:/N,$2?W!^52VU@]Y:?E6KK4VJ3/;_`-J1M&R@^5E=OIG^E9Z0RW$@2!)) M&_NQC)I8=P]DI32'5YN=J)"8D_YYK_WR*!$G_/-?RK2&@ZP0#_9MQ^0I_P#8 M>L_]`VX_(?XU?UC#>0N2MV,ORD_YYK^5'E+V5?RK3_L+6/\`H&S_`)"JUU87 MEB@-U;21!C@;AU/I5*KAY.RL1*-9:L=I^DW6IF06D$;&/&_U?D7H.U>F:*/\`BAH_^O5O MZUP4&C:I)$C)IUP05!&5Q7/@I4HSE[0ZL3&;A'E*/E)_<'Y4>6G_`#S7\JTO M[!UC_H'3_D*3^PM7!R=.G_*O3]MAO(X>2L9Q13%_<7\J/)B_P">2_E6G_86L#KIT_Y#_&JD]O<6LNRY@E@D M]'7&?I51J8>3LK"<:RU9K>#@%\0QD*/]4W0>U:FIQR2ZOJ41^:ZDEMO)')S# MQG@K@T MZE,X_2HWCUC2E.Y;Q7F,Z8/[N+TYYVYZ&O0NM9-CHUM8.7MX0CL?F8DDGZD\ MFM:N&3NSOI0<59A12T5)J)5#5U+:9]*:ZAN",TT[.Y,E=-'B^ MG77V*_M;K86\I@Q4=<5W2^/].V_\>]U^0_QIE]X(M)[AI+:>6`L3E=NY?_K5 M`?AZ/^@DW_?G_P"O7I3K8:M9S/*A2Q%-M1+G_"?Z=_S[79^B#_&D_P"$_P!. MZ?9KO_OA?\:I_P#"O?\`J)M_WY_^O5#5?!K:;IT]U]OW^4N['E8R/SJ5'"2= MDV:.>)2NSLM(\0V6LDK;$[E&65A@@=C6#\0N;:S_`-\_RKG?"CF+Q-:;21OW M*?I@_P"%=#\0/^/6Q_ZZG^5*-'V6)20.LZM!MEWP,<>'Q_UU;^E:>KZ]:Z3! MNN&_>$?+$O+-]!7#:5XBET[1ELK.`RWC.QQC.,^W,I@[?Z+IP/`['_XH_H*['2M$L])A`MH_ MG/WI&Y9OJ:@\/ZI;:KIR21*%8?+)%_GUK6\"'.B2YYQ<-_(5D^/O^0C:_\`7(_SK5\!_P#($E_Z^&_D M*[I_[I$XE_O#.$U`8OKTYZ2R?SKT?5YY+/PU+6D?V*VNL?O%E\O M/^R0>/TKC;+_`(_[7_KO'_Z$*[CQTP.C0KD;O/4X[XP:\O$THPQ$5%'=1J.5 M!MB^%M074]%DLY\--"OEOG^)2.#^7%2GMCL/Q_P`:]>M64*?,<%*GSRL: M]D3X?\*/=$?Z9>'*`]N/ES]!S5#PID^)8"S,Q<-N+')/&3GUJ/Q'J`U#56$9 M_P!'@_=H/4@\G\_Y5)X4_P"1EM?HW\C7E>QM0=26[.WGO5C%;(U/B!D75B!T MVM_,?X5>\$VJ+HLET%_>/(VX]R!VJE\0/^/O3_\`=D_I5SP/>HVFRVA<"2.0 MMM/!(/\`]?(KF=_JJ-UR_6'77]5,TA%[*@W'"KP`,]!3?[>U?_H(S_F*Z MR7P)9.[.MU<*&)./E.,_A3!X!M>]]<'\%_PK6%?"J.J)G1K-Z'*_V]JW_00G M_.H;O5;^]A$5S/YJ*<@LHR#]:[$^`K3H+ZX!^B_X5S&NZ%-HDT?[WSH)"0C$ M8.?0_P`ZZ*-;"RFDEJ85J->,6WL;G@#_`%E^O;$9Y]>1_2L7Q.,>)K[ZK_Z" M*VO`'^LOO]U/ZUB^*/\`D9KWZK_Z"*QCIBY6-9?P$=IH,IB\%0R#&4MV(S[9 MK@QX@U=VW_VA,,\X'`KN='_Y$5/^O5_ZUYJGW1]!2P%*-2I)20\74E&G&QI_ MV]JW_00G_.EC\0ZO#('%_*V#T;!!K.I*]&KA**@[(XJ=>7,M3T#QI9H^B+<[ ME/^-%D'C4?\5"1_TQ7^M=#X=MX[+P@+B/AWC,S'U/-<]XT_Y&,_\` M7%?ZUU6CHTGA&"-1EFMR`/4XI5?X$!4_XTCA!K^KL,G49LGGBE_M_6/^@C/^ ME3KX3UO8!]E3./\`GJ*=_P`(GK/_`#[)_P!_17=!X2VIQ26(OE`F[(FS17`CQKJW?1P M><+C9&;X8_Y M&6P'?$]$N_[26]NHF@CC!*+(,%B1U]L"KGC M])62PB2*1^68E5)QT';ZUU5*D7B$TSDA"2H--$O@>Q@.F-=>0IE:4@OWQQ6[ MKFC0:Q8M#+\K#E)!U0UE>!MZZ(R/&R$3L,$$>E=65SWKCK3?M6TSMP]-.DDT M>113W_AK6"=H$J<.O\,BUZ;INI6VIV<=S`Q*MQ@]0>X-4/$F@0ZM;#'R7$8S M')_0^UO0M,=JNM4B_9^1-*#7,> M8^_K13UM[@C_`(]YOPB-'V>Y_P"?>;_OT:]Z.(IVW/*E2G?8?9?\?]K_`-=X M_P#T(5V_CN)/[)AD*C/G!<]\8/%<=8VER=1M!]GF&9X^J$=Q7;^-8'GT2,(K M,5G4D*"3W']:\?&5(O$Q:9Z&'A)4))H\\.,'/2N]\*7Z:KH;V-R0TD(\MLG[ MT9Z'^GX5POV>X_Y]I\?]'D^F?\``5TFH:': MZIJ%G?L1^YZCLXZBN%UVXN=5U>2=;>8PQDQQ?NCT]?QKCIU_;\L);(Z:E#V- MW%&0!@8K<\)_\C):?1OY&L@V]Q_S[3_]^C6UX3MY_P#A(H&:&14568DJ1V_^ MO7H8NI3]@TF<="G4=5-HT_'Y'VG3_P#=D_I7'AF5MR,5(Z$'!KL?'=O+)/8L MD3.`)`=JDXZ'_&LW2/"L^K67GBZ90U74 ML?\`(0NO^_S?XTHU74A_S$+K_O\`-_C71?\`"O[KMJ$7_?H_XT?\*_NA_P`Q M"+_OT?\`&J^LX3^4?L<2NISHU34C,I_M&YR",9E)'7N":[+QP@.@V[$)[_ZK_P"@BM[P';R1_;WDC=,E0-P( MS6)XKMKC_A)+QE@D8-M((4D?='^%7&I'ZRV$JK?UKS M93\@^@KU#3X!:>#H8YPP7[-\^!DC(]/QKFT\!SN,IJ417J#Y1Z=N]3@\1&C4 M;8\30E.,;(Y6CO76_P#"O[K_`*"$7_?H_P"-.3P#,Z@GE@Y;$1Y'YUZ%3 M,:,HM')3P=1.[1K^,&!\+R<_Q1_S%87@3_D,W'_7#^M6O%VHK/8QZ?;(\YWA MG*QD@`=!G&,U7\#0S1:I;"26'DCMDG[:)4\:G;X@;/_/% M?ZUU6DDCP=`58@K;GD=C7-^,X)GUR-Q'(0T(Y121G)&*UO"]\DVC'3;E9()$ M!4>8A&Y3W&?K2JR3HP"$6JLCC5U;4M@_XF%WT_Y[-_C2_P!JZC_T$+O_`+_' M_&NB_P"%?W'\.HQ$=LQ'I^='_"O[K_H(1?\`?H_XUUPQ&$2U1RRH8BYSO]JZ MA_S_`-V?^VQJ.74+N92DMWE>9CY*56Z/1P,6H:CJ***XSN"BBB@!*1@#U%.I*`(C&/2E\ MM?2I**.9D^S1'Y8]*/+'I4E%%V')$8(D#;MHW>O>AD#=1FGT4#LB,1J"#MZ5 M)12T`E8C90:;L4<[>>G2I:*/0&DR(1(,_*.:<%`Z"GT4,+(CV#.<4>6N,;:D MHH"R&!%QTI#&/05)11<7*NQ'Y:GC:*7:/2GT4#LB,H,=!2!!W6I:*+L7*NQ' ML4_PT@A4'(4`FI:6@;5]R/8OI2>6N?NC-244!9$110.%%*%`'3K4E%`6&T8] M:=10,:5'I3/+&?NC\JEHH%8:%7TZ4TJO]T5)BC%&H[(;CMBD"!>@`I]%`#<4 M#D8(IU%*PAGECTI-B_W14E&*>H)(C,:GJHHVJ!@`?E4E%&H60T#BBG44#$%, M,:DYVC-244"L,"C.<4^BEH!*P4444#"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH K`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/_V3\_ ` end GRAPHIC 6 image_009.jpg GRAPHIC begin 644 image_009.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX. M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_ MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`"!`<<#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHKA_BKK=]I&@V M4>EW,EM=WEZD*R1]0.<_TH`[BBO,/BWXLU'PO_8D6FW#[ M'FM'Q+XCNKG7_!UKI-V\,6IR>?+Y9^_$`#@^V,T`=]17#'6-0M_C,-+DNI#I M]SI_F1P$_*''4C_OD_G0^LW^M?%9-+T^ZDBTW2H/,O0A&)9&Z*?S'Y&@#N:* MX+P/K=_K'B/Q7<7%W++8VESY-O$?NIC=G'Y"N3T^Y\9^+],O_$FDZ^8Y;>9A M%I<0S\HZ*1ZD>HYH`]IHKB/%7B+4=/\`A7+JLTHQS7HGB;6XO#WAR]U27&((BR*?XF/"C\210!K45YI\ M)O$6KZE+K%KXBNI);F$Q2*)U=K`RVS32N!D M=R,_@OZT`>ET5Y?X>U'Q+X?^(EMX>UW5TU6"\MFE5@O,9&2.V1]T_G3==G\2 M^(OB7?:-X?UQ].@L[5'?C*[CC]?F'Y4`>I45RGA#0/$>D75S)X@U_P#M.-T" MQ(%(V'/)KJZ`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M\V^(#C4?B'X/TCJ%G-RX]@1C_P!!->DUQGB2RTG1?%EEXJU*2[:95^RQHF"B M<-SCKW--)MV0I245=F)XDT]/$_Q;72Y5#0V^D29ST#/D`_\`CPKF?AI<7.J^ M.M*LKR,AM!LYH23Z[B!^6['X5Z+H@\/3>*+W7[/55EO+V)8FCD<*$48X`(![ M"KNC>#M.TCQ)J.N6;R&?4!\ZD@HO.3MP.YH::W!24MF+_!.G^- M(K2/49)XUM7+KY1`+9Z@Y!XXK6O=.AN='FT[<8()(3!E"`44C''X4AGGGPRU M"#0OAQJ/B"^60QRW5/O7H]AI6AZ%X7709+B.6R$;1LLK@LX8DG./K7!Q_#WPO;:@DB7&I7 MEK&^]+21P(L^A.,D52A)[(ESBMV:7Q3O7U/P=H%L5VR:K=0%D';*Y(_,BCXC M2P6?C#P6;AE%G!.N>3T'2K M/B/PMHVN:4UCJCR2-NWH\1PT;>H_^O3Y+"4KAJWCB#3M7=O!DLR@\+P#CN?Q%;_A3P'8>&[YK MVS^TW=Z1M6>X()1?;'`^M;.F^$(]/U_4-:>YD>\O@`[2L/D4?PKCH.!^5-JV M@7.(\!ZO_:?Q.UB2XL9=,-W9JX@E'(V;1Z#M4>H:-=^*_BQK*Z9JTNG2:?:I M&DT8.2<`;>",#)-=^WAFP_X2R/Q`UW*;I+?[.47&QE]^^:-&\,Z;HVKZIJ,, MUQ+/J3AY?,QA<$G`XZ6/\`9[\X MQSZ&LS2_"47COQ=XGU&35;JQ2*]\E#;L!O`R.?I@5Z-I7ABPTCQ#J6K6D]P) M-1P98CC8&'.1QG/7\ZY=_@IH^;+YADG;)'`&/TKH*Q/"WABV\)Z3_9]G+--&9#(7F8%B3]/I6W2&%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5R?CO4M,LK:TBUB MP:[MYY&QM;#1D#J/SKK*Y3QSK-II-O:)J&FQWUM<.RLK=5P.H]ZTI*\T95W: MF]3C1H7A;4_FTW7&M'/2*[3I^/'\ZM1>!]53!L-7M95[&.X9?Y5`+/P9JH!M M[VYTN0_P2C37JCR7!/:*?H[%^+P MGXH`PU]D?]?3583PCJ)YO-2@0=]TK-5*+P3J:?\`,4M,>TS5;3P@(^;O5[11 MW^;/\S42G_>7W&U.F_Y'\V6X]$T>RYN]561AU6/'],U;BU/2K/`L;(R/V>3_ M`.OS5*+3M`L_]=J+W!'\,8_PJY#J]C;G9INGC>>C2=?\:S?O=W^!TQT[+\2[ M&VIZERP\F(_\!&/YFI@EE9#YCY\@[#H*Y[3O%(U^_AM6DN8!<%A`\L#)%,5S MN"MW/!_*MRXN=,T9(&F+3O,[(@C7>2RJ6(`'LIK)R2_X!O%-_P#!+"W-U<\0 M1[$_V1_6I$T^5SF63G\ZN1W,3P)*&"HR[AN.,#'?Z4IN80%)E0!_NG<.?I6? M/V+Y>YQ_B?69=%U2UL;6YTV!I+>2XDEU!BJX4@`#!')R?RJ&T\>V$VB^?);2 MQ7OV5Y,%&\DRJFXQA^YZ<5LZAIMA!K%YK^KO;RVT%JD:I)&&\G:2Q/?DY'2N M1T_11XB6[LVO9H8K*9IXK2>S,4P$K;RS9/S?+N5<>O-3S,=D=&OC728-+M;B M[\[SI0P>.*)F*NK!&&.N-Q`'K2V_CW19A*2+V`1HS'SK=EW%6"LB^K!B!@>M M8^FZ)"$O-;OIS91G4/[0\F!1J&GVJ+J5M,\$`D1 M94.R0M,969@"#M;('X47'8W[3QEIMUFYN7=/),!#1%"`WF#^$#(YK MHJY7POX9AT.^\];NVE9[?R]D*A1N+EG(&3Q]T>OR\UU5(`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"H;FU@O(C%\3 MSR/X:7B==0@(_P!QJOV_P^VG]]?`_P"Y'_B:WKW5+FVNGCCA#*.AVDU!_;5Y M_P`^Z_\`?!IO$U'U%'!T8[(2V\'Z?!CS#+,1_>;`_2K\]I'8:9PN4MIG)53`(=F? M+C+;`3M)7>3SGC-=Y+XAN(-AEA5=[A%^1N6/05)_;5Y_S[K_`-\&I*."O_#6 ML>5NEM;C[%9W\D$,46S^%[HR:C##HET]N%,1\Z(&1!O1<1N#^]4HI;!'R_6@^%M M6N;J['V*ZCD9Y()&$`1?+D<(%5\Y=!'SP`%Q7K]%`'GV@>%38>*+6ZATLVL: MW5W(7`P%B`"1)]#RV/QKT&BEH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`HI"P7K2;Q[T`.HIN\>]&\4`*3BJ_P!JR[JL M4K;#M)4#&?SJ8N*B@&QIB?XWW#Z8%`@^TM_S[S?D/\:/M+?\^\WY#_&IMXHW MB@-2'[2W_/O-^0_QH^TM_P`^\WY#_&IMXHW#('K0&I#]I;_GWF_(?XT?:6_Y M]YOR'^-3TA8`XH#4A^TM_P`^\WY#_&C[2W_/O-^0_P`:FWBDWCTH#4B^TM_S M[S?D/\::]YY:,[6\P5023@=/SJQO%17(\VVEC7[S(5&?4B@-2&._,L:R):W! M5P&!PO(/XT[[8_\`SZ7/Y+_C3K7$%K!"Y&]8U7&>I`YQ4^\4!9E;[8__`#Z7 M/Y+_`(T?;'_Y]+G\E_QJSO%&\4!9E;[8_P#SZ7/Y+_C1]L?_`)]+G\E_QJR& M!Z4Z@+,J?:V_Y\[C\E_QH^UM_P`^=Q^2_P"-6=XR1Z4;Q0%F5OM;?\^=Q^2_ MXT?:V_Y\[C\E_P`:L[Q1O%`69BZQ/)+]A"VDXVWD;<9]ZT/M;=?L=Q^2_ MXT7D9F:W*8_=S!VSZ8/^-60PIMZ"2=RO]K;_`)\[C\E_QH^UM_SYW'Y+_C5G M>*-XI#LRM]K;_GSN/R7_`!H^V/\`\^=S^2_XU9WBE!##(H"S*OVQ_P#GTN?R M7_&C[8__`#Z7/Y+_`(U:/`S2;Q0%F5OMC_\`/I<_DO\`C1]L?_GTN?R7_&K. M\4TRHOWCCZT!9D'VQ_\`GTN?R7_&D%\3)Y9MK@-C."%Z?G5G>/2HB/\`2UD_ MA"%?QR*`LP^TM_S[S?D/\:/M+?\`/O-^0_QJ1I412S$`#DD\`4+*CJ&4Y!Z$ M<@T`1_:6_P"?>;\A_C1]I;_GWF_(?XU-O%)O6@-2+[2W_/O-^0_QH^TM_P`^ M\WY#_&IZ"0.M`:D'VEO^?>;\A_C1]I;_`)]YOR'^-3;Q1O%`:D/VEO\`GWF_ M(?XT?:6_Y]YOR'^-3;Q1O%`:D5O=)F`/Z5:WCWH&.HIN\>]&\>]`#J*;O&?K3J`"BBB@`HHHH`BG.-G^]3-P]:+ ML[8P?>JGFT`6]P]:S-8\2:;H)A&HS/&9MQ0)$S\#J3M!P!ZFK'FUB:[H*Z[J M=A+/*RVL"2I*B2,C2!P!C([<89HQ&%WEBX`"^OTIPFC8`K(A! M&00PY'K]*X6Y\&S76M7UQ(]H;6X@EA5<'.UD"H&'3"E[:WCOF+I,(2QC M(7.2`<]-N01GUH`S[G6/$T<4\,?-"Q(ZJ!T'S$KGOCUJA?>*/ M%EK&T:QERLX4W(LV(^:)7"[0#QN)7/MU%;H^(6A&>WA^V2!YT\Q`8VZM367C?2;_`,O[/-/F22.--\+*6,F=I&>QP>?:@+''ZQ>:[JNH2C4+6X#V MT%XHACMF5$!B&PB0?>+<\=JO3:]XEFN[[3[1+N"&*R?RV^S?,KJBE=K8P<\] MR?I71_\`":Z0M[96C73K+>#,(*''+$#)[9(.*I0>.$_MB_MKF&Y2"&X%M`JV MSF1W"[F)[8Q^G/>D.Y'8>(-LQSW-A>VUI(L<\J,B.W1<\$_EFN0N_!5\X>WCO(+NQ\R.4078 M*@L(S&<[`!C[I'N*`.PC\16,NF6%^K2>3?LBP@K\V7Z9':KRW<#M(JSQLT1Q M(`X^0^_I^->?V7@:[M;[39I+FUF%F+?YVW;XQ$"&5.V&SGFK-UX0E>_U.>!; M%XKR\CNC#(&`E"K@QOCMGYA[T`=?J>L66CVHN+Z8I&6"+M4NSL>@51DD_2IK M:^@N[:.XAD!CD4,I;Y3@^H/(^E!\PYH M\Z/&?,3![[ABN"LO`4=OI]M"[0>?!9RQ"503MG=LB4>X'%4D^',CPQ1SO:B- M(Y@8A([+YC1A5<9QCYANQ_,T`>DK7VL:SX#O)]0MVB>XG1%C\DDP1JP#.R#EQN M!..X-:/P_O)WTJ:UN+"6S6W<&,R(R^=N^9G4$#"ELX7L,4^]\>:)I[`W-VX_ M?&$,(RP)`&2#_=&1S5*_\;33:U%I^AP_:W:.;+.C!6D7&-K'`(&3GZ4(#M=P M]:1F&TUDZ3^^93)(M MA&TB11[L"1L\A<\5^/+"UNC`EI?SNMVEH?+AXW,<9&3R,BLW7/'5[ MI>OZM916D4D.GVXF!"2,\A*$]0-J@$=R..E:4OA;2)[B:XDAE,TLB2&3SFW* M4)9=O/`!)XJ2Z\.Z=>7MW=2B<27L8BN`D[*DJ@8`9>AP":`,;2_B#*HN)-9@ MN(XX8X45%M=KS2NNXE^*U-2\>Z?86LT\5IJ%Y'"B.[P0Y12V"%+$ M\-A@<5+-X=TR=2&BD5BR.'24JRE4V`@]OEXIMQX9TNZ\\31S%+B,)*@G8*^` M`&(S][`'/M0`Y/%]O#/>)?))$(2[1@(=S!55BI_V_GZ"K5EXIT^_UJ;2X?/% MS$#DO'A&(QN4'U&>:J7'AO2KOR_M$#2&.Y6Z4M(2?,"A02>_`'%6;?2K.TU& M:^@619IF9G'F$IN;[Q"]`3BA(#9W`LG^]5BL^&3=,@]ZT*`"BBB@`HHHH`J: MB=MKGW%97G5I:N=M@Q]Q6#YM`&)XJN-5EU?3;+2;B2)[B&W()X MS@UT7G>]'F_3CI0!S.G^*[X:?;W-PR2RRVMOYDC[A#$S,P9F`'&,&&>U;WF_2CS<^E,"Z9<$C.:GL7W7:"LOS:N:4 M^Z_4>QI`=!6;J;[98_<5I5C:X^R6'Z&@#)O=)L=0EDEN8F:1U12PM5+CP]HJ:9(;.75=&DMH&7S-Z2 M!6/RR;6#;3['&*`(F7PMM-]]JMTC=5MV=)R$8*,*I'J!3DL_#06UACGC5I$B M6VVW!#D1D["IZ\9//>LV32;Z\77+N2WBMYM12)$M1(&"[/XF8<9-6X;2]L?$ MU[=I;174%^8LR&0*;<*,$8/4=QB@"_!8:)!+%)#(JM;LMJ,3G&X$E4;U;)/Y MU>73;-;PW0B/G-*TQ)8\N4V$X_W1C%1BU403:I]L$XF7E.!C;U MSQ44^F>(UT]TMKR7S6BB+[KC<6<,=X!/3(QZ#BCI<#HX_#.DQ-&P@D)AV>7N MF8^6%;:H:*MY;:1;Q:C,9KI5/F M.Q!/7@$CKBKWFT`;FEMO\P^F*T*R=#;<)OJ*UJ`,6[DVW<@]ZYGQ'/J4NHV- MIIDLB/-#,MW4I-NH2CWJMYM`&$_BK4+=)1+#:A8[S[ M']H?>$4JN3(^.@/0`=S4-QXGN[Z2P@*):^8]M(PRX>0,_.SC[HQSGUKH_-^E M'F_2CJ!S_-3+KVH3CQ`C75L1;V@EM M?(5@PS'GF>_6NA\WMQ1YOTHZAT+IEP3S6M8 M'-HAKF_-KHM,.;"(^U`%B3_5/]#6$)JW9/\`5/\`[IKEO-H`ENX(+^.-+E2R MQRK*H!QAE.0:Q_L'AVXN3IZR1O0)SN`C.]>/8G-:?FURZ:!="_U:_,T MBS/++)91JZA0S1A0^<9!_'%*X&EI_@[3[>RMTOE:YN8@H\WS&&-K[P%'89YQ MWJZ^EZ3+J4@D7S+AUDE,+R$JHD^5V"]!NZ9KGKG3=;6[A2SN)A%MAQ,UV?W) M'^MW*?O[JBM=,UV&6:YD):Y6)$#FZR;@K+O./[@*\8I@=)'X:TJ&VM8(H'1+ M166(I*0P#^?>I+;0].M;]+V"-Q*A=D_>DJI?[^!T&<5A1VVL2R0F\5VC MD\T2(EYM$.Y\J3C[X"\8J+2;#6+&;2(C&4M;>(Q7`-SN7@G#`=23QP>/I3`[ M7S:42Y(^M4O-I4E_>+]12`ZH=!5;4#BT8^A%61T%4]6.-/<^XH`S/.H\ZJ?F MT>;0!=$N2!7$/XQU-?[2_>6W[J.;R0T#+L97"(,_\M-V>W0]:ZKS?>J,VE:= M<1B.:SB=!OPI']\Y;\SS0!C:=XEU:30,/=POJ9O8H#YD&3`KMC;(HP-XP>![ M5OZ#JUQ?Q7<=YY)GL[EK9Y(G7D53'A_2%BDC6QB"R$,^"=5/S:/-H`T[*3==H*V:Y[2Y M-VH1CZUT-`!1110`4444`0W-NEU"8I,[3Z52_L&U]9/^^JTZ*`,S^P;7U?\` M.C^P;7U?\ZTZ*`,S^P;7U?\`.C^P;7U?\ZTZ*`,S^P;7U?\`.C^P;7U?\ZTZ M*`,S^P;7U?\`.IK72H+2;S(]Q;&.35VB@`JK>:?%>E?-W?+TP:M44`9G]@VO MJ_YT?V#:^K_G6G10!F?V#:^LG_?5']@VOJ_YUIT4`9G]@VOK)_WU1_8-KZO_ M`-]5IT4`9G]@VOJ_YT?V#:^K_G6G10!6L[&*R5A%GYCSDU9HHH`H7.DP7,QE M?<&/7!J/^P;7U?\`.M.B@#,_L&U]7_.C^P;7U?\`.M.B@#,_L&U]7_.C^P;7 MU?\`.M.B@#,_L&U]7_.C^P;7U?\`.M.B@#,_L&U]7_.K\$*V\*QI]U1Q4E%` M"$;@0>AK-.A6I).7Y]ZTZ*`,S^P;7U?\Z/[!M?5_SK3HH`S/[!M?63\Z/[!M M?5_^^JTZ*`,S^P;7UD_[ZH_L&U]7_.M.B@#,_L&U]7_.E70[96#9?(.>M:5% M`""H[BW2YA:*3.UO2I:*`,S^P;7U?\Z/[!M?5_SK3HH`S/[!M?5_SH_L&U]7 M_.M.B@#,_L&U]7_.C^P;7U?\ZTZ*`,S^P;7U?\Z/[!M?5_SK3HH`HVVDP6LP MECW;AZFKU%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`% J%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'__9 ` end GRAPHIC 7 image_004.jpg GRAPHIC begin 644 image_004.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX. M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_ MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!+`*@#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`I" M0`23@#O2US'Q!U*YT_PE>K8HTEU-&R*$ZJF/G?Z!N5./R/4>QJMK'B[3=!8_VE]HA3.T2&!BA/LP&*\L^#.OBRU^?2)6/E7J M;HLG@2*/ZC^5>QZKIL&L:7<6-T@>&="A![>A^HZT`TJ%#^1KYE5Y_"WBI/M"9ETZZ!=3_%M;^HKZ%P^W[;(3G'$#?X M5U]>7^&]`L(?$GB'Q5?JBV%G=3?9P0-N5/S/CV/`]Z`.]_X2&P32VU&ZE:TM M1_'=(8L_0'FBTUA]0MUN+.QN&@;E'DQ'O'J`>;'ER'T#CC/L<5L; MOER.1[=ZP/'>BQZYX0O[9E!D2,S1'T=1D?X?C7"?"'QO+/,/#^HRL^5+6;N> M0!U0G]1^-`'<:KX\TG0Y%35!=VQ?[N^W;#?0]#4VA^,]'\0Q7,FGW)*6N#*T MB%`N>G7Z5@?&2-&\"M(R@O'0?!'79WGOM&E$$_<.<,!['(->OT`%%%%`!1110`5DVR)J>H7EQ M*@>!`;2//(8?\M#^)X_X#5C6;UK#3)98@&G.$A4_Q2,<*/S-5M/@U*PT^&V2 MVL_W:@$^>W)[G[O"_&LL^U:/=:- M,V9+-O,BR?\`EFW;\#G\Z`.?^-6@?8];MM7B4".\7RY,#_EHO?\`$?RKK?@Y MKQU+PJVGRL#-IS^6/4QGE?RY'X5N?$#0/^$B\(7ELB[KB-?.@_WUYQ^(R/QK MQCX8Z_\`V#XTMC(VVWO/]&ER<`9/RD_1L?G0!]`ZM=M9:;++'@S$;(AZNW"C M\R*\^^*6/#_PXM=*MS_KYDC=A_'C+L?Q(_6NWN/].U^"#Y3#9+Y\G_70Y"#\ MMQ_*N)^.-NS^&K"J>/3?@_I7U([;49 MO09KY:TFV;5/%=K!&"3/?`?AOR?TH`]K^,G_`"($O_7Q%_.N7^!7_(0UG_KG M%_-JZCXR_P#(@2_]?$7\ZY;X$_\`'_K/_7.+^;4`>RURGQ../AYJ_P#US7_T M(5U=+2H6NI\=#,<*J_\!#$_4UUU>;>'OAAJGAK6CJ=GKR/,X(E$L!(E!.3NYSU MYKT>/?Y:^807P-Q7IGOB@#,\3:+'X@\.7NFR#F:,A#Z..5/Y@5\]^"=;;POX MRM+FO@A@"#D'H:^;/B)H1\.>,KN&-2D$Q^TP;?1CGCZ-F MO;_#6C:_HEK;V5YJMM?6L(VAGA990O89S@X]Z@\8>"8?%6IZ/=.5`LY\S`_\ MM(NNW\P/S-`&CX2M[J/0+>XU(AK^Z19KA@,.P4K`R)[NW"@?B:\T^#/A"22[_X2&\0B&(%+4,/OL>&?Z#I M^)KO]4\*R^*+F!O$$ZFQ@;>EA`3L=NQ=NK?08%=)'$D$*Q0(D:(NU%484#L, M4`<-\9CCP#)[W,0'YUS'P(_X_=9_W(OYM77>,?!>J^,8X[>XU>"VM(GWK%'` M3N;L6)/.*H>$_AMJ7A#4GN[#6XI%E79+%);G:X[=#P10!Z+7'_%5@OP[U3/< M(/\`Q\5UD7F>6/-V[^^S.*Y#QEX4UKQ=9BQ;4;2TLPX:H*LDD!VNIZ@\UZ59_:_*/VT M0>9GCRI^@ZFL5_B#HJE@K7#XZ$1' MFHE4A'XF=%+"UZJO3@VO0Z>DS7&3_$JS7(M[*>3T+$+_`(UF3_$N]9CY-C`@ M_P!MBQK)XJDNIUPRC&3^Q;U:/1LT9KR.]\;:W=@K]J$*]<0J%_7K61-J%WSW6L:?9$BYO;>,CJ&D&1^%9LWC;0H M?^7Y7YQ^[4M_2O)DMIYCN2&60GNJ$U:BT34YB!'I]TV?^F1%9O&5'\,3J618 M:"_>5'^"/3(_'>A22!/M3+EMH+1L!]<^E1S^/='AO_L_F.Z#.9E7*9QV]:X( M>$=<./\`B6S#/J1_C3U\&:Z[`"P89[EU']:?UBO_`"_@3_9F7)W=7_R9'9Q? M$327@+R+/&^XJ(]N3CL<^E)!\1=+EMV:2.>*54+>6P&"?0'WKD3X&UX/M^R+ M]?-7%*?`VNA,_8U)ST$JYH]OB/Y?P']0RO\`Y^+_`,"1NCXF@[\Z<1\IV_O, M\]@>*;_PLX[%QIN7_B_>\?AQ6"?!.O8_X\NG_31?\:A?PGKB==-G/^[@_P!: MCVN(\_N.A8+*WLU_X%_P3I5^)_7?IA]L3?\`UJN)\2M/,2,]K<*Y)W*,':/7 M-<+-H6J09,NGW*@''^K)_E55K6=%+/#*JYQDH0,U/UFLM_R+_LG`5/A7W/\` MX+/3%^(NC'.5NACUBZ_K5J#QUH<[A?M+1D_\](R!^=>3#'3-&*:QM3R)ED&% M>S:^?_`/;[;5;&]4&VNX)<]-K@FK6:\'4;6##@CN.M:MIXEU>P*^1?2E0<[9 M#N!_.M8XY?:1Q5N'9+^%/[SV/-%<3X4\97FJZJ+*_2'YU)1T!!R.U%=E.I&I M'FB>%BL+4PL_9U-S0\2^#DUV<74=T\5PJ[0&^9,?3M7+_P#"N]7\W;OM=O\` M?WG^6*]/HJ)X:G-W9U8?-<30AR1>B[H\^M_AG,6_TK4$4>D2$_SK2B^'&EI_ MK9[J0_[P7^0KKZ*%AJ2Z"GFV,G]NWIH8-IX*T2TZ60E;^]*Q8UI1:1I\'^JL M;9?I$O\`A5RBM%3C'9')/$UJGQS;^8@55&%``]A2T459B)12T4`%)2T4`)12 MT4`)05!&"`12T4`49M%TVX),UC;.3U)C&:S;GP3HER2?LGE'UB8K7045#IPE MNC>&)K4_@FU\SBYOAM9MGR;VX3T#`-_A6'?_``^U6V4M;-%=*.RG:WY&O4** MQEA:3Z6.ZEG.+IO65_4X/P1X9O;'47OM0A,.U"D:,>23U/';%%=Y16M*FJ<> ,5''B\5/%5/:3W/_9 ` end GRAPHIC 8 image_002.jpg GRAPHIC begin 644 image_002.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX. M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_ MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`"?`$$#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#U7%)BGXI, M4AC,5%+<00!?/+(6.`0-P-3$51D1;VZ5)(I`L+'!XPU`$YGM1UG(_P"`&FF> MU_Y[M_W[-69[.$XD6($A<8QFH#&J_P`('X4`,+0/PDW/HRXJ-A4CHK#Y@#]: M810`RBEQ10!J8I,4ZDH$4-8XTN;'L/U%5-.SL7K5S6O^09)[E?YU!IZ?NUI% M+8T5SMJ$\EOK5D(<5`5PS#WIB(R*C(J4BF,*`(\44[%%`C1IRH6/%1RR"&)G M/:JL5]SUH&7+G3UNH#&SD`X.<4V"P>``"8''_3,5+#U+$G>,GVQ5FBBPC,EA:(_,./45"16I,5*%6Z&LU@,F@"/%%+BBD, MDU+FUQ[U@M.T4@`YK[&YF8`#/;K M3BG)V0;(W+:]?'05HPWKXY`KS<>.YH#_`,@>210GF>9#-YB;>1GDQW);JM-DN6QPM<+;>.[C4; ME].M[%K&Z\IG,L^6,8`SG9C+''0?C7)2:=J.H&&ZN-2DD\\2OO!=V"IWP.?F M[8KAQ$I4)\CCJ*516T/6+F\=0>!3+>0R(Q/K_2O.]"AU#_A)TL[K4+FYALXC M,R2;PJL1A?O=?O<'VKT&R(*2#G(;'3V%*,^=7L.$N8GHI<451H1WI!C7)YR< M#-V&DK"G$2I,_P"Z/(/.,D\GKW_*K"^%O%)N#*C:74-M% M;WH>3JTDN-J;=Q;KGC%>C#$5[URC:>%_$&FW"7QLK.^:"&.&..&8 ML4\L<-V.:W MNU=R6*0S;@`6QST]SQVZ$U'_`&AI,4W-<=;!U:M24 MY+])#Z%2:8S%7M-2M8D08< M$_T_&IP+]97\K5+!%#G`=02,]O;C%5[^PBATV4VEA')*Q5,+#OX)&3@=:IQ& MYW/Y^@`NQ)+[6.,;0?;!^8CGIBNJG&36EOP,VT;,1U!8GSJ^E_+AF? MQILLETDT9?6K$!,+,"@Y.[G'IZ51A-RKN&\,QA)0"0%?Y2".O'/+9^@II;4) M6V?\(]`CN^TR/&W0\D@'KC/Z&M'"?E^`KHVA?6MQ/Y<$\;N.=JMDXJW9_P"I M;_?-5Q96]O-F""*(],JH!Q5BT&(F_P!\UQ,I$V****11FP\EN.0.M12#]X/I M3[4YW_2LK7M>M]%53*09&'RH>_\`G_)%%TMP;LAFNVS-+#1V%163VTEM>0O?W\S,@W.\+?(H<$@#.,G*BN9G\=ZA*Q\AGC7MM(3^0 M)_6HE\7:MG(N9QGDXG?_`!K2./I0CRM_=_PQ@YQN=?;O!%:3Q/?:K+YR(N_[ M.Y(`)8D?-WS4<>FPW5PEN+K5&WL`K/$5"`#N<_\`ZZPK?QMK$7_+U.?K(K?^ MA*:OV_Q&NU(%RL4J^K1E3^:D_P#H-:+,:4OAEK_7E;\1IV-M;+8VD%LKE MUA0)N;J<#K5BT_U!YS\Q[]*XZY^(%LT7[J$>:>``Y;G_`+Y'ZUU]F?\`1AZD MFL')2>CN:PDGL6,T4W-%(LRK(Y,GT%>>^)[*:^\2W(!+G=M3)Z`#H*]`T\Y, MGT%*%)71BE#(CHVE8)3C`Z<8!Z>HS4Z10&*/=I# M,1QNYYQP>G>KZFX1R_G,"0,D^@J>">1$PMPH4\]5YR?\:Y^2_P#PR,W$I/:H M8MJZ0R,>A'89&?Q[4V8++,\B:(NXD[@1QSSTQQ6RES*3@70W+Q@$<5`99'9O M+N3M8'V_PH4/ZLB6CF[S3IWFAEDM%@1<*-O0]Z]3MOEA`^M<*\+LZB1V8 M`]S7"#W%2H$M'+1Z=)(FL0#M^?/&:T(=+C@0%((XV(`;8,#_P#56W;: M5;6V##!'&0",JN.*>\(`Z4W$31STMH/+)Q\VX8K>4\"J\T((P!5H1,>1C%5% M6%%6#-%+Y+>HHJRS.5\,0Q`S4Z*-WS**LW.C6]T"-SJ?536;_8&IVS?Z%JJE M.R3Q;A^8YI%&K$D?]T5;2./TK&C@UV+[\5A+[I(R?H0:L(^JC[UA'_P&X'^% M,5C7"1XZ4UDB_NBL[S=2[6*#ZSC_``J-O[7DX"640]2[.?Y"BXK%V0CHH&?: KJ4@F3^$XI]O:7"2>9=7?F$=%1-JBKWG8'K0!E>=-Z&BM3S5_N+^5%(#_V3\_ ` end GRAPHIC 9 image_003.jpg GRAPHIC begin 644 image_003.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#8S^5.'`%1 M9-.!S[U!H29IP]*CZ#K3UY[@&D,=29I"<=Q^%)NH$.S2@^]1Y`XH+*!UH`DS MWI2:K><,]:7SQZT6%E%@N29Q034)D/84FY\]#0%R0\ M4QNE)\^.E-*2$]1180A-,)&:@O+FWL/*^U3F/S3M7Y2AJ17##V- M.P7*6VBG2C9(1CCM1189?IPIN:,^],8_-+N]/SJ(&AGVT@)":;D]JB5][A1W MJP132);&'-49[E$D,;2*&'4$\_YYJ]*)?+/DA#)V\S./TKDK[Q3JMEXDBT7[ M'9M+*R!9`S$8;OBK4+[$MFZC&0D*22!GH::)6(R(ISQVC-0:Q=:[I=B]["EE M=QQ#=)$$9&QW(.3FC3/%6FZAI(OWD,`7(E5E+>61ZD#I[T7%)^]S@02]^P'3\:E.$5'GOMW" MVF*]>V?RS2Q7$4Z%HB7*]4QAA^!IH(''ZU) M#!=.OM059/+CCP/EY8GC`I.+0*<6]S'N].M;H*ES"LNPD@'^$XQ58-P.,CUZU99<'%.S6Y2:>QE0Z-9 MVMZMW"FQT1@!GCGO]>`*6-CY:<]A5]@`?F^E9R']VN?05+`9HHIMR> M4XSQ12L-&D:;FK5M`LD99QGG`J<6L/\`8J*:&(-& MHC7+'GBFA%*QB.WS&SEC@9]*M=Z?)\I4^])\OJ*8AM>>W_[SXN68/12GZ(37 MHF]:\XU!/MGQ26".:2W?*D2QXW+B//&:TI];]B)=#N]8NH;+1KRXG($:0MG/ M74TI5;F1]T2JVX1[\``]6632AI-P1 M'>6A($;'ET)R"OJ/I6YKNL1:/ILLKG,[`K!".6D<]`!U-923YRE:QQ/A*_GN MK46]RYF8K@-"\/76CZ,+BZ&+BX??(G_/,?P@^_6NUL;I; MFV5L_.!AAZ&M*UG%-'-1?+5E%]2UQ62Y$^NI$1^[A&0O;.,UJEJR+C,5['?Q M@M"W#D=NV:BENS2OLO74VTC#M\SJ@]369??9['4X9HW9GDX8*,`]JMK(CH'5 MP5/.0>*SG3[?J"2`?Z/#_'V8^U%-V>H5]4K;@LQ36;DB)FPO11D]J2R!N[^6 M\P%C(V!<\_C1;2(=8NFWKC&`<]>E,#?V?JKE^()N<]@:T?5=;&*TLWM=EZ]` M%A,`.`A`%6-+M6+*9(M`@/WCN/`ZY MR`!^9K*SY/F=%U[7Y$H"0QEC\J(,GV`J-)A,&(5E(."K#!!ZTHFCEMY&F:*2Y(S'_N MBBH91O6[X@3Z5+YE9D<^V,`]J=]J%.X6+YEYZU!/-BXA'J#BJ;77-5Y9]TT; M=AD47`U9FRJU$'`]Z:[Y1&[5%OY-426-U>;W%W!9_%AKBZF2&%/O.YP!^[KO MY098FC65XL\;TQD?3-4K;0M*MI3*ME'),QRTLW[QV/N6S51DE<35RK)XXTH$ MK:1WE\W_`$[6[,#^)Q6+JGC"WF8->^$KF15Z-?Z7XX\-PS*XT8V3CCS(HU;'Y8-=5;SZ!X@=)XQ97L\:5)! M+OM;@IGLU61XICOT`A\-WL9_OR.$'ZU&?M\Y^::*W7TC7>WYGBB+E$F<(3U8 MKP2;,WMT/+'51\H/U-,;5;8#9`KSXXQ$F1^?2I$L+;<'E#3O_>F;=^G2K0(` M`4`#T%#D@4&MO\S(9YV8F/20H/\`>_PI6OKU%Q)9+L]-IQ6OFC-/VBZHETGT MD8\>I6_22T5?=0#5^.YM;D;0ZM_LM_@:=-:P3?ZR,$^HX-49-(4G,4I'LPJK MPEY$6K0[-&B8XR1E%..!E:M-#$UC%&8UVONW#'7FL%;/4(N(YQC_`'O\:T_* MU!]-C/VA5=2ZY`[]1_.DXV^T:*;>\3`N++3+6%]MZWVA.(U3'+=L@]3GJ2:; M%NMI;2\E2=K)"%0RMEHFP0V5_P![^7TK5L-)@A\QY(68L<*L["0J,JR$JQ]^#48D(R# M51$R\)/>J4^H7$$9*Q!G\[:``3E/7ZT"0U6;^T,MY=U&`22NZ+.!Z=:8BS;: MGO MYT\KJ"X,=[&S``9DB_,\?A3NA:EI-:DVIYEFZE@#G/`]SQP/_K4'6I6P4LGV MYPQ)^O`X]N?2H%;5#&=UU;A\<%8S@'(]?;/YT%]7(&)K3(QD%6YHNNPK,L)K MCNH9;*4\9(SR!^7Y>M.;7&6W@E^RRDR[OES]W':S"2'9OX4]2N1W]<9_.BZ[#U'-K[J6/V.0JI(SD_,>.G'^>*M6.JO M<^:'M9%,8'W>=V?0&J\$NH;PT[Q%<\HGISW_`"_(U&TVLF!2A@\T`[@?NGGM MZ<8I-KL+4U9+F97E"JN!#OCW`Y+<\'\A5,ZG>*[,8E,:N`VU23C';WZ_I5=Y M];R#&D&W`R"1R>,]_K4UQ<:O^]^S1Q?>'E[B/NX[\]*KF;6\1^7%`.]&:5UV'8BLYGEB;S0P=6(.Y-O';]*TK4"1)(]V"!N4>N.OZ?RJGNJ M2&5HI5D7JIR*0$I&*KQVR0LQ0MSQ@G.!Z#T%7Y%42?+]QQE?H:KDE0/;Y8G?(">>'(Q6AMYJ-D M&:5V!0$#!0!/-PVC1K M3U:Y$9!E5GXPQ3'U[U:\ND\L&CF8K%6-KT2*7EA,>><(07WQ1S"L2B?WJ1;CWJ MKY611Y1^E',%BZ+BGK<"L[RV]31AP?O&GS(=C1DOHK>!YI7"QHI9F/8"HX]; MT^1=R7D+#!;ALG`Y)Q5`[V!5L%?1AG-0BU@CW;;2`;U*MA`,@C!'Y4P=-ZW<17._>H MWU*T$SHTP#("7)!P,`$Y/3H17)06]E&FPR3$&1I&(;:26QW';@5T*/IMX[22 M)O>12KMYAYSC/'X"@-226\M[F-A#('^0D$=",X/Y$5&?O&GR6-M:0,]O$$4K MM^4G!&I*#2XYHHIC#'>FGK113!#2<& MCK110`G?%-*]Z**EB&[105&:**3`-HI-H_*BBA`&T9I2HHHH0A-HP:<$&*** M0PV@4A`R:**`$VCI2[!FBBD@8>6N:0H,9HHI@,:)::85(S110(8UNA%1&U3M EQ110BB2-Y478LS[#_">15I9G(YVD_2BBG<`+ECD_I1113$?_V3\_ ` end GRAPHIC 10 image_005.jpg GRAPHIC begin 644 image_005.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX. M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_ MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!;`/,#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBJ5[K%AIW%U3L)M+G6TS0SWD*2)PRLW(J/_A(M)_Y_P"#_OJJY)=A71I4 M5F_\)%I/_/\`P?\`?5'_``D6D_\`/_!_WU1R2[!=&E16;_PD6D_\_P#!_P!] M4?\`"1:3_P`_\'_?5')+L%T:5%9O_"1:3_S_`,'_`'U1_P`)%I/_`#_P?]]4 MLT5D6M[?IN'WV_'M^%]'0X[BBO!J59U'>3.*4G)W844F1G&1FEK,044F0.XHW#U%`"XS5B MWO[NT_X]KJ:(>BNCN2/RJ"BK=2!K+S=1F MNV'RPIM4_P"TW_UOYUW5>OEU/EIN7@;A116?KUZ-.T"_NR<> M5`[#ZXX_6FE=V$W97/)M3U3[9J]W,ISYDS;?IG`JW_8FN?\`0+NO^^*P?"R' M4O$VFVI^8-,I;Z+\Q_E7I_CWQ9<>&+:S^QB)IKAVR)`2`H'/<=R*]6HW"<:< M%JSC@U*+G)G$7&G:K:1E[C3KI$'5C&2!^54/MOO75>'_`(K-FX'M[U-\2O#L$-@=:LXQ')&P%PJC`<$XW8]0H]`\/ZKXD9O[/A'DJ<--(=J`^F>Y]A72O\+-6$>5U"S9_[ MI5@/S_\`K5I*=.#M)DQ4Y*Z1SWVWWH^V^]4=8T^_T&\^S:E`T4A&5. M]:NE>#]5U?0_[5MGA\G#%48MO;;QP`.Y'%6^1+F;T)3DW9(@^V^]'VWWJ[?^ M"=3TGP_-JNHSP0+$H8P`EGY(`&>F>?>I%^'VNR6-OMU_A?K2P[EN[)Y,?#M>U&^FM5M# M`8&VR23':@/L?XOPH4Z35U)`U-="+[;[T?;?>MB]^&FN6MNTL,MK=,HR8T8J MQ^F1@UQ;7+(S*X*LI(*D8(/I50Y*GPNY,G*/Q'363-IZUZ5JVGQ>)]&BDMI`'_`-9$QZ9[ M@U\M.NZ]:K4AJUI'T-J5VFUN4_$UI::IH']J6X&]%$BN!@LO<'_/:N)AA>YG MCAB&9)&"J/-$&TPEOEQ]/2MCP3IWVC47O''R6XPO^\?\` M`?SKSY_[3622L^OZDO\`>31U?]DV\6D&S2)#B$QAMHR3CK7EXR!@]1UKT;2= M7_M#7-2A5LQ0[1'^&0Q_.N!U.'[-J=W"/X)6`_/BM<=RRC&4-M456LTFCN=# M6TL/"L%S=H@0*7=F3)Y/'\Q4-[XBT0V-P(&C,IC8(/)(YQQVJSJ>FW-QX6AL M;-5,FV-2&;`P,9_E7'7_`(]\1:(UC.L#QF4QL$`A(YQQVJSX M@TNYO=#AL[)59E9,[FP,`?\`ZJXV_P##U_IEL;BZ2-8P0N0^3DT5ZE6DN6$= M$M[!.4HZ):&6.`*6BM?PSI?]J:N@=2?4]OP&*UJ**^FA!0BHKH>@E96"BBBJ&%F^9A^2C^M=&%CS5HHRKNU-F7\)[+[1XI MEN2.+6W)!_VF.!^F:/BQ??:/%,5L#\MK;@$?[3')_3%=%\(+'R]&OKTCF><( MI]E'^+&H-=^&6HZWK]WJ#:E;(D\FX*8V)5>@'Y"NQU8+$N4WLCFY).BE%;GF M-M;RW=U#;P*6EF<(BCJ23@5[IXUC\SPC)8EQYEV\-JA/=F=1G^9_"L[1O">A M>!D.H:A>(]PH.)YR%"^NQ?7\S7$^+_'H7FDW=IX=33?#DD%FZ*$6212=B]R`.K'U/K7*VW M@OQC:78N8_$RM(#DB1I'5O8@\8K8OX;;X@^&XI=*U&2VF4[U9'(,;8Y1P"/\ M\BL'3/AIJXO%;5==E^S*:3<_MD]/UKGIOEB^:23ZW5V;35VK*Z]39^)- MBMUX'FGN53[1:;)59>@;(#`=\')_2IUNAX.^'$$VP-);6J[4/>1L7,DMPBW+27321J,_=P3@GN?3%;WQ=O?)T*RLEX\^?<1_ MLH/\2*I4[\E/HW?Y?UVTY_)N+IBH=>L:*.<>_(%<'\-+#[;XTMW*Y2VC>8^QQM'ZM M5OXK7WVGQ6EL#\MK`JX_VF^8_IBNF<(RKQA;1*YC&3C2>AR:O_$_Q7>V=_%I.G7#VX$8DG>,X8D]%SU`P,_C3 M?@]8_-J=^P_N0*?_`!X_^RUQOC&^_M'Q?JW2N%\1K'=>/;](@-C7A!Q[?> M_4&O1?AO"NE>!'OI1@2M)<,?]E>!^BUY;I#M=ZX)Y.6=GE;ZG)_K6,Y\GMZL M>B?Y?\`53^'"+.OM+*XOYC':1-*X&XJOI6CIFK7OAR^:&13Y88>;`QZ>X]#2 M>%KY+#7(FE8+'(#&S'H,]/U%==J'A6SU'5!>R/(I."\:XP^*^1P]"4H<])^\ MF:0@VN:.YG^.K:-["VO%'[Q7V9'4J03C\Q6MHNEO8:`ELK>7.Z%F?&=KG_#^ ME0ZCY>J:S::<79E#IL*E,=\YZUSGB&SSXP,0'$[QG M\\`_RJ32?$^I3:O:Q7%SOBDD"L-BC.>/2MK5[,R^,=)E`X*L3_P'G^M8OV=: MBE35DFOQ)?+*%H]R;Q-KTVBBV%ND;M*6R'SP!CT^M<]_;]WX@O;&SN(X4C-R MCG8#DX^II_CJ;?JT$7_/.'/YD_X53\)0^=XCM\CB,,_Z8_K45JTYXCV:>ETA M3DW/EZ'3^)O$,^C36\=O'$YD4LV_/'IT_&N6U;Q+=ZQ:K;SQPH@:>5"J;`J8QUS_6N/\1Z1!HMW%##+))O3>Q?''.!T^AJL8JZ MYG?W0J\^KZ&2B-(ZHBEF8X51U)KTSP_I`T?35B;!F?YI6'KZ?A6-X1\/&';J M-XF)"/W*,/NC^\?>NMK7`8;D7M);O8NC3M[S"BBBO1-PHHHH`*\0^)M[]K\: M7"`Y6VC2(?7&X_JU>WUD7/A70[NYDN+C2[66:1MSNT8)8^IKHPU:-*?-)&5: MFZD;(\%@U.^M8A%;WMS#&#D)'*RC\@:?_;>J'_F)WO\`X$/_`(U[G_PAGA[_ M`*`]G_WZ%'_"&>'O^@/9_P#?H5V_7J7\IS?59]SP&662=]\TCR/_`'G8L?S- M-KZ`_P"$,\/?]`>S_P"_0H_X0SP]_P!`>S_[]"G_`&A#LQ?5)=SP6UO;FPF\ MVSN)K>3^]$Y4_I5RY\1ZS>Q&*YU6\EC/56F.#7MW_"&>'O\`H#V?_?H4?\(9 MX>_Z`]G_`-^A2>.I-W<1_5IK2YX%#+);R+)!(T4B\JZ-M(^A%/N;VYO"INKF M:]?\(9X>_P"@/9_]^A1_PAGA[_H#V?\`WZ%/Z_3WY1?59]SP M6WN[BSS M_P"_0H_X0SP]_P!`>S_[]"CZ_3WY0^JS[GA%OJ-[9H4M;RX@0G)6*5E!/K@& MJY)8DL223DD]Z]__`.$,\/?]`>S_`._0H_X0SP]_T![/_OT*/K]/^4/JL^YX M0NI7RVWV=;VY$&W;Y0E;;CTQG&*M>'_^0G_VS:O;?^$,\/?]`>S_`._0I5\' MZ"F3'I=M&Q&-R+M(_$5SXK%1K4)TXJS:']5EW/.*N1ZOJ$,(BCO;A8P,!0YX MKI;[P(.6T^YQ_L3#/ZC_``KG[OP_J=EGSK20J/XH_G'Z5\?.A6I='\A.$XE. M.YGA9FBGE1F^\5<@GZU&[M(Y>1F9FY+,Q`H)5@RD@@Y!' M:IC?73.KFZG++G:QD.1GKBH**:;6P7'2RR3/OED>1^FYV)-+%-)`VZ&1XVQC M*,0:8H+,%4%F/0`9-;.G^%=2OR"T7V>(_P`7%(VXCT+9_E6KI'ANRTC#JIEN.\K MCD?0=JUZ];#X)Q]ZJ[^1U4Z5M9!1117HFX4444`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`$$]E;70Q<6\4O^^@-9\GA;2)>MDB MG_88K_(UKT5$J<)?$DQ.*>Z,+_A#M(S_`*F3_OZW^-2Q^%-'CY^QAC_MLQ_K M6Q14+#TE]E?<+DCV(+>QMK08M[>*+_<0"IZ**U22T104444P"BBB@`HHHH`* &***`/__9 ` end GRAPHIC 11 image_006.jpg GRAPHIC begin 644 image_006.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH MI&8*,D@`=S0`M%95WXBTJS)$EVA8?PI\Q_2LJ;Q[II_P"/.Y_-?\:5/B5I1^_;W2_@#_6M/JM;^4Q_M'"_ MSH[2BN4B^(>@2<-+/'_O1'^E7X?&'A^<@)JD`/HY*_SJ'1J1WBS6.+H2VFOO M-RBJT&HV5R/W%W!)_N2`U8!!Z5FTUN;J2>S%HHHI#"BBB@`HHII=`<%@#]:` M'45%+<10Q-*[@(@RQZX%8_B'Q-9Z'I7VHR*\LB_N(\\N>WX548N;M$BI4C3B MY2=DC9AF2=&9#D!V0_4'!_45)6#X,FDN/"MG/*VZ23>['U)P4 MI\\%/N%%%%26%%%%`%2_OX["#>_S,?NJ.IKB=4U&[OF/FR$1]HU.%%=9JFEM M=$RQN2X'W3T_"N5N;8J2"I!'4&NW#*&_4\S&NH].AS\ZXS5.&UEOKV*U@&99 M6"K_`(UHWB;ES.,')'A."E5C"6S9R_B+ MQEIWAV]DTW1;"WO[J`E)KZ[&]-XZA$Z8'J:P;CQ]XDA91>V=B$<;ECFT]4#+ MZC@''OFN=U?2]1T34Y;;4K>6"X1SRZG#'/4'H1760_$V>]:$>)=%T[65B78D MLD065!['H?RH]G:*E%,(+W;6^1>TVX7Q!%;365OY,L\AA:!6)"R>G-2^+O%5MX>5Q@_0UP7P_T*3Q/XN,MR#+#;(]W."V6=F9`QY/&?2O)-+E\G7+.7^[<(?\`QX5Z M#\0'_L_P'H6F@X>YN9;IQ[#Y1_.JJTXW4$M[%1A:JIKHF0GXX>*Q_P`L].'_ M`&Q;_P"*K=\'?%CQ%KOB*.TO%L1:)#+/.8XB&"(A;@Y]A7E_A[73X>U(WJV% MG>L8R@CNTWH,XYQZUZ1:>+FU7X=^)]2DTC2[!HT2TADLX-C,9.&!/TQ6>(H0 MBK1AOU.RG4D]7(RC\^2*JM1ITU=031,*DY?:U/6;3Q';W.AOJ15XXTRNZ1<;B.I'MG- M>6W^HR:A?SW7*AW_`,_C70>*;_SYK;0-+7]VFV-47N>P_J:J>)K2'2XK'38. M5BCRQ(Y9B,DGZDFOB\?4]IS.&D8_F?:Y/15!P557G/\`!=_F4[+6;O1=$OKR MV9?.FG2W4N-P`"EFP/7D5R]W>W-]<-/=3/-*W5G.?P]JVM3MYQX7T]TAD:)I MIII)`IVCD(,G_@-<]7UV248PPD7U/SSBC$2J9C4C]E,]R\"_\B;I_P#N-_Z$ M:Z*N=\"_\B;I_P#NM_Z$:Z*O-K?Q)>K/9PO\"'H@HHHK,Z`HHHH`*RM5T\38 ME0?,>&K5JK>7:VXQP6/-7!M2T,ZJBX^\<)K.G210/)L.T#).*YEKU[3P1K.I M6%M;7%]:S1G]]")-D9ZG!_&N[U;4I;F,VJ-@2G80/?BO/]0\9>'?!?BB\L;7 M1[Z:2W/E2,MT-DO`R"I'(YQ7I1E*4.6VNYXWL%[=3CLM[^9@6'Q9U&YNH8/$ M5M:7ND@%9($M$)QCC&>*X[5'M]9\1S'1--:WAN)<6]G'\Q';`^O6O4O''_"! M^'[RQ^U^$#+<7MN+EEM[@Q"//8@''K^5:GA6?3(K:'7](TBUT32TA9KB25?- MD8[BH"MU)..GO6D:T8+VD(6O]QU33^&3N>9>,;R2RL],\*+("FDQDW&TY!N' MY?Z[<[?SINE^!?$]]:1W&GQQJL\?F*@O$1V7&%3YW>X+&1B3WP>#^==)X?M(#XEM]9LLBV*RBXB?DP80G`/]TCI],5E]>C" M3P^TTKZ]>IM/!UO91Q,8W@W:_;H>"J3%*#T9&S^(-=W\6=1CN_$=A;PX$5MI M\0`'8N-Y_0BMW1O$7@77O$%II<7@.)9+N81B0R`@9_B(_6IO$OBSP19>);VQ MN/!:7L]O((#/Y@&_:`H_+&/PK>5:3JQ?([I>1DJ:47[VYROA5H[#1//:PL;F M2YF;!NK=9=JJ`!C/3DG\JWO'%Z(?AEI<"VUK:MJ%ZTS);0B)2J#`)`^HJQXI MU_PCH.M-I7_"-7'^CQI\MO=>6BEAN(QCKEN:@F^)7A"_MK.TU#P?)/!:*4B, MDP]SGA3G&K+FGIT.`\.ZS;Z%J1N[C2K74U,900W(R@)Q\ MW3KQ^M>J>!_&-OJ]UJ7V7PSI>EB&T+/<6JX;E@`O0<'K^%.E@\'Z3HXUW5=& MTI],N`/L$<%N1-A;Y<=#]*YRV^)?AZQ-S!9>";:"UN,+*$N,.P!R,\8X MK/$7Q,)>S@[][Z'7AY*G).;TOMU->WOYK6_^VPRE)QNP^02,]>M/O]0N-2G$ M]R^^0+MW>OO4VBS:9J6J65PB6K:3^13)M/N)[I@D M,,,+O@?Z3'A5_P"^O2OC\3EN)HVA?F3[7/M\#G>!Q,I3:Y''2[:_`GFU&X/@ M6[MFE)@6XBAB7C`ZLW]*Y'%;7B"^5KVYT^S\I-.BN"T21*`"<8W9[]*QJ^XR MO#2P^&C"3NS\KSW&PQF-G5IJR/3CK75AH7;9PXRI9*(^P'VC6K53]T/N/T'/\`2OGW6K_[;XHO[]AO M$EX\N"?O#=G'Y5[XAET_3=4U62-TCM[*5U,5XM\/="M_$?C2RT^]C, MEJP=YE!(R`I/4>^*]&C*,7.;V2.2G%N*75LK^,?%4WB_6AJ4ULEMLA6%8D8L M`!GN?K7=>)]2ET/PGX:T2'Y#'8+H:9?JA^RM;BVW=E9>@/U!_2M5[/VM.%M-2IJ3 MISD<3X7YO+UF/S%5QD\GKFN]TR_?3O#_`(EN`<*NG-_WT3M'\Z\I^TBV83+) ML9>01UKTS4['4+7X-7]W=VDD%W=M`TJE<;8M_'T/0D=LBO*S'+9+,(8A/1M: M'N8+-8/*Y85QU6WGU.9^$-H)_B!;3N/DM()9V/IA<#_T*L73D/B#X@6X;G[; MJ09OH9,G]*G\'^*8O"XU>0VSS3W=DUM"RD`1L>Y]O\*O?#&PD?Q+)JQ0_9M) MMI;J1ST!"':/KGG\*]6HG&4YOM9'BQLU&*,CQ5>QZCXYU2ZD)\E[ULD<_(&Q MQ^`JWKJV'BGQ>(/">FBVMY%6.*(XCW$#EB,\?_6J+P3H\7B?QK8V%XK/!.[/ M,`<$J`6/-5DM([?QREG:%ECBU(11$GD`28'/K5:1?*MXKY"U:OW9T'Q'MFL[ M/PS;0R-+I\.G".*7&%:3<=_T.<(O#%SI5CI/B+0"(K4G%[8OLD;/4 MN/XOSKI_$OQ!&CZYJGA]_#&ES6,5RRLDP8[A_>QG`)![5PWBU_#MQK:GPM!/ M':.B[D<'_6'J%!YQT%8T4YP49IKJF5*Z=[ZG77UO9V:0V>GQJ+%098760N)5 M?!W9//3'';%4]H]!4IB:UM+.SVMTB?V;DD?@21^%,KMHJT$?*XJ5ZTG?J M-Q13JT=$T6ZUW4DM+93@G,DF.(U[DUP>"8VC\'Z<& M&"8RP^A)(K?J&TMDL[."UB&(X8UC7Z`8%35\K.7-)R[GW]&')3C#L@HHHJ30 M****`*&LJ[Z:Z1@EF*J`._-0:=HD%JHDG42S]M%6IM1Y49NE%S MYF87BJYTB/19;36@[6ET/+:-,Y8=<<=.E%M0^T3RK+ M#DZ>+2+D\'`!)XZ=:R'\!:F0@\V`@%%.&(P@!SV]343K8N][MEPI8!JST^\I M>']+^'UE?Q7MOHTJSF;9$UR3($;KD`D@8]>U=H?$GAW5K>[M9KB*2W"$3+,A MV,AX/7J.:Y!O!FM"-@88QLB=EVR`[G)Z#\*+K3-4N-,M+0Z(MJ:'BL2]:FK^93P>#>E.6GJM/\R1/A9\/[XO=V[/Y(/S+'=G8OMZC\Z[ M"S\*:!:Z))I5G8Q16,T;1NL9(+JW7+=3GUS7F?E&!8?MT$J13B25D"E1(XR% M&.W-,:>[A$5LT\L;6Z",*LI4HS'/0=<9Z4WF=1KW[_>+^QX7]R7X'H6D?#WP MSH.H+?:;8&"Y48#B5CQW')JC/\+O#QU'^T+:T2.Z\WS@SEV^?.<_>'>L5/$V MH6\%UMU!VDED$,!D(PBH/F?![GC\ZW-#\1ZGJ%]I5F7CXK' MC^%MYILGF:98V$]9OAKQ)/KM].CI&D:0HX51R&/WAGZUT]0\7/$ M+F;NC6.74\'+EC&S"BBBH-@HHHH`****`"BBB@`HHHH`****`"BBB@!K1HY& MY%;'(R,XJK)I.GRS^<]E`TO7>8QG/UJY12:3W&I-;,PCX.T,K(!9*N]"G#'Y M0>XST/O56T\%6MAJ,-Y:WMVACP"FX891V/'2NGHK/V%.][&RQ-9)KF=F> M&+R?Q!+J<6I>4LJ^6Z>7D[,8(!K.T[P7?6C;Y[N&0V\7<` M>.(0V^Q20!NR2??K7?T5/U2EV+^OU[6N8.A>&(M$OKJZCN&?[0,;-N`O.:WJ M**WA",%:)S5*DJDN:;NPHHHJB`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHS0`44FX#J1^=-,L8ZNOYT`/HJ(W,0_C'X4PWD?8,?PH`L455-X.R'\Z;]K? ML@H`N452,\QZ$#Z"HI))V_Y:,/I0!I5']HAW;?.CSZ;A7/W+2#[TCG_@55PF M9D_WA0!UE%1;SZ"B@"6F-(B'#.!2NVQ"WH*S?O$D\DT`7_M$7_/04?:8O[XJ MABE"C(H`MF[C!X#'\*:;P=D/YU754_QD4PW#9^:8#_`($!5"Y8G.237F7BGQ=>P^)SHEA<6MBL>!+=7*Y`8C.. M^!T'2NFEAG/J<]2NH'K@F#=)@?\`@=.VLWERT<=M>/\H1<';N*]<^HK;ZBWM(R>,MN MCWGRSW%+Y=>*ZMXU\0V&O)ING7ZH-J`F<@C<>>2W`&,5-?\`C[Q=I6BI-<7] ME)<37&V)HHTD78J_-R.,Y(_*I>!J=&BEC8-7:9[+Y=(P2-=TCJ@]6.!7E>A^ M+O&-S>0RWE[ITMILWM'$(V1R16]JU]=ZJCP2LHCLX_,N#&,#>>`O] M/SKBQB>%AS.S?0[L$EBJG*M%U?\`7<[&6Y@CA>5764)C<$<<#U/-.LIEN[5+ MA1\CDE,_W8PY6V;DX9N1G@X'_P!>O3=-C\G2[2/^[$O\J=+WL/&J]Y$U MDJ>*G13NHEH`4UQ@4\5',?E-(#'O&R_XTQ.9X_\`>%%R?G_&EBYN(_\`>%`F M=#BBEHH`9>OL@/N<5GB85/K3%+9".F\9K'6:@#3$@)IX8;OPK+%Q@]:DCN?G MQGM0!JH13]U45FR.M/$WO0!;W4A((P:K^;[TOF\=:`*%ZT<+'S)%1,XW,P`_ M6O(?$S7U[JMW!JGA99Y&1EL[JSW*[#/R,6!(=<=L5M?&*Z)TW3;$@T.VT-+*);^6L]7])U-[WQ!=W(Y&U/QYHUKDC"1/(%..3\S'\A1 M#%2>*GAY1M97OWO_`%8J>%C]4AB8RNF[6[6_JY271)=6\97\M_8W`L]TC`LI M0-CA<']:A\4:7+%)86.GZ=-`IGW$&ERV/D[(YG#R2,I#,>W)K MA?$-RY\33KK'V];#E;;R3MP,<,,\-ZD5U>@/;CP]%`+NXU"V:0R1R2,8V7C& MW'/3G\Z\3,\NJXE^TA+6UK=//4]S*\SHX5>SJ1TO=OKY:%V!3)!&NPC,FU3_ M`'L]?YBO4E7:BK_=`%>=Z;&U[J]K$BG8K*0NQU>&62PG\Y(VVLVTC!ZXYK$U*D_WZ6'_CYC_P!X4LRDO^-1PDB[ MC'^V*"3I:*6B@94UF,R:=+M^\HW#\*Y!+L'O7>2*'0@]Q7#WOANX2[9K:8", MG(5NU)C0GVD4@NPDRY/4$4P:!?\`_/:/]:BF\/ZBR@K)'N'3DT78]#8CN/E' M.14HN17.QIKMLNU[#S`.Z,#FE;4+V/\`UNG7"_1E-T[P?96FO:MJLUY)=/J221RQNH`4.,N_`+#`.`2P'3ID_I3UL;5[8PIJ,@!D\PLN`2<8Y_,UNJSM;F M,725[\IF6OPM6/4P\VK;K%&W!$C*RL/0GH/J*O\`B;X?2:QKPU?2]46PF**C M(R$@87;E2.1QQBICI"&)%BOR&``+D9)P`,GG_.:E&DGR_DOI%EQ@-N.%X`&! MGZG\:T>)FY<37$\L1P^%(55`/` M&2>:LR?#=V\0Z3?17\"VME%#&\;(=S%.I';D],UL"WN1!$B77EE%()!8Y).< MC)J95NP9#]K.&7"C)^4YZ_E6+QM=2:6OW'0L%1<4V[?>6$.N6L M^FW3#)N2Q95!R,`@[3]#S73Z3X$M]-T^"S%\[K$.2L8!9CR3S[U8`OPY"WC% M,\9/.,4])-1!P;@L.<'>/3CMZYJ7CZVUK?)#^H4?YE^)M6&G6FG(1;H=S?>= MCEC3-5TN'6+>.*:62/RWWHT9&0<8[UEI<:J'4>8I3<,G()VX_GGFM.WN'%O& M)GW2[1O/O6<:TIRNT[^9M%`$E-9%;J`:=10`SRD_NBD,,9_A%244`0&TB/\-,-E&>E6 MJ*`*3:>C5!)H\#CYHHV^J`UJ44`84GARRD&&M(#_`,`%5F\):Q-_O1$?R--.GZNG\5L__?0K MM]B^@IIC0_PBE8+G%>3JJ=;:-O\`=D_QI/,OT^]8R_\``2#_`%KM3!&?X13# M:Q'^&F!QAOY(_P#66UPO_;,FD&MP#AG9/]Y2*[(V49J-M/C;K0!S"7L,_*RH JWXU9!Q,A_P!H5K/HT#?\LHS_`,!%0II&)!G<1GIGI0!J9HI?+-%`'__9 ` end GRAPHIC 12 image_007.jpg GRAPHIC begin 644 image_007.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX. M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_ MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!#`(T#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BDS1F@! M:*B,\:G!D0'W84?:8?\`GK'_`-]"G9BNB6BHOM$7_/6/_OH4J2I(<(ZL?8YI M6871)1110,****`"BFLP498@`=2::LR/G8ZMCT.:!7)**04&@8M%1O*D?WG5 M?]XXI//C`W&1`IZ'<,4"NB6BHUE5\[&5L>AS3Z!C7<(I9B`HY)/:O/O$7C2> MXE>WTUO+A!P9!]YOI70^.+R2UT!EB.TS.$)]J\UA4/*`S``]S7HX.C'D=::O M8\?,,1-U%AX.U]V."S7#EBSLQZDDDFK`TJZ;&%?]:Z[0X-&M85>XNX"_H6K= M&IZ(HP+JV_.B6+KMZ*WR'#`85+WI7?J>;?V1=?W9/R-;OA6*[TZ^;Y&VR#!R M*ZS^UM%_Y^K;\ZCN]2LVTN[FTV:)Y8HRV4YVUG.O7J+DEL_(VIX?"TGSPW7F M;2D[1FES7E*^+=:(XNR?^`BE/BS6^]T1_P`!I_V?4O:Z(6:TVK\K/5:,UY3_ M`,);K1_Y>S^52P>,M8MY0SS"1?[KKUH>7U%U0+-:3UL['>^)/^1>O?\`KF:X M+PA?O::DRKD^8`IYKJ;C6X=:$WU:X>E)T) MP>CN8XJO&.)IU%JK=#VA&W(#ZTXUYBOC+6DQF1"!V,=;6C^/1/,L.I1+'G@2 MKT_$5SRP55*ZU]#KAF-&4E%W7JB;QSI=U?I;RVZY6+.[G%33#P_;VTBD" M*0D?C72^.M2N+9;/[+.R))DG;T-+W)AHUTV"(SCZ4O]B76?]4?RKL-( M\8:9+"L=]&()0.3C*FM?^WM#/2[@K.5?%Q=FOP-H8;`35XO\3S@:'=?\\S^5 M7;*TN["VO,H0DD>&KN_[>T3_`)^X/SJOJ5_87VB7PLI8Y&2,[MO:H]O7E93V M]#3ZMA8)RI[V?7R.`T2W6YOTC?[IKK-?\/6MGH$L\8^=0*Y?PW_R%(_K7?\` MBO\`Y%:X_P!T56(_WI?(G"?[@_1G`>'[-+V^$'[;3]%\^(?.&`K& M$?\A-?K77>.?^1:;_?6BH_]L^:%17_"?\F<7I4K+IM\@/RLG-0:)`ES?K&X MX-/TS_CQO/\`PX`YYK@_%>OIK5VB6X(MXOND]6/K7+@ MH5%5O:RZG;F56DZ+C>[Z%&^O7N]+LTE8DQ;E!/I4#?\`(+7_`*Z4EQ&4LX3?\(]>?\\S^5:.D:/>Q>?#AE2=-K'%>D>4G]P?E0(T'10/PI2Q=62LV M5#`8>#YHQ_,\]TWP_<6&K)U90>N,5V>KZ?\`VEI$EKO*;P.0*T-BYSM&?I2X MK*56IO"A"%/V<5HN,5U7B#2_[6TEK;S"AX;(&>E:8 M10<[1FG8]J'5FY\[>H*A!4_9)>Z>=Z;X-ORJ_8>%;F9U#( M5'9I\/DR%6A!RH&=U8 MUOX:N+BR:)\H5;<..M>ED`CD9IHC4#A14QQ%2*23V*EA*4I.36KW.!\-:/HEI%.T'KBN_Z`4!%'10*6LYS GRAPHIC 13 image_008.jpg GRAPHIC begin 644 image_008.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX. M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_ MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!*`*P#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P"?;1MJ3;1M MKT+GG6(]M&VJM]H\%X&89CF/\:D]?<5R$Z2VT[PR,=Z'!PU;4Z:GLS.<=JZZ&WCMTV0H$7K@45( MN_C998UD0Y5P&!]J\]GA>WG>& M08=&*D5UGA6\^T636SG+PGC_`'375B8MQ4HG/0:3Y67M1N196$T_=5^7ZGI7 M'WUDUM9VDLF?,G#.V?KQ70:WF_U6TTQ/NY\R7'I_^K^=1>,(@L%H5&`"5'Y" MIHMQLGU*JJ]WV,GP\VW6H?\`:R/TKM=M<+HK;-9M3_TT`KO]M+$_$@H?"1;: M-M2[?:C;7/AI@BD0Y7!JWMHVUR3PM.4N=:/NCIC7G&/+NO,HW)8 MVLPV[24(!)X''>J>@VYL=*2&5EW[F)*G(Z^M6/$3B'0;LYQN7:/Q-'AV,#0+ M3W3/ZFMU"K&GI/KU7^5C)RIN?P_C_P`.<]XGTN22]6YM8VD$BX<(,X([_E6? MI#7.EZG'-);SB/[L@\L_=-=OJEDUWITT4+%)=N493@Y'2N`BOM0:58H[F?>S M;0-YZUU495IPY=']_P#P3GJ1IQE?4Z?P]`]Q=7FI7"E7E+XB^ MFPE`6*R]N>H-;UO:"&VBCD)D=5`9VY)/)R]MHKRV[&-U=?F4X.*QC.JZ MB=E][_R-90IJ#5W_`%\SC+"*:/4+=_*DPLBD_*?6O1CMR?F'YUYRNJWN]2UW M,0".-YKTI44J&"CD9Z5IB?:W5[?B10]G9VN197^\*4#-57U-X?$D-@\2BRE4 MQ)(5Y:8=>?J=M)J.HW.E:K;37!1M)F;8_P"Z&Z)O0GT[_G62A/J:.4>ASUY/3VJO9RWM_I:7B210RRHTD5OY(9,#.`S M'YB3CJ*=F*Z)]M&VLJ;7I+FSTBXL=D'VN?R)XV0/M;(R03]:O>(+V>RGT];, MI$MQ<>0X,8;N/F&>_-/DE=(7,K7)]M&VJYN+A_%EQI@N5BMT@$JGRDW9XXR? MK27&HK;:C:6-Q=Q0>=#YGVL1`K*W>I]!35M-M%M;S3)FC4_+(K+\H/8C-5=*FO[K1;22PEOI-4^UD,Y9 MS'Y8_O$_+C]:U]%O7AU_6XW^US+'BUO/$0GN+U6@<"U,!9,3[,O^-=G MH\NIQVZPWFF2^?#'\I5E/F$#@8SQFL[4M=GU#PBL]E*T=RJ!KMD."NU@N/;< M3G\*U=TCE;4XG27F0_?)R_!.!SZ>E7]=L;W4?#$R1V<@NKG9F$XRK`Y/.<8ZXK M.N/$,I\(VE[;MMN[AUMFDQGRV'WF^I&/SK:?1X\K%%/<1R1L,R&9R9`#\P;G MO^E9MRC;FZ,M)._+V&MI[W.CK:7"21>=:B%P1DH<`?S%9+:D_AK1X;;4+>87 M,49BBD5*3PI)%>VL0NY;][EKPHCJ\A4`<@$YVXZC\:L^%&: M[T^_2Y9IU:[>+$K%_E`X`S]:;7+=2V0)\UK%(>'I?^$;TTZ7)'=7%M.;@D'" MRGC(4GTP/KS4^K6>K:G+ITZZ7)#%!#2V49E\$&_:>Z^UBWD?S//;D@D#(S5-M/Y_F2DFOE^1:N M--G;QA/>SZ7)<6CP")X:Y$TB0B)A)"TC,O M8[AG..`:B3<;)EQ2>QEC2KV'P9)8R`SW9A,:J&!QEL@9/&`.]6]-M)[;1;*. MXA:.2.((ZMV(^G:LS0=6EFUZ[M[BX67[2@NH`&R(SU*#Z#M[5:TR20^)]>B, MLC1Q;`B,Y(7=UP*)*6J?J*+6C7H:0B9AE5)'L*3;CM61?WRVNMW%KK)N;:WF M*_8KJ)V"1C'3`XZ]^>1S5VBFY- MW\Q**5O(HZ;X:>.UO8DOU*WEP)I=T';.2OWNAZ5I:MH+:AK=AJEO="UFL\@# MRMV\$]#R..OYU8T_JU:%3*I*]RHPC:QA6_AB-+O6)+J<3Q:J,21"+;L],')Z M5#8>&[C3K>QA.I":.RD+H&@PS#!`7.[MDXKHS3&Z4O:2[C]G$Y*;P]:_V=J5 ME`S0?;YO,=RF[8,YV@9'O^=6=/LWLI87DN1.(;=;=`(MN`#DG.3R<#\JT;G_ M`%QJ&KYY-69'*DS$3PQ;^1?VTUPSVMW+YRQI'M,+]BIR?7%7[>UO(D1)]4:9 M4'5;<([8Z;FSR/7&,UVN7,CP>4K%2>NUCT_*M6BCVD@Y$9NEZ,FEZ+/IRW!D\T MOMD,>-FX8/&>:+?1TM_#3:/]H+91HQ/Y?123#E1CGP]&+73Q% M=R17E@NR*Z2,?,N>C*3SU]:M365S`&0 EX-101.INS 14 skvi-20130930.xml XBRL INSTANCE FILE 0001085277 2013-01-01 2013-09-30 0001085277 2013-09-30 0001085277 2012-12-31 0001085277 2013-07-01 2013-09-30 0001085277 2012-07-01 2012-09-30 0001085277 2012-01-01 2012-09-30 0001085277 2011-12-31 0001085277 2012-09-30 0001085277 2013-10-01 0001085277 2013-09-23 0001085277 2013-01-01 2013-03-31 0001085277 SKVI:ConvertibleNote1Member 2013-01-01 2013-09-30 0001085277 SKVI:ConvertibleNote2Member 2013-01-01 2013-09-30 0001085277 SKVI:ConvertibleNote3Member 2013-01-01 2013-09-30 0001085277 SKVI:ConvertibleNote3Member 2012-01-01 2012-12-31 0001085277 SKVI:ConvertibleNotePayableRelatedParty1Member 2010-12-31 0001085277 SKVI:ConvertibleNotePayableRelatedParty1Member 2011-07-01 0001085277 SKVI:ConvertibleNotePayableRelatedParty1Member 2011-12-31 0001085277 SKVI:ConvertibleNotePayableRelatedParty1Member 2013-06-30 0001085277 SKVI:ConvertibleNotePayableRelatedParty2Member 2012-06-30 0001085277 SKVI:ConvertibleNotePayableRelatedParty2Member 2013-06-30 0001085277 SKVI:ConvertibleNotePayableRelatedParty3Member 2012-12-31 0001085277 SKVI:ConvertibleNotePayableRelatedParty3Member 2013-06-30 0001085277 SKVI:ConvertibleNotePayableRelatedParty4Member 2013-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure SKINVISIBLE INC 0001085277 10-Q 2013-09-30 false --12-31 No No Yes Smaller Reporting Company Q3 2013 674315 450507 1218 67143 10000 27299 22437 18769 41188 1145 1015 515 748955 498235 3891 4459 1098536 754247 584536 636314 131499 25264 1000000 1991 19792 3619936 2372635 3619936 2372635 20968993 20841670 1800 -23601123 -22571365 -2521400 -1618388 1098536 754247 345690 251553 1099862 1088386 110730 109507 803905 593227 568638 169080 27236 38950 110729969 .001 .001 200000000 200000000 110729969 109507409 -322477 -318519 239208 213205 61724 102200 541965 155942 154847 67202 919956 1036956 48370 13635 22920 83548 1754 565 1944 46616 13070 22920 81604 27006 9824 8068 43982 616167 220021 316856 996189 643173 229845 324924 1040171 -596557 -216775 -302004 -958567 97 97 25000 25000 -436398 -125825 -11866 -81886 3100 2400 -36 1691 -433201 -123328 13098 -55195 -1029758 -340103 -288906 -1013762 -0.01 -0.00 -0.00 -0.01 110374484 110683012 105073960 102694597 21200 228244 432602 -3668 8998 17299 -8895 -500 -9691 105099 23174 -581572 -175771 -120575 -56023 -7527 -2681 312900 14000 7500 925955 297719 223808 65925 97194 23554 78361 326510 19385 111110 69776 97283 1000000 -5000 -40043 -12475 422 223868 78361 3100 -1691 -19792 -50000 23554 -9719 16100 -120575 -56023 Description of business Skinvisible, Inc., (referred to as the Company) is focused on the development and manufacture of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Companys non-dermatological formulations, offer solutions for a broad spectrum of markets womens health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.   History Skinvisible, Inc. (referred to as the Company) was incorporated in Nevada on March 6, 1998 under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Companys subsidiarys name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.   Skinvisible, Inc. together with its subsidiary shall herein be collectively referred to as the Company.   Going concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $23,601,123 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Companys ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Companys contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Companys ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.   Principles of consolidation The consolidated financial statements include the accounts of the Company and its subsidiary. All significant intercompany balances and transactions have been eliminated.   Use of estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.   Cash and cash equivalents For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents.   Fair Value of Financial Instruments The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items.   As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.   The three levels of the fair value hierarchy are described below: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;   Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;   Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).   Revenue recognition Product sales Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.   Royalty sales The Company also recognizes royalty revenue from licensing its patented product formulations only when earned, when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments. Distribution and license rights sales The Company also recognizes revenue from distribution and license rights only when earned (and are amortized over a five year period), when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments. Costs of Revenue Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.   Accounts Receivable Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects managements best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2013, the Company had not recorded a reserve for doubtful accounts. The Company has $1,000,000 in convertible notes payable which are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®.   Inventory Substantially all inventory consists of finished goods and are valued based upon first-in first-out ("FIFO") cost, not in excess of market. The determination of whether the carrying amount of inventory requires a write-down is based on an evaluation of inventory.   Goodwill and intangible assets The Company follows Financial Accounting Standard Boards (FASB) Codification Topic 350-10 (ASC 350-10), Intangibles Goodwill and Other. According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.   Income taxes The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, Income Taxes, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.   Stock-based compensation The Company follows the guidelines in FASB Codification Topic ASC 718-10 Compensation-Stock Compensation, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to a Employee Stock Purchase Plan based on the estimated fair values.   Stock based compensation expense recognized under ASC 718-10 for the nine months ended September 30, 2013 and 2012 totaled $21,200 and $0 respectively.   Earnings (loss) per share The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 Earnings Per Share, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect. Description of business Skinvisible, Inc., (referred to as the Company) is focused on the development and manufacture of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Companys non-dermatological formulations, offer solutions for a broad spectrum of markets womens health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada. History Skinvisible, Inc. (referred to as the Company) was incorporated in Nevada on March 6, 1998 under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Companys subsidiarys name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.   Skinvisible, Inc. together with its subsidiary shall herein be collectively referred to as the Company. Going concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $23,601,123 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Companys ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Companys contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Companys ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties. Principles of consolidation The consolidated financial statements include the accounts of the Company and its subsidiary. All significant intercompany balances and transactions have been eliminated. Use of estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Cash and cash equivalents For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents. Fair Value of Financial Instruments The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items.   As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.   The three levels of the fair value hierarchy are described below: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;   Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;   Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). Revenue recognition Product sales Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.   Royalty sales The Company also recognizes royalty revenue from licensing its patented product formulations only when earned, when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments. Distribution and license rights sales The Company also recognizes revenue from distribution and license rights only when earned (and are amortized over a five year period), when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments. Costs of Revenue Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue. Accounts Receivable Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects managements best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2013, the Company had not recorded a reserve for doubtful accounts. The Company has $1,000,000 in convertible notes payable which are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. Inventory Substantially all inventory consists of finished goods and are valued based upon first-in first-out ("FIFO") cost, not in excess of market. The determination of whether the carrying amount of inventory requires a write-down is based on an evaluation of inventory. Goodwill and intangible assets The Company follows Financial Accounting Standard Boards (FASB) Codification Topic 350-10 (ASC 350-10), Intangibles Goodwill and Other. According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows. Income taxes The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, Income Taxes, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Stock-based compensation The Company follows the guidelines in FASB Codification Topic ASC 718-10 Compensation-Stock Compensation, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to a Employee Stock Purchase Plan based on the estimated fair values.   Stock based compensation expense recognized under ASC 718-10 for the nine months ended September 30, 2013 and 2012 totaled $21,200 and $0 respectively. Earnings (loss) per share The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 Earnings Per Share, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect. 1998-03-06 1000000 Fixed assets consist of the following as of September 30, 2013 and December 31, 2012:   <table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">September 30, 2013</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid">December 31, 2012</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; width: 54%">Machinery and equipment</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 20%">48,163</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 20%">45,208</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify">Furniture and fixtures</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">113,635</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">113,635</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify">Computers, equipment and software</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">38,540</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">38,105</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify">Leasehold improvements</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,569</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,569</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt">Lab equipment</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">113,461</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">113,461</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify">Total</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">326,368</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">322,978</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt">Less: accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(322,477</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(318,519</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 2.5pt">Fixed assets, net of accumulated depreciation</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">3,891</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">4,459</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   Depreciation expense for the nine months ended September 30, 2013 and 2012 was $1,003 and $943, respectively. <table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">September 30, 2013</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid">December 31, 2012</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; width: 54%">Machinery and equipment</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 20%">48,163</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 20%">45,208</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify">Furniture and fixtures</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">113,635</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">113,635</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify">Computers, equipment and software</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">38,540</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">38,105</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify">Leasehold improvements</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,569</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,569</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt">Lab equipment</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">113,461</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">113,461</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify">Total</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">326,368</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">322,978</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt">Less: accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(322,477</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(318,519</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 2.5pt">Fixed assets, net of accumulated depreciation</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">3,891</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">4,459</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> 48163 45208 113635 113635 38540 38105 12569 12569 113461 113461 326368 322978 1003 943 Patents and trademarks are capitalized at its historical cost and are amortized over their useful lives. As of September 30, 2013, patents and trademarks total $584,898, net of $239,208 of accumulated amortization. Amortization expense for the nine months ended September 30, 2013 and 2012 was $26,003 and $43,039, respectively. The Company has secured $1,000,000 in notes payable with its US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods".   License and distributor rights (agreement) were acquired by the Company in January 1999 and provide exclusive use distribution of polymers and polymer based products. The Company has a non-expiring term on the license and distribution rights. Accordingly, the Company annually assesses this license and distribution rights for impairment and has determined that no impairment write-down is considered necessary as of September 30, 2013. 584898 239208 26003 43039 On January 16, 2013, the company terminated its licensing agreement with Panalab dated January 23, 2008. The agreement provided Panalab the right to distribute, market, sell and promote Skinvisibles proprietary formulas made with Invisicare and Adapalene through-out Panalabs assigned territory. Panalab had failed to sell or sub-license the products in the territory, thereby not fulfilling the conditions as set forth in the agreement and allowing for immediate termination of the agreement. As a result of this cancelation, unearned revenue of $19,792 has been recognized as revenue during the nine months ended September 30, 2013.   19792 The following is a summary of option activity during the nine months ended September 30, 2013.   <table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt"> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: center; padding-left: 0.75pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">Number of Shares</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.75pt; width: 54%">Balance, December 31, 2012</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 20%">9,400,000</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 20%">0.05</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.75pt">Options granted and assumed</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">300,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.03</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.75pt">Options expired</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">400,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.05</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.75pt">Options canceled</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0.75pt">Options exercised</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 0.75pt">Balance, September 30, 2013</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">9,300,000</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">0.05</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   As of September 30, 2013, 9,300,000 stock options are exercisable.   On September 23, 2013, the Company granted stock options for 300,000 shares of its common stock with a strike price of $0.03. The stock options were exercisable upon grant and have a life of 5 years. The stock options were valued at $8,400 using the Black-Scholes option pricing model based upon the following assumptions: term of 5 years, risk free interest rate of 1.33%, a dividend yield of 0% and volatility rates of 443%. The Company recorded an expense of $8,400 for the nine months ended September 30, 2013.   Stock warrants -   The following is a summary of warrants activity during the nine months ended September 30, 2013.   <table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt"> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: center; padding-left: 0.75pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">Number of Shares</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.75pt; width: 54%">Balance, December 31, 2012</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 20%">6,765,200</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 20%">0.06</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.75pt">Warrants granted and assumed</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">471,280</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.06</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.75pt">Warrants expired</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,562,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.05</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.75pt">Warrants canceled</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0.75pt">Warrants exercised</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 0.75pt">Balance, September 30, 2013</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">4,673,980</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">0.06</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   All warrants outstanding as of September 30, 2013 are exercisable.   271,280 warrants were issued during the three months ended March 31, 2013 as part of a series of convertible notes with attached warrants. The warrants issued allow the holder to purchase one share for every two shares issued upon conversion at an exercise price of $0.07 cents per share.   On May 22, 2013 200,000 warrants were issued as compensation for consulting services. The warrants issued allow the holder to purchase one share at an exercise price of $0.04 cents per share. <table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt"> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: center; padding-left: 0.75pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">Number of Shares</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.75pt; width: 54%">Balance, December 31, 2012</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 20%">9,400,000</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 20%">0.05</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.75pt">Options granted and assumed</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">300,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.03</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.75pt">Options expired</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">400,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.05</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.75pt">Options canceled</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0.75pt">Options exercised</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 0.75pt">Balance, September 30, 2013</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">9,300,000</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">0.05</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> <table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt"> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: center; padding-left: 0.75pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">Number of Shares</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.75pt; width: 54%">Balance, December 31, 2012</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 20%">6,765,200</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 20%">0.06</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.75pt">Warrants granted and assumed</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">471,280</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.06</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.75pt">Warrants expired</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,562,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.05</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.75pt">Warrants canceled</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0.75pt">Warrants exercised</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"></td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 0.75pt">Balance, September 30, 2013</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">4,673,980</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">0.06</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> 9300000 9400000 0.05 0.05 300000 .05 400000 0.05 4673980 6765200 0.06 0.06 471280 0.06 2562500 0.05 9300000 .03 8400 0.0133 0 8400 200000 271280 .04 .07 2013-05-22 P5Y On September 23, 2013, the Company granted stock options for 300,000 shares of its common stock to an employee. See Note 5 for additional information.   During the three months ended September 30, 2013 the Company advanced $40,143 to employees of the Company for business related expenses. The advance is non-interest bearing and due upon demand. 300000 <table cellspacing="0" cellpadding="0" align="center" style="width: 60%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify">Convertible Notes Payable consists of the following:</td> <td> </td> <td colspan="3" style="text-align: center">September 30,</td> <td> </td> <td colspan="3" style="text-align: center">December 31,</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2013</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2012</td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-left: 5.4pt; width: 54%">$52,476 face value,10% unsecured note payable to an investor, note interest and payment are due on demand. The note could be converted to option rights for Skinvisible, Inc. shares at ten cents per share ($0.10), these rights expired January 12, 2010. Note is currently in default, no penalties occur due to default. During the nine months ended September 30, 2013, the Company made $12,000 in cash payment to reduce the note balance.</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 20%">40,476</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 20%">52,476</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-left: 5.4pt">$27,000 face value 10% unsecured $27,000 notes payable to investors, due October, 2012. At the investors written request, until the repayment date the note may be converted at the investors option to shares of the Companys common stock at a fixed price of $0.05 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.07 per share for two years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $19,385. The aggregate beneficial conversion feature has been fully accreted and was charged to general and administrative expenses during the year ended December 31, 2012. The beneficial conversion feature is valued under the intrinsic value method. Interest due to lender can also be converted at a rate of ($0.05) per share into warrants. During the nine months ended September 30, 2013, the Company made a $2,000 cash payment to reduce the note balance and converted principal of $15,000 plus accrued interest of $1,277 to 542,560 shares of common stock and granted 271,280 warrants with the exercise price of $0.07 per shares for two years.</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">27,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">$1,000,000 face value 9% notes payable to investors, due two years from the anniversary date of execution. The notes mature at various times from September 2014 to December 2014. At the investors option until the repayment date, the note and related interest may be converted to shares of the Companys common stock a discount of 90% of the current share price after the first anniversary of the note. The Notes are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company has determined the value associated with the beneficial conversion feature in connection with the notes and interest to be $111,110. The aggregate original issue discount feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of $40,476 and $8,910 during the periods ending September 30, 2013 and December 31, 2012, respectively. The original issue discount feature is valued under the intrinsic value method.</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,000,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,000,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,050,476</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,079,476</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.5in">Original issue discount</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">111,110</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">111,110</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0.5in">Unamortized debt discount</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(61,724</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(102,200</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1,099,862</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1,088,386</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> <table cellspacing="0" cellpadding="0" align="center" style="width: 60%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify">Convertible Notes Payable consists of the following:</td> <td> </td> <td colspan="3" style="text-align: center">September 30,</td> <td> </td> <td colspan="3" style="text-align: center">December 31,</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2013</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2012</td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-left: 5.4pt; width: 54%">$52,476 face value,10% unsecured note payable to an investor, note interest and payment are due on demand. The note could be converted to option rights for Skinvisible, Inc. shares at ten cents per share ($0.10), these rights expired January 12, 2010. Note is currently in default, no penalties occur due to default. During the nine months ended September 30, 2013, the Company made $12,000 in cash payment to reduce the note balance.</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 20%">40,476</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 20%">52,476</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-left: 5.4pt">$27,000 face value 10% unsecured $27,000 notes payable to investors, due October, 2012. At the investors written request, until the repayment date the note may be converted at the investors option to shares of the Companys common stock at a fixed price of $0.05 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.07 per share for two years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $19,385. The aggregate beneficial conversion feature has been fully accreted and was charged to general and administrative expenses during the year ended December 31, 2012. The beneficial conversion feature is valued under the intrinsic value method. Interest due to lender can also be converted at a rate of ($0.05) per share into warrants. During the nine months ended September 30, 2013, the Company made a $2,000 cash payment to reduce the note balance and converted principal of $15,000 plus accrued interest of $1,277 to 542,560 shares of common stock and granted 271,280 warrants with the exercise price of $0.07 per shares for two years.</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">27,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">$1,000,000 face value 9% notes payable to investors, due two years from the anniversary date of execution. The notes mature at various times from September 2014 to December 2014. At the investors option until the repayment date, the note and related interest may be converted to shares of the Companys common stock a discount of 90% of the current share price after the first anniversary of the note. The Notes are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company has determined the value associated with the beneficial conversion feature in connection with the notes and interest to be $111,110. The aggregate original issue discount feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of $40,476 and $8,910 during the periods ending September 30, 2013 and December 31, 2012, respectively. The original issue discount feature is valued under the intrinsic value method.</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,000,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,000,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,050,476</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,079,476</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: justify; padding-left: 0.5in">Original issue discount</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">111,110</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">111,110</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0.5in">Unamortized debt discount</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(61,724</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(102,200</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="background-color: rgb(204,238,204); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1,099,862</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1,088,386</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> 52476 27000 1000000 0.1 0.1 0.09 0.05 0.05 0.10 0.07 0.07 2010-01-12 12000 2000 15000 15000 1277 1277 300000 542560 271280 0.07 P2Y 19385 40476 8910 2012-10-01 2014-08-01 0.05 0.05 0.9 44476 52476 10000 27000 1000000 1000000 111110 111110 61724 102200 On December 31, 2011, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before December 31, 2010 and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $802,864 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investors option until the repayment date, the note may be converted to shares of the Companys common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $538,295 for the notes negotiated on December 31, 2010, $45,557 for the notes negotiated on July 1, 2011 and $1,123,078 for the notes negotiated December 31, 2011. The beneficial conversion feature is valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of $124,818 for the nine months ended September 30, 2013. As of September 30, 2013, the aggregate convertible notes payable are $568,638, net of unamortized beneficial conversion feature of $541,965.   On June 30, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before July 1, 2011 and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $325,023 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investors option until the repayment date, the note may be converted to shares of the Companys common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $209,809. The beneficial conversion feature is valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of $32,161 for the nine months ended September 30, 2013. As of September 30, 2013, the aggregate convertible notes payable are $169,080, net of unamortized beneficial conversion feature of $155,942.   On December 30 and 31, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $182,083 of related party notes accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $182,083 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investors option until the repayment date, the note may be converted to shares of the Companys common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $182,083. The beneficial conversion feature is valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of $27,223 for the nine months ended September 30, 2013. As of September 30, 2013, the aggregate convertible notes payable are $27,236, net of unamortized beneficial conversion feature of $154,847.   On June 30, 2013, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements, $106,153 of related party notes accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $106,153 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investors option until the repayment date, the note may be converted to shares of the Companys common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $70,768. The beneficial conversion feature is valued under the intrinsic value method. The aggregate beneficial conversion feature will be accreted and charged to general and administrative expenses as a financing expense As of September 30, 2013, the aggregate convertible notes payable are $38,950, net of unamortized beneficial conversion feature of $67,202. 802864 325023 182083 106153 P5Y P5Y P5Y P5Y 0.1 0.1 0.1 0.1 0.04 0.04 0.03 0.03 1 1 1 1 0.06 0.06 0.04 0.04 P3Y P3Y P3Y P3Y 538295 45557 1123078 209809 182083 70768 124818 32161 27223 On May 22, 2013 the Company approved a financing plan to offer accredited investors up to $1,000,000 in secured promissory notes. During the nine months ended September 30, 2013 the Company entered into twenty-four 9% notes payable to investors and received total proceeds of 1,000,000. The notes are due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods". 2013-05-22 1000000 .09 1000000 P2Y The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. The Company has 110,729,969 and 109,507,409 issued and outstanding shares of common stock as of September 30, 2013 and December 31, 2012, respectively.   During the nine months ended September 30, 2013, the Company issued a total of 680,000 shares of common stock, with a fair value of $16,100 for the conversion of debts totaling $18,000. The Company recorded a gain of $3,100 on extinguishment of debts.   On February 11, 2013, the Company issued a total of 300,000 shares of common stock for conversion of principal on convertible notes payable of $15,000 plus $1,277 accrued interest. The Company issued an additional 242,560 shares of common stock for this conversion of convertible notes payable, which the shares were fair valued at $7,277. 680000 16100 18000 2013-02-11 242560 7277 Lease obligations The Company has operating leases for its offices. Future minimum lease payments under the operating leases for the facilities as of September 30, 2013 are as follows:   Fiscal year ending 2013 14,050 Fiscal year ending 2014 33,156 Fiscal year ending 2015 5,526   Rental expense, resulting from operating lease agreements, approximated $14,942 and $40,434 for the nine months ended September 30, 2013 and 2012, respectively. 14942 40434 14050 33156 5526 The Company has evaluated events subsequent to the balance sheet through the issuance date of these financial statements in accordance with FASB ASC 855 and has determined that there are no such events that would require adjustment to, or disclosure in, the financial statements. 4.43 40143 134 7661 EX-101.SCH 15 skvi-20130930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - FIXED ASSETS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - INTANGIBLE AND OTHER ASSETS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - UNEARNED REVENUE link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - STOCK OPTIONS AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - CONVERTIBLE NOTES PAYABLE RELATED PARTY link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - STOCKHOLDERS DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - FIXED ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - FIXED ASSETS - Schedule of Property and Plan Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - FIXED ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - INTANGIBLE AND OTHER ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - UNEARNED REVENUE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - STOCK OPTIONS AND WARRANTS - Summary of Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - STOCK OPTIONS AND WARRANTS - Summary of Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - CONVERTIBLE NOTES PAYABLE - Schedule of Conversions of Stock (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - CONVERTIBLE NOTES PAYABLE RELATED PARTY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - STOCKHOLDERS DEFICIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 16 skvi-20130930_cal.xml XBRL CALCULATION FILE EX-101.DEF 17 skvi-20130930_def.xml XBRL DEFINITION FILE EX-101.LAB 18 skvi-20130930_lab.xml XBRL LABEL FILE Convertible Note 1 Scenario [Axis] Convertible Note 2 Convertible Note 3 Convertible Note Payable Related Party 1 Convertible Note Payable Related Party 2 Convertible Note Payable Related Party 3 Convertible Note Payable Related Party 4 Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets Cash Accounts receivable Inventory Due from related party Prepaid expense and other current assets Total current assets Fixed assets, net of accumulated depreciation of $322,477 and $318,519, respectively Intangible and other assets: Patents and trademarks, net of accumulated amortization of $239,208 and $213,205, respectively Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities Accounts payable and accrued liabilities Accrued interest payable Loans from related party Loans payable Convertible notes payable, net of unamortized debt discount of $61,724 and $102,200, respectively Convertible notes payable related party, net of unamortized discount of $919,956 and $1,036,956, respectively Unearned revenue Total current liabilities Total liabilities Stockholders deficit Common stock; $0.001 par value; 200,000,000 shares authorized; 110,729,969 and 109,507,409 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively Additional paid-in capital Stock payable Accumulated deficit Total stockholders deficit Total liabilities and stockholders deficit Common Stock, Par Value Common Stock, Shares Authorized Common Stock, Issued Accumulated depreciation Convertible Notes Payable, net of unamortized debt discount Convertible Notes Payable, related party, net of unamortized discount Accumulated Amortization Income Statement [Abstract] Revenues Cost of revenues Gross profit Operating expenses Depreciation and amortization Selling general and administrative Total operating expenses Loss from operations Other income and (expense) Other income Interest expense Gain on extinguishment of debt Total other expense Net loss Basic loss per common share Basic weighted average common shares outstanding Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation Amortization of debt discount Accrued expenses converted to notes Stock issued for interest expense Debt paid with common stock Gain on extinguishment of debt Changes in operating assets and liabilities: (Increase) decrease in inventory Decrease in accounts receivable Increase in prepaid expenses and other current assets Increase in accounts payable and accrued liabilities Increase in accrued interest Decrease in unearned revenue Net cash used in operating activities Cash flows from investing activities: Purchase of fixed assets and intangible assets Net cash used in investing activities Cash flows from financing activities: Proceeds from, net of payments to, related parties for loans Payments on related parties convertible notes payable Proceeds from convertible notes payable Advances to related parties Payments on convertible notes payable Proceeds from loans payable Net cash provided by (used in) financing activities Net change in cash Cash, beginning of period Cash, end of period Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for tax Non-cash investing and financing activities: Loan payable converted to convertible loan Common stock issued on conversion of debts Beneficial conversion feature Common stock issued for extinguishment of debts Accounting Policies [Abstract] DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES Property, Plant and Equipment [Abstract] FIXED ASSETS Notes to Financial Statements INTANGIBLE AND OTHER ASSETS UNEARNED REVENUE Temporary Equity Disclosure [Abstract] STOCK OPTIONS AND WARRANTS Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS CONVERTIBLE NOTES PAYABLE CONVERTIBLE NOTES PAYABLE RELATED PARTY NOTES PAYABLE Equity [Abstract] STOCKHOLDERS DEFICIT Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Description of business History Going concern Principles of consolidation Use of estimates Cash and cash equivalents Fair Value of Financial Instruments Revenue recognition Accounts Receivable Inventory Goodwill and intangible assets Income taxes Stock-based compensation Earnings (loss) per share Schedule of Property and Plan Equipment Summary of Options Summary of Warrants Schedule of Conversions of Stock Date of Incorporation Accumulated Deficit Convertible Notes Payable Stock based compenstation Machinery and equipment Furniture and fixtures Computers, equipment and software Leasehold improvements Lab equipment Total Less: accumulated depreciation Fixed assets, net of accumulated depreciation Depreciation express Patents and trademarks, Gross Accumulated Amortization Amortization Expense Unearned Revenue Beginning Balance, number of shares Beginning Balance, weighted average exercise price Options granted and assumed, number of shares Options granted and assumed, weighted average exercise price Options expired, number of shares Options expired, weighted average exercise price Options cancelled, number of shares Options cancelled, weighted average exercise price Options exercised, number of shares Options exercised, weighted average exercise price Ending Balance, number of shares Ending Balance, weighted average exercise price Beginning Balance, number of shares Beginning Balance, weighted average exercise price Warrants granted and assumed, number of shares Warrants granted and assumed, weighted average exercise price Warrants expired, number of shares Warrants expired, weighted average exercise price Warrants cancelled, number of shares Warrants cancelled, weighted average exercise price Warrants exercised, number of shares Warrants exercised, weighted average exercise price Ending Balance, number of shares Ending Balance, weighted average exercise price Stock Options, exercisable Stock Options, shares Stock Options, price Stock Options, expected life Stock Options, Value Stock Options, interest rate Stock Options, dividend Stock Options, volatility rate Company Recorded Expense Date of Warrant Issuance Warrants Issued with Convertible Notes Exercise Price-maximum Stock Options, Shares Loans from related party Statement [Table] Statement [Line Items] Convertible Notes Payable, Value Unsecured note payable percentage Shares, fixed price per share Shares, exercise price per share Expiration date Convertible Notes Payable, Cash Payment Convertible Notes Payable, Principle Converted Convertible Notes Payable, Principle Converted Accrued Interest Convertible Notes Payable, Common Stock Shares Issued Convertible Notes Payable, Warrants Granted Convertible Notes Payable, Warrants exercise price Convertible Notes Payable, Warrants exercise period Convertible Notes Payable, Balance Financing expense Due date Price per share of interest converted to warrants Percent of common stock discount of current stock price Convertible Notes - Debt paid off Prepayment Penalty, Rate Prepayment Penalty, Amount Settlement Gain Convertible Note Payable #1 Convertible Note Payable #2 Convertible Note Payable #3 Original issue discount Unamortized debt discount Convertible Notes Payable Promissory Note, Value Maturity Date Interest Rate Conversion Feature, fixed price per share of common stock Conversion Feature, number of warrants to purchase for every two shares issued Conversion Feature, exercise price per share for warrants purchased Beneficial Conversion Feature: time allowed to exercise warrants once converted Beneficial Conversion Feature Financing Expense Convertible Notes Payable, related party Convertible notes payable, related party, net of unamortized discount Date Financing Plan was approved Secured Promissory Notes, max amount offered Secured Promissory Notes, interest rate Secured Promissory Notes, proceeds Secured Promissory Notes, due date Common Stock, Shares Issued for Debt Conversion Debt Conversion, Fair Value Debt Conversion, Amount Convertible Notes Payable, Date of Conversion Convertible Notes Payable, Additional Common Stock Shares Issued Convertible Notes Payable, Common Stock Shares, Fair Value Operating leases for 2013 Operating leases for 2014 Operating leases for 2015 Rental expense Assets, Current Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses IncreaseDecreaseGainsOnExtinguishmentOfDebt Repayments of Notes Payable Inventory Disclosure [Text Block] Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] AccumulatedAmortizationPatentsAndTrademarks OptionsIssued OptionIssuedPrice WarrantsIssued WarrantsIssuedPrice LoansFromRelatedParty UnamortizedDebtDiscount EX-101.PRE 19 skvi-20130930_pre.xml XBRL PRESENTATION FILE XML 20 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

SUBSEQUENT EVENTS
9 Months Ended

Sep. 30, 2013

Subsequent Events [Abstract]

SUBSEQUENT EVENTS
The Company has evaluated events subsequent to the balance sheet through the issuance date of these financial statements in accordance with FASB ASC 855 and has determined that there are no such events that would require adjustment to, or disclosure in, the financial statements.

X

- Definition

Tabular disclosure of significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 855

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662

+ Details

Name: us-gaap_ScheduleOfSubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

EXCEL 21 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!,"'?^XP$``$,7```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F,U.XS`4A?=(O$/D+6I< M._S-J"D+?I:`!#R`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```/__`P!02P,$%``&``@````A`+55,"/U````3`(```L` M"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7 M^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X M8<'%#U1?````__\#`%!+`P04``8`"````"$`+K7Y<_$!```Z%@``&@`(`7AL M+U]R96QS+W=ON_#^$T5`VTTXNP%P%U.?IH[M:?/]T^^KU+^4>QVXVQRKOT ML39=2N-7:V/3^8.+BV'T?;ZS&<+!I;P,6SNZYL5MO>7EU4-; MF_#0DICJ^3CF1_]_\V&SV37^?FA>#[Y/?WF&_3F$E]AYG_*F+FQ]JDTI17NZ M0[+(FHW]AYSLAZZ<:R2'5\IR>(7DR,V<&G961&J8YU90Y MF924TN_184)RY$)9CEP@.5?*:JZ0&&)E-<10CK8Y!-WA2V5W^!*Y(]J1+#"2 M9=9(CNFXSXPK>'A?(SNT1Q=/KC80"`*!\_N$*BYY"5LU*Y]*_$_34DH?1+A! M=EO9TA2W21B0D M)&FK(2B'M8'-$-@\*[!+Y$XS4TH?*0S/4**=?(*C3QN9!)%)VL@DB$S1!H/` MU-'F`L2"=J=@HTC;&H+>L#8R&2*39T5FR3L0@?"`*=J9(S!S1!N?`O&IC2M, MJ]QCS<^AA>3V[(OO^@T``/__`P!02P,$%``&``@````A`!\FQI&N`P``=PL` M``\```!X;"]W;W)K8F]O:RYX;6R4EE%SFS@0Q]]OYKX#P_L5`W;:9.)TL"TW M3!/P(9QT`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`18!Z/D&BR>38\)H6VP34`G,>/CV'Z2,#X=A>@F32,OI!H'I*>C9@_UP"0 MKF>4_+T&&:9!Z.\BIM`U,+Q\!("`[B2/,8JNP2(^!"SEWTLA4?`$X^C^#QZU M%-;!3,)L'8RR\S#HBK`.YM(SN+SL"L1VKG@](8/.GBMTDXOL4`H][%8-_%=B M'4RY9]#9TUD(Q8M2LH@W>F#^[.E@RCT#UPM3ARUZ.AA[SP!W.'D@&-6$^\(' MX/2GB4?G^4'$Z&&'=?`)\`R,+^M@C#U\'F`Q(.B"$+2("\+'P3.(/C\=M55( MQ\LX3K1U'.A,,D&\0?5Y'4XET?`PT+'Z['MTQ-GJ"2?0-HGOSMH\/ M((T+ZND81+<;-AC`O^2P#B8:+F)&8Q=&,<,ZF&B_G<5.BS1V]/!NO MK&X*7FU,LK1-@U4YWQ?5<6/^\_?C(C2-ILVJ?7;F%=N8/UEC?MO^^LOZC=?/ MS8FQU@"&JMF8I[:]K"RKR4^LS)HEO[`*+`=>EUD+7^NCU5QJENV[1>792\ MO`#%4W$NVI\=J6F4^>K[L>)U]G0&W>_$S?*!N_MR15\6>ZV/\H*@;1 MACR)##QQ_BR@W_?B$2RVKE8_=AGXLS;V[)"]G-N_^-OOK#B>6DBW!XJ$L-7^ M9\*:'"(*-$O'$TPY/X,#\-L3S[[-8TJ-.8)*UV79=\S<#J@;> MV5PR48-D!"[#P?GAO+!\`]RC'T=^[ MNT8$R+7D&H)(TFN$0J+)H5^1(\!088KW`7IS+"&N`O&0P+N(Y"XBO870Y($C M\[,EP!L38C>&X_LU M6;"?YLL28"3+'6F[[1!+B-O)\GPL:K!.M12U1X2W_Y$%C2O^DMA)8U,8HH??YV0Q1@E+5`CVHL(3)K4>A,0>U*=:>: M0]N?-HAL[*K9"6"8T=E3U>Y2X!_MFJCH*Z($&(E";L42(D4Y,&,YJ*?O5``E M?N@AQQ,5`*5(?!2W5`5$D4_"Z9S4I!$84N8GK$,C<1.Q[!X]9E`7A2XN2`U! M'3?":4TTA.]2@EMOJB&([=KDLS.-B+-[=DEV:%UAB-I;W&.DPH4#P0^N),J! MH8=0&Y*,2C?16;S(]SR<1!T2>5`'$T1/HSCCYXN4$P&V+QLPC:;)\;%Z=FU]ME:A9T\DL>#-IR2O#R M5+,3/YIVAZY+'/KS=F/4C<\+>WF= M//GZCP!Z[L00H(@2/[HIG/>WAS*XX,`#3(@B&_<8N?L(@<&+VF0*;=\^U1F$ MV)X=T,A'D4@P$PU<-T2;7=RY3)L=T6RE:WJK(2X>2U4>V8^=S8^3\ M1=R84(CF^'2\S7EPQ(]Q]#PF*[@BN'Z>B-L?\=P:%\#ERR4[LC^R^EA4C7%F M!WB5O0R@.=7R^D9^:?FENP)YXBUPG0S9,%``#E&@``&0```'AL+W=O MZJ>FN:P-HTY/-$_J67FA!=0&0I30HT[><%@T&J>@Y::#_]2F[U-=H>3HE7)Y4KV^7I[3,+Q#B)3MG MS8\VJ*[EZ?K[L2BKY.4,X_XD\R2]QFZ_#,+G65J5=7EH9A#.P(X.Q[PR5@9$ MVFWV&8R`:=MCJSV0=6Z9N[#:MH'\S^E'W_M;J4_D15]G^]ZR@8!ON$[L# M+V7YRM#O>U8$%QN#JZ/V#OQ9:7MZ2-[.S5_EQV\T.YX:N-T.C(@-;+W_$=`Z M!:,09F8Y+%):GJ$#\*GE&9L:8"3Y;/__R/;-::O;BYGCFC8!7'NA=1-E+*2N MI6]U4^;_(42Z4!C$ZH+8T/NNWII92XBS+LH[CT*S%)Y%PP<3FLG2)ID MMZG*#PVF''2XOB1L`I,U!+QJP4'<1'WE"02Q(,\LRE:'ZT%!#3?W?6<3G)OQX!1WX8.=Z,_]/&99P2F!B3E?"8$Z) M6."+!0$6],<+ZX?7%HXQ-L]$8\R<9V(YPPT;5M3T83-XJX/3W@QS^+8]9.#S MQ@B$KR0"));M:G*LN;O@VPC[]99KFO=;VLZMJ%]/H'I`Q+(^<'Y@AYONA\&B M'Z'O'C+0_I=^E$2`Q,)M!9DS86F%\NI(J#97O-U8UC[G9O&(&P:+;ER^90\9 MF1LE$2B)$(E5)\\4IFX]F^?.)P:([84Y[R,C<*8D`":>=-W.3 MK(1=)U1&B)1$+",X0RO>$$M>;,@,Y:;818(I2QB%AXS,E)((D%BTI@AD^T(; M8;]^6!TI&XAE!*>)@)/^3)KFJ;U*%"4L%J^#NE$Z@U'Z'2!1&:B14-5,I(X1 M2Q'>%TLB>RMOHB]VE>A+V"P\@M!U5KC"YN]W]5)=&$*"A(I6(G4KL13A;;'T M\G%;F)1R:90EI'D>00AMV>TFS#\._(Z0R`C42,BUX\PM9R$LUD@=))8BO#&6 MFCYN#!-:WIB0]'H$(8D/7XT$:B3L$+PUEDNLY4"9LBNQM!U>&8SH)Y2QJ\0E M*:0Z'D%(JDR)!.HH88=@WC$ELU#'C*4(;Y!EM(]/.LR#^4DG9O/L'`4T2PTJ MD4`=)1Q!;$O80J,12+CEL13AK;%,MV=-GEH0S(O[MN!XB-^RO`[B;`EKQ^^8 M;N.S%HYXFA*,1>$;"KD@9&4OA9Y$/$#@G]"/6-H*+XJEM=-%81+<%V5;8JI/ M9)ER^QO75R.!&@D[!']JCXK"GB`P-P>_Q6,NPG+5\\A+8IGM=$F8!_.2Q)R> MR)+E3I(2"=11PA'$[ATCX9G#*"3DC/$(=)^9O"^6XO9\34S$,#'FO-F#1$R6 M/7?>E$A`E$C8(==?FX-?VHKZ6-H$9PN.SW_"5GN5$RTQ42L@[@]B]]M?#42 MJ)%0C40=XOP]=,(A>%;`CP'SVEUI#X]GVLM+=_8&X`Y_&2[E=[> M3CS;[.Q7*/?(&HZ@1\JMM3?&^]8:#D6!-VZ!X"7#)3G2/Y+JF!6U=J8'Z((Y M<^&!6>%K"OS2E)?VM/ZE;.#U0OOG"5XG43@G-V<`'\JRN7YA#=Q>4.W^!P`` M__\#`%!+`P04``8`"````"$`^PF$[:,"``"I!@``&0```'AL+W=OG7])#KTR)3FLB]Q&B48L9[*BO=- MB7_^N+N:8Z0-Z2O2R9Z5^)EI?+W^^&%UD.I!MXP9!`R]+G%KS+",8TU;)HB. MY,!Z^%)+)8B!H6IB/2A&*K=(='&6)--8$-YCS[!4EW#(NN:4W4JZ%ZPWGD2Q MCAC0KUL^Z)%-T$OH!%$/^^&*2C$`Q8YWW#P[4HP$7=XWO51DUT'>3VE.Z,CM M!J_H!:=*:EF;".AB+_1USHMX$0/3>E5QR,#:CA2K2WR3+K<%CM"VYT!AI`G]SSPRK0EGDRC8I9, M4H"C'=/FCEM*C.A>&RE^>U!J1062[$@"SR-)6D1Y5LSF_\,R.;+` MI,7TWUIBGY>SZ988LEXI>4"P]4"Y'HC=R.D2F$=_?#;!L;\9!DE:DAO+4N(9 M1N"%AB(_KB?)?!4_0F7H$;/Q&+@'S"PYAVQ'B*THZ`LBP;A3D6\7;]1BP5:+ MK8`5M_$3IX&S%W'?0"SR@#F3`AY=+L6"8<> M,G=Q\R3-)R&L]\Q_?UNY%^9;AC\+@JF&;5G7:43EWK:#%)C#;.A4-YEK-N$# M=(J!-.PK40WO->I8#4N3:`;1E>\U?F#DX$[:3AKH$>ZUA5\"@]V91`"NI33C MP.[]$-9_P$``/__`P!02P,$%``&``@````A`-98B5D%!```\PX``!D```!X M;"]W;W)K&ULE)==CZ)(%(;O)]G_0+AOH!!%C#AI M97MFDMUDL]F/:X1220-%J++M_O=SJ@XBA0[07JCHP\M[SJFJ4[7^^E[DQANM M><;*T"268QJT3%B:E?EZ>E:7`1EVFE MB0JK>HH&.QRRA$8L.1>T%"A2TSP6X)^?LHI?U8IDBEP1UZ_GZBEA1042^RS/ MQ(<2-8TB6?TXEJR.]SG$_4Z\.+EJJXL[^2)+:L;905@@9Z/1^Y@#.[!!:;-. M,XA`IMVHZ2$TG\DJ(G/3WJQ5@O[+Z(5WOAO\Q"[?ZBS](RLI9!OJ)"NP9^Q5 MHC]2^1/<;-_=_:(J\%=MI/00GW/Q-[M\I]GQ)*#<( M2%.MB-N(S,!]\__<\MRYO_R,BM>HP.=5Q;7;(Q+I2F*1;Q9U^QB MP-@#Y[R*Y4@F*U"^Y@>C:3/VJX1!D%+D6:J$IF\:D`L.57[;N(&[MM^@,DG# M;)&!]Y;Q'1W9W2-$)Z(K(6L.$;1A0(J[83PN[]6MA*5;62-I?XL_=*VYP4Q_ M\NX!HQ/1`R+P6D:S"R-ANET)P[CK)([X0:N+$2`#!6R3.]>)W2@1#1&:>WC, M=/<2#DW(3>O,#7K>ML@,N4=BH896,'/D2X\O&M+0W,.\G>Y>PGWW"_W)6V2& MW(\2$1(87R\\S?SB,^8EW#?O]\PC,V1^E(B0"%1Q',NYS1S-.JP.T_,NX;[U M9<\Z,D/61XGHGG"#V]S2_,LM06>E'%YB)*S[AZKV_",SY'^4B)!8JM0OO,:1J$&:B&[5UMW+#C9Y&!'L=]W5<]:97XU[A`;=CR)1\ZC&O6=Y MOYC&1+:YZ0%@4]0#N#7%)@"$!@-`Y,%`5Q*1B6T#81MR M?>(N;Z.XB0-E&N)1'VXTIE1"-KWIE<`6J5>BW\WDUAZBQ%;D6\K?[T? M<.2HXB/],ZZ/6DU'EKP0K!*;=GW3,!A0WT]P>&2PB;6L0`^ M,":N%W*+W!Y7-S\!``#__P,`4$L#!!0`!@`(````(0"JUN(54@,``-$*```9 M````>&PO=V]R:W-H965T7U2%*7*]^OAAN1/R496, M:0<8&I624NMVX7DJ*UE-E2M:UL`_A9`UU?`H-YYJ):.Y75177NC[L5=3WA!D M6,@Q'*(H>,;N1+:M6:.11+**:M"O2MZJ`UN=C:&KJ7S9J%N@6/.*ZQ=+ M2IPZ6SQL&B'IN@+?S\&49@=N^_"*ON:9%$H4V@4Z#X6^]CSWYAXPK98Y!P5N"[=')6T&VE?XC=%\8WI89R1^#(&%OD+W=,99!1H'%#*R,3%0B` M3Z?F9FM`1NBS_=[Q7)3I?<$.'"3J$!VHZ22"C+^E\D@^1#=A$ M-IDR4F[Q13],>#[,Y#UA#!BJUA>?S#M>C(R8:0\3=8@3@P`9;]"`4P*NNK2% MR3%Q&!DQL4U\G,01C(?SD6&W]2.;:D^@&]Y.L5DT5'#,*2I`S-PJ\%T_/A\^ M_I_P9M$@_&S:\6-XQ&`"IDD0SB[XAQWZ?O]FT5#`L;(H`#'_\F_.@UZSO9UV M`QZ&/>85PR(&?8=1'$:7"C\_C3RN\&;14$$RR#QB.N/'O)SL^``VV7CG%CT, M/!L$WH-.VNU"U0,S>GIY'^?>KAJJ&/;\'C1*Q;OF6H!S[*3OYT=_6/X]:%3T MP;@;F0.<::\FH$_BE00?M&CML;X6&JX2]F<)5T<& MAZ/O`K@00A\>S*6GNXRN_@(``/__`P!02P,$%``&``@````A``-*:;,_`P`` MT`H``!D```!X;"]W;W)K&ULG%9=;YLP%'V?M/]@ M^;V`R0=)%%*UJ[I-VJ1IVL>S`R98!8QLIVG__:[MA!`W3>GRD``Y/O><>^W+ M75X_U15Z9%)QT:28!!%&K,E$SIM-BG__NK^:8:0T;7):B8:E^)DI?+WZ^&&Y M$_)!E8QI!`R-2G&I=;L(0Y65K*8J$"UKX)]"R)IJN)6;4+62T=PNJJLPCJ)I M6%/>8,>PD$,X1%'PC-V);%NS1CL2R2JJ0;\J>:L.;'4VA*ZF\F';7F6B;H%B MS2NNGRTI1G6V^+IIA*3K"GP_D3'-#MSVY@5]S3,IE"AT`'2A$_K2\SR%\4VIH=P3<&2,+?+G.Z8RR"C0!+&5 MD8D*!,`WJKG9&I`1^F1_=SS798I'TV"21","<+1F2M]S0XE1ME5:U'\=B!A1 M'4F\)X'?/0F9!.-XDLP&L(1.D35X1S5=+:78(=@U$%.UU.Q!L@#F@S.GH_/Z MFE609TAN#$N*$XS`A8+Z/*[B)%J&CY#3;(^Y=1CX[C"D0X2@II,$,OJ2SB?Y M$-F`3623*2/EUCWHAXG/AQF])XP!0]7ZXI-YQ^LB.\RXAYETB!.#`!ENT(!3 M#*ZZM,7),7$NLL-,;>+GX\A\SD>&W=:/;*H]@M-P.<5FD:_@F%.GP&'F5D$4 M1*\8G_Y/>+/(#S_J[+GP#N,2,+K@'W;H^_V;1;Z`L2?`8=[R;]X'O<-V.>T& M[(<]YM7Y=ACG^U+=YZ>!A]7=+/(%3#W?#O.6;P)[;+AQB_8#)U[@/>CDM+VR MZ8GI/+VT#W-O5_DJ9KX*U]0&J7A76R.NC9T>>[_A[$&#HGO=;F`.7$L[43$[ M9MGM07*F[QTQ)XV/F$;5J\3E`V#17@5F?NO;@_:][]+9-R_L?O"!*3C3_69^ M][/4*7[U&+C!PKUW:R8W[!.K*H4RL35#`X&NV3WM!IJ;V(XDW1\P3[1TP[Y3 MN>&-0A4K8&D4)*!/NHG$W6C1VK?Z6FB8).QE"9,C@W=C%`"X$$(?;LS,T\VB MJW\```#__P,`4$L#!!0`!@`(````(0"2MN9$6P(``$\%```9````>&PO=V]R M:W-H965TP;]\Q3E#:;*7T!C#\_F;^F3&+Y[.JR1&,E;K):!+%E$`C M="Z;,J,_OF^?II18QYN1;J'!+X4VBCM/,'112`$;+0X*&A<@ M!FKN,'];R=9>:4H\@E/<[`_MD]"J1<1.UM*]=E!*E)B_E(TV?%>C[W,RY.+* M[A9W>"6%T587+D(<"XG>>YZQ&4/2+Y!D%`W3T63Z`(6%C#J#&^[X#08$S;4I&)Y2@"XOM.2[3\73!CEA3<=&L M@P:OO2;I%0RSZ5/"-&Y3>KO(U\A>["/[HOM4UN'%;9CT[3"#_PGCQ=BUV^0G M@YX;(@?-\$8SZA5_&$3)XP:].*/HJB];.I[UW!`Y:*9=X9/99/:WXS#8H>\* M3`D?H*XM$?K@AS;!??W;_CRMTNY(]!]PGEM>PA=N2ME84D.!6^-H@@-LPHD( M"Z?;;JIVVN$D=X\5_K@`>Q-'*"ZT=M>%/W/]KW#Y&P``__\#`%!+`P04``8` M"````"$`SM7#N-8"``"N!P``&0```'AL+W=O"[FO6:`N1K"(:_*N2M^I$J^D4 M7$WD\[Z]H:)N`;'C%==O'12CFJX>BT9(LJL@[E=_1NB)W0VN\#6G4BB1:P=P MKC5Z'?/27;I`VJPS#A&8M"/)\@3?^:MTCMW-NLO/3\X.ZN(>J5(?>$- M@V1#F4P!=D(\&^EC9J;@9??J[8>N`%\EREA.]I7^)@Z?&2]*#=6.("`3URI[ MNV>*0D(!XP21(5%1@0&XHIJ;G0$)(:_=_X%GNDQP&#O1W`M]D*,=4_J!&R1& M=*^TJ']9D7]$64APA(3@_O@\<()%Y$?QORFN==0%>$\TV:RE."#8-+"F:HG9 M@OX*R*?(K(\^UK^%"C$:R)VA)'B.$42AH#POFR".UNX+Y)0>-=MKC3]4I">% M*078ZSU"Y)<>_YSUDQ4C-E9,%8RWK9T`]MG;:-UKQ?QL;>`$,C3=B1%#I2\6 M]N?A<.FMU\I!MX`,MV;$2<8`C\G)8Y'WJQFT94S6LP6R\50D%H! M7'O(V?S`&FSRZ=:,>&@M'BV\M9+8;K1P&7@C06H%$YS%_^/,B(?.@G@^S,G6 M:H[68L\;%3R]?#X+O7#9OS_(&!REZ1DSXK$OK^?:4V`UMIB^U_V&"NB?AO)> MSFQ_M.VC9K)@*:LJA:C8F]X70#GZV;XMWP7F)([FM]"NN^;F]@^@7;:D8$]$ M%KQ1J&(Y(#UG#I64MN':@19MU[1V0D.C[&Y+^"XR..F>`^)<"'T:F#[2?VDW MOP$``/__`P!02P,$%``&``@````A`%Z$E]7,`@``!@@``!D```!X;"]W;W)K M&ULE)5=;YLP%(;O)^T_6+XO8"!`HI"J2=6MTB9- MTSZN'3#!*F!D.TW[[W>,$PIDRU(N"(Y?OW[.L7V\O'VI*_3,I.*B23%Q/(Q8 MDXF<-[L4__SQ<)-@I#1MJ5C*:=X/JRO4]+W)KRAML'1;R&@]1%#QC]R+; MUZS1UD2RBFK@5R5OU4TU72RD."#8-S*E::K8@68"SB2S\9V00DAES9P9U0T&M8#6>5T$0 M+MUG2&%VU*S/-?Y8L3E7!%XO<8&OAX30AY!_3_L)SH@AP1CU<"0.>M\N@+75 MA`/-;*S87%*,V&"BZ]F,.,7@W;,%P63FM=4D75K#,(RC"=FP?^8/^T=<$-SU M7$8\Y9K,N[::J.,B'CP3KF&_'P_[1URPN:[G,N(I5SR>=VTU`ZXSLDN*$5OT M'C8C'K/Y9'H(K.;(1N"9)NV"8$06OX?,B*=DTUUF-9;L)B*Q/T'?C`3$\^'& MZ1,_0C-WW*""7#Z<1CQ!B]Y\[>&T&GL`B#>?)]&TD+>2VH47;5;2MT%"`N\\2[EL&Y&ULG)G;CJ,X$(;O5]IW0-Q/.!.(.KT: M`@$25EJM]G!-$Y*@"2$">GKF[;>,I!OX_%.NWS8^O/SVHSQ(W_.Z M*:KC7-8FJBSEQZS:%,?=7/[[K^471Y::-CUNTD-US.?RS[R1?WO]]9>7CZK^ MUNSSO)5`X=C,Y7W;GF:*TF3[O$R;277*C_!D6]5EVL)EO5.:4YVGFZY0>5!T M5;65,BV.,E>8U<]H5-MMD>5^E;V7^;'E(G5^2%N(O]D7I^:B5F;/R)5I_>W] M]"6KRA-(O!6'HOW9B*NJ;PR--^P6%%9ZI9>=`W_4TB;?IN^']L_J(\J+W;X%NRVH M$:O8;//3SYL,,@HR$]UB2EEU@`#@5RH+UC0@(^F/[N]'L6GW<]FP)]94-33` MI;>\:9<%DY2E[+UIJ_)?#FEG*2ZBGT4,B/[\7)_HCJ59]B=4S$LH(/?I6!1> MKRY-?MJFKR]U]2%!VX/(FU/*6K(VTT#YDB!>G6O*'F4,4L54OC*9N3R5)4A& M`S9_?S4,YT7Y#M9D9\;K,[I(+/J$H8J(SQ'XO7N1*S+!`&-J(K,<8E`XX1!C MB#K1`&.@>.(!QK1$G=4`@W76`PQ*3S*`W,DH8/K5>3"[Y[P!'6RX:UR,9J68 MT:RK,.<]?&.!;_C\!D1VL\Q$<0=/,,LGF/`))AIB3-&.^`EF-<38HL[Z"289 M8J97'<$S&$$$S\:]8O19,2M)PB>)H$_H+HIDV6=0HPI)(B*)N$_T(EGU&13)ND_T5))Q1K`59@6? ML)71R%8+#8T>9R"$ASV4)'R2"#AA3[LNJD[PYY(4"$DB(HEX/(@5*;`>%T@> M/A8LM)&%;$I$?QA9*6PERJ+'F3$K2<(GB8`3[ME)%0^UI$!($A%)Q.-!K$B! M-1*XC:+=M"-Y^%BP$B:D0F]D5IK0"L:_FZP4MA+-#3W.C%E)$CY)!!>"3:A1 M8UI>GCT<%T*2B$@BOA`#$:PNSQY&L+X0`Z63X6>"?6P5CAV):'*X)`5"DHA((AX/8D4*K)$`&D^2AX\%*]T!*^F>R$IA M*]'[/AJXZ/L!V.C47=PSM#8\[2B$\CP1FQNR^FINF&.D7+I*6`F)9EW19HW?TR%H0&5RB",14G=JWVHJFLMV$^_&7,)5O M/@CK39PG3^/0J*DDXI]5SH[IIJ/=JM#Y$=#O6=)(2".1$(JA:S;Z3L>TQDK0 MT*N:8UD%!%M91L.][8^-\%ENX.]P1BEW3M#W!A'-5P5=8.%0%BNH>NH M*_DB83LVWDD,SL1((UK22$@CD1"*9KNJ@U9G,2VR$D3`70,-=&M:(Q$T#,>] M6R6*WK+MA__A+=^U$+LN&GL\V*=G#8#OXMC:5$=?XH4`:*H.9QW7;:RN5_H" M89F::Z/F$9R)46MY'"-(2*M$0BB:9;DFFN+'M,@*B9B.B1KSFA9AYQ]W>9WJ MZBT0[BT_W>#;]F5>[_)%?C@T4E:]LY,+`SY;U[O74Y6O.MNB1?<];0;[M?W[ M"VT&V[9P7[D6@$.04[K+?T_K77%LI$.^A5>IDRDLGFI^C,(OVNK4'2*\52T< M?W3_[N&X*X>M874"\+:JVLL%>\'U`.WU/P```/__`P!02P,$%``&``@````A M`'>,^)^]`@``2P<``!D```!X;"]W;W)K&ULG%5; M;YLP%'Z?M/]@^;V82P)I%%*UJ[I-VJ1IVN79,0:L8HQLIVG__8YQXM+TLFQY M(%P^?Y=SS&%U<2\[=,>U$:HO<1+%&/&>J4KT38E__K@Y6V!D+.TKVJF>E_B! M&WRQ?O]NM5/ZUK2<6P0,O2EQ:^VP),2PEDMJ(C7P'I[42DMJX5(WQ`R:TVI< M)#N2QG%.)!4]]@Q+?0J'JFO!^+5B6\E[ZTDT[Z@%_Z85@SFP278*G:3Z=CN< M,24'H-B(3MB'D10CR9:?FUYINND@]WTRH^S`/5X\HY>":654;2.@(][H\\SG MY)P`TWI5"4C@RHXTKTM\F2RO%IBL5V-]?@F^,Y-S9%JU^ZA%]47T'(H-;7(- MV"AUZZ"?*W<+%I-GJV_&!GS3J.(UW7;VN]I]XJ)I+71[#H%BLFV)LSR:%W&6`!QMN+$WPE%BQ+;&*OG; M@Y(]E2=)]R3POR=)YM$LG1>+$UB(=S0&O*:6KE=:[1!L&M`T`W5;,%D"\R&9 M]Q&ROA85,CJ22\=2X@(C2&&@/7?K+(]7Y`YJRO:8*X^!8\`D`4'`3;`$-J:6 M7B[R0=F!G;(KNK-RY6],9=*79;)_D7%@Z-K4?)$%7J_L,;,)9AX03P("Y/2` M#EQB2!7*EN6/A?/*'C-5SO)74L-^FVJ[?F?P/KQ=9+?HV,-Q>H]9C,U/XO'W M7C^I/JP2Z<5>#NY`Q_K/G;5ZWI,_O?D M[FLP>=?>5G;@8^4\)/+*'O.D[VD1,#ZU'VK^G9=<-_P#[SJ#F-JZ@96`ZW`W MS-++=!R'X0',LH$V_"O5C>@-ZG@-2^.H@)YK/PW]A57#.%$VRL(4&T];^&AQ M>"_C","U4O9PX>9M^`RN_P```/__`P!02P,$%``&``@````A`/28#N!1!0`` M$14``!@```!X;"]W;W)K"L8UB&`M(G/S[?K.86?"">Q]RXW#FFS/?<@Z> MQ;?/^N!\E&U7T6;IHIGO.F53T$W5[);NWW^]/"6NT_5YL\D/M"F7[E?9N=]6 M/_^T.-'VK=N79>]`A*9;NON^/\X]KROV99UW,WHL&WBRI6V=]_"QW7G=L2WS M#5]4'SSL^Y%7YU7CB@CS=DH,NMU61?E,B_>Z;'H1I"T/>0_\NWUU[,[1ZF)* MN#IOW]Z/3P6MCQ#BM3I4_1OJEK3:_54T)V88ZL0J\4OK&H#\V[$^PV!NM?N$5^*-U-N4V?S_T?]+3KV6U MV_=0[A!.Q`XVWWP]EUT!&84P,QRR2`4]``'XZ=05:PW(2/[)_S]5FWZ_=(-H M%L9^@`#NO)9=_U*QD*Y3O'<]K?\5("1#B2!8!@F`O7R.9S@)41C=C^()1OR` MSWF?KQ8M/3G0-;!G=\Q9#Z(Y1+Y\(C@*PWYG8+X$R'90AH\53A?>!V2ND)#L M`L1$K,>(P!\@'M`:N,&)IW-C8,BKZPS<`C2$Y?0S`2$:)#01ZUL(@QKL,YT: M`R]=B*VH87/C3$`2GM,H)@&RF>D`$OJA'P\1#&)PNNG$&-@B%@QA1PB<_=,0,ZU M'+68>$QXJ4%5AL4&-V9ID_6"@2U.5J$R`1&<8I*DH=I75%('D#3!@0(8Q%*3 M&$L:@2ZXG32VR")HE2P3$$$P2%)+4];Z8T+"*WV&H'S3T\;1EI:IP&(N)0;& M;Q`5E1B1N9L0(W?(.KS.P12QXRB9'I(V&46HBU@<#0=Z&2(),D$^?) MK8>$E.NB2ZS:91)S'H@T"0-K9-8&)`X))JJ!378/.0(2<@X_A^H1VQ(DYF:% M19C+$),>TVDM>=,T!;%55H55=60C"HQ(8IB0"SG4$5$0!4BIN4F2J;9&\O;L MLAR(^U;X*2I>X=,.A7O_>P MK\`ZR3L=./8.^\4SXQ&7KB"'_31*H`>'#$EZAGOX"4%1K&;(')&'#`2/#214 M\B6+?#:06P.LNPA*-"4WR3WD(GCL(J&2+4E.MX@G'$0^0GB4/A.$PQ@%D9)( MDZ)E)G<*/#:1T%9GK#O$$W@_(EI^9($-#(H0V(B*8Q*T;.0.P;%]:%\>9`X% M1MP*0/-?>#^%6R_V$B0@%]]/Q:66N/,YYKOR][S=54WG',HMS+$_BZ&%6W&E M)3[T],CO>%YI#U=1_-<]7#V6<`'DSP"\I;0_?V"79L-EYNH_````__\#`%!+ M`P04``8`"````"$`N"^9]/D"``"P"```&````'AL+W=O?SRG&-C9W'STC;.,^&"LF[I(B]P'=(5K*3==NG^_'$_ MF;F.D+@K<<,ZLG1?B7!O5A\_+/:,/XF:$.E`0B>6;BUE/_=]4=2DQ<)C/>G@ M3L5XBR5<\JTO>DYP.0QJ&S\,@L1O,>U@V3!-:@(VC#TI]*%4_X+!_MGH^V$"OG&G)!7>-?([VW\A M=%M+F.T8"E)US&&LD@K6@`#\=EJJ5@8T!+\,?_>TE/72C1(O M3H,(`>YLB)#W5$6Z3K$3DK6_-80.43HD/(1$8'^X'WKA+$9Q\N\47QL-!=YA MB5<+SO8.+!IXINBQ6H)H#LE_KPA*4>RM@H#V^CX(0 MUL`QP&B=.NY&F\EU?FJ0Y6(]LM0EL56`>LQ@((H&1.&868:7GY?%6R9 MS8Z%#SMBKA$]N6&4A8$%P*FD,@X`BL+@M#RTF#YT])[G```4````>&PO3KWW^=E^YF*TV$V2M+;;Y]=7YUL[#Y311FE MHVBJ5F:_&46 M'^J?>CM[S_9?%\G^ZW+_*!O.)G%:*L"ACM,R*1_4::H7`-RO7Y7[KU]QJ!Z^ MI]YG:7E78.@H'H5/^_'TI>JU6ZK;[O3"A^?#\J5J=^8_=&`__Z?3LN]/^Z9MWQ^KT[#!\;F8Y!#[R:`P\C.*/ZD_Q M0SCN>;O=[K1WM[H[.^$CMY&KAVES_4Y[X\\+W[B(\R0C$4;J*"H;+Q^`3",A MU7X3C8O&.X>S/,=FU$E2#+&A'^(H7SC_\XV-3G>CUPEG/B6QA2\B M]7T\'F_\F&;WJ>K'40&V':G3HIC%^>_#UYZ?9>%/_DS?9>-96D;Y`V`;SWG= MC7U>J,MXFN4EQ$;URZB<%$L= M9I-IE#9&FNGP=)(!"64V_+&E^G=1'A?J?%:*/`/2$`K'%H82AM8GD+X&Q,__ MW)"=\'4AY/R7YXG>FV@6DJ"@P M1>-I5-R%OQT,10,5*H^'1LE(Q1^A%HM85%A6WH&,0\/W\Z&]RDH(P_(Q)\E'+*O?;ZDT+E5V MHZ(AE.5,0S2*H7B'251"2_+96J_;;6WN[`@4:[W.;FNKL]?"!HII/"R3#_&X M`?\I!""]38`8#W2]Y-ZUN M>U=#UNWT\,?6B0.DL-*@'U*!Z4 M:@0U2A,J]-[NM':ZFQJIG7872(7A6T;NA0OB+8_+YR_OK[P'QMK;VC9+M]J] M;?ZY?/'K%+J?ZCJ/(7.SAB@^__M__?V_0CS7!64)X?3`)0-$4=YEXQ'<(>#R M)ADF9;B:T:D%=>HW:JW]$D:6@J\^1.-9_`VT\PTVGOM;;:.ZW-]IX=GM!40:HA0UFEJU54PII-RW@R@.JP M[HN,.H+JTK\:M;@C$>0A2Z%=J)@VDE0-HVD";1/N5?!A&2Y\"/'QU,Q< M7&F$"ZH>P6J#-+*Q5=X,K<8%C!Q\O[A,X$N\6&1%:*)C<5.@%$^2%(8G`3XN MLD)0H_[M8$`/;5C^>[CMNDW%:NH[$G[Y,&-Z#QPC+!\NSDK#;ZTC?.KT>G.N M2F6%8@'.=H5%"3G4_C7(S%0L^@M[+7 MW_`;3A'Q3.!Y.*Y83/]+K9F:SD4&2P`XC>9J/'^;9P64=Y[=-'6*V1M<1^,D M--X^\NTX-8-O/AN(@_]+/_0V3H&SL8A2-)HDJ40=M/+A&UK\$+<1Q4O`>,<] MB,MCQF9I`]1S\6T2C5&"NFXVU7#E_)$A1/`ZM'$U+X?/WR)Z5/!IXH\$>)84 M=U:::0/#T69_`MF""<_@/(VQO?#5-U&1#.6)`GH0KXI++9I]_M#[.+F]HS<8 MP7!'MW'M%;!RI=+#]QW["<,?PEM5)^/L?B'#RX@;&>'3!/2#XDH^B-/3<-$. M1O\Q*THBJU!E!G8=9M!]]"X,`O@K_SWD^K,"&R&F'6LLF5K,Q<8@XCO`$]U= MD=APG[[04V1J7DMCL''(K&1@9E%O6(.`4K^%KVBS9O@!QW:(U\EZK`@$C"WIG$YM2)YW$$.YJ@YRR$^X;L(2KC> M[!'OCR+Z*%>&"X1"0FP7HN26@5#DSALOQA(,@)M<0#0WSFS`.6_- MQ^"\T4[)2R\DU/L/+:$00IRL.8D4D(`)P$_1:T:OB2 MD;EF%-*8Q`?(BNKCKQV,/C#T-QJI!G!C!0_,3P1+MK_(K77$@ZG^D"!]J`8/ M:MWHP1?@!O$5:V0)090I1$^0J\FQX0@R94L-D`=,4]I;L!D4+/)J\P'EZ<75Z?J;.3]2;Z_[I MV7&_WU)_..U?G5_^H`[.CE3_^OW[`_P;`_JG;\].3TX/#\ZNU,7YN]/#T^-^ MN'.XT;0(9)^+;(R-0'P6N:VY)-'C8I@G4YL*&LR*)(VMPX,1_/\+_%?Q5\:R MS,D_>[7_>IB-26]D]I'\[_"7_`3)=3WD*IE@U;/X7EUFDRCETYMHDHP?S`S\ MX95,*K6"KXMI-,0TL$Y%G'^(G^VK?_SM?ZO^CV"9I*"::"&=/7S94NMY?!,C M*RQ&/H)>N(LQ]/^!#%.D.__QM_]\`6)#ER$QB3&@,@>,X)J/LZDX@G0\`='L M!EK>2`-D+?L`A^1##,]ARO"PQ2156B#<1V)5=/MD-LP*_'N:C:$-<^/,C.(Q MWD(6N'@H$#:J,A[>I<#++7'.E2APV5-)BVW`(1J1 M7&;T*V@8Z#RMDN$O#>"@X^G=PRC/IG=(6@UE;O-W-L#?!BP58S4R=_%276'C MR^&Y@R.J!GD6T9,;P?G#1B+H#&!``TRG!XJ**)PB8S$!C682/K=4AFUOX,&& M\%JJ[.!J7 M4*Y0:"DY`!XX&:(E8(H'9)!FX,$8&O0$A(L_QD.L!VR1IF`#4!>`)#1,F.P= M^/"[^#8J6N#X#]$H>JE%$B+C:D_X=[G_!\19+EU,J?K5"-8J+CPV4%&HBR2DF)SWR3`'JX*@?4L\+=/"J!;G\MX] MR`*BRIOPMN!6)#/6''IZD60G;Z_B^$EP_>300`(!)>W$``T=(>_CC!$ M,1L4R2C!E/*G`S1*QUD,H@Y`3RH=Q8VC/)6Y=>K3JXN:;)BWFBQ0[C=A*K/; M&#*0*XDO"'\%%=-^XS'X-H^!Z0'C111Y3#(>GMAR/6AXT-8^A?_>9M0C,&K# M.$\=@%^,"Z\@_`PE1'6+_G/YML(F7""WHJ5B4!K6`?E4K=8C=>MO1B&X3(#Y M^[L$7(@=0AM/Z2YJ"X%(8NR5%'1E0(29"HC!:$%[8+P"+U0CCW-(RI(U_8%9 MKIU_:R2UGK7LB]"`(L+R#2)=G06EVDA-""UZ0ZUU>ZUME)([W9Z"J45EBX3G M/[0-II+)X[_,$EA#FX&E&I1AWMY@WW3T+6I7&S9J/:*RBF$8#9?1CU#A8^CO M&KS"][H,\L!A>92P#E6E@4WZ%RC(L]GMG:#B9B9VDRZ5=LVA;4%#UA.MLP7Q MERJK7BP;4(N*\<50;W;G`6H[4,R&M'HW,WBKGL'&.Z2`0;&`7,,!MB6^G,,% MV("X($[%BDOBMJ5FXS)!VP$*65@.*"'SE3YD.@4G!9]J+MHMD(^`4?>0"AXT MG(C`)"A)5,0P=L1#;+4U>$"@:C:FKW$'9T>1[S)4%03W6OP11994E*-LAO1# M-$!FR%\TI)H#@&JJ+A::`!B`%9,1-N_<;DSOR5@=QUB8^1-RY'@VHM^!G MA^Y0?]B!4`"DX0=:\W%P%?8F4A65A[1L5#E+/JMLA(7N18-T'D M(LFN"G9,\>M0615(B]!I$4>`D:G MI,!`5\%!8S"W,+;66+Z&A#N*;"[IO`B[UUI],=-!83`!R9?T1:Z`)*W9Q>ND M\[8*ACD(W#5AQX\83X-H*K]IQ4(FU0VQPW-6R:`8M$J_3A/^);E59L^,OJT\ M0PKWA(K3(4M0#^,QFXBBIFV!)$1P28=:0F&@4+S&K,C"2U(.F_&,C6]82,4@ M*!=%`H`QY=R$2M]9"D*,M'$?S^.*F$7C)P'FZE)R+Y<'G4T`_IN97;]CJ!4 MLA!@441-T!W089!\6*=L-N8^Q"N77#,JFF`QA[(Y?%CN2V*!<$E:@)A'7(E] M-\+C$ZC;Z0PQ4Z&U`7?LU)9P"G/1DNFNQ1*"%N1HH%?%A4+B'1PP1A,9^BUT M&H+V2,M2@1ILN5$BUM,)9WC$:((>2Z&]HI(ADFT>>)Y.5M'>X1_>?915(-A`-O_`4,%D*66 MC1(XS!UV*N0@]AJ8H66#>$VLEJ^V<>!D31)HG,)#QGMDP1&55\0Y,?W+0?Z,.^HQ5$#&^EX]1L[21=Y#%D>(2]@H=]-`S^4ID82YP%J"DA3 M6:(ZA)E2ZDDZGM1,D<6FT:@"X^.)G\:./$^O-L3E"OL6(D+( M@&(C?G2>+$\J1TW9^DA26@-@>H#,SWTSKZ@I];6Z3K5G@Y&/(+;"*RU)(5DI MJY$-TXF/*]J9<@?]@\U*-FF60F&6H+G8!JW<,<*S!]^$XJYYJ?NU^G/(,3:U MX>A,7TVS$9B%A!6V=8\K8K;44CZ`*.%U.B3&`P6CD./@D8^12H)^-$9'S).H M/--$];``_-[7"NXV7W,TZ+4 M>'>]0`I<&^0!U7^3805M8,@7#98SY7Q8NF$&CXRQ89U$$E%?Y-EH!N,O.2'] M_$OZ4K8'H7+)"1C)!K5.0%$R/I64*A-T?_]OFS-L@ MW@'&YF.;4&C3)C4W21BP7-:37@ M5L"P(HP%Z\'U&E)KC9-;DX#D4O>P>7"&XY$.ZSA3#&I*6L`TA7%YV.@[N$=2 MN$:_)OT==OA"!\/U@\O&B-S5O\CG;C^(C>"PT1W3V=R%SC.[VIN9ZLOL`8E% MI(`E+?B9>&"?Z?$K;-N$Q3H_Y>@'&VN@LAZ>^&;([*+T3@O&X%@GGXD6P\0D M@4M65Q342#;9MB]&3A(HCQD\+J.L$6/(8#WS"C<"ZG<@26.AM4:%81N$W23> M9Z+=?#:2@L=2BL)D,IQ,D29!^#=% MNSA^(,F*NV0ZI<32E(V9-E%]^Q.?PRL<24\7"BW8(ORRE-Y`S6K2!)K4)C4E M1WKP+!*9`QLP7`8-\%_2P#F@H.I,5S[W3-3ER%V"J6^898)'3M/"I"]^;6;`Y# MWKQ/X`.2M09D(($.@&,YVIQ\!)N)"I"#4.\,A;.(48]E)&_W-DR5N>./NE=E M*7(I#>B,<$&=!`QPP\7G!L3H%D+W\CU8'25+_`Y?U^:X9#=&"%HJ`3U2Q'QF MES5(YNX220_1'?G9R>G#][@0D+E)W)*GA.YD?>"%32<9WF"BOB M+B4*7QH4T\6'(`O$=RMH72(S4O=(9L0;(P;7$%1?=%"EMK&8__(B0KW%9D4T M:'$6=+E]2:MPY?&RR<9X.35C,ZC-D>S%>=5\I-YD^&]1?>M,)+V`*""):1H? M3**IM]7>Z+35.MI+D&=2^D]VF+38:`J?*)3PD-P5LN)]L2P5C,*Z;.C>X`2A+2V.R?@1Q!AA!9 MX"#Q+7@<&8C_@/7C[,9;%3&`]H<4H7N&T&7%2K:&AVC95`"`' MKL&0H1DF-44`V'4:;QQW\& MN5CMK9EL%LT&Q-`TTT4?';M!QWN)2>$M4_,'QL4:HK*!)`[EMM11J/`8Q%47 M@O2S05S>LVL#XFI[/2&M3E.`)8-:!N")/\+04K%8U@]@H?W!?$CZPN,P!U/) M!R+2VAP+C.(+ZA4VP#5((8T0.!VML%M*CBLAL!$21V]29`DA>)P9V@?;9KE$ M_P0-114CBC#Z:!+^0FKP)7?.P)J]'2Y[SNH8FU/0!@C/R4<8E_9G'C"'-624 MCL7!^CBYC'0<'.TKS!OKHB,\C55H2&5BNI<(2[43X\"#)1@HX1&"4S*J@5X' M)M@(E(X+6[DMP8EH6::[%^F4/@]*+#SWX=G.7\9:S<\%-!(MUF/@OG!@B%E` MAE9`P5)%TMFE=_"9/0%Z[/;TS(:@5YQX^]-G=`,:JH7H"[/QY%]/W8"U'/3" MZ@Q)J-7I<*/;+8\-L]BH.Q+)A6?,R#Q#=^MTG#W$5#Q0!+I\Q=X9S9HBJV8$ M]`Q8#RTYNDN4P^W+YA'*RF@;A.L`(=.&E>Z&.K83:.2Z\QX7[#)R+K2(@`DO MT5+CJE"VW`G6=OE'M/T)+/KEN2@P:*((ZI2$6"K-8$0/ET,+L"LVQW`@T+DP M_]`O;E#H`EDXM8LQ:]T.3W8+OM;:GM8[,%NO$K^;9Q^3&=R M-!VFR7\+HFTGA,%.T.:-U5>#L4#OTQAI;,@Q9`V=`HM?8]`]18!!NT;@4*G- MI'&*'J;H$SE[!IN?6;NGA=#![+4QUL'7V3)IBZDZ5[VSG!QM3#:EDLS3;;4%0`&>=3,J MH;/NA8%6O390R3( MDJBN3#;L7@P<<_P+M-"<_NOQ$:*H_O%5XP@,4D]0726R?-3;R(<#B<=H_M%' M0!8=AL&<_I$^D_?A9HD2[29HYY2_+5"_.+=8OW.AT7OP'DE1*'-X?V*6+%A: M]JTZ+O?7PA].9M!VTGO+]W#ZD/]NM$P=PL9":'(F0.W4LE"1W90@5.,$TSO4 M2458%6)G'&W3S3?AXFB'K^8+'\HIZO#'=XC*OZ86]BZ#F,+2Z3MGPM'KYOZ9 M\/?&V?!U]SJ_^<'RY@*_/Y-8&**6J8PPI+803D-\&)US@@>UQ MD^(&$Q;0K]`5IJ];G'ZZ]DANWB'R0O<3$@V07"06R&,<&M0+@1!$7[,B9B9; MDC?+TN.ZQ*S=-0\$\4[4VM;N9FMW;]=1"WWQ^J8?2)=/.3\)A-6\FR%J3N0G MT@K'2=IM0RS0J@T8ZGY2KW^6(HU.W0_])=T:Z$_JFSJ],O;R=[LX-[#;VNN@M^99]09G ML7>4R-K'*4J#0RCMZ^\V#A1N+8^D,O+8SQH\^<[6"\`% MKM8,XRA=%G`/X2FY4H(9\A->]*80'"DXV&[%.F#HT,X1@8Q3G0CJW0N MZ7#[%#R!AB;'40`7/,M4$-2EZ?'1]@)O6$Q@ZZ6)`QW@?(?'$&IA(X`Q@0_5)APE9=^3S'(PBJ8(D1!4F<,M&ZS1&&C`0VCPN^69!9A2 ME%%0I'II'X*`$O,QOH(J%K@@&LA:;UANX&8L?Y+[^;>;2-`K/4Q0&6RNNT%M ME0CE*!!;7\)$$)CR(0>A"\Y,4B%0]#.KNWR306(R@8O&!+.CF%?S=^^)MI;" M)$]NB&L#+L9I@R&C8+R!@S+!;0L0Q`QU,FD&:S__QM_^S M>$8=+#2N+G#[:'K0X5P'"[1<2^VU>O8NM7JF!^)MPA0&I0T.@[JKEM7*R2H\ M:T(LUNHI)(J86Y+QK8!&"S_T#[^)J@%7(2_.(W>DH\@/KH/K:1U8GU;LI@>P MDNJQ@"!J2H=%,#,W,L^63B@OG$EJ1U(C6MO%U7%M&%6K6=[@^-^/&_TAXG+" MKH\:$D`.F&1(>YK\ED!`751)"K3AS)QY^5K4"_=D8(&WE!0_HB,&AR'DP!++ M4LR32OUD,2(]O"H_95L\$-&O8/>7!PGPTN"U7ZPSWWL^F-;[7_:Z5H[A$ M>MW8!>+KGB^27S?`AO8-:3V`U;VW(/EY#*A]4*`2INKFP4=$L+N#G.1NNYI5 M9,"D.SR=JQO^S?D:G?)\+X?,S26O/5I(MLH1#H@)?40'^>3HB*R45')BP'FH[T;T@<04ZP@$B0 MAD)N&D&()7QKLB2<[4A02<5/VOJR[6P^NIW+XW<'5_!'+PXNKWY05[#N_8-# M,?BAY%V:Q/P%;\]55[R1@U*&W2PQ\;^T@@K>U!XOK;)5A^=GWQU? M7DD6X^S\ZAA1[\$/![BH/"3JH2>=+2F]?Y80#(4!NVC",, MHF3AH>]@4ODR^0LVJMF1KVXQE#:1AHY-1J"1$CFPS",^:+L5>QX$3,8-GM7,)*68HT MB32\NYFQ>YFPD[N59..3.<-##J\=W7-CNTYF[!2VE%&^F/$0@$YQ`L@_MM0E9%GH"H`4M2V;2W MO((P,`UT6I9JR*5GWSY1.42H78MHKZ@:!-^:S4@8R`9OD4`V&]"O=;9DJBDR MC4([.FG.S,F`%CZ&06VWM=EM;6V[&[KQK"Y]H+>-#YM^+.\()8\^*B?Z:B\Z MCB(H#?1YF65/L^U])U21#]3CFRSHDC M3$-[8M55M20SR=*T2?KOM;_B_Y`TQOH9)UYKT$I-2;,V.*G"F'F-0&ILN5Y``IB*;N6^QRCC6 M=.X3]2TT-(VFO:'3N+^T%N0)U)?`HJ(HX%#3/R3\R"WLH<'+4]4(T7`3)]I. M]&U]E4A4H2_>()R6T4=H>$P''S7 MA32HPJ7W+*_K+T6$[Z^;CT:$OR\,!%"`\`*_\#6$;2'B\,T"4L>ZC&@.2_'U M&[1,B.&%!:86Q\%-*"MHJ1K+Z800,U(N+K)MUYP25A"'O(QHN]0X/$$^3$7` MZ:6P$0,SQ0W(=#^5-*W9Y?$6;`X.=$%OPD&H#)$$Y]6?$`;6+T`;E!3,6N:I MW(8K9K5F1"B]':+K[FIJUR$H[U==^;3:'>R"DL` MR-2!@QGWX1^5!%LO`*[U3U7T/T6G+_!\-SW_\_-ZOMO>RA7+_9I]WZW>;JN[ MIU,5%;-[/./FK*\?`V"R?USGYG\74=+KH?NAXN%FAP5.J=]!;3=.C=5=E5GV= MHC6:C7VI#M:VMG=;V^`%N9D0$\X\:[`<21B\MK79P7=JMAIN*Y3X'U$]M!^A M0>J!S/(K4.`-WOPUZ.Y>%U$)KH#T//R&:?@?W6U#3(8GN[OX(M1N M>^^?1T/VNJW.=JV_I4CW`;JK'==`B7M$KP0.;\\Y`( MLVL-0;X^E(LF/B!UZ>>[Y8I\Q$_ZXRF"83098Y"M;^/6J"D#+*_NA-RX+7"$ M42E.F%7URU7*>S6-C=X#Z6673">N"$C+!YS11[_!Z_!&E7FGPO/;P;?/3D[0 M-H#_^_2/#NTOK:6M!`FP_LM\^8AN-OH=>8GE"$3AQ[Y!`7U%%EQU=T>4]FET M<@=Y@I6`_IG0-Y\O=5G9%C57KD"N!/A/Q[8T?Y\MJMY=_X:.Z02GR]DS_X?S M=T?'EWUU=(R/@YU>:916W5FF1W[QP<2YGR_FKG`X#O7 MM7*YYE";_V-Z==E7KF49W5+A]YE6%=]:60238?FF4I?4O6.V#CIL3V"@`!>WN#>!6UCIP,_&2]=QU!K?VI3J] M`EOR$+MSA3J"JR9I=I^[RM@Z-B M1?K")+J]_(*6U_"GU/DJBH*/2[4&H[_3C&@.S]^_/[UZ?XQC+7+&!273J].S MM\=G\[[F!ZSC&Q=RP%-8^[!VB?(*IU[D8@7DS58+ZY M`^8>\T0R*I,(87F^PGQI#7=UZ2\/X:!^,L%7WF28;<'DO9?L92)%YL[$!XB& M>-)`RL4+U0?*(X!&-Y\6IO6TKG%/T%H"HVP[MRB//#:G.INM]E8[U+WS1V^J M'D1S:WNUT5L*];=N8_`EG"<`8MH9I,_`]'E+STZ`A^KRQP)UWBE\"OVA![0Z M`'*D*W75CBT0/524GY!`D!?9L!:T.H2;ZU^_Z1__^1J,KW@8L7FJJX]K&-E= MB6Z,8UZ_N*S1VS=9Y!]SIR%\)EZ4C%=YD;V9#$:,]+=W?'1,ZX#UZ;\D*M7_>/ MU%J#`$=&(Y#DYNNM308$@[EK+G#-'`[5E2'<>F_Z.M\S"4,N=#=Z.%!V;<[B MP8_BC5FE',T-!];X9T.MR"EJW>Q]X8YK\]K1JV`J1@>4N=^#1@FMQHTSKTLN MNW"`K;"4OE)!=WU5%TNTU-L<]U:%>*K=&'&,N_MPW",<$QZ3?PHPU_;`]"45 M^JPQ]Q)9!-4JF3)2YY9>2*`W[OO@[BQM=9N2]D?#_>N.BQ[FQ=F:O"\4]<;E7!L,;F<__<3-N8+1PI'BE\J>*`YU'M)++Y6]):#Q4`Z. M&\V&V[;TY0WS?$MMT=W(^1HZ&"1'$QY=TMQ#R^L!PK'/S?G\\/=@G>]P$WSC MW6",:^5G(_`C\\DU@7':.$<>3!D<^P\GM;DF^.OZW/\"LVV=,R,ZZM3$<>%\ M3K0X`"&B9.`:'EGXUG'M/HZ-282`>38)1]7ZVFL'FIV^6L&C"?#3ERLFPJ66 M>->K.[2X'O0]DDCX:"74=_-*CQ`KJM.`(CC"J[J/CN@]-L(=`VZIN1QY/?^( M+HYD\%PL+D\)%]`(Q"?MO*.2[HS]HL%6&:'@PHL[%HX'-R8,&Y!79<(@G"Y$ MH;>Y0WX9%(X_$WI/>,W%PNBFE;M^B M^K@J,E&W^EU3)RVZPZ!^=,GM9`6MCLXE>!=H&F""N('.4(]:T.H77S1VC^J6 MB%2Z^`T,.SOL?%PQ4D_%3>;X0Z1(K.'J\Z0 M9%E@3=[K#SGCUK`YVMMJ1'4YYZ'>CQ2(3F+.@B7FFIA0UD)`YTU4.UJ#0?N377PO@D[;H7"66&T6?&S).Q: ML.ZP^WXGZBTX8%8=C`LA?MZ;KVJ7+AM.4NGE!?YBR(Z>D:RU0(<3^^^EDKR; MZN0=*QYC\,D(A2BY<'A.O[C5LN&DM>:?IV@5\7JKO4HFF+<0V.:?<"&:EMY& M>VNCVY#/OKGX))`;5(C@[58G8V_8LA-.N_A=9YWF!@P+ET1)2MI<5E^(=Y3, ML[,2&P9-$4_!L._BM/3=[(7Q<41 MSS.ZBP8V+,FB@5LA-NI5V.KIJZ(H]_^_`````/__`P!02P,$%``&``@````A M`-6O\X?+"P```6\```T```!X;"]S='EL97,N>&UL[%W_;^+(%?^]4O\'R]M6 M=U(3P)@`N9#30N)VI6UZNDW52KVJ,F`27_R%&K.;W*G_>]\;?WN#,1[#P+!2 M#]T&#//>YWU_,Q[;-]^_^I[VV8E6;AB,],YE6]><8!;.W>!II/_MT;H8Z-HJ MMH.Y[86!,]+?G)7^_>UO?W.SBM\\Y].SX\0:D`A6(_TYCI?7K=9J]NSX]NHR M7#H!?+,((]^.X6/TU%HM(\>>KW"0[[6,=ONJY=MNH"<4KOV9"!'?CE[6RXM9 MZ"_MV)VZGAN_,5JZYL^N/SP%861//8#ZVC'M64:;?2B1]]U9%*["17P)Y%KA M8N'.G#+*86O8`DJW-\':M_QXIA',`\8?_ MK,/XN]\E?][]\=V[]K^__>Z?/SKS?_WT3?F[G[[56QD;0A-LL)OF97LG6?@Z MH=Q*);B]680!$<0$-:&VKE^"\$M@X7?@#"`>_NSV9O6+]MGVX$@'XT[R2\FMN=.(Q=_MK!]UWM+#AMX@#E&^CO?!3/AP5;"X;1\IH@F MDVF`,#B9NGB$RN2#2#8>W"V3_?,6F3A>O7I>A^B/X\6DV"V7-%YEORCI\!!> MN:T(G^AI.M(M"W)(I]U&M5*#'8G9<-(&?B=C=M4[F61=JVOUI4K&^6+9;LBP M:\E490U#ZWW_[F3JE,^L2KHT#9\J`C#@Y&K1A=#=$=]]"U^G\),3%[3C6(Q1 MY9(^"[TB-SZZOK/2'IPOVH^A;P>H6%K4V*^YFKRF]I%/GC._?/*Y9]62/JQS MX<*SEE=C(VP3(R^`Y8AL0)_9>@5.X'I>WMAV>]CZP9';&^BQ8R<*+/B@I>\? MWY;0^`4P'4#O:26_J_GU4V2_=0S6_H@-6(6>.T<43Q/6;J;23J[NKMB^[`^'PT'G:C`8#,UNQS29DJ>I1[O!W'EU<,8H34UE!#U`,.P.AE<& M`&F;`\;JI`BZ`*#?ZPUZG:%APO^LPAP?@6R=]G355B4(%%F5(%!D539#:4G( M_&FDP&*-XE@E"!19E2!09-6^Y`S<5VY5@D"150D"159EZVH28Q46017'*D&@ MR*H$@2*K2FL^TPP\5&Y5@D"150F"4ULUG59A8VVQ599R9R:M/\ZF<)/[^Z2) M;\*+S1IAGCH-HSF>,XBAAEIY#X]X]\X7,*_TS".X=S. M[/[NS%V#&+:XDNDE8'(M#GO5,G$V8 M?;/=-WO&53)AD\3:=^;NVB]+E_/>ZI>@1M1MO>!$AT'.)'6'8H&OA59(S2NS=L@6C=:.:2HKY)=2;(P-?+'N>(ND M-2/*U":J=J MT@1VSX8GLZ=DY@BV8',I,I7&J[[L;.U4>PXC]Q>89.+57S-83'4B':\6C-T9 M/?(ELI>/SBM,19/S/*^+ZK5>0)*M;VPZ(X^P$E/!'U:R=:T)<^GZ.0#+X8JH ME9Q-ZFL7YC<\@U_KV%V\-CP+')`"C-`XT=31U9N M:A,,\1CI@/9EWMV<`>WR#HNM61[?>ZEVC@'P7)6%>R<$XIP4J@::VEXN^?#? MP\!L]X8`Z`KG[V[.?L_._XX`<&__.P(6VA4B#O@.#V# MTB@A'JCC&KC-E;R7$(<&?8T4NY*2$KR<9\/-1<[<26K@GIF3T,D?K6<0BT7? M6HY,$2GV8$E2L:3;CAR1XQ=GRX5S*GE6JO21%UKF.T ME12@L!-5]46G3I$'`^:23J,Z*F1QJ27G_.!QVBLG.SY$^#9]KR0GV(94>>>I MX4JU_OD7<#[X2_V&2.F3X"-?F]+WP$N+U+%+PEXUZ]@`FU1T/&&?5?1C**L) M%DXO7#:2G]L/-]P1`)ZKL@0+"V2X17:B@S2*-( M0+AL+T3IV9F]:!.XD4Y.B(\'+*,BA.Y?EYX=V'$8O6EXM45.CC=Z3Y#E3(FXIX?$#O;0(L#_NHZ)&G$4 M(8+[3D2(/+HQW)4N"V*.!,(2(A'"%5`YB8V,(DCC[W848+1PH;OAHQ42%=>3 M0?<_?RUNQ<7T'N/CSMA-NO+Y`"AJ[BSLM1<_YE^.].+]7]C]'L&9TE_]X'X. M8T9BI!?O/^*--"&*X\N>N9D?'=G#=M&>_)?4!D^&^X:'BYVP+/7V#/BX(JRCGF]\N`);5$J M;`K^4W%LI),/"7QV]SR`#;>5RX1HK?)GU]W^#P``__\#`%!+`P04``8`"``` M`"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H96UE,2YX;6SL64]OVS84 MOP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B0-))?1O:XX`!P[IAEP&[ M[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.(H4,B M).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ)!%! ML#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7"-/90 MC",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9VP,^ M8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51K;OX M`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P;8%' M1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@.<8UW M5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$'6!\ M6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z@DL^ M4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM`?H6G'X# M0[TJ=?L>FT1.[P:3?$45*&'=`X+&(_D%,(48SVN2J#[W$W M0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ4ZDC M&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_J]#> M6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C\S210*:D`XD2+N&\:(9+:6L\ M]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&WUV%6 MTT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1L;:[ M]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8>\.%V M6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D-9PD MU0$-D*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A84-=`YMZ;_=0 M"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF_US$ MO#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+AP(O+ M&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[.(+& MR0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P8VL[ MMM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO M=V]R:W-H965T;]N_51R"=5,J81.#0JQ:76 M[&J5C*2=8OJR@T\;^'6A#?8.JSD-1XBSSEE M#X(>:M9H:R)9133PJY*WJG>KZ35V-9%/A_:&BKH%BSVON'[M3#&JZ>I3T0A) M]A7$_>)'A/;>W>#"ON94"B5R[8"=:T$O8[YU;UUPVJPS#A&8M"/)\A3?^ZM= M@MW-NLO/3\Z.:O0?J5(?>8-@V1#F4P!]D(\&>FGS+R"Q>[%ZL>N`%\E MREA.#I7^)HX?&2]*#=6.(2`3URI[?6"*0D+!Q@EBXT1%!0#P1#4W)P,20EZZ MWR//=)GB<.'$B1?Z($=[IO0C-Y88T8/2HOYE1?[)RIH$)Y,0Z$_S@1,L8S]> M_-O%M41=@`]$D\U:BB."0P-[JI:8(^BOP+F/S'(,L?XM5(C1F-P;EQ0G&$$4 M"LKSO`F3:.T^0T[I2;.]U/A3Q:Y7F%(`WL`(D8\9_YSU'L6(#8JI@F';VA?@ M/;`%LWTO%)C*+0#<&",_^%M)JHI$FGD&^I9@P@LF8 M\6TV(TXQ)&!(3IC,=MY:S;(KJQ]YL3:&B6W=\2 MOHT,;KOG@#@70O<#TTN&K^WF-P```/__`P!02P,$%``&``@````A`$@'_DZ< M!```U1,``!D```!X;"]W;W)K&ULG%C1CJLV$'VO MU']`O&_`$"")DEPM`=HKM5)5W=L^$^(D:`%'0#:[?]\Q`]G8[-I)]R$;S/'! MY\QD/'CY[:TLC%=:-SFK5B:9V*9!JXSM\NJP,G_^2)YFIM&T:;5+"U;1E?E. M&_/;^M=?EA=6OS1'2EL#&*IF91[;]K2PK"8[TC)M)NQ$*[BS9W69MG!9'ZSF M5--TUTTJ"\NQ;=\JT[PRD6%1W\/!]OL\HQ'+SB6M6B2I:9&VL/[FF)^:@:W, M[J$KT_KE?'K*6'D"BFU>Y.U[1VH:9;;X?JA8G6X+T/U&IFDV<'<7(_HRSVK6 ML'T[`3H+%SK6/+?F%C"ME[L<%'#;C9KN5^8S623$-ZWULC/HGYQ>FIOO1G-D ME]_J?/='7E%P&^+$([!E[(5#O^_X$$RV1K.3+@)_U<:.[M-ST?[-+K_3_'!L M(=P>*.+"%KOWB#89.`HT$\?C3!DK8`'P:90Y3PUP)'WK_E_R77M\7P]BX4KZ@1&:9NN MES6[&)`U\,SFE/(<)`M@'I3A.JY:OY(*&CG),V=9F8%I@(H&XO.Z=OU@:;V" MIUF/"<>8P!8AFP'"'>2\T3#PP4O$*?&`&*8D.-!99X'&JU"P[U;HYZ$;]'`P MUS.PAC@`W%>!CKB0S1@12&N-QA"))!XC9))D#'$_;!04NX\HYF!(RUN!CB]* M#!$SO<%X(F*C141:1*Q%)"J$X``L]?Z8<_#*!'NO(?:E\(0(F7<)3N(G5U*/ MM^'SRB#Y$ZD)8BU!\B6!H!N*ROVZ.5C2+0D+$>)WNF'KP3])/&)4XN]@B;4L MB9I%L`'JV?TV<+!DPU24&"($;2#$#ISYW)^+F`UB5#;?&; M_OZTB^Z3*VVHD3#='<=>N$_\N=10)%?ZSW8<43IOBVYR_[XB0+"9NMT37;DA M"7N0*@OTD*B'>)U34^(2R:M8SY$H(:(=O(MZW`[LO00[''FO)`A2VJ&%1#T+ M)I;;;;C2[T+_G$0)$?W@+=7C?F`C)OHAY6A(5-U:5T8W>DC40_HRX8W+A)XC M44)$.R!Z_\,./DLL&*XCMY`$0"JPK"HAPQ5V/%\>1/1DR1*B.@'[[T>]P,[-M&/4?'0 M-GX;..?0^H$0["F"3[)#2\%/4[Y^"KJ!IR5XF%#2^D`WM"@:(V-G?A+B0B&_ MCEY/:9X=_DHMC8=D`6_^X_&(+.#U'L:MZP0X5#FE!_IG6A_RJC$*NH='V9,` ML'2[X`ZX'R%Q4$:&3@'B\2D665X>( M_/7GRY>OQ).*51DK1,4C\L$E^;;]\8?-632O\LBY\L"ADA$Y*E6O?5^F1UXR M.1$UK^#)7C0E4W#9''Q9-YQE[4MEX8=!L/!+EE=$.ZR;,1YBO\]3_BS24\DK MI4T:7C`%_/*8U_+B5J9C[$K6O)[J+ZDH:[#8Y46N/EI3XI7I^ONA$@W;%3#N M=SICZ<6[O1C8EWG:""GV:@)VO@8=CGGEKWQPVFZR'$:`:?<:OH_($UTG=$'\ M[:9-T-\Y/TOCMR>/XOQ3DV>_Y!6';$.=%-O]P0N>*IY!Y8B'%=D)\8JO?H=; M`021K0"#R'\O89Y"C.+W8F6.\PG2R-XU79ZI8T2FB\E\&4PIR+T=E^HE M1TOBI2>I1/F/%M'.2IN$G0E\G_7S\'&3:6<"WYT)!;_/"7P]FC91STRQ[:81 M9P^F*?#*FN&DIVLPO)T-2`-JGU`(B/+K`5"_9YE)"G7Z,.\WG?-K'U-SCP\5Z/)]>VDV^T&U;W"$AQV;LT.W; M&YI[?+ADC^?3"[S%Y[8N'6X"H=-%R0W-/3X8I\DW;@[A(-&'FIYDC<'GO"BD%XJ3GB$I9#[_FY_)N\.R_T# M.-W6[,!_9T[<"07GVO;G$?[\<#AW!1,0 M[X50EPL\U?5_I[;_`0``__\#`%!+`P04``8`"````"$`#3N3,8,"``#B!0`` M&0```'AL+W=O+*[R2PFBK2Q9^?7Q*V]N29V%IO/QE9?)$M8+*Q3+X`:ZV?O/2Q\%MXF5W=?N@+\,V0 M`DJ^:=QWO?T,LJH=5CO#@'Q)"@G*S!N@?ID92(C75:_0ZB9(<*D'0'&:#[W7D:I9,LR4;_ MI[#@J`_PGCN^F!N])=@T^$[;<=^"R0S)^\B"CT.L_PH58_20.T_)Z9@2C,)B M>9X7Z6@P9\^84['3+*\UR;EBM5?X4J"]@T>,_-3CW[.^M^+%WHJO@O>V#!O( M/GJ[>.^U8GRT=N8$,W3JQ&=K@-WTMB-_"74G!I)L?&YA&33#$TUVKEB]I3CS MB)!3CV][\^*<8@*.R1D-S]^\#)I)7]8DCB_JBG/G$>%X.CR>!E-AID++*3`5 MK*!I+!%ZX^AA]S#*=ZFOWL7^$D>\'PAV.,`1ZW@%7[FI9&M)`R4BXVB, M,V7"D(:%TUW?Z&OM<+CZQQJ_I8#=$4?$'``#__P,`4$L# M!!0`!@`(````(0!S'/:X$@,``!X)```9````>&PO=V]R:W-H965T7;`!*N`D>TT M[;??M9V00+8LS4,(YO#CW'.-G?G]:U.C%R85%VV*R<3'B+6Y*'B[2?'/'X\W M,XR4IFU!:]&R%+\QA>\7'S_,=T(^JXHQC8#0JA176G>)YZF\8@U5$]&Q%JZ4 M0C94PZG<>*J3C!;VIJ;V`M^/O8;R%CM"(J]AB++D.E[SG7?G`6DQ+SA48&)'DI4I?B!)-L7>8F[S^<793IW\1JH2 MNT^2%U]XRR!L:)-IP%J(9R-]*LP0W.R=W?UH&_!-HH*5=%OK[V+WF?%-I:'; M$11DZDJ*MXRI'`(%S"2(#"D7-1B`;]1P,S,@$/IJCSM>Z"K%83R)IGY(0([6 M3.E';I`8Y5NE1?/;B<@>Y2#!'@+'/80$[X:$>P@5VST%CD?* ME?5X+AL;=48U7\:H MNNR28N`=WO+KO1OQV/O=,->ET\RL]YL@C'U"@G"H63G-)?]#"KPH)(R/-0XJ MB-]3@1&/*ABGNW2:V%9`?/L9^7>*2_XO*0;N83VX/G\C'KL?O71+IW'Y!P1V MXY%W=WW@?22!_P%LCL^Y MY][+97:_DS7:<&V$:C(W&!E+FYS6JN$9WG.#[^D&$F6/I6-TG15@^]=-*;LR-TM+NBE8%H95=@`Z(@/]-+S';DCP#2? MY0("40K$;SL"*PZ[<.`, M3S&"6`U483./PVA&-I`Z=L`\>`Q<>\PK@H!HKPQJURL[L%-VN76A//B-4YFX M#V0@,_H?&0>&XIP$'X>OO%[98\8GF.1M98!<;]"!H09@J\_;96X]Z`II:*I3 M:=>O211,_]JRQP*[2AUVNJ8?E!`:[MS- M9!R\:\8=&RH<=H9FQF=F_!3P'XGDNN2?>%T;Q-3:?>$QM'V_VP^?1>PZ\WQ_ MG"ZZCB7]"Q@*+2WY,]6E:`RJ>0&485<8[<>*7UC50N0P&92%:=`]5C#].71^ MZ(P72MGC`H1)_S^9_P$``/__`P!02P,$%``&``@````A`/U'XNQU"0``@2T` M`!D```!X;"]W;W)K&ULK)I=;^.V$H;O#W#^@^'[ MVI;DSR!)D>A;:(&B:,^Y=APE,=:V#$O9[/[[#D52Y/!5'7NQO:@WCV9&G)=# M:DSK]M=O^]W@:WFJM]7A;NB-)L-!>=A4S]O#Z]WP[[^27Y;#0=VL#\_K774H M[X;?RWKXZ_U__W/[49V^U&]EV0PHPJ&^&[XUS?%F/*XW;^5^78^J8WF@*R_5 M:;]NZ,_3Z[@^GLKU<^NTWXW]R60^WJ^WAZ&,<'.Z)$;U\K+=E%&U>=^7AT8& M.96[=4/CK]^VQUI'VV\N";=?G[Z\'W_95/LCA7C:[K;-]S;H<+#?W.2OA^JT M?MI1WM^\Z7JC8[=_0/C]=G.JZNJE&5&XL1PHYKP:K\84Z?[V>4L9"-D'I_+E M;OC@W13!;#B^OVT%^M^V_*BM?P_JM^HC/6V??]L>2E*;YDG,P%-5?1&F^;-` MY#P&[Z2=@3].@^?R9?V^:_ZL/K)R^_K6T'3/*".1V,WS]ZBL-Z0HA1GY[3`V MU8X&0/\?[+>B-$B1];?V\V/[W+S=#8/YR)M.YF0]>"KK)MF*B,/!YKUNJOW_ MI8TGQM3%\%4,^C0Q9HM)X(D@9QP#Y3CM'+WY:.%-5L'BO"-=;4=-G^J._F(T M]6>+Y6>WG"O/1>=YX2UIP;2WI$^=Y.B2'%?*CSZUW_PB1X]J04Z-*`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`MPS4RM.:\0U'(2C!$%"&*$26(4D09HAQ1P1#/^;K. MECHA]V&@D#/USE>2T%AUJQY1C"A!E"+*$.6("H:X#**%NWP%^++CLU>]0FSJ M55]H6H,(K6)$":(4488H1U0PQ'/^*3VFCSVF0O:!C+8R/5^DD>D,8X4^.9-! MQU0C$S[3R(3/%?KD7(8YC##''E'M.(PA&MJBF#2"-3!K%&\J1FNO!\]Z`XT2;&*]7( MQ,XTHH;&#`IUDX,RIS6@FQIU>S.NVW4MJH\MJD:LX%;.]Z906;&"D[%HQ]0U M&&LK67#^C'[OQ8(#MU2[V07769T53EJ9@G.&7>C([1BY<*+'O*+@9$O*"DXA M7G#.U(6^LC)%$6ED2B=6Z)/S&G1,-3+A,XU,^/RB\`5SY&*Y'>\/G37XV`AK MQ(O/.6,)E14K/M4NF[QC9?7)>8V.9:HVU<@N/PB?7Q2^T+%Z"DYTMG;!_9B& M(HK342K$ZG#IGM?XRLH(%BEDG]=H),]KIO-%L,*=3T4R]95B\$Q'(B'/[7PR MECFO<99/H2/CSB=^PCRKYV7G-6T8+JA"=I^&*$(4(TH0I8@R1#FB@B&V/D5G MS;0XWW:TYD[.LFL75\QTK=R#4^5('WK+CQ#%B!)$*:(,48ZH8(C+<%V+3MVG MNY84HEOH!$-$$:(848(H190ARA$5#/&<^UIT?S:BW>#*%W%$T^ML+0H)Q:VJ M<+<68Z5%BQ#%B!)$*:(,48ZH8(@K=%U/3LT$R"`1JPI`D7*TK&)$":(4488H M1U0PQ',6#:/]L/ED0Q#FSH8@$9MZ^/80BH:%'*V<(T0QH@11BBA#E",2;T*: M04@9Y)N-\G6U?7EZ+<-RMZL'F^I=O+5(W]_N;SLL7ZE\#&;ZG4KWBN_?B._( M5-SNE6!"/FW;`%?$&YKM+@)7*!HMY[YH`5T)>J],ZPM9>OC#].:!IKXG=5*K5RR:X5Y[TK!?0@I$/Y+TW,&C4/2[`5T9=UG3"[#' M]6OY^_KTNCW4@UWY0J4V:5]=.OO\'``#__P,`4$L#!!0`!@`(````(0"ZUCPV>`(``!0& M```8````>&PO=V]R:W-H965T&ULE%3+;MLP$+P7Z#\0O$>T MY-BJ!*-;R.D#6'JS^/AA?M!F:VL` M1Y"AM3FMG>LRQJRH07$;Z0Y:_%-JH[C#I:F8[0SPH@]2#4M&HRE37+8T,&3F M$@Y=EE+`2HN=@M8%$@,-=YB_K65G']F4N(1.<;/==5="JPXI-K*1[J$GI42) M[*YJM>&;!GT?XVLN'KG[Q2MZ)8715I<9F#)D6\T*B`U]V8J#, MZ3+.;J>4+>9]?7Y+.-BS;V)K??AB9/%-MH#%QF/R![#1>NNA=X7?PF#V*GK= M'\!W0PHH^:YQ/_3A*\BJ=GC:$S3D?67%PPJLP((B391,/)/0#2:`3Z*D[PPL M"#_V[X,L7)W3!#MC`]:MI:>B1.RLT^I/^!F?*$)P<@K&]REX/(TFZ6@UXHXOYD8?"/8*2MJ.^\Z+,R1^VP@Z\-BE!^C&>`MLZD7]8V@"Z0QGXXE^[;=(;<[Q^OC^IS M&*I\VCDOMLV5\*;/B!0]GQ"NZYJ61K20,E4HZB%`V;,-9AX72':>)T M:8=CV7_6>/L"MN`H0G"IM7MW$@%QH44J4;9;?25EJM]O+L&`-6,4:V<^G?[QA3$IJJS;X` M-L?GS)D9AL7=459HS[41JDYQ&(PPXC53F:B+%/_^M;FYQT4C5/\3,W M^&[Y^=/BH/23*3FW"!AJD^+2VB8AQ+"22VH"U?`:WN1*2VIAJ0MB&LUIUAZ2 M%8E&HQF15-38,R3Z&@Z5YX+QM6([R6OK232OJ(7X32D:\\(FV35TDNJG77/# ME&R`8BLJ89];4HPD2QZ*6FFZK<#W,9Q0]L+=+B[HI6!:&97;`.B(#_32\YS, M"3`M%YD`!R[M2/,\Q:LPN8\Q62[:_/P1_&#.GI$IU>&K%MEW47-(-I3)%6"K MU).#/F1N"PZ3B].;M@`_-,IX3G>5_:D.W[@H2@O5GH(AYRO)GM?<,$@HT`31 MU#$Q54$`<$52N,Z`A-!C>S^(S)8ICN;![70ZF=W&0+/EQFZ$X\2([8Q5\J]' MA1V79XDZ%KAW+.-9,(U'XQ!$/R`A/J+6X)I:NEQH=4#0-"!I&NI:,$R`^&U' M8,5A5PZL+T"`*BO3*H7:_LP$[9Y=:% M3`P^ENIVV MZP>9A(Z[L#.!B-X7<*>&`MW.T,OKZODIX#\2R77!O_"J,HBIG?O"(VC[?K;K_4FR:CN6]"]@*#2TX(]4%Z(VJ.(Y4(X"-P2T'RM^854#D<-'K2Q, M@_:QA.G/H?-'`8!SI>S+`H1)_S]9_@,``/__`P!02P,$%``&``@````A`.J+ M6X!4!@``TQ@``!@```!X;"]W;W)KQ'WX_*T\C[[F=5-4EY5AC2?&*+]DU;ZX'%?&/U^"3W-CU+3I99^> MJTN^,K[GC?%Y_?MO#Z]5_=R<\KP=@<*E61FGMKTN3;/)3GF9-N/JFE_@ET-5 MEVD+7^NCV5SK/-UW1>79M">3J5FFQ<7@"LOZ/1K5X5!D^:[*7LK\TG*1.C^G M+3Q_BQJC,EO'Q4M7ITQGZ_P+O9_%)<6AAN#WK$.K;#?45FP:(`C MZ;>584/#Q;X]K0QG.O9F$\<"^N@I;]J@8)+&*'MIVJK\CY,L(<5%'"'B]B*+ ML6M[LWDG.H[=3-1!Y^B[IU/ M"O.E>U+X%(7@V)V&%H(/GQ_KF041Z%IB_WE/WTP^HEU`=FF;KA_JZG4$LP[& MK+FF;`Y;2R:&T>!/W8?EK:Q`2)C*(Y-9&6`8Q*"!@']=P_`\F%\AE)G@;&YP M5,86&2R!3':G`[X.!#H0ZD"D`[$.)!)@@BV]-S!X_X`++&/&$K:D?G#A,!N8>.-\;0&<. M)S''>Y+N4D_I72*(3Y"`("%!(H+$!$ED1'$)#%%/8!;Q<]^L/_B1-X@!.,@94B;*UO!DD.$D)0BA$2,;&^J3=P`&4-1B-"0 MSPBA@14C]*9T@HRN2#6)'?1DDWYIQ6:'%FWZ(:0&3%L\M\@:4K`3D#TL]CY" M+DY!5Y_(`0H-V0D1&K0C%!JT8X3>UDY0Z$;$V)E0=N_^BF[Q(R3H#1$3D!HQ M+>1;4:A$C!?:0PY\9/$<./;4F6JK;8"4H2I$2,X8T8Z1A=KV8J9I)TBY$3)V M*)1M^K60\:.EXIZ`U)!I;YM;2["&(.P$I(2,L]A%@C39M4-$@%JPQTLLS8H0 M64.+$6TQ1DAM45L6$M1ZJT5U.H,6<=IFI>\^?;$W%WTN"T@)Z4Q;Y+>B4`DI M+[0''WQDS;JY[,P7VI8<($&.J)"1(]HKR^.@/5*,6KPQU_6(N4+F1F;9&?=> M9K]45]A2;QYEI4.@MO` M;U/Y95F9U\=\FY_/S2BK7MA-*8SM^J&'^37NQIK"/6X7>_++#&]XM5]VLR6\ MD<#.H.$1%-S"X:KXL=M)-/Z&72'?T-G82[C6H?H;9PEW&Q1_=)>/8`;]8>,N MX37_!NXMX17X!@Y>=%:8_9/"E?(U/>9_IO6QN#2CV+-+Z7YEU9, MLJ>JA(7:-CL_QRQ_@$``/__`P!02P,$%``& M``@````A`'.R"$"4!0``,AH``!@```!X;"]W;W)K?%9FVA4BB(2FWO^]P M2"DD15I27X)D,IPS9S@\'-/;K^]EX;W2NLE9M?/)8NE[M,K8(:]..__??QZ_ MW/I>TZ;5(2U817?^!VW\K_M??]F^L?JY.5/:>A"A:G;^N6TOFR!HLC,MTV;! M+K2"_QQ97:8M_%F?@N92T_2`B\HB")?+55"F>>6+")MZ2@QV/.89?6#92TFK M5@2I:9&VD']SSB]-%ZW,IH0KT_KYY?(E8^4%0CSE1=Y^8%#?*[/-MU/%ZO2I M`-[O)$ZS+C;^,0A?YEG-&G9L%Q`N$(D..:^#=0"1]MM##@QXV;V:'G?^'=G< M)XD?[+=8H!\Y?6N4W[WFS-Y^K_/#GWE%H=JP3WP'GAA[YJ[?#MP$BX/!ZD?< M@;]J[T"/Z4O1_LW>_J#YZ=S"=B?`B!/;'#X>:)-!12',(L0T,E9``O#3*W/> M&E"1]'WGAP"<']KSSH]6B^1F&1%P]YYHTS[F/*3O92]-R\J?PHE@4B(6IO:0 MMNE^6[,W#_8;O)M+RKN';"`PSRD"9B)"GZ4K2_!\@8J^[HG MX(5J9-+G7OC`ST^?WB.`;/J4(`TU)7MY.F3NS)&A\)C*O3"H,*$=)IH# MPYVA,FKRX6T?5R`+GUCQ27H/C2"X3"?(G6%S@-9GW0:U%4X3H*%15&B^W6&$ M_>9HPZ[.?"&FT1=:6J!9E,36=L8K'?;ZEG)G'4I:1">KK0(=9](A)%E`:MGQS<*&!PF.!2=\>Q\'F9T4%OEX_]#;0I(98 M.!FBP3FMX@F4A#8`5G]\B#3IE"+'-LV2#-)KQB>:-%DH622!)-'B9O00\;O+ M:+W.I).*':1FJ0(9RD)GLI`RA&&D!89R0*QZX-!S8@C"Y*X8:@.&@F[4#^_* M44!#,$98#I6"]%(!C:)=4>$L74!O_0QU)KT3/F<"'/.4HI0RH**YE2*T*(49`7SVIB>XT*CEE(J=$Z.JS:<)17H;:`YI8*/ MF:JP\CX/5WQ8';FC<*&!(L5#XQ0[+MS04`H.G)`)$H4+#>!^F%#FEMAQ/8:S M=`2]#32I(T.)"BVB,8W34#4P%@#KQ71['"+Q4X.M*B-X&&@^`%325,)JE$>AMA)8:H2EA[+@3(YML3)EH<:$! M;)LP8L<=%LV2#?0VT)RR$1FR,;(Y4A@4E<4`.S_&#[+J^!]9=($LPPG"@"L- M`E(8]'UR7+W1+&%`;P--"(.%DT47)GVFB8:ZT)ET2HY+.)JE"^AM4!*Z,*04 M_U]9P(4Z2&?2*3GN]WB6+*"W@29DP4)IEBK$4@*4GNY,PXLAMDA`N(;3=?W< MX#(C>ZL`..:&>)8`H+>!YA2`V!``?GVO80-'"`V%``,!JK;YB6-HB`UQ&$&3 MIU_=(FFR;)%Q^CDALH9-'L&0PX"*(4TZ(\[ M20]#L9P&5%+2I)-RC",)>$V_NM%;[[O.-"25&,6K;>*82Y)9ZH#>!B>G.L"3 MN]8`V'JKV_%/2KC00)&:H7>>.?*(%WKQ#%[2^D1_HT71>!E[X:_O(;Q?]];^ MFX$[K)QICS=WXAN#H/\/O-A?TA/]GM:GO&J\@AXAYA)'DEJ\^8L_6G:!W.'= MGK7P5H^_GN&[&0K/Z4O._/"2Q.2Y.G:JNTZ8?/WP['IRO9=-6]6GMBJ7G.N5I4V^KT\O:_>?OSXO$ M==JN.&V+0WTJU^[WLG4_//W\T^-;W7QI]V79.1#AU*[=?=>='U:K=K,OCT6[ MK,_E":[LZN98=/"R>5FUYZ8LMOV'CH>5]+QH=2RJDXL1'IHY,>K=KMJ4G^K- MZ[$\=1BD*0]%!_S;?75N+]&.FSGACD7SY?6\V-3',X1XK@Y5][T/ZCK'S<-O M+Z>Z*9X/D/NK_JMU_+ZF7?0;E#R$@E]K#]_JEL-Z`HA%G* M4$7:U`<@`+^=8Z5:`Q0IOO5_WZIMMU^[?K0,8\\7`'>>R[;[7*F0KK-Y;;OZ M^!^"A`Z%0:0.X@-[?5TN91**,'H_R@H9]0E^*KKBZ;&IWQSH&KAG>RY4#XH' MB'S)#'E<<[V5*N2H@GQ44=9N[#J010OU^?J4I(^KKR#I1D.R(4101'Y!J$H` MNRM%2-RF."[ZA8D"*R:J"(I:AF]`["LUR>X[1,2&&F$"`LUGHL!0:.O&J4?O MG"$DL"`A1>13"$(-@LRGIL!K%_*^:I)$],890I*^E@OAR30.$PK)&43X<62D M)>2@R6URJLE\6(33E50?8OJ9LF!M$0(\KGEP_:80A&)$*4Y34V"J7QQ3<3*$ M1+U^,H9Q3:_G]O7`3Y,;RL&2LI6;IJ7`E%9JPJ)B"-&T!-@(HX77B:(&0@13 MWF8-CFEF"LR8^?3.&4(T,YG((*"`W`8$OHP\DQLAEMY#3($9,7;?#"$W).E5 MS1%RX>XGD5DJA)J`II\O6H]FY%A_9QH3]'T62",)$KM>ME;(C7H*-7YG%[1' M,VZLQ3.-F51.8U"Z./$CL\2I'(YT,.%Y6@1B\LR\&*X%<7X@HO<5, MC6B+V;SA)G"PP^_KZ$KY"-$8HA];$Y,0*B"$L6E.KU>AT*R\IJ=QE&@,"KCP M(ZOI=?-A$`0D:6H"4&;,'=YAAA/=+FTZV&H@!F\L8LD!N=J[07J:>I*D9EE1 M:LP59M9V:`^#]LH$@G#A+L)A^]D&L4AOMQ]SB)D4AU8A/-/@NL"V641I'+,% MG@L;D,8R,3.=RGB75XBA6<#^@S9^ID&ZQ%[H#6ML^X7T16P&`"5WEU^(H6$( MSZ2MA;/]8"'2F-MPKL/H!H3J6_4G[.1=CM&CZ;(5GLD;V6G0Y=Z)"&.F;DXA M(@[C6SMB>9=K]&BZIQ.>67N:'WX/F!I[.LXXA.JGIOS=TUFB-]A#1O`=7*9! M6D?82X4Q2R6GD!"V+*95*$UF(M,S4*)Y4'KCZ0W)^-=IB)'3$6PL9=ID*YUX'F!6:Z:'88A&5R=BS1S%\'=18-00]CVJ)^K0LB.0-36QP`H M.^8M\R3TT3[(ZR@D`1.$TF-F\@Z]$1.1W$3\&28R MC:$,F8W,'#+H`Z30_.%+YD^9A2[T%(3R_"$_\4?\Q-J#ZH+;;B'],!P4W`8L M5$N,3YN`V ML-`:@\_3X>%E:&WB2)WA&(M,Q9D:CMB*Y+;2A[X\]1#1X)F$.D)3,_9&(D@3 MS\CP".E8-B]E7AX.K;.I7]7YEX3GD-=WKV=S'_NC.?9^!F=V_0'7ZGH!CLS. MQ4OY1]&\5*?6.90[".DM8YBZZX8NN/O<'5\]U!X=E_;][.!PMX;C'6P)X M5]?=Y84Z3+H>MS[]#P``__\#`%!+`P04``8`"````"$`2-[H1@T#``!&"0`` M&0```'AL+W=OM(AMZ(0+?+SY\6.\:?14V( M=,"A$QFJI>SGGB>*FK18N*PG':Q4C+=8PB7?>*+G!)?#IK;Q0M]/O1;3#FF' M.;_$@U45+<@]*[8MZ:0VX:3!$OA%37OQ[M86E]BUF#]O^YN"M3U8K&E#Y=M@ MBIRVF#]N.L;QNH&X7X,8%^_>P\6)?4L+S@2KI`MVG@8]C7GFS3QP6BY*"A&H MM#N<5!FZ"^9YX"-ON1@2])N2G3CZ[8B:[;YP6GZC'8%L0YU4!=:,/2OI8ZG^ M@LW>R>Z'H0+?N5.2"F\;^8/MOA*ZJ264.X&(5&#S\NV>B`(R"C9NF"BG@C4` M`)].2U5K0$;PZ_"]HZ6L,Q2E;C+QHP#DSIH(^4"5)7**K9"L_:-%P=Y*FX1[ MDPCH]^NA&TZ3($G_[^)IHB'`>RSQ#.;@K"*+(#\?1P8A MJ3UW:M.P%=0"RO&R#--PX;U`"HN]9O6!QE3DIXK('R4>$V0$/KUD&H3!(.< M$3)()J/_$,A*:^(C36(J\G,*@Q%N=,QX/H%*G"'P/F*;F7=>:T9E_),(W20W/K4IJ" M<#8Y"`RRV35D2FR3I5;.M$:3W41A&$^L,R4W%0$$33F?4,JV&I3/:'2YS8A'H2ZD'1XPUYPGQ#.^$TI((3RW&PO=V]R:W-H965TE#23YF/GL^C^VQ\_#+U\M9>ZO:KFZN6]U<&+I67WIOVI3M55:\!P[7;ZJ>^ MO_G+95>>JDO1+9I;=84WQZ:]%#U\;9^7W:VMBL/@=#DO+<-PEY>BONJ4P6_O MX6B.Q[JLPJ9\O537GI*TU;GHH?_=J;YUG.U2WD-W*=J7U]N7LKG<@.*I/M?] MMX%4URZEGSU?F[9X.D/<7TV[*#GW\`717^JR;;KFV"^`;DD[BF/>+#=+8-H] M'&J(@,BNM=5QJS^:?FYZ^G+W,`CT=UV]=$GK3LU[TE;'WZMKQ6H#>-$1N"I M:5Z(:78@$#@OD7<\C,#OK7:HCL7KN?^C>4^K^OG4PW`[$!$)S#]\"ZNN!$6! M9F$YA*ELSM`!^*]=:I(:H$CQ=7B^UX?^M-6M]<*T#1>LM:>JZ^.:,.I:^=KU MS>4?:F,R)LIA,0YX,HZ5NW`\8V5^!XG-2.#)2,S%VG%L=^U!3SYI'=X.$<"3 M.7KW.;K,$9YCBV.O/VD0IL[0(#Q'OZFG=VJV823PG.GUG20FI`L=/9(W;&CN M57Y),V%(K+#HB]U#V[QK,%MAL+M;0>:^Z9,6>$I12<8D^RC'(+D(RR.AV>J> MKD'^=#`QWG:6X3PLWR"92V:SQS:F;!%P"Y*YA#94@4@%8A5(5"!5@4P%<@%8 M@BRC-I#B/T(;0D.TX5'M.2"(I0C!+;A+J`*1"L0JD*A`J@*9"N0"(`FQ^C%" M$)JM#O_')#&]E1SYGME`)HY&2AX%H\FH#D(BA,0(21"2(B1#2"XBDDBPEOV( M;"$T,!EA*$8!\%2B1JO/5!I-1I40$B$D1DB"D!0A&4)R$9%4@H4;J62Y9+OZ M8!?C*PQQ''3A\>PI8L/L%91RY7P*F)$USKZ0(@YL!(*;)[M%HQ%O+49(@JC3 MT4:D7LO4V6C$J7,1D<2"/B*Q3&=!]LC^5)5>1J-[WD4,4(2Q)J.-G2',"U%F_$]9\U%1-(&]AJL MC6$-XLSH`0G&!2&>LB`4L2%IA938R'T+J)&SGC2BB"O.0M,U9+>(&5F#D+9A M>TJ&QB,+CSE!+:6CS=1!U%(FM>18J*5\9(&6)"W)^4`L`C[7CUC+^E$$].,A M!!01Q6+(9K2)*.+2\I)L]S&R21!/BFPRQ).+-E*@4(!)@9)J9P7@YP$3+SE@ MBL@)8RHC'U`C40.&"!I01-0`V22()T4V&>+)11M)`U+E(1$L=[V`5>5S'09/ M60@&R8NPB>HZTN16=X7UA3FZ4\Y$'"(S]6UG&O`GSZ686TQ."88@ZYQ:#DZP7*0_OGQTFK29A`^>38<\@$(E#`8,D1:BCI`B#Z%ENF"+< M<0HNX9`H`>+*N-7$E7-H)F92"8HQ#\>"NU974KDHLX5!2I(H:W_`K"1)*)NG$,SDI#"3Y5DM0+T_JW8I,4C-,(38<\@92E1 M=MN`6TT]#3DD+"8,M]=RIBTK)3THY`];77QG>6S2"E-2 MCT+*>J4>0YFCE&:L6ITR(6)6#EDGQJL14ZT!.1<4+J.5Z2HGAX1;B;F'6LSF M6U0..#GG^JA%.2%)Y?C_E:;UIZ0TA835*(#[4Y24%'+$^AR5OQ%S='CYL-FL M766/B3GYE(()A\1$O:>]3&UOO5ZME7$EE\%#,$+RTLM=>@=WJ=KG*JC.YTXK MFU=R<6NYL':/\'BK_#@,N8+OR6TS6<95W/+A)F<&7_EP>X'Q1]M_A([B%WO; MAX,\QC//AX(3X[GG0]F)\<`T?+*]XSS;Z`*],F>C]F@&/23 MV3=0$_KI[!LH#7U2"&`V*`E!W[DWH>/#=0#V2!T?SO(8#UT?3L<83UT?SK<8 M#SP?#@\8#ST_G,,CSX_F\-CSXSD\\7PX5&#^U//A:`'X+8-#W_ M0AH8?WG:_0L``/__`P!02P,$%``&``@````A`,^A:X]D`@``OP4``!D```!X M;"]W;W)K&ULE%3+;MLP$+P7Z#\0O$>TY%X* MFB8C2J`3NI1=7="?/]8W'RBQCGX-#6SO0%>AB#5LFPTFC'%94]#.N'BA3LL+NB5%$9;7;D$Z5@T>IGS+;MER+1MP`=\,*:'B MV]9]U_O/(.O&X6U/,2&?5UX^/X`56%"D2;)@0^@6#>"3*.D[`PO"#^&]EZ5K M"IIA9VS`NK7T5)2(K75:_8Z'J3S9#H?C5/4>H.$12,AKP?N M^')A])Y@KZ"D[;GOO#1'XM<301,>N_+@@LXI0:\6B[];9MEXP798,7'$W$<, M/@=,.B`8B@[*J':]L@=[95\/;^4^;IS*9*_+C/]'QH,+BL^_YN?G"4;,Y`0S M?5T9(=:,=3E#X;/!'"=@MHP3!E=;N98'";/CU+O\` M``#__P,`4$L#!!0`!@`(````(0"L<22HW08``+<:```9````>&PO=V]R:W-H M965TN_YE.#7-:`## M==B:IW&\A.9?G+2]5> M3FNN(2?KF7(TP_N'4W@;*=JGOH;M4_V_';1&H:ESHLGJ]=7SV=(>ZOMEO5E'OZHM%?VKKOANXX+H!NB0>JQ[Q9 M;I;`M'LXM!`!DMWHF^/6?+3#T@[,Y>YA$NCOMGD?A+^-X=2]9WU[^+6]-J`V MS!.:@:>N>T&FQ0%!X+S4O--I!G[OC4-SK%[/XQ_=>]ZTSZ<1IMN#B%!@X>%; MW`PU*`HT"\=#3'5WA@'`_\:E1:D!BE1?I\_W]C">MN;*-XVG9AC3%E&91OTZ MC-WE']QH$PKL[!!G^&3."R^P5C;T=2^)2TC@DY#8B[7GN?XZ`))/>H?6:>CP M21R#^QPAP,D1/EF/;-2?=`AK9O*#3^;'1WJG9AM"`I\SH[Z3Q(8\P=.&$H9, MS;W*+W$*3!D55V.U>^B[=P.6*4SV<*O0HK=#U`/-)2P)RZZ/D@NR"K$\(IJM M&9@&Y,\`*^)MYWC>P_(-LK@F-GO=QI8M(FJ!4A;1QBJ0J$"J`ID*Y"I0J$`I M`$N0A6D#*?XCM$$T2!L:U9X"@EB*$-2"NL0JD*A`J@*9"N0J4*A`*0"2$*L? M(P2B@;U&2!([6,F1[XD-9"++)"6/(F;"U-&01$-2#00D-*$9%$@KWL M1V0+HH'%"%/!!'`\7U$)&ZT^4XF9,)4T)-&05$,R#[EE*^LT8>TTBE1#,HTU9S;3"6'9CJ(-:Z>LI8A( MVL!9HVMC.9,X,WI`@E%!D*7Z+A/-9M,X\DUFT+C*44;*5`HP*1`4;6S`O#S M@)&7'#!&Y(2QE9F/L)&H`4$$#3`B:J#99!I/KMD4&D\IVD@:H"I/$\'QUPO8 M53[78?*4A2"0O`G;6EV'NMR:OK"_$$>?YTQ"(;12WW:V!?_DM912"^Z448A3 MYQ3B5@6%,+43:-0EM9B<9+U0>7C_ZK!Q-0D'.%T,>P*!2!2*""0I@ATE10B$ M+W'3$J&./+B,0J($&E=!K3A72:&9F%$E*,8\70ONVEU1Y:*L%@(I2:+L_1&Q MDB3!7)(D!.)AI-11E(18B9)H7`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`:1BB0D!G@Y(0])UKB;T0G@-TC]P+X2ZOX[$?PNU8QW,_ MA/NMCD=!")<''8^#,)[#DR!,YO`T"-,Y/`M"N%3H_'D0PM4"\"7+*/C9X%8] M-[]5_7-['8QS#BP&\_W&PO=V]R:W-H965T8\!W MC1V-`7/1KK1:97>?&8QM-,98P,PD?[_5=!=](QY/-'F(X^.J0_?IT]45^N'K M]_)LO.9U4U27M6F/QJ:17[)J7UR.:_.?;[LO"]-HVO2R3\_5)5^;/_+&_+KY M_;>'MZI^;DYYWAK`<&G6YJEMKRO+:K)37J;-J+KF%_CE4-5EVL+7^F@UUSI/ M]UU2>;:<\7AFE6EQ,2G#JKZ'HSHUJ8[ M&TWG8]>&<.,I;]I=02A-(WMIVJK\CP;9C(J2.(P$/AF),QM-G.E\\1$6>%XW M%/AD+&0B=PX!_-PEPR<.X>[<)R5#>N**T-U[-?J9TL%:T18'@G-VIR;!JQ"`_YZW3A3Y\%Z M!4]D+&:KQ]ARA(<1Q`"$UE>!0`5V*A"J0*0"L0HD`F"!++TV8)3/T(;0$&UP M5EL$!+$4(3`"4WP5"%1@IP*A"D0J$*M`(@"2$.[G"$%H8.<*)K'G2WGF6Q8# M3NR=-)5#O#ZD5T=#`@W9:4BH(9&&Q!J2B(@DTN1S1"(TL!EA*7H!G*DK2["E M0>XME?J07B4-"31DIR&AAD0:$FM((B*22E"I!O;4B%2P]E1DS]N*UO&!D\&% MND*K#2'I-,*Y;2GB.OTF\UC,K$=\AO"-&%"$'"&]UO9"*4H[+2UD"*>.M)B8 M(BZX1:!6*F(BIDDJS125!M2`4:,<)%J6@R%P5`A/5TSDT2"G.[EIN64(/39) M`0X8XG0E?3D9DS^R%W=:4J@11WV,,)Z90A33('?2/6L\&BO[/NE)8-4EM>#8 MD3QU6RT2+:O%$%@-0:V)/$V/!?%%]QDB^(DABVX&[I!86DZH\49]C#`<32P: MY!(3O&Y`+&5QDYY$%8NTU.*!?ULL$BV+Q1#96LI2>31(M!9#!&LQA%IKT%E: M3JCQ1GW,+;%HT,^=U9.H8L$L/R`6B9;%8HCLK)GB+!8D.(LA@K,H`LLM3',Q MEXEV6EJH44=:3'P/=2*F27N/](R21+2!_&!![UADZ1"")PN[;N8;*>I(^]I>>WZ@IF>_?_-+0=5EHQY5S8DI]AU]_LQ7@,+HVO M0X$.[70HU*%(AV(=2B1(UHOTM+?TNJLILVEG#(_!26X9)+9E&,7]X"/$71,P MZ)W.3$\,$>+T$4*R9!$;@,?(6Z#`"':KTWFMK/0=&-$/"O$+,X=(20= M`'I%HUR\9]-T$Q\F&X[TOA\P'&V5)<,Q2#+<4JFI'@A&=),,QR#NG`"CJ.&< MZ^T<7IBB!"GCQ#B]/%=](F4*+N,],&B6+_6A]!N6C(?@V3S M*?V79],HR7P4DGHY!H'@?#VT5ABYN&M#A$3[:?0QBW)OTB?(-6`XF.,G:$A8 M%!\R2/+A0NOE6!0WB@_O]0F7U,LQB/9RD]G<7>J5CS%Q?X6,"78;GO`1)Q=6 M0Z]\E(OW!S"M^0^9(@)B`;CW16\&-2?_#B!(0T235;P MC@P2K'Y$<-]Q38_YGVE]+"Z-< M;K9R>%TS'H$[#E75XA?R@/ZN;/,_````__\#`%!+`P04``8`"````"$`#IC( M<=("```("```&0```'AL+W=OT!2EV$O/ZN:/`ECI6XR&@<1):+A.I=-F='?O^XNKBBQCC4YJW4C,OHB++U> M??ZTW&GS:"LA'`&&QF:T:;Y5HG"5;.V!3?%SZ!0SC]OV@FO5 M`L5&UM*]=*24*)[>EXTV;%.#[^=XROB!NULP*]$>*G1V\$UOIW5BYNM1NF6.KI=$[`OT&M&T9WIXX!>)#3IZAS_*M)"$[)%DC2T;GE("^A868\8&03(^081#,T!6WW=CFOK06=(PT492F.[ MI]$BN/RHP7BNRZ*O\SXR*G2\.&T8Z(>J[W<4P6.I?<1?Y.%-@0LWY$4WD\6' M7O#46&`?&7E)HM->BQV"!W;@4$ZHN[\S*,`KLW[)>L.OE)!+@B-/;W^K/W<]<--"5.*+Z*N M+>%ZBS,U@:G41_MYOTYP<+R.3],U:,%&V._`'&Y9*1Z8*65C22T*X(R".=@Q M?I+[A=,M)`K36#N8P-UK!7]<`9.I\UYH[0X+%.C_X:M_````__\#`%!+`P04 M``8`"````"$`!J_($VP%```8%```&0```'AL+W=OJ. MBC3HDG?P_NVYO+9B`0!%M:=-1GX+?& M.*!C_GKI?L?O"2I/YP[2[<.,R,3"P^<.M04X"C(3QR=*!;[`"\!?HRI):8`C M^IO2K*9%!4!9B\"GTP$ MRNO.V(#%PB>+M1\>'T;KQX=/I@'3N7/\!8N%SX??W89T]0.3+X^^O44ST2=V MEW?Y>MG@=P.Z!;QNKSGI/3LDPCRE-`%#DK_*,227J#P1F94Y,PU(7PN%^;9V M_.G2>H-B*AAGHW-LF;'E#%(Y1':G`GL5B%0@5H%$!5(5R`3``EL&;R"O_XUX8!@EF($9_"0G0KL52!2@5@%$A5(52`3`,D(]X81+A3+[;[G-4&B MH,.%FK#]F3S1#>.`UE`XODS9#I3!#`W9:TBD(;&&)!J2:D@F(I(GW@U/R%KX M8.,0&>@]<'XPP/&5OMA0$G%\(*DN#93!)0W9:TBD(;&&)!J2:D@F(I)+8,B- M%IK,`._.9?&RP3`CZ+\;E>3",D(7%R+2>\3GMF%(O]7UG"U#O*'+=A1QYOUJ MY-F^I]3>?B!PV4A#8DTV89P%DW5FGEROZ4#@LIF(2.[`-B2Y<\,%V!BY#80M MV\`0T!_JPO87\OML&2D8G6'(N"+M&<*\FMN!*XM$6DBLR28#1WB;0-D$4GDD MWYG.Y9&R007LD\R"S>4!LPA;-HLAL/6.9@5*IVTIR>F/070+8@@]@Y!-:<\0 MIZ\`VW8#5VG&2(N)-=U$XZ0_U,W$&,D;^I^0_TD)B33;1.*DB:T\5QS,Q1'(&TOV`,X0M.\,0N6J4 M[MA2DE@U#!&JAB&L:AP_4/HTTD)B33;1..F/9#,Q1'*&G/8D:^C1[\&UN5>1 M+>.07$W*,KGE+*&<&.2,R_J>0QYO-D]MV8@+C548-(R;ZB"F'Y!&5%2'C6E^- M*#M-3JJJTPX)O?NL6=_+[GRA;+X1 M)XS%%W-(+-%!69YZ+"+W)&2RCE"S]-Z#_CRN4'-"6W2YM$:! M7\F=!MG3!I3>M^S\$,Z,T-$*GO@A'/IT'.YGGOH50.%OR+W-#?[&">$WF:ZS M<4/X8:+C3U[X!//2_['Q0CBC`VX-(\.]S#4_H5_SYE36K7%!1YCCM%_]&WJS M0Q\Z?(4&@AL.W,&-3/_U##=P"$Y"TPG4[Q'CCC^0`88[O?4_````__\#`%!+ M`P04``8`"````"$`]P=T&F4"``##!0``&0```'AL+W=O01C)6ZRVD2Q91`)W0INSJGOW[>7]U0 M8AWO2M[J#G+Z#);>%A\_K`=M]K8!<`09.IO3QKD^8\R*!A2WD>ZAPR^5-HH[ MW)J:V=X`+\=+JF5I'"^8XK*C@2$SEW#HJI("[K0X*.A<(#'0\_-;PF!/WHEM]/#9R/*K M[`"3C67R!=AIO??0A](?X67VYO;]6(#OAI10\4/K?NCA"\BZ<5CM.0;DX\K* MYSNP`A.*-%$ZVA"Z10.X$B5]9V!"^-/X'&3IFIRFRVB^C&<)PLD.K+N7GI(2 M<;!.JS\!E'A3$TEZ),'GD62VN)2$!4-C?'?<\6)M]$"P9U#2]MQW8)(A\?L! MH0F/W7AP3I>4H%>+17@LTMERS1XQ<^*(V08,KA,FF1`,12=E5+M";<7C8]`%GJ.&PO=V]R:W-H965TUVXL>J^',SG*Y6ET]J1H]"F.E;C*<1#%&HN$ZETV9X9\_;B\N,;*.-3FK M=2,R_"PLOEI__+#::_-@*R$<`H;&9KARKDT)L;P2BME(MZ*!+X4VBCEX-26Q MK1$L[Q:IFM`XGA/%9(,#0VK.X=!%(;FXT7RG1.,"B1$U4F6!)C6JUR"`U]V9$21X4V27B\Q6:^Z^OR28F\/GI&M]/ZSD?E7V0@H M-FR3WX"MU@\>>I?[$"PF1ZMONPWX9E`N"K:KW7>]_R)D63G8[1D8\K[2_/E& M6`X%!9J(SCP3US4D`%>DI.\,*`A[ZNY[F;LJPY1&R32>`QIMA76WTC-BQ'?6 M:?4[8)*>*7#0G@/N/<=D'LT6\20Y34)"/IV]&^;8>F7T'D'+@*1MF6_`)`7B M]_V`$8_=>'"&%QA!KA;VX'%-Z6Q%'J%PO,=2!X^E M^DC7]"->:+C_V9*V5A4BP(HX\Z+"4,RO#C=0N8PZ;2#Z=8]5O`O$W"2XPB,%UJ[ MEQ<0)L/?&PO=V]R:W-H965T/NXL/E%C'VH(UNA4Y?1:67J_>OUONM'FPM1".`$-K MV%KO/AE9?)&M@&I#G[`#&ZT?$'I?8`@.AT>G[_H. M?#.D$"7;-NZ[WGT6LJH=M'L.CM!85CS?"LNAHD`3)'-DXKJ!!.!*E,31@(JP MIYPF("P+5^E<(`G$KA&8&X^!ZX")!T0( MHH,RJ)VOC&!4QJI@*C<^,)9)3LND4QDL>@JM>]LH'@+SX-69._09C_5)#.7>1Z!PH[1> MJ?AB*OIVI1$\E=I'_-B.!P;F;FSF;5X$3WGWDH]0=? MJ"`7A*:>%B_*Y]>LWV5*F$I\%$UC"==;7*$);*CO&+VS\XW4&BL'RU@X7;W];P@Q6PH2+\S$JM MW>$!!89?]NH/````__\#`%!+`P04``8`"````"$`XE/IGB\&``#M'```&0`` M`'AL+W=O2V=E/P2UY!_=4ZO5>,M2US<97'Y M^G;]DA39%5R\I)>T_H%.?2]+-M].>5'&+Q?@_4E8G#2^\_5YV+CU_+ M]/![FG.H-O1)=."E*%X%]-M!F&!Q,%C]C!WXH_0._!B_7>H_BX_?>'HZU]#N M"!@)8IO#CR=>)5!1<+.@D?"4%!=(`/YZ62I&`RH2?^Y\"H'30WW>^>%J$=TM M0P)P[X57]7,J7/I>\E;51?:O!!%,2OK"U)[B.MYOR^+#@WX#NKK&8GK(!AR+ MG$)@)CVT68XE"=D))P_"R\Z_\SU87D%EW_>4+;?!.U0C49A'B8&_+8:TB`"R M:5."-/HIV)IP31H"A,OWDZ7WK5T:6&-;#1"U" M(P@0=X("#,T!6FW=*.LJ)T-+D$-H&)1^:-%N&N*\C8QA4V>Q$--H"ZTL,"QM M8H2N[8Q7>MC;+17@`>.NB9*Q!#DPAJ$T&1,2+2#[VUF(=3IA9=$(A]V4:RT6 MFMW;5K=#";`>2EGDUNWOC;7N%[I5$QF0]W3]\4<6$L1@G3:?4J426?==41G#;GURWU[L(A`#YK=J9YJMD2YL+;($XG" MQ=WD;A7GJ#'CC4GGW;5$YSU+H8A%HD@XX.VL4<00J8FJ#Z4)'4`C=*Y=0CI7 M0YR<9VNH4Z05JMXA$*[:L=?C&N(UP;)5K;[KN]:UFBV)KDL@D-7XOH]<:0*A*$W MC4GCU+L%ZX$-O1%[,"(.0D=;Z>E:IDQZX)'3G,Z2&D0;Q53J8RFF15?<.`V% MA=J$A8T0* MP&8I!Z(Q6J<AJ9;H4FS`#C,B(TRH0.^"(CBOH5<328A5!F5ETOHYVA>JSU"$7SC856D-!)T@/)8@IDTYZY/K"9DD0H@>DNWVC2#>J--UHBTRY M_7S&ACK5F'3>(U<<-DNG$&WP7G>>%>U&N29I1Y"B.=]$2,+M7N,R?<`;D\YY MY`H4S1(R1!O1A`,P#:]UD46EG*ZJN-"(HG0*@K5B0J).3;3#.YJE4XC&:)UK MRCH)E(U4*(=-"V\W!HVDJ_OIKW"XT*!MU2I3(>7+$/G&(>/EB?_"+Y?*2XHW M\:(#?J+9;UNS>@O#[C8/L#?@/!T\66\>H`&6)U$(3_!:8:XAJ\T#_$IA64/` M&US)+4]"`AE8GS#QQ)H!@PS@'+!X8Q$\6=F>@#.[+R!CPP.5M&UL(*($`2B@``$` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````G)%!2\,P&(;O@O^AY-ZF M:4%&:#-0V-\\>;XOU;+73?(%SJO6 MU(AD.4K`B%8JLZO1\V:5+E#B`S>2-ZV!&AW`HR6[OJJ$I:)U\.A:"RXH\$DD M&4^%K=$^!$LQ]F(/FOLL-DP,MZW3/,2CVV'+Q0??`2[R_`9K"%SRP/$`3.U, M1!-2BAEI/UTS`J3`T(`&$SPF&<$_W0!.^S\OC,E94ZMPL'&F2?><+<4QG-N] M5W.QZ[JL*T>-Z$_PZ_KA:1PU56;8E0#$AOTTW(=U7.56@;P]L/[=-8GW^PK_ MSBHI1CLJ'/``,HGOT:/=*7DI[^XW*\2*G)0I(2DI-T5!24GSQ5N%3ZWI/IN! M>A+X-_$$8*/WY9^S;P```/__`P!02P,$%``&``@````A`*I:%N\6`P``DPD` M`!``"`%D;V-0&UL(*($`2B@``$````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````G%9=;YLP%'V?M/\0\=Z2?JB:*D)%P&G0$LBPDZY/ ME@M.@T8@PD[6[M?O&I0$6I.J?3/V.=?G?G%MW;VLL]Z.ER(M\H%Q<=XW>CR/ MBR3-GP?&G(S.?A@](5F>L*S(^&E3+GH@8E<#(R5E)M; MTQ3QBJ^9.(?C'$Z61;EF$C[+9[-8+M.8>T6\7?-SR=*82?#2GJ9Q68AB*7OH)>:9938/+5"' M>;PM4_EJ]RVS^6GAF&7`R9D3D4=*`(@=5WFIE^R&P0)%I-(Q2X/M)[A^=# MC'[-@4%5A#M"=KH4+K1:FK5`"7N"5M/BNK.G6%I*=Y#5/5K*:0\NM9R6!QC^ MZLDVXZK+JE__QQ2/2Y9F@@:L5$VY@__EH1./#7RB):BGI[SM"L`U;M+>+O^`D6?]!/7@$;M-=WMJ-S24KKSKP+Q28I*["_U8OM],"!:"]1M?< M1Z:6'XOZC65?7)_WK_KPLFCL6>;Q-67_!P``__\#`%!+`0(M M`!0`!@`(````(0!,"'?^XP$``$,7```3``````````````````````!;0V]N M=&5N=%]4>7!E&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L` M````````````````'`0``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`"ZU M^7/Q`0``.A8``!H`````````````````0@<``'AL+U]R96QS+W=O; M8`4``/T3```8`````````````````$X.``!X;"]W;W)KPG0S9,%``#E&@``&0`````````````` M``#D$P``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-98B5D%!```\PX``!D````` M````````````B!P``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`)*VYD1;`@``3P4``!D`````````````````PR<` M`'AL+W=O&PO=V]R:W-H965TA)?5S`(```8(```9```````````` M`````&(M``!X;"]W;W)K&UL4$L!`BT`%``&``@` M```A`&;9#":H!0``A1L``!D`````````````````93```'AL+W=O&UL4$L!`BT`%``&``@````A`-6O\X?+"P`` M`6\```T`````````````````96\``'AL+W-T>6QEP``>&PO=&AE;64O M=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0!]@7TOU`(``+('```9```````` M`````````"""``!X;"]W;W)K&UL4$L!`BT`%``& M``@````A`$@'_DZ&PO=V]R:W-H965T&UL4$L! M`BT`%``&``@````A``T[DS&#`@``X@4``!D`````````````````[HT``'AL M+W=O"0``&0````````````````"HD```>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`/U'XNQU"0``@2T``!D`````````````````N98``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`."]/!"7`@``E`8``!@`````````````````$Z,``'AL+W=O&UL4$L!`BT`%``&``@````A`$1N M;6W?!@``OAH``!D`````````````````<+P``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`!!&5;2N!@``&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/<'=!IE`@``PP4``!D````````````````` MQMP``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`.)3Z9XO!@``[1P``!D`````````````````2.4``'AL+W=O XML 22 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Statements of Operations (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Income Statement [Abstract]

Revenues $ 13,635 $ 22,920 $ 48,370 $ 83,548

Cost of revenues 565 1,754 1,944

Gross profit 13,070 22,920 46,616 81,604

Operating expenses

Depreciation and amortization 9,824 8,068 27,006 43,982

Selling general and administrative 220,021 316,856 616,167 996,189

Total operating expenses 229,845 324,924 643,173 1,040,171

Loss from operations (216,775) (302,004) (596,557) (958,567)

Other income and (expense)

Other income 97 25,000 97 25,000

Interest expense (125,825) (11,866) (436,398) (81,886)

Gain on extinguishment of debt 2,400 (36) 3,100 1,691

Total other expense (123,328) 13,098 (433,201) (55,195)

Net loss $ (340,103) $ (288,906) $ (1,029,758) $ (1,013,762)

Basic loss per common share $ 0.00 $ 0.00 $ (0.01) $ (0.01)

Basic weighted average common shares outstanding 110,683,012 105,073,960 110,374,484 102,694,597

X

- Definition

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12317-112629

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents a sum total of expenses not separately reflected on the income statement for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 7

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.7)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4,6)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OtherExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Reflects the sum of all other revenue and income recognized by the entity in the period not otherwise specified in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.4)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 4

-Article 7

+ Details

Name: us-gaap_OtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 4

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6386349&loc=d3e3636-108311

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 23 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK OPTIONS AND WARRANTS
9 Months Ended

Sep. 30, 2013

Temporary Equity Disclosure [Abstract]

STOCK OPTIONS AND WARRANTS

The following is a summary of option activity during the nine months ended September 30, 2013.

Number of Shares Weighted Average Exercise Price

Balance, December 31, 2012 9,400,000 $ 0.05

Options granted and assumed 300,000 $ 0.03

Options expired 400,000 $ 0.05

Options canceled — —

Options exercised — —

Balance, September 30, 2013 9,300,000 $ 0.05

As of September 30, 2013, 9,300,000 stock options are exercisable.

On September 23, 2013, the Company granted stock options for 300,000 shares of its common stock with a strike price of $0.03. The stock options were exercisable upon grant and have a life of 5 years. The stock options were valued at $8,400 using the Black-Scholes option pricing model based upon the following assumptions: term of 5 years, risk free interest rate of 1.33%, a dividend yield of 0% and volatility rates of 443%. The Company recorded an expense of $8,400 for the nine months ended September 30, 2013.

Stock warrants -

The following is a summary of warrants activity during the nine months ended September 30, 2013.

Number of Shares Weighted Average Exercise Price

Balance, December 31, 2012 6,765,200 $ 0.06

Warrants granted and assumed 471,280 $ 0.06

Warrants expired 2,562,500 $ 0.05

Warrants canceled — —

Warrants exercised — —

Balance, September 30, 2013 4,673,980 $ 0.06

All warrants outstanding as of September 30, 2013 are exercisable.

271,280 warrants were issued during the three months ended March 31, 2013 as part of a series of convertible notes with attached warrants. The warrants issued allow the holder to purchase one share for every two shares issued upon conversion at an exercise price of $0.07 cents per share.

On May 22, 2013 200,000 warrants were issued as compensation for consulting services. The warrants issued allow the holder to purchase one share at an exercise price of $0.04 cents per share.

X

- Details

Name: us-gaap_TemporaryEquityDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

+ Details

Name: us-gaap_TemporaryEquityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 25 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

FIXED ASSETS (Details Narrative) (USD $)
9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Property, Plant and Equipment [Abstract]

Depreciation express $ 1,003 $ 943

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES (Policies)
9 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

Description of business
Description of business – Skinvisible, Inc., (referred to as the “Company”) is focused on the development and manufacture of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations, offer solutions for a broad spectrum of markets women’s health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.

History
History – Skinvisible, Inc. (referred to as the “Company”) was incorporated in Nevada on March 6, 1998 under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.

Skinvisible, Inc. together with its subsidiary shall herein be collectively referred to as the “Company”.

Going concern
Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $23,601,123 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

Principles of consolidation
Principles of consolidation – The consolidated financial statements include the accounts of the Company and its subsidiary. All significant intercompany balances and transactions have been eliminated.

Use of estimates
Use of estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents
Cash and cash equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents.

Fair Value of Financial Instruments
Fair Value of Financial Instruments

The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items.

As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The three levels of the fair value hierarchy are described below:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

Revenue recognition
Revenue recognition

Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

Royalty sales – The Company also recognizes royalty revenue from licensing its patented product formulations only when earned, when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Distribution and license rights sales – The Company also recognizes revenue from distribution and license rights only when earned (and are amortized over a five year period), when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

Accounts Receivable
Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2013, the Company had not recorded a reserve for doubtful accounts. The Company has $1,000,000 in convertible notes payable which are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®.

Inventory
Inventory – Substantially all inventory consists of finished goods and are valued based upon first-in first-out ("FIFO") cost, not in excess of market. The determination of whether the carrying amount of inventory requires a write-down is based on an evaluation of inventory.

Goodwill and intangible assets
Goodwill and intangible assets – The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other”. According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.

Income taxes
Income taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Stock-based compensation
Stock-based compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to a Employee Stock Purchase Plan based on the estimated fair values.

Stock based compensation expense recognized under ASC 718-10 for the nine months ended September 30, 2013 and 2012 totaled $21,200 and $0 respectively.

Earnings (loss) per share
Earnings (loss) per share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_BusinessDescriptionPolicyTextBlock

Namespace Prefix: SKVI_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_BusinessHistoryPolicyTextBlock

Namespace Prefix: SKVI_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_GoingConcernPolicyTextBlock

Namespace Prefix: SKVI_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122427

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02, 03

-Article 3A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 860

-SubTopic 40

-Section 45

-URI http://asc.fasb.org/section&trid=2197723

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2196966

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 325

-SubTopic 20

-URI http://asc.fasb.org/subtopic&trid=2197087

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.3A-02)

-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=16385135&loc=d3e33801-111570

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph k

-Article 1

+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144384

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for determining the fair value of financial instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2155942

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-URI http://asc.fasb.org/subtopic&trid=2144439

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-URI http://asc.fasb.org/subtopic&trid=2144471

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144681

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-URI http://asc.fasb.org/subtopic&trid=2144749

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32247-109318

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32280-109318

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2196772

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3-5

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 20

-URI http://asc.fasb.org/subtopic&trid=2196816

+ Details

Name: us-gaap_ReceivablesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2228939

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 27 0001255294-13-000875-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001255294-13-000875-xbrl.zip M4$L#!!0````(`%N);4.1&Y^VZD$``'6K`@`1`!P`-Z[ MJ9TJR^:+2)%VDBW'CG.NR3C>.,GL?IJB24C"A2(T!.F7^?77#9`29%$22-&. M/4YJ)I%$H/OI1J-?0!!\]8_;26)L?;,'8.D$8MI.GJ]\^6R=W1Y M?':V8_SCS7_^AP%_7OU7KV><4I+$!\8)BWIGZ9`=&N?AA!P8[TE*LC!GV:'Q M-4P*_(6=TH1DQC&;3!.2$[@@.1T8SIYW9?1Z&F2_DC1FV9=/9S.RXSR?'NSO MW]S<[*7L.KQAV3>^%S$]LR"(RH_6OMY\^&)??:'I-.;U*R-[M$/"?A#E< MLTW+^1_[Q++P+^>S;1^8@X-^7Y-/'N8%G_$Q;WU3_I'=7]U>90D]P+\-&(*4 M']QR^GI'$>W&V6/9:-\V36O_7[]^N(S&9!+V:,KS,(W(3M4KH>FWNGY6$`3[ MXFK5=*DE,J]X./MX^2KD<\H(<$W[)21P-_MPM6I(.>O;UF"=?+)%U:'@O5$8 M3F<=AB&_$HW+"S5@X$K&$L)K^X@K-9U2EJ;%I!Y7G&?[^=V4[$.C'K0B&8UF M_39W6NP`&/#G>G3B2@VZRU^^GLTZX!?1Q@P<:$VA'!UQ8ZR1G9P66*;F+'V*](R3D2L30GM[E!X]<[IQF;5*A,*V?R M<]";\Y]U(VE.\[O9K[/?:8Q7AA3\DD!)%M16F=?QV2\[;V"V6J;OVH/!J_W[ MG>?L]FOYE=RFH'(6+Z.`N9/EZ&;>S,6I*,VO+74#7ZAT0KGG[..%+M7O"P"J M'TN5KM;S$?\X?+:ZE9XIKU%2=:53)=D]^`^FR+-54BG`PRAI/F,'?ZT9.WA: M,[;4LZWHV7[^>K;;Z-E^'#U;?RT]-X]`#ZKGTKE:S]VY6@_I7&<1Z#D:X$($ M>O@P[?0L$TS\^2JI%."!E00#83O/64E"@(?.9=3JPWE^_JF3ZL-1W-J#Q-B: M*N_WJ.`YF_Q^S-)KDN6X8G/.,"/:_C$@:@N:.;BG?>8-U]D&]Q*_V:XFKP/;KD?TE MR];&AF._.,.Q?QA.%X;CO#C#<7X8CFXY*#+^'Q;S%"RF96&[4+,]2&%KUEO) M17@7PL=/)`&.\06@O7MYR!]8TBI=7]ZY6PGZ$A+S(R)MRM^P!M*F(59<662"U%?0OQV%&^$H6I;Y$H]8\`-_% M"CXQO0:K6M8M]CW'O;.XMWW9J!KHX#[&.JH*TQ.2L@E--['=K)?[?.L(5]<7 MM*"AT`N2P3S)-XS:%#[JCUE,Z,$[8?^?R(CR/`,#QEWU1FF?GW`S\;JMP)>_ MG)U_/;L\>_OAG7%V?OQJ?Q7%98['($P6)F=I3&Y_(7?:+%47M9*:RNZ$107. M_,]W4WW!++/W3TE?[5Y']D+,[W=RZ5J;OGJ[9"4UE=T17(VQQ6D2CK39#,.$ M$\EA@8!*^;C(,OR9\BA,_DW"K*DLO2IE6D=MV0!^(TGR2\INTDNP4Y:2^(SS M`D*%+MMSIAK`"FK+;+^RI$CS,+L3C\SPENSN4:DQ;ZF'3V3*((ZE(_F8BC:W M?Z.+V41MF:M`55S`N&W$)**@ M3_YZ!YAY@[YCN:_V55JZ]*OM[NOH]UW3-0?MZ%L:]"W;\MNBU]&.U7?6DS^* M(@83C7\B$:'7F`2^SQCGY7QH.RP6/A\V9[R>R?:0=$;2'MA!T!;2&63+*209 M,$E3RL>^(/`5E()77Y+0]&9%W$\ M&!+5C73%7,ONG8'MJ8&S$?.'$+DANVV%7'+$,=@!92F4W)`YG:7'X93F8=*Z M?#`#SP=9%;=;SV`+'%HJ,/V^Y0W,QCB.V63"TLN<1=_D"O9E<<6CC%Z1^&V1 M?X$*A$/(T%-/N02^T0FTY[FLBHKG7!MGYZ=84ZD^5X_A?9B?2![2E,3OPBRE MZ8A#^"PFA:A)P*W@_9>V5M.S'<^T+%LQF\W,NH&G8TP]VW8'EN.YV\`3VAZS M)"89QX0TOVNO+=>V^NIX+M-NQUU+&99G^8Y:'F_FKO@?B#C=:6(I_=[$J`M@ M;5+VIKAPJ2,G'^@U`4^5A^D(;X;*O'^;FJWO>H%B-NNY;(])+Q&U7-=IB^G> MK>+MD],@\#U;=92U]+>`H96SF3[,,*\%C)E;%P=BM5:#90Z<^G`AZ+;AJR=W ML+B@O8)OW2X!7K--H*W\OND$)CA[73Y=X-):ZPH/^'3R/ ML1Z^/-1BU)2KM\JYC5&_(K/HF\W1+!1VTPS(AKB*`)\3@A]P&7F"&R?^%+^OO/70NMB# MD-\?#!:6L3L!])B":M65CN6[5O!\!'UW&R4%.O%R)>D#"3F)M[N?9#N!;?K= MZV`=UJ>B'ZUJT7)LT_V^^CDA5_E9RO-,[!_ZDH:2`2"@7-QANLC(A!:3+0IU MSQK8?7717IMCQV#UJC;;5@//]T/;<:W2MP)UR>\YR*55P;ANT+>?EUPZ=8WE M]GUUS>TYR*53[G@#V]QNN$2EM-A/!?$@+BRP@L"MRLR6O!\*OYY7<[S.!)C? M-;@F:4&T]ZNNW?+B.^KMK8IT0Y9+QP6OW[BP<%>Q#$A&AKEDN' MR*Y=_7/`D6QF>//]T,T\ M&@VI%?1U52MVVD*>.+QWN[#M+/4\2UG(5Z@W9]QPKIJJ>VC/>,L9NQ7C9O/6 M\LR^%F.U5+A7(70QYO;`-#TU8*_DMCVP1C81^(M5Q4/A:FHRONGYCX2KD47U M'=!8*V"7)$F@FI0OZTFP<3S!W>MY!LVO2;E!N0MC`_=B>4K6J\>Y4[R-;!!K M1=OZ?GB;VJ9C>;[K?5>\C6PV"#S+#[;%^W&*C\Q"O_)Z)QFKUW>L@7*K?XE) M6Q0-#3#PU8SC$%?.NK`-QU+M4SQO@/$9EF)ISZQTQBC\%E= MYJW@EAQ;W8ZRP*$-^Z8N"?C[7;%O:C#X'LDNF3?S1*YK!:XF]W.2=YR56J8= M#%Q%^@46;?@W&WD'TG/3Z8I]8U=A^WZ@KF1MS;[9V%N@I8&Z&WLM__D5Y'<, M_&E:@+,H$U66\@N2O0TYC99WJ.G:QZK=:CUS3_4/#:$\C"3K+6V=).93DF2C MT3XG2=;;_^-8UV^$CL8YB8^NH?F(G!=X`_KC<&EKJJ#0?):LW@[H#/I]7REF M&P%Y""G6S)#54GB^`\/W5*18/SM6;H9TS8$3>.83DF+-S%@IA>T%?5>MS[>2 M0K1ZB]N^\/PK2#"ZNQ]D+>R/JF?4'HY&7-UTPU6]E?%Q>$K3,(UP,QSCXA'Q M:F-#)TF5;?NV>C=6EW>7F)O?"+(]=0].6\S@NC/<67A"Y+]G:76XT?VGO=MF MK([G+:R?K.&W-;C&-VB#H#MLRV=D=;,'PUX\F6,SVZZ@-E^D\0.W:ZCE`4K5 M*1&U!REUL]Y_+S=K@>/AI&F^.+ZP8M&-.(M;SBJ:Y9$UU8I<)S8/Z8!J]%J, M.T/;>(':L08KMT9K@H4Z$H\;O,@8GL(;O[W[PK'Q[);&4933Z^43.%K;NF^Y M@\4R5I-]M\";%^`#=Z#>'>P<.'I\_@`:AX3+56_AZ;/O%GCSY2Y(,YPN<'\" MAW,GUTC% MSPJ);MUA8+L+IU/J<^\6=^-0'T#T";K`+;J)$Z7OYV;=5+2.;]X[*;F>VW:X MFNK/W.#U;"]@!EPYD M$8\ORP>73XH,YH`<8/%DO'SZB(LE"N5)I$L204N<)3"?/@Z/XO\K>"Y\5B=S MP7'5IQ@ZQ??HPC<.!K[C68\D_&+AHY!X2U)Q`%F8S'FZN%X1+7^7O^.>ZU'-@/'7_DDZG,15.L93OS3\9"N7AE;=Q)P M)QN>(8'Q=);HU@%Y.'$:;RT?V+[3M3AJ72$.Y^UF2>O>82A+7%K!:%[.ZX$0 MCY@>Q=>0QA+^F3U`=0Z%$[YL8RVC!30751V3+C8ZKC]OJ:-5F_Z@.G6M(?^N ML6^1F@D(2N@_9=G66V57W`+MVW:IKK7\MD.F=W-VK39*+U#MVRK'@<2?F1B' MCM.2MBP;EZ=0]GG5678;^"T]R8XUP6\T'RNG$#V$&AJP:IGLKF.S`.5^N!#[ M.A]ZOW!3SETB;K[<+NXB=0KY+/V2DC!+2=SET0.]\E!Y398=(&P5>5>-_P:$ M&)JK]R#,I[$2/+!!A[6R/M-N8#:_NRE6X5K"5-S!+.K4F7$+PURU,7A19-`9#Q:TEM]4Q5)!-WS\0N=-[98TX=P:W[1VR5FBK1/QMP6E* M.#\A>.C]M'J>6U8ON$[#\&W"D"$#V+=)@]#\YJ&!>V-SW0"GO"CPT)B1/C005R],Z`B^XFH1'=[-N!7X09'28$/CJA1>H!$-C)_"R?3P;Y8+ MU"Z_T?2:& M^#Y%Z`%LL7D,OC9A\HC`,(U!A+08AI%85P!8-$W9M7@D&5A,:10FNP:^0);' M)(/1%UA$MR)B/$R,*4L@R\]Z5[A%#H@GT#.[,_@=S\D$E!*-4Y:P$190V&W( M,G%.'&Z/!5X1RZ9,WK0V*%CF%,J$-.]!\B;.@"U;[T^Q8N,H"KZ9=')%\:Q_ M`65\%V=L.H:B-A+TR^_L"KZ7T`P"-'!=@N\9GT$!ZS&-0Y#\*F-A#/!B&$<0 M)ISB:ZW+!C>06U&IRBDXD4D8D2(7>A*`&(C?@XL]8<0DVS6F)./XN@N#PYA& MN"D9F8+V)B1'U!E)0X`V?R]&V(@)3$N$J#@XU&.\W=`X5:9498D0VM`4W\/`#7)+HD)8#[25.,($]`RX*`PAZ-3X`';[E8Q"0'M. MKL,XW'OD"2DE]+FB6_@I)_/>8%/<][?A.KT(FC,I;;1#_P: M@L,VO%W#"@(?W#R8E""9XFNGP3)^I5$&4PBLZ[*RHA*,,NH"CNA[(WR)[`V! M(!T19')*KK(BA.EC2T;!KG$S)JF!I\R(1K&8\J(72+4L^.?Z.<"+*TYC"I25 M7P68&?PP31@!0[NJ8*,Z('2Q&>=%AL;%PDPN>[T,LUS6>\Y&!">Y<'5BC!25 MBRD]!B<%7B(C8%57N%J1)`1O^I+DSF@6H5Z(DF=S_STKSS:/2);6>P`T^Q!R M(*&I*LX-Y9)RH MRY@T$/]A/--$F"J>?@-`GH"/F"E MXY%BWV'K+*2<2"2SL#W#D8\S5HS&0C/#0B16^"(GL=B+`D:BK(&!Q(P6$K0B M_8;O3)=\V14&4I&=X7#,J0^K[14R.>!%A"G1L)`IF9K50;\5Z<."9N`?,>0S M#7$9X%&%(N,3G'>-(LDA[\^)2$N8(!WF*LBI.-P+:U%I(C-ZF-O`X").C`,X M/@HP)!;)IZ:(`D*J0='U7%+A72"OP=QT3,#2T#)9QN5P2#<%%4=.RSPU9L45 M!*8K5N2K-*+PF6'!6+$XAR0F^`+,:2RT5SLA%S5OQ$R&)9:C^29%C%D1I)/* MW>Y\'.9@DT(P4+0QA*)&T`#,XBP)21)D#4%]@@TH"?@7"`Q'`0WXI7G1BPST M2:=)-9^J<4'W4.=3!2Z](:P&*B^]<%$SKM4LF8=%2-\A(G)`3"'/!1,$.I#\ METX<7'`B9O_,=XGY)=VJZL:A>IH`*`#WTD;TBXP;N)T6?L0<&3FC(/_):7X3;SR@L^"CX`P M+Y'0CTPPDLP$$<8"4;683.5HBQD?0ID6Y64`AA0=*8>3F;$I45B-MO@]ICR" M6%E6Z])G`>A20HMB'5,0.QV%LCBY19/Z%> ML=T&IDB4%\!#>CH,1D6"\F#%6OD]QA75O;0Y@!L#Y=H`?D`#NX;:&50^GPR/ MB^P4`O:T@!*RS,Q$WE%9B#`_!#I,V`W?G8U[Y231PBB^6<\0Q0(=C6%2)12D MPBF%&^?G=L;'8"H]<)@3(\:[.'2VU42NMQ@LHP`6C&>"6TND50M`&2$&)%/Y M&+[+=8\$%XI@&F)=5WS@]NGQK'%T>[RIJQ^)G(JG$AEQ`%O6KF-8]T'VF M-A[#=URWNJMJ60C;#(?H3UG*RN%)IP68A%CPQL5+05TL)<\)A6A%"7JM`^/O M'[!P,JR?H?#B))-/A99$H/`88^,_"B;JI:Q:P0RE_93KIX<5$?MG!<*N7"C% M<"]M>0.5W3(QP+@^1T*H(!+#$$0Y^$^L<-/JVZ&P^)*Y\S.4!/.>JC*`EU08 MTA)*A[P@!^I`+64E`,P.PDJS_]_>TS^WB23[KU`YIRZIPEY`Z,M[=U5>)[G* M5;+V6R>[=3]=(0G9O,7"!\B.WU__NGMF8!`@`4(2MB:[F[4EF.GIZ>GNZ4^^ MZUI6CKO41@V/";]MDA(,-U=9OSF2HT&.!)(^/N(B$8]%],H.1XBN%][<&803 MD-_Y?D'FE'X.FBR[@0(<)43)M5KF'DCHTJ%[.-E+N49YG[(`IEV2"6:&A$*. MH^4"@YI@<-(?F7(*3TBZZ;Y%XX'(A3.(<^U_5A&^BN7$8L!V0F='GLYQ`8/0 MUW,(G39$,HOXS]PJ!2H9J5N<;&EOY*UYW@."IB[>D0_DDCT6FNN=:]>,V`+& MF)BIEYR@H(R[C*P(%,'U5\EM`I(L8]O@BI+$ZV1&@$))%D7:NVCYP.^0D^=" MV<--L<_OCT1Z)!JZZ*T!QS4`_&8-6+N`B?USUO<6EIEXGL&93JP%W?Y*9>`*^C<8#,YLN0N&1B+IEZ[$#@M2#$*]&#&Z)U M"&\;P%X!)Y(%^PGN*4#V[DP71I'0G3PSLQV+7V.*$A8]`GCX6<)L97*OH/-_ M@@:EB"FZ(C65>'.RKBCP9\S`PT(H7H<)L&`R`Y4EIKDY;:V=,/V/K`FU!P01(KPC:$KS1: MQW?6[K6\Q[.5>;25.5;W57LG@"&55_04TS"N!ZZF<\3[,SS*K9KO]9TR&1;C M5)T.UO&;[M$`U>E".<&E2/G1QB=EPS/WTJ#G[RG!+X"'#I=@@5K(@Q/&W*$9 MW7D/#WC*40_QT5VFW8B/*&8,_O*9MP_A\3#,BMO3,VH/W8.9FYR9T#,PO09V M74=U$4EF6EJ8H_BHB@.'LW`1]=TB!$)%"'`9'KFK*"A MC@4L\:`#4`;070>7&6&M(I\#(WH1K=(O'`)@!W5RYAS=KD217 MC%AF%G+8=,]]PM-%;`"ON_XSCT^D8!A^C3K3/L^E$#J0[@@IQD9P@[D3)^$S M0%H4#>![?Y*SW5F@Z3QX(GY!3W(#:22-*#NS)UC;2;A/DJL=-Z[2`$\>7/SP M=IE&[?"X,EK3-`AGH'A@`)4`F"TT`OXSO2M$!K?1LO'='Y19)_"M%>(:#YTN MV?O(?N1&T;UP8Z%G`3B7%S_!B;NC0!)=\JB1/LC.HJYY<_2IZV*U&6@*5WNF M71#/N4'O'B;"`K"ZAL'#V:A+QGEG]+[`#`B`T,5[#;-T4'P!W*43O.3#74Y, MW3`,_(_[($6`/H[KIK9K9G=#01!AZCE=E1*72A':D3036>;Y`+=OORY1(W@I2@,(`3";(D?$9/:Q*Q3+!PQ4B'&V5P"1N0 MJO+'QOQ$B<2R(,Z,Q07^XN98_A+SC7'9-\PX;=!,./N8B`#NE<+J_@2 MA!H\&$;QJ2=^P*"6=V\^??YT]>8]R2)=8X$F=`BC*(WP950I.$_&U+\@O'QMQ_!,VDE@/Q8DD.1#<`+H^ M0$6<7>Z@D)QV:5H$QB`L9DXXTWX)X&]9`KQ#-\M[&&5&2@MM!7/#]/K&J6EH M[])8S(N;2_ZI%#BL2\&:"*G'J%VL@=^^4DK/K)6J*-+Z/&DC,,J3H`\III\N M[$`XB2-9)\HO1Q@/0P69CT<%Q`?>CWEL&;ML^P&HVV3G_%^*J@B$WNXP&0': M/RB*1.@H;!8+#$-(90X1*Z#="^FW"0OX9T>!C%RGS,C%2!VX-IRH3ZGM:\X= MS\DJY%,QXR5HW9GL+!=VKWN,K:.X$UCY3QBF__!`L6PSX9=TN`<3F#)I*=]) M]4FW3L\<78+C43A\130(%HQP_.F2A?UQTSW`@=H">2](F,DN(GR%F?'G'DO- M3F`_ML/,6SK%6$"HPE54UG5%/*HG#<%\+'@62$TATB;7:,&1Q5T>VFR7"T\E M#?LM@6SET*TX\Z*,D9'S_UD2K.W\*(LZPF7P,%9\"F47C.A2-*L3L\LU$0DZ M!BF:AWTW<>,G#&HC4W$^PHA`R(4`8`S8#R]B`;KE45`P)IP_R9>/D.&AXU\C MG*1!LJ-Q"FN`"_8,%+0/THK7QDR%;NJ;7D;,_^F0(PM'#TD3Q2@#]E'`>`:+ M)/[!O,4:SF#.4*!7L`8Y$+UIZS.P.4J4,6\ M0G8#13D/+S,S)3R$A[*G-?%YS`W+-\-P6,RQY5@1]W&'CB$@=T;\`H/1@VDI/-3;D#0;),]!%.CR+(?P$T+"+SW`7> MG?,7;MI!3#B&78H=8&?:B67J%MR5\8L30V+P_M'=(CXZ(6:Y@DZ/J3'OD?6R M$U6-J;"PG8CLQH7#U-5$K(%1PF\22*]A[)L$Q%460^"QWB-K@&)&P25W%L^\ M1X]8`!=#_'GGT?%\H7.(=!I\_R[P*>241ZL]\48D\`)U(F'N&FI'(B?B4"V` M=%!0$CR?(*@&9^3=PXLAB>D-R\.K^4.< M)[PTS!!I<%2KH`]-4\PPYPK3DALQ[QM+^8HEM28)45G>4V2G&TX]EBX@2P+N M0*'87R$&5L!\E\F\D@*#6>">A#BZ)L;>J5@3AZ68!Q5SA?*J`VDELMH%$#+U M'@K>IA>>MZR7H,H?J/('JOS!(><:]AAKM6'7"R@ MPZSSJ$H<2,U1UFS/ZE9^QXJ#'Y.PH`YMGJIFH*H9K*EFD))[EH2+VA)=+&;X MOX^IL:K#3$M5,-A?!8-L0ZF-9+)*6QC`0GG<2=]DQY?J`K"WNT1;JIB!*F:@ MBAFH8@:JF($J9J"*&1P^L5P5,U#%#%0Q@XK%#%)EO9+>G>^<3#?4W]+@NPY? M`E5-`U730-4T4#4-5$T#9LU1-0U438.BH_VR:AJD&LQ&922OO8BLY2[;KE4] M`U7/0-4S4/4,5NL9R(ROC(_E>X/SU/?4@MQ)GJ?*�K8R`W7R_?Z56J$+GR M!9T1.RP7534#5Z^CG-\WV,8OOF_.CP>58%#51!`U70H'E!`UGV M%Y_V5:Y`*;&_(`^5T_"O1+H?#(.\Z='%;/0.!MZHX@:JN,$+,,N_EN(&*7]I MP#=668](S;]V0QJMPWJ)JG>@ZAVH>@>=K7>0LJ4-/$6PH)GKG7^D(+O/:9Y[ ML/@`\N=JGOFH,A?"G-U3`WX=_.VGZL,79``)H^6O:+.\9B;+2TS46\098"ZB MJ[D$@+8$Y8"^^'[SX0T0\A3$J1_]_0W"9M"?3";+FFE6@;H.,2'@-S MQT!NRF]KS8)87H]B+X'XWH\T:H[;#9,P0U(1V04)/B-(2N3I!W?*/S7I4VM_ M88?\0[3<++*NOXW:#+M-3EW?CQX<3&I$BJ'?'Y#%\-]INK^_X8%D`OPG;Q;? MG6MV_^W/V@2-]N$IN94>(O=<$S_]K.$J3R/07-A2WZ1`X/RA&(TH*(MQRRXZGJT9@B_RE$T&``KXJHP!2P2D`5YZ"4HX&L1P M$]^!,P&#:I0#5!J6ER>IKH%.0^=(7)Z!?@Q+-G<"@]V&`6BM2")!>([WGAB( M8[M=3^B?DV+??DNO?G6FZ,L*6;*@*QC69J3R<H?.';[M;VY$LCF&9/'_3Z.YS_%2_T@,SUC3!MP3TB MQ.``P4U9L$\PCY_$-;/+NP('L6\;KY_Z8)VF<5#BVR7O^X+7<;0LH!\Q#![= M-+FRRYMB6GI_,'[]Q+>#=1Y4K2S3L;\XDSI:Y5:J>H.;1:,=K3-!5MC9`[.) MVM4&5A1FM\=LA]C[-W1'=)[+]:R!WALTN&J\-';>LRQ]/&QWH=WDYVX4G:,+ MAI5"HW*I#Z$[]5+'[;&RH7=(!/9PV"8?>G_DA+F(V4),J8K0;##T/K'76 MY^#*)G>=J@ZR\/^6CE\ZT=:[24-1]+GO[HIBRN>06+$^&K>B"S3#S6$Q7,$^ MV!BQMF[W6SF*FU!2<"I_8K4:Y8^ZY!O:C;OM@W2T,Z%+A=$KZSQN%,'R)#(_ MV&^4\TXY[Y3S3CGO7IY/ZV@6 M>D#FJIQW+XKZE/.N@YNBG'=H<38+3_]SS"(HJ;9?O;('/12D,HGV`X4ZQ3^ M[9GK0>E;QJ@)*(F5%)[\Q&VD6R$%]/%!KR^5NBZ;8"M(JN"D-B3412XQX25X M@\=ON/EN*\ST1GW;X+WJ-L_2`E!5D-0;F4:_-E`"I8F=Z;-D9MJ.?*S^8)SN M6?D$VX%2B7[J@D)(_.),VN$N0+YPK^5;DQNU_IP5CTR%.3?RX.V.B36`6V,% M3M\23)5.B67!!:\I3)DXC(I1!QNRS"6Q(X]>=V9+FMFJ,//8WC`Q$8Y4+VTQ MHP)Z%Z3"OI(L]FLJI\Y+JIMK*H MB[E2A)N5_UI&+E9?I8J`Z\JZ/A2#075FM)/^R`95>$2W!H*!=1D>H_-W]18A M5Q:$&:7?-D<-K:UY0Q%#U@!#A@@&"ANR>[H!<&0CAW(E9D7!V&RIV97RLJ(_ M]_<;C6V*J'U^RRJ.K[;?_2O;CIOE(IJ&6.V#]X&(SG$(AE!1<>0O(]VT1OK8 M[)UK;](W<*2`M0EF\W]H%3F5$^8#)D2D8 ME+6E2@M\LFKO45J)FU>S6P3R4]EJMZ*S)3R;-JQVLOR&8!`'NZWXOKI"(G=3 MH)JI7V"/41S>$#]@WW?+J MSI>%4WKX(^/N&V%LJ*=8`U)4ZDS;%JAU%1N[!S)I"U"_+U@;"]X6X95H.E<2 MGQW(Y>1%OV]1A5N4VX\CJ?5,6K^=!.6ULW!\9Z*Q_LQB7*N'XQHCI@&DKW!V M/DM>R_0'23BB*^H.ZZ`Q\-+D7!K<@ZZ@W?SI47\FM!])-:7E@O"\&0ZOV$B@ MICV=B+%>S)P'+)E%_1&#Y>T=U2OG@&$]8^RE06640V"P5"0/Y MK+@9@JFQ%G:G0G)D^D#QFJ3)8'K2-@=KAX%J./=\:NK!>UZSZF145AD[WLVQ MNX#&&^?$&9R2VBFJ+#$!R6%M50_FWF&.L8C-1W MI94;Y1AVJA@P::95.?Q-U/G%ZV_\_`V5\A?-[[YEZI!Y2/71\OX>N412=R_I M[$>P=)9R7T6ALAWYN1G,J6M"M'$:UG'6[#WVH)D7]=>D?B:5:5P3`_CRHC$: M9I'\(>JC7K#ZJ-I'45R3VHH>,HQCYSYFF=1SZ2"_L#9#>K[`XF:%*(<=8D%GHG*2&[B63*L?@K7D176`I)-V;%=CO$X4J"')I2\'Y9 M>1/*%-38(&?KA7+A##62??$%4&!C'OIR*/#5)"95(#MVEW\!=,='Z)N[!.%U MK[5KO%`*T:S$()FJOH94CR`T=AO24`DE'4)N)\1")C)SS1E,KH=ME&%XA;'' M8[VQ8J[BCS\DLZ&KH]_T1G(;:\1B<; MWI69[S0[+,7/2%O!VBX3&(F3E#7]T7QO3F/U63?'TM%X%V;Q-7++EVAYS^8ZY[$U"3PZ<('H M3VT>NMB]"[[$'J\A[P5OGO5Z;W58!/7,@<@EN,*[EG%\#?3C`HFC*);CB$ASL"B&=,'OD6/P?0G2_ M1)^@/31U:_2J/3(-R/&%LN$L.;X4IR`6M8+_E%OPI;L%$\I3?L'C66O7^&$U MOZ#$))5C<+^^*X7<'2*W$X)!.0:WF4.NG3,8]O1Q$^U<.08K.`8;W5.58["A M8]#W4R-WL(RC&*[)S(>3\Q@2**PDP%$Z!BUV*4_Q17XT+XK0CR;Y!.*[T&4N ML8QCX*L33N^$P:V'"'YP0E8#3HL`".;,F@8+XOMHH6?U$9BO,(Z=Z1V,(B9G M?KT$%`X%Y0,2$%C:AB=\QX'VL(2Y'?2`+5SFER0/F/N(W2+BIT#X*ODPY-=C MD$24)!4S+QJWHF;\E4.RO,)B@$AHE".AAJL%[.BS9EE\/RWN]2VB#N:C)1\P M.B)98B9N`";M+_T8*0=(X!'06G%CM>)-7;=1-D%1:;.*T5>ER<_:),),"N0- MDO/2=Z_F/!IPBX1#Y=#JY(U7.;240TLYM%2.F\IQ:\..JW+<.NU*4#ENG:9` ME>/V*IQ9*L?M^-;:-5ZH2X\2IP&XRM M)899$8ZA++/E>Z8LLZ]#HU666669W7#'4:D&52VS*M7@Y9AF5:K!*V+#JU&T M+\,VJU(-7HEU5J4:'.%:N\8/5:I!QTV("KD[1&XG!(.RSVXSATHU.)Y4@YQ] MMMCFFC'0 OY- M?NE5N]&4H6$5"_)$16CXR*ZOK:&AB/3X'`73\V_:1T..&N29BO!P29":9)96EAQA>DB82C?[:J267:]*L&W6^#*-@A]D/F< M1K(#UYRS,E\>#`=]RZ@]9VNL>5`X<_Y(5)R^+GNN.WW;'-H>FE9NQXM8],IW M.^%.J\@HY=/B@;89M=4?6/T<,1:QZI7O=LJLB^8J!&;7_#HWS[YXVZY9=FZ> M72^,2EYFY1&+5VA-IRZ9H12*]0S5ZE75M'H%\^?G7W[#Z:Z6)KP&![B(N.J5FKVC)\A2E<'P0Q6:W@Z%@>C%R9FI> MH/8W7I^6]Z1MH^^CM`O%DZP1I7]X\=UEFGO\*Z4>M\;0Y2.Q>=[VP>Q54H*L M(BE<$4S!L^B0?75^>/?+^Y9O3S:'K&BJ-F#I5=:8SHQA55@^P,E+K!J(2Q1: ME4/(V,_]4TNT,RT<;@U/?W"GH+I\P9K8:T[W/Z[[_RYDV.GKJ]U2?W.I6?>U M$\;/WP"8""L$TY%_+;VB=UX$/0XH6?W^P0^>7?<,)G0U/%A:GT9`,QN.Y_B: MM\"VSI0V?R35!3ZLE)-84V.:(*$2!/+N.+-'/!HS[<0V=-/N(;8%JB/1%%H\ MC.B>8/UW-$VSD39HF@Z+TC`Q\,*V8M@<9J4;I^X#D)*0RVS)B]-C7_7% MK.WZ`C6.72E78$RMFK2O8E'+C[TB[[-BX]IYWF-KY18"<`?&Y@#<*H2_Y\A< M^3A)>Z`QG8'O`E7@\*(X.1))+?CS%OSYL!S`.B"V]Z8(0BF.-'NB]SFS')^Y M3T=B"_YA'OO]1#&X.)<_J^Z9*L!0_1C@,@B:>3"[OB1K"_K84QA<_\PN"$8^ MZ5NZ/1QH$NKLRT3@H9"# M)^\!650'"P5>*NY(5M(+TV#IST`\BHI.,`L,S)NID!>2*4HW?$,7H2L2=<^ M+Z9G0F5R8MB=Q6IU)>W=B7%F&N])%X-K(Q^)A_II_W(62^Q=8;*R1,89TZA` M:L-"0QC*?X:E`+1S9^G'N#88&E2LF,I/3>$A6A!`RA\YHSV8A-I/F:T6'WRH MUPHCJT'>.S-7.P%045$$J*9.=)?@%D"`!2VG+AL<5S%AX0)GFT]6QT.D024# MF%<4-0B]&IA*Z_UW"ESI,%GL^/1ZZXN3-T!Z7 M'+I[YSG+Q9SL\$F#J#B0+GO2,9?GS]S_L%B9-O=^P)B90F5]B=LY?@#LA97` M2^^#276T^J7M./1EM>S2F:E#%+Q.7:LT9QZ[K&.45!8/$<4XON!H``@P3FQY M!`W$W?ASCWXU)<'G;M.O,3*<52!;^'2_29]B=$" MK'N"K'.L]T9]?D&[O0W=6]RZ]>,BB!,7:&"^]$$8.--IZ(JL40>KOV7" MZA8&"F$42F>8P9)`40[A%O[H)I=#N>XA8HIS_ES2#X-QPXHCT90,CB+'-HA= M&#_RIAR/]VY\%X"8%89=(:U\EUZ9@N"&6UJ0HU@GZ3'VCDCLO;33,$<@U564 MQ9O6KJQSX$C3B:XHZ0CSZ3J`5A=3[P&PA_1J]FFH!W\9T2XBXA(MA1[0K>$0 M1^_;&&$OVV*RYQ`F$9DK^1J7@O`VGI@H>V362.F.Q$.;+Z(B3`OI%@&0M$^)ZRE#PC`O# M7L(D^1MHQJZ/HP!SK2')"#+F.L*Y*9>-D?`7SWUTB[ MO`L0J&L`\!ZH84GD"!O^YB)7I@!\&M0GZ[# MX#((8XZ?H?WS8=0!W-UD5X5N8)JZB1?`K'(0`%_PR*:.^E"Z?3GU(*,8U%0* MG(@TNP7(,)28HOVFMV`[>"$YH1=A&BLDY$^-@U9GP#)X@4S$K#X45["TGLY M54,'RHC0<0,@^<]L_9M674/U..I,AH2#JBR1EXS;0UR'%0U4HX%^8]N0PNTF MW`['^\%MU]1CD7@ENDU<%8O#SM]DN$[S^J]LNUAH)VR@:Y-S!7E^7X"*"-/^ M'_;5<"=Q!0(]`O[U;F#J0\MNDWN]/VZ$FH;5M'I/)8P>6`RH--`J::"@%HS' M^FA0H2Z50FX#Y(Y&>F]T^$3;IH%GE4*X5H-#TW3>R\22$UW-*5"L6=R7"N/" MQU48EPKC4F%<*HQ+A7&I,*X.Q"RI,"X5QJ7"N%08EPKC4F%<*HSK8+9R%<:U M)Y>`"N-285PJC$N%<:DPKA?N^5)A7*\"MX>X#BL:4&%/"X/NRLT-\G='M3 M[5-XC#[:P:FL4)N\#)H]@%QX*ML%.5-DMAVH"SEV.=2FD8&Z$*#]`%Z70H9= M`;PNG=0%G,KR4XG8#ZOUQ!M3!]8?-O`MTTKJ'XF`L6 MHI($[K2Q%=9P6!?X%3#VN99M]FD_*[TDWS[=A!CW+&@0U%H_L7HP[![\RMM3 MLKB^;?4'NUMKPW>0936U"31=%C/1H"4XD8_K>5JO?`$"O*0!5UE\?`!'BDA%8C=>/?Y(&P$4C-YN[ MTM+KS2W%3J"=9-N5#\RA92=&[L*AFTY?;=^MM+ELE?E+U.),]Y]&=12ZTUYK M->#9S"8:A>[IPKT-8HHN)VA$=P4#`8''?3T&`-S&D_A$S(OQG*07AR0U7,A(> M8&>\*`K"9S[?5"KF0+E;F90$EBLH$IA$A/<9@8&AX"`\YG=")W:Q8UCA'JT@W,XVW(H6#0-@NC:.%C(U8X^)EP1#9O;!:O(E$>4^TB$EKHY%SS-HH_!.N,^AUA\F9Y`S"7)G0E= M.['[>K\_S+Y&<&1?_=<23@<_YRQ-PM1-JZ<;PU'YE#D.42O[DJ#8G('9*.>T M?E()05,_L<2T;'UD2CBJD+`)YY2.44$J)T$19U8LP/QS=5J<$6NX$@APC*`XGR_#L$0@G M/:NO&U9O_[*L*!V10-JW+"LJ(&`SX7*@(@*2'&."=J^RK("C<+UCLRRSC+$^ M,L9MY^H+:MV#M-B4@BA0L2(M>I9N#LRVA(6V05`PZI2%A3D8Z\;(:"@LS'Y? M']O6\0B+5+\QB`;2S,]#R(T3B+ER&!.SJ M,K0J1'H'O0S9+_(RQ*EI:P%",!SDNI$($'9*JUXWK*%NH1JV"P$B;4CI;0/G M[PT:RP^X*]G#XY$?\F6CUX+0>`IJBPQCH)O]%RHR..Q*9"B1L;W(&!KZ<#`Z MM,1X\GP?P=GNQL&.:8'`:'Q5R'+YWD@?]S?=$LHV`ZED`&+"*+DH%+/>IA6N M"QTN*R$%@F?@>_DL'^XE,HO#5@JFJ1+U/#*LT_*<;5)6ZI`^U]B;\N$8BKN8BL_19<\QOMIR#\B+?8 M;T]!:1Y."Z>S9,%FV6IK`[R']6]S=%_'^IN?Z]>P_FT._8'77YA9#2.)X<7@ MK9_[]I@M*%9>].HK>\[%\2ZV%N0/2O7&!+ M-$RB$:.+T:X6TY)L]2VL)#UQ M:-5FWN^-K'%_\]JV@=@\-8:G1EL0V_U^?[AK@-M$L6E:/6,XVBW([?HI+&,\ M2LI?[0SBG?DM=@1QNWZ,H3$$2/>NH79[$+OD,]XX+YW`V9XWWFL?8THK'<\@$?D-KV>(ND&\QJR,F9 M5K,]5Y+2(2"E[J+!Q#046Q(Z/*YFZ[HR'S\^U9+ER&R$,)M\$1L->11D`D]8[+)8AWW[G^XUV M#6,`&+SSJ.@<)F+?.#K_&FDWRT4$N^HNL$T.]LN)SO'U!_;Z@JP1VE]&NFEA MZY?>N?8F?0-'"2(*FR%(*'CDX^(.(X9FVO??3R^TBPGL/@YQ$SL3S_?B9\+N M5PK_B-Z<9=95&F-6&-2PXPU$_8<370BB+^8B[#RRG_NGEB@1 MMVZD7*-PMBM?@L7M-S>\SY5D:Y+LGK0!?O8HE/EJ`>M^W>!/P.N\/&_2S@Z MS!NW0^&ROP!/.:#-`\ZY!'X04I`4LF5J>&$Q!DO-=BB5*PD!Q$`ZP\1@3![Y M)@?_Y8/E3-/0A]98'P_&Q'Q,8ZSWC:%N&^,D;@\^#I9Q%#NLC55Q$T81;EP8 M)E:IS]5Q1.]6%_($2#[`5^P*%[Z`[\&(*1?%&Z.+@-BYXPF:H*#I@6YB(\$@ M%U8)WV+3BHC-(-2=$W.4RO0TVGB*E=41G%O'6[!<)!H7Q@$,P,M++[JC2%8Q M[)%L-.B4G]Q)R)J9FT6AVF(GF2(G=K-GK-M-VJ_L7DE-51=K`C!7.Z[R[JH\ M4IN')C-9E-WCA`W(<<#6^HZLC*J\:`744NAT[-8RO4M46CXLQ8*G=$LQQ"=# MA+NM$-#:`F7%VEY8#?%3$*+.D=YS6Y/6<-3E*C+59L]J>YFO/@%NZ]2G7Z^' M#3/DQ%XL9#(?" MSP7.#$KLZ]!+<>0E_O#%I:R/"3Q"!<&9B8"^TKBX[<,XDA`AR%#?#!Y<3#L` M#O,\7+M,=R MJ&5]E*!(=5),\-E_Q##U:RR'0-.Y2F\@G($T0Z&EU$JUI"D&EC M,\!MPF$*[=KZM@U&MK`W$IAK3S]ULO`),>M%M+K`6?<8B$)`-LNY5.P#+=:21_X M:O.%)-/GC(5)O[2;Y21R_[M$.GS$U[OD@UJUS+EXY27&Z1*L6I0`CW9`D4X\ M<7QT*<"-V74QP38,EKK4'7@/O/$IX*0##[2!&$#9TA-4@@:]Q&A?^*LK*CWP,?R!#=,VM23L:G M5J^"-\`^LX7+M'R*#"1?`F<1(47*[MD2SJ05`E\<_X9?_Q]02P,$%`````@`6XEM0Q%D M^]R!"0``YEH``!4`'`!S:W9I+3(P,3,P.3,P7V-A;"YX;6Q55`D``^[X@U+N M^(-2=7@+``$$)0X```0Y`0``U5Q;<^(X%G[?JOT/6J:V:K9J";=T]R33V2D' M3-HU!+(8,MU/7<86B2I&9BP[E_GU*QE#6[Y*`6&VJR83C,[1=RXZ%UG*Y]]> M5RYXACY!'KYJ=,[:#0"Q[3D(/UPUYF93,_N&T0`DL+!CN1Z&5PWL-7[[S]__ M!NB_S_]H-L$00=>Y!`//;AIXZ?T*QM8*7H(;B*%O!9[_*[BWW)`]\8;(A3[H M>ZNU"P-(O]A,?`EZ9Q\7H-D48'L/L>/Y\ZFQ8_L8!.O+5NOEY>4,>\_6B^<_ MD3/;$V-G>J%OPQVOK]?3$3"?$'Y&!"U<>/:ZI/@'5D"_Z[8[O7]V!YT.^]&; M=;N7[4^7Y^>"\P16$)+=/.W77]J;?QORSR["3Y?LQ\(B$%"C8'+Y2M!5(R'= M2^_,\Q]:W7:[T_IZ.S+M1[BRF@@SX]BPL:5B7/+H.A<7%ZWHV^W0S,C7A>]N MY^BUMG!VG.FWJ&1\`@E!ER2"-_)L*XA\JW(:4#B"?6INAS79HV:GV^QUSEZ) MT]@J/]*@[[EP"I>`_9_ZR&Y6\_=[H\4>MJAAPA7$@88='0&-6\E<12`H\ MXO+HP^55@SP]HR8S>ONBUV93_21"&[RMZ1HAB+EX`[0DT5U;+M.@^0AA0*K@ MY`X^X/QWED^%?80!LBU7"DPNY7[(V`*"3/EDLIRL662A2J]443G5X1#U+?(X M=+T7*4`9HOWP#""Q?;1F$DZ6UR%!&!+R!1$:@M^HQYKA:F7Y;Y.EB1XP6E++ MX.#.3[8A>H6.1HC`JL@9NM_TL]#_ M#-&:A:X8@X2?RS,]F#RRMA$@55/+R@*5Y7/06E<6K""YD@C8W*VG^#M!_WTG M.\4R;)\<2H@"?DJDD/4:239JNA99T+)\E&156="2;)1@3B2)S0BV+TUH%F1> M(.CN!V"MO*,[D&U$6!ZNXY,%K=Z+,-G[AT@%-L*5*_FIA!VQ8`(['P2'G;]MS M&+L4V&ZGF/X>DX"8)D:TQ>1Z-H?#9>]K&RM,@B>KL2DN:#9:U; MS,@MZ`9D^R0R>[/=B5^R_!0__KZI\OJAS_;WMQ.XU@*ZT;3?XW&I8:WZ`+,] M]F*#Y=HE>-3KN]963Y-F?;[!NK>$2+L$J',6HB:LPM_=+W M5F7ZBG7CY6!-JHU.T@`O$#T\!A1>K6K6;-L+:5280ANB9Q9W;WR/"#A*!9V8 M:;HUFT9,^I,SFH'9KAMM^X<((T)KE!O/,,0CBD M8B8*K<2F8=8V!LVE*93TYR]SY<&TA1W]=0TQ2^Q^5`4^(6,QJ'VJV MFH0>3LZ&(V0MD(N8GU6:+&_L":3:N+^A>J=/_!`Z,C)),:F_/BH6K2`32RCG MY'S3P`'T(0EB&2IM632^_MI)V&SE(A_00CEM..W+OH\\"Y-4"GH;P$6>UAE! MR?CZBZ%JK5>(<*+K(D*<>J^?$ZVY4?77/\)K($^\D[-!Q8&4G`Z[B*#^&D?8 M,D*G<%2&)XEC-JE`)40I9HJ/M8PVC!72NPV".$2'AC[=PI4NIE+[^5NX] M"TQ`)2=GT2E[>8RAHUL^1OB!:+8=KL*HK$L=GLY:4X2V_C90V)+BJC@Y*R9* M!G:05"(K5U/6G^Q$I2NNH^0,5^MVG8R$)0-+!?W<2LLYHI^5GK;(OY?(';WH ME1Z]`#]S+/ZEX'A(Q95%#NQY"NP/6N`M08*ZOJ`0@\`/\7NBDAXI9VBM'?O: MAS;:+$#L:"O/#]!?W,&BO!Z]A*C^&%9HC$Q37BG[R64?$[J4Y\/FSPZX#+6S M8F_Z@\UYM%CBDLY0D+[^."UJ13F-G$*P+K\=S86^#Z6ACQ&#F/KP9PX/(B.UZ)/0A^Z";_:EQ-S,F8S`9@NNY:8QUT_PW^&*8L\GT&]#&`V#. M;V\U^CL=8!HW8V-H]+7Q#-Q-1D;?T$T%@N==K>8$^9069&A\U0=`,TU]I@)0 MY15K#MTO:73&>*:-;XSKD1XI=#+[HD_5@2VZ@LUAO$ACG(]U;3JF2ISJ]_IX MKBNI.,KO8R2L9J3'/[3IE'JB"AU6WM+FL';26*?Z2)M1 M7=YIT]DW,*,H3:T?`5>`M>JU$0>UFX;:GXSO]>DL>0?_6% M<`YH)E'U)[>WQNQ6IZL]6OK4_C-C?*./%66@PAOC',Q,&C+GUZ;^WSF%"5@4 M51*:#GDGG),FD[8.41W01C:>5$4/6WS+G),LD^R2Y0+X>4.JIL<6N7&>Q-J5 MR'LJD8O=1>>09[)@<9!6"%S%M7-.S$P&/^_'<\)DZX3BF$Z_W+#>[*Q&S)4NDG=?GN=$S!0/HB)N MN=4OGV?E*>7J3"*N]4CR2-[,9\31Z;LJ%,:J>OYG(3B M/7LJ[R;F81^CF92NLWUN\7,BO[?A/Y*)Y;VT?%/@F,E,\$\!<.B%-@Z.MKSD M_S8`)XS' M```5`!P`&UL550)``/N^(-2[OB#4G5X"P`! M!"4.```$.0$``.U=6W/B.!9^WZK]#UZFMFJV:@FWI+N3Z>P4`2?MF@18##W= M3RECBT058V5\2<+^^I6,32QLV1)8#J32#S38.D??.9]N1T=VOO[^LK"5)^!Z M$#GGM=91LZ8`QT06=.[.:U.]WM5[FE93/-]P+,-&#CBO.:CV^W_^_C<%__OZ MCWI=N83`MLZ4/C+KFC-'ORD#8P'.E"O@`-?PD?N;\MVP`W(%74(;N$H/+1YM MX`-\8U7QF=(Y^C13ZG4.M=^!8R%W.M;6:N]]__<7A^?CYRT)/QC-P'[\A$ M?.IT%+@F6.OZ<3&^5O0'Z#Q!#\YLJM=[[2.7CRK%O,4.MM%-AB#N4+^Q\UI7:O^QW>M02XV,(?!`CA^U[%4QX?^ MDA#J+D*0&'BHY=X%\_.:]_`$ZZ1]-$\[35+5+SRR_O(1=R@?SE!.OU#)-KI"B2VPU5#SEX/>:3QC!`/L`#Y-*8V86L M%8A)P91TQ);XLE3LAE7$:>5[*FRP]\BV\,JV#_#X!GVN-IXMLBMKBP7TPQD$ M]QU,@(]7]7AUSS&*;!RN8#Z7-BQ/2WD5F M1UI`RDS`AXE+6,I8QX>/2_C-VFP?^`:TO0'QF@^?"H='"565UH;K)/RU`AL, MYR,7X?6Z3R"-<&2A_A7`1S)T11@$VKFXTM+L$>6&0U3.6E84J*B>4M>ZHF`Y MQ:6,@/5U?XKN<;;?+=5)MB&^4I81#'U2K!!M-8)JY$0MHJ!%]4B9545!"ZJ1 M@CDQ2:Q*D"UL#\^"I!5P-O<25$N/Z$KBAD=E>1&?*&CYK2@CO-MJ?.%3(2UB M%&\-PJKRL!NN&8Q6N&X`+R0]5[8VTTT88#97BI7$QU;:#J^K^5;YH^&8Y_ M*MU!7]&G-S==_!T7T+6K@7:I];J#B3(:7FL]3=7+MSLK24C9\7G3CDOMA]I7 MNKJN3B3@*',@P;JAYZ\<_N>(Q;H00/%N8:*:BM M3:AC];H[P9X<=<>3G\H$@]2[O1!W^5"+,I`4TO8FTMYP\%T=3\*&.1A.5!UC M_MG%ORH#FIF*I$!WN$'3CB_?A&(''V]BE>S4O"PF!>PDLSM]&U[WU;&.YP`\ MH&L3&:079S0IG*GIJ3>\N=$F-RKNYV&GQ^1/M,&5.I`S[S`SGA3*U.2C3R]T M];]3C%(AHZ>,,:G,E"9E3&JR*F-%@!>94:42UI?L'"EE6&J*2RX1E%]7HE*6 MOSSITB34ML!L)Q$X7QZ5`IZ:^]B#LSS<,C*FE)6I>;.<+A)5KJQKE]M7MLBS M4EY(3<14?\)M-E)/8J*X@C!L)U4HZSK6=LNUEH_9U(1-CQ%5,"2FDUA7LT+0:_,XS'!DF]-8#M>_&5,!E7;[:B M1U]^B2[?KO<+L=N`AK^N^Y5MS(`=UGT;%*F<9:9IBSBB7<_@ M)\O&#)K>EI`(X]3Q'H&)@PY@]:/$+Y,4MDBIQ*13T46L9#H<\8)G$=1NOAN& M;EL9MI1%4IR:W77\VX7%T$`6D9UMBEJNJSLBKHX*WV:-EWON MZB1TYC0@U]5QA!&^`H#/X93([.'&Y\B%)D$17F(XG55\O]V=BYHYLLAP MM/J"688>X/=UIL0AN)L-G+D2+-?CZLLC7!W_(N^"83B9+K3??LW`RG+E\9L& M1V/P:"RCLW%],/,S?!\5W2RYOP3D`6:Q<%+)V@1W,,>$CS:([K_NHO(M5-+R M^\N"N!DL;CZ]$3==TW0#8&DX#,>#9%;7$+)Q0]T[82[+*A:1GRLADAQ%0DZ8 M'%I-;YKG!:(]C:'D($G+LX5%U9=*J(I3=E?D4Y2B#>&#I";+!A8EIY520JT) MMR.&4G'0]*0MR$'F8%_I&X;;?O+[*Y& M,2DO><<@7,*0(R(H=Q>+4.NR9H\ZFJ#<_R*]AO MYPO:P>2GY$V$*`5`7B2R#J[B_H`%M2RYTQM80R3+LE;!61^ M&QG0&L[GG$NSA,1^TU`$G.GRDD/^D1OOOXZ`8]C^!C++[K>;V9"9#BXY M@$\AZ"Y(5^-U\:KT@3DY`9J9#"PY`M>![Z^.8%UEGQD+\VA4H?UV:@96IB\3 M0?+7QH89N)*':@Z-"[VWBSI(SO\<],9C38EZR,^P)IG/,NSR=B_*XFT?HOXX M2/]QD/[C('TQ61\'Z0_@F/;'0?I]9^CC(+W$\#9C\2!TMIXM?X#'[?.-*7LL MW)H@H4/Y;/G;XW?!4-(:%D7'E7,D=)J?+7_[Z5UPE+2&Q=&GRCDZWI&C2/[V MR[O@*&D-BZ,O)7,TPC9!ST/NDH#*>QPCHR2>-O=Y[X2)F.7<:HZ#W)"$'_27 M.9DV#LD]]SVW!6\SI_?A$[2`@_M=N&&9L]M=+'A83#`-8,8Q,HA(G$1(/SY" M):5R:>%7&!RZ1J^*RR\DSXC[.NXOB M0Z-U2P.9JVK)1&<^:X21QO!C\-P$S<; M+C,NK21TRGHM-5_HE)3<<\=S6\#B8MNC*S(.;$\=8X&P,?\#5GR\;.2"!0P6 M`Y#S_*J`DCUF4KOO)_4$L#!!0````(`%N);4,`AV#`7"X``":(`@`5 M`!P`&UL550)``/N^(-2[OB#4G5X"P`!!"4. M```$.0$``-5=^W,;-Y+^_:KN?\!Y]VIWJR1;#R=9.YO;HB7*8446=2*=;"JU ME1IQ(&G.Y`QW9BA+^]_/RWFZ!'G M19*E/[PZ?GWT"N%TEL5)>O_#J\^3P\'D;#1ZA8HR2N-HGJ7XAU=I]NKO__.? M_X'(/W_[K\-#=)'@>?P>G6>SPU%ZEWV/KJ(%?H\^XA3G49GEWZ.?H_F*?I)= M)'.__VK>7OE%&Y*MK?.7KZZU'U3Z7^MWF2?GE/ M_W,;%1B1AY(6[Y^*Y(=7'>N^GK[.\OLW)T='QV_^\>ER,GO`B^@P2>G#F>%7 MC19M1:9W_.[=NS?LVT94D'RZS>?-;YR^:>"T+9-O$XU\!TF1O"\8O,ML%I6, M6\:?04H)^K?#1NR0?G1X?')X>OSZJ8A?-9W/>C#/YO@&WR%FYOOR>4GX6B24 M;J_JSQYR?"<',\_S-U3_38KOR0./Z0^]HS]T_"W]H3_4'U]&MWC^"E%)PD*E M7>^XMFJE-[[!7N,\R>)ANAGJOG8@^.3=RS=AFI71?"/P74WOL*_P M9CV^UO/?TV0RP9OU=$>3ASVG'UZ2/W'`\5-)9B$<-]!I6YH!COT4&W?KMMO6 MLQG7[IP.EEG.]TCQY3$YI'//T;O3(V;OY*>?1[^?92F9MDLZ25UE)3[^A!>W MN%5EN']XI95\TT=#=09Y`RG*9P:[:HDWLXP,^LOR<%[U8*5^EV<+`X#:]$PK M]OO\MFVSZB7RLPKPG%B."S:W.SVDK@7F/JRQ+>9$EOI+.#W\/'GU/QUA1*71 M\=_>K%OQ5<7@?1$J*GK4&61^.$[NAXP3PT''B-G2<^.'`J34'3D-SX-2.`Z>`.7#JQH%3/QRX MCIZC6^JES9GK3'SF9WNO0J<?"'7*@(AG.5VJ-5\*\1PG53GQ MPDVU;[OBSBO=T%\=[NB7CGV6Q%%Y^#-!ZF95(^TTV)?,%B M\H/;HLRC62DSVT[/&]U%J'LU':8R??L+/2N,$.;_$4,#DF=$3`D0-.3(%-VIAQ*01 M$0_!CF8O`20Y>C!0B_IB@`EL0P:5'`A>&,`) M"]=*'%7RB"H$'1PJ9^47/)__E&9?TPF.BBS%\:@H5D+8Q$+>KSMI@,V[E0IA M$"2R0=AGTJAH%J81HIJ'7Z@J:G11I?SW<*3Z.9NOTC+*GUE^:C\E0B/GET0* MF#QY>D*`2"-'IB-+JX&82D"&U(/A#5YF>9FD]U4ZKWKYI1#WO(;5@NXM9:6R M@-BC!:@DT9\*U&K4.=BH;BD@FQB;S\@\>I_EZ@A(3\HO=Z00>K..1@,0D2Q@JD*K3!,Q MU0-4*:..=L@87+6PJ\(^%^0SF3NCD?4=BU/"[DI!HQ><>QN`%%*957_GD1!=,EP+T,#D*QB/=3";9:NT M+&[P#">/-&7S8YX5#4]57#8H>1T>K`S@Q@FM!ACZ6,$4YIE:">6M%@R>C=)' M@CJCVR)I4CS@^&.6Q:ICN2IAG[S2`^[R22X)AD=:>,*60B,,@S7G*WQ!GDHG M#SW!*M(H9'UR1@NW2QFI(!C&Z-`)B_(51K03R(!3)?HO::(_#/9%P^X)QSQ!0]8*7IDUD.IG1Y9J$&AG7V6/LUP0O.R/SKU6RI"&F M*ZP>IW0J?@CV6RU6%7S8XR7 MQ#=/V+$E^MT?3T].#MY^]QT;M?YX>OS7@V^.WQV0Z;18XEF9/.(YD-F4NH\E MOB2(XE%:$IOI8;_JC2/=88@CV2K[I*R;05WRVFF"H;$37'%%T&ATYM6*W^]? M`C$WZA-(1'0GX`LAGLJ;(\,DC6!0MA%BQG@1Y5_D8VFTH#EO_UZ/I2>G[PY. MCOY:C:4GQZ?D+]]`'$NK/M!Z,2&\/K6[!X92'!RY;P?)I[M,HMMDGM`%-/$? M6(+,0S:/<5Y07Z)\-DR;]NH^R>)J5)=.MKI@".<(N$_)R]'@P^AR-!T-)VAP M=8XFT_'93S^.+\^'-Y,_H?/AQ>AL-`7'5;O-09U"(#Y:;!.JI2%RSFW#<+Y6 MA,&I9C^B+@="WB#R2;["L6BB81O$JH40&T\.ILEVH2S4P?#2';-R?VI9UX>A MGEI4-0*/O<1IQ:0/R]I>/5%5PGXWK72`^4TKF208IFGA24C%^)/42@VY]E1L MZ#*+TJ*W0?)\CF^E%88TPM[*"AD!M[6$E)+!B6$%3W"^J#S8[2F&KB:XRA'@ M1+SZ5!)PG!?5^3XX.32@Y)38T0"QH\PJOO::@1)*::_Y5WK(7$J67!0,9_3X M='7N4BK>4*F-3ZW2.BK%8OVW)8J3@OD\+$#U[?'!=R=OJ_C4\=')`<&XV_B4 M767&0E+@3S;@6JF%JL:H,T)5AU&F$YR*CD"M.G*&=LGY[OC=P;MOOJW9 M>7!T^BW]*\3XZ3F^P\0CC,_(OTE9-,D"UHM*!WVO^4.N9G$Y1;;*P?F^*>(^ M\3^G.,II:8T)X*R,^2V%_0"=G^<]WNZ"L3_OTMFR4Z++6RSS&R/][/K.97K MH;Z8WX6E'"2_HN1EP)!%`4STUUFUA(+*?8_^>/3ZZ.B8NNCHD2I]C^B:\*CZ M%Q55+85H53YD.?78OT?'QT=D#4D\]6_?,4_]^.C=P3='WQV\/7K7B">TU%A< MY>NLJS"@J$03TO^LCCLZ)0M/RA0F=8YG]:?'[-,3B$[_(([9V=IH?ATE\2@] MBY8)&;Y5>Q4J::][1'K(W'Z07!0,N?7XA)!\*XUH:O9ADJ)9I0"#2T*MD\GJ MMICER2V./ZS*SVGU!IG?WG5?N@Z(C;!1],M#>D"[[S%I@F&<-5;(_V4G_!N02BMZMM1L< M>EUAMYZ`M1Y5XI,O2PNP2PE33IQY/:Y0@Y3%:`AU2'5@\.<.0EF7T*M&9-V+%!^O7RNGT8KP_--QVE19FS8J2?U\DTYW4NS76.%\EJ MH3Y[ZM2"W_P39]/X#!1K=3!4=L=LNOJV:.Z^-:<$[NLV7,ZF;@:9"UNW:\K? MG;G;&;N^1G>S=H(3>0?@'1AMGU$(8[#>U4PU?)K-5W03M=[VNL11@6/],6XO M/_T2?22;SMR'_Z3[W>#O<0!C=7Y7]S=@O,JC=)8M<%MWVY`1I93V>QQ/"YD_ MCR<5!4-+/3ZQ:`R51NLBZ=#*H=]4&<.JL7O]M=\=5!X4OT]:?0>&$#U`?08T M7\-XW&=948[O:DS*\`XGXS=()H''A\8Z`F`H($,E^I(%)SN, ML+M<40J#88X)89]'K7Q3ZQ7(>-+UU'L.NC+NI-'P&_,S0N=C?$IQ,*PR8Q2J M6'>+?\0I>07FU*QX00NZE_2%>,3U"Z3*/+)4]IK3Y600 ME^=EI0F&CDYPA8S52AG=5]H5.3E]&/041G+;$3_P_&DU;\)*ZU+!D^=Q94"G MS-:**E9P21Q$D[U=R2"D$:%*:;,6`S,&J;&)!5**NF1.S9PLA<(8>CCIK6,S@,.GX`(,!35TYO;LL2(6HX:=Q@'LB8!@AQR6I*%^5Z:L'!QC,^!@E M:4$G/UR,T^$3G2M72?%0W0XKJ>[GH.F..SFW MXC]7PME$,8?"N@DP?-P,=Y^Q3(!Q%BWIU7=UE1&J`8/$O^#D_J'$\>"1F'6/ MKU:TXLCXKCI+,5[7*6&&*+K*L0V?!-[(O"Y]G1H`0]Y-4,NI^[5N"4554QR% MBVXE&QA\;K.;QG?T/N^+>?;5%);2J_@]46\&SY^M5\N#X:(%2+$B2).B1M8" M5`DQ+7`):\0?H>BN\^PQB7'\X?ES02_5:N.Z`UJJJ3KJK:?@)@UY]BDW-+3G M>#JV`H;$&T,74J\HF^\8F[OQ?%H(K&T"R!5^@_C_5D5)7\-BFMU@2I-DCCD_ M?9KMAO_[^2F_1<7VUUE\1;+=_PZ8MVR/QHFUT-J?0F6&\N;'V.D9YJ^33^F? M9_2%717L)A/(;ROS[3[0XP1GV8)&2W2)3BIAK\Z.%C#GYD@EP;!6"T]:[.SP MEDI35[H5AT&B;E;6^.XB22/R4J3W-%^85JMI#JLI3U=9JWL=FAV-XH9;2UTP M9'0$+`R+O3KI;@VQ.M!OG@/'(` MJ;KQJTEI(N-;KG!B M_O=MR0H5HZ]$O@T\4HT],8(L,W)Z(O<<5_]G&]M6B0?NZMZ8LX%1+9L<=+TR MC$PKMUF!90FY&^)^B;D)?2O).ICNEJ\7P^Q<.?'Z.C4GR6+:?$A[NU8];U#N MH@MZ&Y;;-!E\I-VM'4+\\H'\C=YFP`5#6%,LN;13H11(8$3LAQ%Q2U/R:^I; M?0PZ81DN@:_G;T/ MFFM$[53#LD]MC)Z$HAY@+BK!BC[JFH=11UCJECW=SU5Z_/FKO^ MM!64-FTL+&M=#-;SV*8EP,QV@"^I']-R?5DULX[UL&N-6*YF7'0*N0Z#@ M+B_D:Q$V=M2&-V$Z11=:ZH:KB6HP1UT-5:$(AKPN:`U<9;1L`JN>PF>CM+D, M6%'9RUHK6+!,;8(R1B:J!.>3&TZ=C[L">;NS?7;6UNE=4//NMLNW"\[0C2'+ MCH@84W9`LY;&08I=9(]J&P+`8@M#+=BL:04ZJ\W03=FC2=/"+O/1%+/[->F1 M!S(-T*R2IZ9H+?&>B1]"(-*ZU-*X@:.NMYG>U9QVOK=5#,Z^3=#V"=>HTXVO M.]I`-]:?M&V`6NS;OVU;OZY0Q]'MQL_@S-T8LM$;D`V8H%G;9O!MZPUH&P+` M8@M#+=BL:04ZJ\W03=[`7=,"O.ST&[R,GJND"Y9"N-Y8H:=K.W=CJ$=EMR;\ ME@AW-XXO(VZO#X;%&X`6G(L\FV$<5^QM[RVIFZ4',/BK3>BEIS0]<)Y%VU<_ M4SFY]8^/4]Z"SNTKS-HZ>"SUN%R;\.?R;F;,OI8:[IK%?0ZI)M#=X5,E&YQ_E@"UP^+^V*4ZC1$_$B<" MLP-XFEG9(.OO_(4![OK@A4(P.$MLT(FG%ROQZN@B-QS!&'1:[Z"HW0/]H*,6 M#^+'*4!+?;:>K!\ZO:OHE.)[^NAE:="6.'7SW`N:URZI2V@Q^M9RH68R#J9J M"F-"P4C MU)X?A:K3?S_QVL%+UH&3DCBN.A>&0R:+@1Z@6WR?I"E]96D`B34+L7M/`W3O M,-7ZAQPN>>=BFMIKTZU^!T):$NR*/!#RQ_6&4!I+I@%:]&">%:L<&[9.MF_6 M]Z"ZBT[HTW2;-D$-T#LP1#BKOEHNYZPT731G=3$J+?I^S)K=&#+`WV7Y@M70 M`++]TN2*TL/7B@[C14+4UN^"DQ76I]^#X9<$E'1[CIV2Z!8U@$((6E!K&CW1 M@("&$STI_[6'!8AB;>%6!!`Y9+CT_"BC)QC4T(V8HQ(OC/D']OI>E\FN9G&K M9%ME,!1T12RL5[+TD,UHG8P9X@?N)<5`L1-!PTUUM+)3@:BS;T<%9,%T2T5O M>Q1.AK0;%E9:P?GF#%6\VBQ*VS-47,6H;OR9!A1A#(^="D?GJYR\"548X.=H MOJJ-+UCIM8[U$SPCDG5]A?%=I_2DXN7=\6_X+6&]A^[A:U[O\`>"OS[[M$J\ M]7U=0*DIM]5N\Q2=@G]`HIW\Z;>.Y1]PBN^261+-UUUS@:-RI;QD8[.FPIUH M=#-6?<#1KATP;\$6X(7;"UJ-+L'O*IT].2R=DF9M"3Q9R2EI+H6#LC?'Q=F@ MUGFQU@S.O8W@V@RM=%$GKQX&9'RM#\+3R2:;DU?%7*5=H^"UH*\1.%?"5RD= MG'O6$"6E5FL%U&B`NQSCPZI(4EP4Y[B8Y2 MOAC^:Y4LZ?!O&%TM]#SG+=F9T$],[0$R3!<5:77!CL-+* M]8:7:?AU:P($0S7&69%5H@^?MVK0?0I?C/XQ/$>#R60XW7K(5*R$6*;I-*LC MSM&\O=!+Y6)::WE;^]B;T"YZS"K!:>2&4]P4**N<\U85K77W5E2H/:C.%:DS MCV#NZA[+##D;U:DW9*T+@V[N@(5:5E?3P=7'T8?+(7,#Q],?AS?['<*U+A'OM&#U6*:*T);KW0LW%*-V5-"P2# M3D`&RN%KV,%*60J#@=G_V$QBR@,F&SYB^#FYO!U?8SYJX."+;'')^G M>906-)\D2TTA:+.:WP.#=D;P!P?U.F!89PFT3[Q:#3$]U%4$-]JI++0/CCBU M`(&9EJ$1!W7P?+7W#F^&EX,I<0ZO!S?37]&4C):3P1D;0/>V82RM0:%=8YAU M/&X/V\'O[`KK%8)SR06EL`<\OOIY>#-EJ]2K\70X(3SZ=4#^YI<\W&NP`9$4 M^J%)I37+1#"I,FBRZ1!;$P]Q`]H^0[TU:LLPB5'%;Y#7#)Z/\*KE85#*#J00 MV]WED+4;_ZQ:[AA6!'TAGUZ6'D>(E@O-#"ZO/B#I<`7Y\&:"SH<7H[/1%`8_:2Y@ M4B5B#]*8S.\T#0:G,Z>#R&YM>#UUO(EYW!%CEP;`\'43U+(LT;H-EC?"M0(Y M+&QEO&G<=6T$'*FU([!;"R^+UN8%R*=/H^FGX=6TBC23!`4G*6^R MNBWPOU;$SN&C)@W%+.[5)3"`YCP`A2P8IAD`BH46&G%4R8,;%">S!QROYGA\ MUS?-Z('::'HEFKTI'.?,:G#H9XU58.+G#Y/A_WXFHQNB20-[2SF19%*SY&E] M%,]&RULXQ=Z$-J)B5@E.(3>V9P?-K.[5\<$XY@!3/LB1DI;>`DP;)'"$K)EJWO?<",&@Q2T;!:- M59#_T<#Q8S2G7KSE&&2GZ[N*H[4Y_5*-1D4PA'-!*RV41@.FK"`57JO#(.1% ME.2L4`N]8[$^%[.N8E';J.@62UV?A'0RITM(*T4PA'1!*YR@([J(*=/Q<7T8 MJJ,/@YKU`8D;/,ONT\3>5[/0\YO-:&D&G\-H4`)#15ND8JHMTT/Y6A$*[9J[ MX"SG99V"7Z*9@/,,4TD#HI8!HJ*R2('6FC`X12M9IC0P8K_CJ%?Q6\O6#)XO M;*N6]\JM1YS?9@6^U%#,`JMPGK-1@4&MCUD6?TWF<\FUV';#ETL#/FGG;EB7 MA/;:8(8[9\ABJ*UJ`/+]YFUU:3MRJL6#5/.V()Y*%@S-#`#%X8Z*TPK?4&(H MDXMWLS MT";JS4T0ML1I\N;A+6T*S3IMP2#W,,KI54#%- M!1H0*J@Z#(FUI70)N3]OVZ_2E:KPNM*49[%2\;=];@F^W\`WRP;GD`%), M:UPL:"D00J):;>^$^27*\XCFN3DP1J43@#)Z^!+.R!6@D4:+4L.:1@_&O+>V M9UV7O1C?,?_0/@M6JQLF#];"''DFK$8Q.`4W0:N;!CO:]*],?Y>\+/#L]7WV M^";&245)\H<^$\E'OP_)LJ5\IJOLG-;)H502\[B/>IWAHNB#@^Z&4`+: M:P5GGS-4(9.62%*><;*!KGF]P664I#ANUB6#V6RU6+$S^^?LW@E%[1^3EN<; M>"VB!@Z8)7M)C2BJ96%,6XJB"V>K/"#J-&(_C@X`13 M/%>YOBBL*E%;JP4:'.2!-ONH(KQ!P(!3&A]$7'RP!!0@_!3-'LB0EC]WU_\? M\ZQ0I9CJ%'R^]F;@77*II<&\[D:(?6:U"BST@G<5==E1(N"*3)'T?BEVV>83 M_5.AHY5&WFO"GPDVE^2G$@;#*1-"(9FOD:\O.*TT]G=%V')5UC4OJOLFTGB2 MW95?R0`KXXJUEL]+P2Q-Z-X&9E`)SAXWG)+*#I7BP7I,8G0J:F48`]0E)E,R M+;HR6BSS[+&JVZ\;H70*/H3FZU?I% M*B%_-RJK`*YO3^Y+!'_T6EC"XXYNH7DWRITSW0!B4@*QMZD<2/0:P1GE!%,H M2Y^5T3S0`IF+(2US/$NJ4"!>SG%S@]PB(ROZ?U>G&57VR9[9KMJ&MPC?N67B M'%,4[U'4B=K%G=\)Q!6E&5?8[0HZ(@_OF5JA%58LR1-Y-E5*Z@%*,;M8=I/' MYO,N[S4B15?P(G[OWA;!\7=JK[\',^A+0(FE1]8B"#^1OVQ?=V1'D9*$++GQ M9?*(A3QM;<#$J.8U;F)I!!<^,>B`H9!'E7\@@Q73V MM%KIS(O<_%=!(8/JM`4B<\F=U+VM<#8PJEW[..A"F0\WQ*W;<>PVL2_F=7YB M^$2W.;`UZVQ5_3'.S9@UV^ST@H]L&X`5Z-711K6ZGPL(.V>#96;II$-=."B! MK+IHL",*@R9&?$*IE%H!U1I[8D6=,SHJBA6.9O118^[BY;[T^8;*X M2K)X4D9YJ9QV9.CZS_<#OD]2FO^"/D3DBQDFZZ[5XA;G=.G%#B+LR[NIT%7@ MKO-D;;YH`B?D^=%+`/8>?T<"*`5$A!8T^(J3^P?J;T3$O8GN,5EHX7R6%!@M M:4/['0@^TEQ@[4C02O@>"GK0^F-!_36,X5Z*J?_L:R%T7TFQ)4Y$&+/`L>?! MH,9I&`UX*<^/7P:Q1X&N""0:2'`Y42'H@$"M/R#47T-B M0@^3B@6XDO(\"-38#(,`+^7YDP,]>*(_4`M`8H*`2CTIU'+>O8+Z=XU^`2_GW3.0P11\@ZX0 M)!I(D5E088L!`4+@SF_V1!6W&::Q9>!.E2U!6M@X;@UB$T`?86R[XCK#WX!E'A4!1=AU,U?,'."I8Q-I%)H0= M";31=HF0=TJHX^V"!"PRF"+N+1/\A]P%B,9Q(5C870]5S06`HX-5\%W&BM"^ M@B;\+A$*,&FH`O""!"Q"F$+PG;G"=PQ>@&CA.02*P^NAJKD`<(2PBL;+6`$P M'.\6"806$E;`>PD1^4T#<+`?P4N(R[-B8?SV*JW=)C-.*>JO+K$>[+HH9%)!:,!#E#*@$H'W\#E^5\>I M"TKI,TF$@CQP^>0@2,![W#K_J/>T_0WX2SPC4\YE,^^"\OPT)FHAX<]2DM, M["UOHM+XS'G9((]>!E?*@*X@/")(T!GXD-0:*"-!#YF!`W$M[6,.R.91FK@$F'4 M2.^Y2$9U=T@=\J(1+QK'DAFA$/3&`RW0E@92*1@LT$%3W=-22Z-&W$M^YR]) M^="_1,(<)Y5K!:+246,?D4 M/26+U4)FG5S.&V]T,%NFR(1@<$.#3-BJ:'8BF.SAHA(.L5&T6>@73.%1$T"# MAS?99Q3X,HO2XH)T]0UF)=RNH[SLWSNN$_17?EP'=%V"7"8%B@@O))&2RH.HZ#HI"2(V#6^DKU#E9#7JR6E`+F[H#B)X".T%I8X2M1"Z#Z:'%G2/(5)92"31`53QA,]_W#M5V$&H]E)L><2$E_`8:9)!Z\28NE_#>.Q2 M3&)I":E',YY)%!9*_[YR7"4X,`S`' M-_0L*A[HWW9Q/YO;ZH4,8.DL6F'4E:/?CLFH;A0UK?JE M]EFV6&0IV_&H/$!UJ2C7%D+3V&":B;P*=="4U6-VF>I90ZC:":N:JC>E_=+3 MHE"1K69H.IK*&MFI@::?71$D#>W:!(BZA3!DXY;-&YC?TX="/*E9MO3CE%\$ M"66(-Z&BEP.AMK:PL[#;=$;=`#A.UL>G'>QO M-4(SKP?=1+5:'#2W>(P.9*H5]\0=YB^>)\4L6Z7E!8[*58[/B"MY3Q92Q462 MDI].TGM-*KMC`]Z8M9%A+=&M1@[5[G'_'B"5+&3T'[E+P>> M![/.>J\^A_%T>3!"9OL*[V2;0/&XN*VI\5T3!&G#(].LF?%DT%VTO3UT=Y-: M7MBKPJ".,U[A[FQ^DY$>H6A/7,[:$%F9H:]U._NB894K,;[K1%":`8]\N,IS M\BW[5+DH=&["'R$W,V[-2C=](-3<"+3`SZH5RLM9%1(K6$@LKEMB7U1MU=_X M7"72;;SK*(G'=WXS2:JP\4*P0]3I<:H)V942(%@Q,Z:.)\U\BB6O@`W>S3N^I!&RSHJ&5E M12,:C@@\6#45*CF@9.#`V="A4MA79AXNRSG+1?\8):G,@+Z$O_P[*;1URAWW M-8R'+<4D)-:U0HA*^7$-ZA#/L<4K("-4I4S4C3KPRXM3>E-/@C#BU9,0I9$:<.C/B M=%\7:.;)?4+\#B[`*S-$(>CO"DT=T/4%@C(I&$S001-NT:QE44*%VUC#W@Z` M18N,L.[?.*;K4AT+E*(>CWQIP7;.>DGE_'#A7<6%%-_3(^.7*DKH,8J'O%II M%-/X@0TM]O`8FG1RQ5YD]TD81.$4B+`%:KVUNK?E?+8@8T*6/]-?4Q[IE8IY M7,8K07:6$(,C&%:#4Q2[-'O]Y"N@IB?Z$YL4CZK-CRMU$(G9,B,,&5E M='5@$,<>:)](C0@ZWV?Y0`Y=4_ZR/LNCB@S;:(5BC\8$%7DD*B"YH\;9ITZS MW[K/$'(%KDBRM$[\$$\>B2S;P`2Y9Q1RQT@V@RJVU$< M-.]OH/HBZQ6[9J>MXEA,LVO2AP]1@2^R?$ADGZ=?,[N#+]NU&H[0&W>!FN+. M30(E_:9VV+P&ZPN>FM05FL:RK-M'=UF.,/T%5'[-ZHM&JO7^?E-Y.]9+JP,0 MPYO>:/K"[IUP:"W[F4[V1=)WC1;):7&%I72,'=3C/=!OPNL>;LL>[E#Y>LO3# M+"]\U=VQV^\>+@T=MZ/$-8']2U0,ELL\>Y1[LGIYKU>$F&!S-X6HA&$,YQ8( MI?>&K,=WJD0\P`)%M1J,XFR3JKSH99;>3W&^T-1GDTIZK2JMALJ5E1;%@G/( MC$U,+:W*OO;V(HL#M(B>4+2H3ZC&T9Y:7"Q&EL,E?9QC'\INQ#1J!R=2';B!2(PZ91#V,]@1:UHI>N:,Y M%6Y0",PY8UL6[)SFNI5]+=XXJ!=1DBLS^Y2B_I9L>K#K MU9I<#@9M]."$-1K/@@-$%7:3[K>;Y1EO3I,]3C^MSA+V3X$YZ/EST@J@B`5G>AFJ9!2]70&:<&IM`-8A:-W<:;OW M"5!A013'";VE@.Z,;5NDV**MT*RT-M=$4V-#H'EKB]Z!R(.V23!UC07;M&[? M!HV$9K/90.?ZV\"%&Y[W.5YB>IM,>G^)HX*8NZ)I")^2E%Y67*>P M%S=XAI-':M0HG7[-?L51KKJ67ROF^"+?/?ODSF7Y#>WB7Q.^U! MYKU@]C:T;QM[L:SO6V!+^F]`DOZ&F%=GX742I?1=U-<)2%XY?`U!>06H))2B M[!.-"I$EH$7YZ3T^CT%1X+*HRX_*^I\3$Q)I^MQ.:Y^'U=29.52R07JY,LD MNDWF9,V/=3TM2@'J;@VX?I]W1`%UO*''87:U31\'ZEH6!'C(YC'.B^&_5@F? M;JV6`M31&G!"'D!']$^H$D:#LLR3VU7):F*5&;J.8%!]D,9V3\>D`^A964/5 MO"DH2N/ZV05Z2*V;4#L'>I>\$0+T&-38U&YT(QKBE,@HG>74(SO'U?]IQ=-B MG`Z?*+)54CPL6$WV?EJNJRZ`)[0Q9+&(AW4;@=ZB[LW1IEI?*ED`3\P:HKAP M:!3H=JAUH:\]/I%1^DC@9/DS/;\RSPIZ8!4_E1_FO0HE-O*`GHP53/']J970 M6@O]1O404_QG*(>-[M=\H.?#*`GN@UZP2>D;1W>TL90M[4#5+7'W(VV17:6AKRGK$WT6_W_<+1@ M\\5@-ELM5NRPV*`Z&\8LN"8?D-&%=,@TCV*\B/(O8JJX@RX``FP,68@HV+<1 MXHE6U%-E:'#?_@ZD*+$]=.9,E,C#[6<]FB6R('K_,R,Q_0?ZN+4X@E8(R<^K! M"3$7F72(GM^V/#>0WC?!T]3F[LI+GD#WHTOR)_)Q\Q'Y#_5MR2?_#U!+`P04 M````"`!;B6U#(6_>!L\A``"S$P(`%0`<`'-K=FDM,C`Q,S`Y,S!?<')E+GAM M;%54"0`#[OB#4N[X@U)U>`L``00E#@``!#D!``#M76USVSB2_GY5]Q]XV;JJ MW:IS'-N9V4UVYJYD6\ZHQI%\DCS9^92B1+8^^L/X(M,4@30(`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`:$8MW:-"<>M3"'CD#Q\Y+6&]DKT$@AD^O6JHO`IXNLF'6&:1`3.D`^ MVW>>E#6)F)8VE8%HV;ZF*KJU506T_I%*.^Q#X#ETN7I)Z/CFQJ`^WBS2E;7- MQHW3&83:#B4@IDMUNF0'C.(`T8XX)7<1^6="/S!^))"!@%,>;1X\P'RH;5Y< MLOZN,CM6!;3,!+`V@82UC'6P]H&$T?KL)8EMUXNF#+78?90.CQH^U5L?/F)[ M6B?QR&Q]$P9TO1ZS)MW0G<7XGXF[94-7W@:%?JY>:6_ZJ'(#$-6SEE5MJ&H] MO:YU51L+%-XUB-7IV+:J-5JU' MRZRJVFC%:K2TN31)9"687SJBLR#K!<#NWD/5VG=T/7$#J;*_'9]JH_7WHH;M M7:OQ!5:%MAVC>F]0KDK4]FU((EI7ZI2]IC]41,A33'R'.$5%3)>6_GSZ,Y/- M3UQ.K".KD"K_T?8=*ZO"*M>1M[AHLQ>L*LWTV`%'$$K9I@W^+&KKZ"Z*0SI: M%Q5Y]AWQTNH_,UF8Z'&;QN:0IDCQWB'K/VLS^DBAR].4E MCK?IT2UIM,_K5$D#03TT"O4E'3*QO2.@&5`.''I'`D@ M*7\SCQ0Q!GC&<>$XT:XQ%PD]QY[NK*"^RF7?^N MU95BX#V;>>@WJ(LX,`6;3>"G/KC%`]4[FB5Q&N1,#50X/`GEH.R8N*4&`(*Y MY\N6@-D>Z(K^QIE$!,6AY!BY]>:JC\\)6Y:#&2D5AO)AY&:'`U>\7R?6D?6+@"9_CD7L7*9KMUG;4=W*15)='1OV]NL#Q$OCHI? MZITI__GSKE&S]97KTS:YM*\'D2MQC.?B,.G.UM%>O2PV0JY(O1R6EUP)UZJ) M<#3I?ZSJRD:^*H>2LE<%SD<`,S@B*5&\"G)_A;-DPZ",6AHL4D(CU:K M(/'C:$Y6Q'UD)^4?PB`JU!&8@T0.S@A48!F;P-?%9B'3`7#N^&ST0YT,0 M.$U+KER`5Q[-%=^"'['.9O!RF9`KJF,I(*84W+U/"ZU$%7I"`<21G/9MR!,`0TSZ`,2U8Z2_MWV;68>"?BT[6M"_]*Y MSK3FMC!M7AS$MI>61+:Z++J>A=:G^^HBO'Y*A.8FDD)S^[>R,[G^9A@8FT]C MG$/'1H1X8*DV8Q6,T0YTUY MF`<-?3#2E`>/C?RU:]^YGLO6LBP+KA2`G)W%:@2**O:G",`:IH]6`H8 MF4$NG30(13?.&R[ED5<>2IDVSXDR96+-N[+#R3RY#FP_JGEMGB_)'2_=1%`> MBK@VUP<<<8DF)ME#VLS:I24-4U*E%)0);1X/Y;[?I*49^$MNVFDX@^()0%G1 MYK)09@5TRU#O0Y+"W4&UP0DD":5!F^]!;9A2ODD)VV`N]H<$UW8^UIH M:^-[ZL';=&JBKV(H_J52]'1ZP[-HW5@O">5'F]R!7H7M'G/,DOO5= MED/H@$Q(*`^E3YNGHHMA`9`Q@\TYN_C%)\[8#GW7OX]&JU6R2=)M2^WBTWTF M(;)0%K5Y.919A"-B!H/["JHL-.`,:?-X*#/$UWCHBT?9\5S[XTLXSQK#.11Y MAJ+1*^LH"3_-+RY4LG_.A-D_UI\K5?SE>S;0`98_%/)9F#;821?2-R1,YWW0 MVH`-'Y:>0F[PR3WA%X3.ZH_#Z9O3A!_ M'3N'S(#Y`D(/XIT:DN<#*]OKM[7M]8NL%:RMDC1FT.4JV)!=P^1[::X`JK\Y M?<5#8+TO)9`WPA*\]]S&5<7,&(@O@HB.#[5G`YLV2)5BV)M8->0;=30#_O1" M`CI\KD7'*)5"V#M2->@;]#,#^'S`]N_SM&G`]3T"$>RMH1HI4MW-H*B\\J@M M.$3;.8$0]O9-#GQ]SR9%P`RJ%L2C==YG;\)[K*G.AMWI$6>/A>3J"ISZ0'GL M/9LJ@6JXF,'EGHX*(R+^ID>5(:ZV0S\IWBF6S0W7=!X&$%DNC'WA1FLJ]S4V MQ+)8A+C">J.Y./:5&8IK#9'.!M&2:24AHRB$?>^%&-0&`JK:F0%[D2@I71SL M%42_KT(%?XZ:9G#PP7;]B`V4))KYXR"9N])`Y#3GYH\7.3BZ*?HN%"D]@ M*,Q@KJ(:<`XQX&8*Y9%+L"Q#1']*8LBRJE8,_58)%?0;530#_9=VL<3O[)G* MA-KKBQ/^AH3G=N2N)-%6RA6AWR"A-O.T@LD,CC\1]_XA)L[HD3;VGDR3S1T) M9^N]MPO2]O,95JP&_;H)%7Y;063(:1N[,/G*"[YP#MM^$!ZV,6$KDS8BBG6G MC%+T:H,4[HS&&G03!H\NI?+\^39B5W_M]M2C5>P^9I'64B7;U&5.3"N7S?T) MLB5B9HRP>MQG,R2KP5ZY'*@U>!KU9JYZO81]3 MMC!HG;";T;'03M3T/0>@D[.A'L:Q!>`Y"[2Z"#9L)2DAF%<>^[3T@-R*(3.# MUG*'VT7T^?L!Z1>%59-0='YO8[%UB^_+XHXRR"] M+ZJ!5"8FE<(^CCT$D2`@M)*7)MEDZ35702@_V&!"$AGLP]=#$0>"3F,B`KM' MXY,;/Y2RI3B$<4MC'\@>BBH)7)I(HDJ$+&K\DF3_3L]IP(=5K`JE&K"/=@]% M9@M86T?$T*'X+H@(?DQ,76F*&O.WOD"7/6OHEZ]7!CV8T;EB]"/M%OOEGM`T M8W6]KTSQ.IGP>CV)&/H)>%\ZF*'*O*7@\310PWT=``E\`ZT99SXMSZQ0Y\X@N32IDU1DR#Z^Q@]\P;5 MVR0+A1\"]Q&D8,!+''IL51U&H^EG>Y"HIU@585WH3X#T%ZT"P$S3('V3A*L' MVI79FYE-:.=JM:"_9=*!M/K% M,.KHZ9J4LX9$,[_Z6?CS:>E4I5H+^A,FW;ELI;=)-DQU7Q'BI+DBL"?R^!+H M3Y[T9ILR5'1%`SF/[.[N]`A8,GBFT2_Y2.YU(3X M$NB/F_0_O7%040\K>)>%%?CDGG4%_+""\B"1/H$*&S/SHN@/H&@9+"LXF&&> M<#W[V)$8\&Y*;\2J(V<&XVFC2>@&3MV!RF=8)(/^0DIOC,J1,8=!,5<*.2B# M8*5SM-TVI741TQ42_M0HY^_S*9S!0V<5MF.0:=0+AV/?@,5-X<.:!OZ*_O'% M_^@[#?"P=`DOB)*0R+U[W6N&]AN3L@S[PM.,\;DXT6=QX:(@F7(I*&O:O#V] M4=!\TU,9"U-88K'C2_N);;[$1-4*0KG2YLG1QE4C(F;0)=)U0L<;R,D)O`HH MQ8=X"`-\8***D"8_'=OEYNZ,4LI9R=_+"G"<=D!9*#WZ'$'*6`?*2IID?:6, MM,LDI$IF^Z3TD;JLX5&:*EI28D%6M&0>=#-;EW)X^!;:\V>@W42?%ZEM-]&# MATD]JAH365+@G/CI@\&V]Z+A%;'C1'1I6;O:H/U#GS.J8__H`J*FT;^4!+G+ M8&U*H.,=VRC(0^G3YWGJ,@LH`X5X2]DE82^R;[/K`,Z3R/5)%/WB1K13/+-' MAI/-Q@Z?9^N%>^^[M-_9?GP3>+3_E9R?E;O,?K2.K)=U*?N/\>)B/KE93F93 M:W9EG=\N)M/Q8O%?UB^3Q7(V_]T:32^MQ>W'CR/Z9UI@,?DPG5Q-+D;3I74S MNYY<3,8+Q(O/\H!^-D+G>@/N&!+((`[,!;TESK/\A%ICE[3OG'O-J>%Y72VJ M0K[R3,YC;01NC1:B-9=B)9NM\Z]UZ[R:_&-\:8T6B_$2T\JX3ZK)C0T@BGM8 MVMRZ%Q8`YJ96"[*E@;G5+0!"M(Y:1E6S4;RK&\7M=#R:3^F$-!__-I[>CK])2ZA!!S<`B.#P^CT< M#M3+GFD[9NDBD66I?++#T/8Y<\')FWJWI_N@BU^M6;I'6J33P:?1?$XW0)A+ MLB79;(.0;O[8/!P_JQQU`D01EV2UUBV9MQ:P!I.((2^ZP&S5%ET@,!`-J_S@ M]Y+:5$15X;Y:?')2MZSY^'JTI//)S6B^_-U:4IM:C"Y2,T.T+)Y.=R+$%;&"=$`9=D<%?L[K=O?Q6SZVWB^3+J@T)A7L\OFV^S%9R!K:`Z/WVWB6:46]H'IXJO MQE:$$"':C7R:>%LWD.]30QDT^(Y?*C6\S@X$`GNO_Q!X%+GH,CV+CYN[^0^- M^_Q?9M>7X_G"NAQ?32XF2\1]2+;ED^\ZZN6PHY5R[+-FL?ZBM,-0J`)Y?]', M3U,@D0HBJ"NJS<;-0I9&OI,]T7=/?&XPP,,'%[./'R?+C>+K,_&1T9;6< M3#^,I\A1`@+-E'($U*K!S).`M!1@C:KU()MD*Y[K*1&MH,.<\)*[B/PSH=6, M'PG7J[T76K"X/5^,__>6VJK%3G-0G=EU%0!/%W(E,*>_U0-Q$H_,UO7F028^ MB##VPX02GNJ3'QR/8<;8"6/M3O:""OJ(M;/^7'ST+]]ZV!UGK]80&99^4.JH M@`@.)DP.JA#7_/JD(K3,R,F@;(]H^QX8-5;MUJD@*_2E,U7A>"`AFT'7+KCT=1[&[L9O?PLL+ MULNAOV"I2DFSHF:0P'(SV?:,_HNY51YMCRTKX<8#$T=_>5+9BE1@,8/)*]L- MT[RZW7N7MO>26I6WG<\D4!S]Z4E5)I5@,8/)/`20O1-'=TI*DQE`%/T-2E4& MP7"8PEYQT2M\&!7)H#]$J-WM6\N2*I=`?FE0E"P)"ZPN/C'DB M\D,0.%]G0EF9V`"'N<4Z.48/B=$FE/'Q*120TNI M`RFE]3CNY>L5>X`SP1/#/A+MR(48#?-R3$2CV%Z.(S^[I-,@-IB(^KY#JU[N M58MFZW2:40JN$HH/*QY?33=T8^H09W5)8MOUHBD;)]CNL=GT]M(;^XFWRC]N M[;[^S0=>E56)R.KU??!X[!`WTX+^H=YX^M/G,6U`_,P"M96\0'+]AV+?<+:?6.W.OKN M`-6@V$>;6H5/TN7QKF4?PB`21!V*9`;J\)3#8,9@>Y7050"[Z3N]COJ)_2F2 ML"40P5X,M65+BH*^^\^W29RGV68-I9O*8!U_H=KR:,CO`Y<*8B]2E,F`*F:2 M_5RS%_]8KO1DLPV#Q\SY(3$@D0SVHJ6M!)3S_X-)"[BB>``KQR,Q> M:D*O7D]?P(Z-;]L?^L9X^#X:KHI3TF83E$IAQ]WW/EJ4L!B^'P!V,K)WHU?;6X/`7NHI)6)S&B@2&-8J0J8->M?GY`<<[:(`\[\3'F+O MWVG(SQB@?YE5S4ZT\\J-.+T>3AY!CEKV:"['A&IEAI@CT*AFZ[7;-GTXG%IL M&&M8OV5MS9IZ$[JKII>Z7W2JE,,^7^[`38.^1O-#MVQT<)/9S*X0]F%S%ZNI M::II>YI]+/^6O-]7"V(?"W>`MTECK1!'=.OCAK*>NRN$?0K?6--4*:_XM M><^M%L0^N.T`;Y/&>GON!5TK$\^3]=U2,>QST"Z]=T];K>#NOB;OP?6BV,>) M'4!NUEKW^$O"E1O)1^!=,>Q[M[J-P35M-8_"^=<@XW"U*/9]69U&XB:M]?9B M^);Q\ZD!MU!UWS8R-7K9F(Q]QZ1MHPH]AN\<-5)DC!.M^$7H1=M[I@#J12MJ M_^Y&4S*^`C;AH%@O-$1'6K.BAGIJJHT5#8J-)0?I31/H;#A+8H?:7JE!>M0X MNFI:J=6^!C&`K\"M)M):,]!BS]I>J4&ZUCBZ'@992!?^"OQK(JTU`RUSL364 M&Z2/C:OOH?"%=.6OPM$FUES[N"'VM364&Z2SC:OOH?"%C<[BN-XXR7Z?S#1;$N7>IM.BN6Z/2LX;C9RL3E`_`+/R7 M8W'FKZ?U+O+R!IH*#=*#Q-3X`Q*+YHZ'<('U@7'T/@"_+ M^EC%=#9RU[!!HUQ\D-XPF?8'`#U]\@Z`=EYND%XQKKX'P'?BQX1B%,_M&`)S MM?@@_6,R[0\`^J7[Z#IT30D`_*7H(#UE(JT/,7H$'L7'H\T%]N^ZP""=9G($ M-%ZY9OO/++.(XN+D:9([L?NA\H\DVT\Q)RD&;4W:07C2A MW@=QHGURXX=Z-BG(<],L^#6XVD20:.*D\**F&X&/]I.[238<%IJ+#M-])E(; M,8-S3M++#V[L,'Y>THX1T>:7,C;%#K"SO<>>YN/KT7)\:=V,YLO?K>5\-%V, M+C)OF%D.,)[>J*JEW6E,,/IRRVPZP- M1T*U!WH9&^>6"=@PJ/):U+=VJT-/+R`4S5ERG/_%@P&UC651::$`ZZ8@5+S=PYV0UA8K(AOAVXP>G(A1%2+ M#Y&+J@:E^1&3C;Q-MWZT)2MW[1+G,MC8KNB-%KZ(8:PT];"]Q^NXRKRL,?OU M656FZY./9'-'0L[58A'D_35_)2:`NE%K38#3KD!6=$?DL`_G MW[TAX8IA=,^#7":$/FJ#4(>IKNLP+76+I^Y&^N'T)Y[KB%L@&82U3 M5RO*%;\N"&B.!/KXK8"U4&EMYP9;]^6%5>Z)0;40=F0)#-1FU._ZDTQJ%#P@V M,:/5*DS22]W32*2N/.U5AQW!TC-M'+@.R^)%L-D$?GK`E,UBPM0:U4JP`V`Z M,2:!YK`\P6X'@`ICQ\ITXN6PEP=(&E%9]+5CI58%>@1-+^0TXH),49I5U9&C MO`[T<)M^2:H@VZ\S6:^!"K"(!Y<"P?7Z#UMH&KL*7>D-\VQ/F<''*0C%& MWK,+-3T4NJ,-,RLHOD5I\+F>80A7M=5UKD?BV$L;]Z$Y@BL]!ZL5@B**O$MN MU@TQ_X2S73Q:K!Z(DWB$S2+%GB*:K;/)1'`/\MDI/!;[R"J^PNY!+GV'_6?Z MI8YW(@\F2!LV=^;)\IX7V&&"33-]YGFO&>A>X];:=7\4UPT.:410N2:8^U4&MM@7=V]O`Q<=C* M7X(UMS1:]$Q[M"6:JV>GOV+B]\1$1$J^)R9^3TSLGXWOB8FHB8D-\[A2 MKJ)('CT1ID/"EQR7@^[YR^U02G(4R:-'O_?+#THJ9$,[E+(C1?+H,=;]\H.2 M0]G0CK<=^7FKR(^^4\!^^7E[$'YNJ!9N%`7A,VN&*+6UL>0@,EH%.AXVH/,C M"ZMB-\#QC[A!DN@S>9?(SB80#D-#<37M379&+`@T@`@.(]<5#H%6#DHAGOMY MMY7('R$C*M4,(S^V+3R'8FN:L$GHY4WA97"3A*L'.R)703BF99^77P)P>E2W MBH>1G-L?A(?BN#$[F[:M:'#17#"W"A6B;WK:<:H,F28N!:'T2W=#1IX7?&&! MKD5[B_;-_)4T:[BGNH>14=PKD(9#%34@V;K*9$L$E(4J5#"`_N(U:6CK$ MH2(5U&]'?EL/2?C&;T06O`NR&\-O/-O_9$>C[38,'KDK.K'(\,)N(1"8D3F\ MR"YWNP[\^R4)-^*+D1H+#RQ*5Z2*UG5&_L6JSQ?T`!I`<("ANW`\#DH(_<\5 M(0[W=0J)T`#C>F$X')0$<:*U1&:`P;X@%!"3FU(/[T/@4>"BRW37&\.63#\T M/BS]R^SZ+I7FX5IKW/2`T7! M39Z[0&2`,/)Y:C,G>Q'58!3,6'SMW58V2N*'(&3;+1!=^T+8!["J//'4-I0? M[DD23S/%$R)M9[+M>#G0J4_C5Z^"D"W*7WRK7"<<5!S[W%7,@9HN6AFI?NS* M=D-1^`VW-/:IJ!QOB:)F#$+51A9)>.S7[!*!IBSFDC-/(HI]S`D:F,`0F,$8 MNY$@N@ZBB$0S?_P4N_Y]XD8/;!<@NWH:((I];`EB#`S!80]ULJ=[`7,*4!K[ MI!(RI2@!\?TB8P/(,>H28\2[W+6=B;9FYOL][F@GF#UR9L0E[K;CN`P\%C[2 MPR@(J`[]_N/6%(*Q0IZ^9%NE%O6@7Y;H*/'R?+C^/IF6Y"IA47H?7=_=))L\XR":DQ5Q'UG/G?C++\'OQ`X% MZ=[M:T3VI+?BOK:[ZPJG&=MT92WHQTG?W:)4)[;O'J5G[&$ZS+YQ%21ASUVC M5"7VZ0%&S]A#U,B.,:?-SL.4A=&B$C'LHPD-!#..5DE_^7]0 M2P,$%`````@`6XEM0T!.[`L``00E#@``!#D!``#M'6MSXCCR\UW5_0U M6W6$$#+927:R6X1'AMH$.$SFL5^V'%L058S-2'9"]M=?RR_\D(5-R%ESWOF0 M`76WU"^INV7)?/AULS*5)T0HMJW+1OOHN*$@2[<-;"TO&W=JLZOV1J.&\NLO M__B[`O\^_+/95(88F<:%TK?UYLA:V#\K8VV%+I1K9"&B.3;Y6?FDF2YKL8?8 M1$3IV:NUB1P$`'^D"Z5S=':O-)L%NOV$+,,F=[-1U.V#XZPO6JWGY^,,7W)CK:+(#_ON8`[.2XW?G72;_= M9G\Z\Y.3B^.?+DY/"X[C:(Y+HW&.-^^/_7_%R&\QU2/B\[/N._K39H:_+)'U MWNW];KVGGS6M?Z9-SU_6QK/V]7%#/\].%[/'LR\OS\OYX.[L"QX.__SX;77\ M^^FU/^0'JC^@E::`Q2UZV8AI\;ES9)-EZ^3XN-WZG@-'_%B8V+KD8?> M/C\_;WG0$#6#N;DG9MAUI\7`]QI%4<\`Q0)\;%%'L_0$ON%$!''D=RT?F$#% M7-0S'Q6'J`8JAN?2YE+3UA'N0J/W'FX`:#%W:1ZWFYUV2&+9EN6N^!(:#FDY M+VO4`J0F8"&"]8AN-U&2`%A@S93+G`?A<*?^]FD4$;`O'L[Q>8>M`29:(7T,TUR[)A-L"\#UI8VWJ- MP=VAX6\?F%]<$-M$<^!481]@MB?[9(TMF",NXZIK&0/+PEQ#K[T$IW$^OC&([J!AH`P0,DATC53=\UR-%M6N"1!0ZCE4GJ_TDPV#=4'A!SJ*SK9 M)-;L":B3K88H4&U`J_C$]=7D5",@SP-R,'#)46L2+M9Q1ZACY8=$7S_62N>1 M6NAD,5FS#`5&"=PX!R;6]6E*U]M.%'NA;+NIK99[>8FO8S1\E;D%C'[X0Z M9KTH7C>UTG$?49W@->M[LKAR*;80I1\QA93[!2*>ZJY6&GF9+%2\M"!0ZYKE M3&T3ZQ@%EGA-!V)[G;&0"2FK:5.7(/9EH/9FH^E\-!DKDZ%R=:>.Q@-5_;?R M<:3.)[.O2G?<5]2[V]LN?`8$=70]'@U'O>YXKDPG-Z/>:*#6RKA#O$%&E](H MQ,8;Q,K_*:W\X>C+H*]T574PKY<21\"_M61U'+CS!.(=B6LT%RI6[_NT>D?C M>7=\/;JZ&7A>/)E_',SJJ.T["VG$0L8,/2'+1;Z2TXUBW9ZG=7LW'G1G8_#> MV>#38'PWJ)5"5^DS!13]KA,`2'(51/E"HX/9Q6L&P^O9^4R;>RJQZ M_ONY.YO!LELOWYTAX`49D!<[+W-0)-7T6%Z8"Q4KNYU6]FQPTYV#,T^[L_E7 M90YJ5KL]3_.U4G;/MIX0<=C*.[8=!)7-BP:??5WG`<6J/DFKNC<9?QK,YMZJ M/)[,!RHH_6L7OOVE:1/%_5FH]02BV`*=PA9(3H-:V2/K[B5\_#2MX?KZM1?\ M'FS30(3V81@=.[&HF`*(M?J.&Q$_3F[Z@YD*=0L4(:-YK93;LUUH?CN`?,-+/F#1F(_&UX-Q[0H^U;VGZ)L+ M8@R>T#;+2[>*]9LI_=2[*W7PGSO0K\(2Z)IE=:_8X#C83DFQ'9-VIJH\Q(Z) M\D,X>KWV>&-[)7,66+-;*$&SV":9:C2^D:+\X/=1+\WF5)UQ+8M1A!H_*5&> MUE/_.7EZ7/]B%+'^,Q5K?A)?2_6_(@[TD:-ADX[9='#P$WIU8,ET*#9MID(^ M3(`)N%`B-NKE$+&0TF3G9`S71)/%E-AKF(+,@E-3LP;?7+QFZ7*@K$PT*D$J M-G*F"$]$+%A.@W'84[-P).](`QM+B0:+S%I;8_)GJPA!;)A,[9Y,)6H^B_*> MQ/"M4!A;;)),X2]XCE-["Z4>X_`-LPM);(_,WD#ZV4_MC9"363>C+"&`)<), M62*QD;(;#/D).@#],?QS,-XH-8TL.XT0MI0S79I*;+O,%D-1VX7#_&6\N!GX M:V!19+&I,CL/HCJXYJMBWL-9OGT*8PL-U,EL5.0_VJV]@7(V)/CV*8HL-D^9 M?8R_K,-3>*PD]3'8/1TZ67CK6R)*O:8#L16+/]1/E;:Q`=E7;\B:!J\"#_9+ M340AH=B<^YX0J/T4W;UJOF*I%)\JJ+WN.0<*!(G?#D2Q)0J=1*B]002'#_(6 MLN($8@.5.[WP_VTI]H==WIRAA>)=^KQ@]PHO&Q2SN[V-H.V!H`6T/3[A9G@- M\`\0[6BS,D,4UK7@TJ=G\[0V@H'#+C2B9WK)7$J%3KS];C![*V0^[,#!#B.? MQH91V#B0X;0.(;*IW9<5&4B0^8:RWK#^#RHD>%]9(5,.^T:B]K:C'%1@F#IE M!4[.MC>2MQ\-$A6T#!-;-91C(J3;@PFO-XKTHZ7]!$;%B>O4.5QP M:=B'YI:XZ/C"R^:B\;F$+60Z-&QY)3?9V^7[L^/UM0<_!2[6%_&4..78)V2N M[\T,%[#L8-N8>ZNCX9+@GKV_6OJO-K@P[)6&K9@P-I'/O*:Q*+D.] M)K:[OFSX?6%`*<'WB9#O$VGY[@CY[DC+-Z?8%[N.D.`[D$[L8$*"[T`ZL1L* M";X#Z4[+2G1A\#>H$Z^0`BWMB:18?$ M7B6W#N\CN40(.YGW,TDG!-W[+[JX;.@$&>Q22%RDE6U!14Y>#N^5_(M57'_, M09554&:'$0Q-/->+,WT'XD'*@_]$!ML4L5W+@0)ZA=W5&&U]=F_RO15BH/LW MU$=7UX$?8[!9(XLB&A@7&7/;,VXH]VZT$M/R?RJ@MX\YHA2X']ID9#F((.H$ M@H3B[4+:=\UYT*"?`WGM5,/&9^P\L/T_V_(XCGLE'[R_5=YX'HXL&`"*U3[R M_[^&^$,GUF##=C-=3!\8^F017U?+D7PWDH^LU#DSFB3=UB?X`3$\6 ML5.F$.ICIQV#=U?XPI;`E]:T$`K]%P%9LT$\$+TTF:Q&[QI/;!@Z MMY.21&$D'RZM45DZ%V@^%O9BMF$(\=RO"+*TTL;"1Q0/>2LLW::#Q0FJ#J/> M+)K;0VR!+K%F;E^[E:Y-BF!*5YGD'B2/GO'-T<:Y,F.90SF2?Q.(F3B@5%RZ.10UE*%,&42*;A]N$.<7"P91+FV(4#`%-$1R3.+&$4&(;;G)X/CY'/N(K<; M32YA$O?!!=+DXLD@#GN#O>L@0J,KD^RRKKUPGB'S@IYH/-W;C2GI7M>-=A]Q MG1"*!Y!4AJZNNRO7BXI=?[_1\XTI-/@'PN9$,]!*(X_QO;L2)++*'>,\V)<3 MREP87=92.I6]SI!N+_U3,#GY;1)#V@(S6-7]6C$4)=U8W`G?I$[TV?&YF1*L MHR2?24!97MG:#6"5,7LX?5ZSX))1Z+:UZM+;9RC@AZ/3%*1\4'P3K<+2@4E& MJ]M6.;0:\,/1:@HBB59[;*$QS8Q>X^UR:#;BB*/;#$P2[0XVB.B8VR*(ZYF)8MA M(5NI()9MED6WO#B6`Y-%MYE0Q@/(HE]^-,N%RJ+C3$#C`631,3^FY4*KUG'\ M]0X!<_$GT_G@BN-(=H,7.2Z1@)?E M/+P2<1$ZN7JH)Z%Q)KT?F>1Q'P)D/:H8YS4\DC;3'*XL*?B>/J3#^`=FO(^? ML($L@\=T#"8/PY]L=K7.Q,Y+GJXS&-4RSW;D->N%;?\1(SJB&=^OYT*EW2!D M/TX;/2YAQ8I_(2\XZ9@#W#/\&]#=P:LN_Q1F\GDVOPC+P:PZEPFS%"\BW6H; MO')7H0`YL*KS&.Z9>^&!?)FG0,YIB$0DVX$CK6QWL/SH+HP1N\PR]1=#;1E) MMQ-K7X<[5,3PYIIW4M6;"=/`E:-XD0^O>JKXK"7F,9_[/)2J!?"V`KP!^K$( MG6FM-B3D3$_0I:7C=>QTZ([YS"60]9EE81F"ZR1AUEI:!UGZ[TPEL5.S_F1+ M;BN7IJHZ9>"M">`%QB#0'DJ@>N,J27:D)CK-;RU216)9(5N'[($4L)=A^ M?44N,,>K0TRS1!(U6821*W9)9/MSJ,&MH#(45:\B06[.WHT9A:C0H:#1)02@ M7FMBK2Q/5G'>GUX7PIN7D\4B;^E(HDAZO&Y*T-J_A39%EF8F-[_R@-7N>V6X MZJZ8V^0R'8$E-8&*',=O8Q=;HU(LW2HI]_RW5+1S)D4,+.ON.Y_C$[%`)]^= M0!VQ0!V)!9H0O(3Q`?=E_FSG;S*]LJ>*3U9D M9.!N6@/[H4RA1/E:*--#Q;YPA2SOS=R:F9&"E:U=T[2?6:$8BA2*,(&5,[,! M?:C.Y%GA!!(5$%KBS"=O'V>?K9IJXBJ+AA&W[,<:/VNTNUX3^VGKD#MP]EMY M#KBEH_I/*)/Y#/^D3A',JI]HL>>SV!J8W`7DE3;U=Q' M/A"/6"&P7;1BYWV*XE=MJB1#0PV31)V0#Y9U^SGOMYZ\,TL\4Q5%E_)1MF88 MWF53%CKW>9A9A+YJ%RWZ'#;CO/L05N_6'UK^Z[OAXW\!4$L!`AX#%`````@` M6XEM0Y$;G[;J00``=:L"`!$`&````````0```*2!`````'-K=FDM,C`Q,S`Y M,S`N>&UL550%``/N^(-2=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`6XEM M0Q%D^]R!"0``YEH``!4`&````````0```*2!-4(``'-K=FDM,C`Q,S`Y,S!? M8V%L+GAM;%54!0`#[OB#4G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`%N) M;4,_U2C!*0P``">'```5`!@```````$```"D@05,``!S:W9I+3(P,3,P.3,P M7V1E9BYX;6Q55`4``^[X@U)U>`L``00E#@``!#D!``!02P$"'@,4````"`!; MB6U#`(=@P%PN```FB`(`%0`8```````!````I(%]6```&UL550%``/N^(-2=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` M6XEM0R%OW@;/(0``LQ,"`!4`&````````0```*2!*(<``'-K=FDM,C`Q,S`Y M,S!?<')E+GAM;%54!0`#[OB#4G5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`%N);4-`3NW*]0X``#J?```1`!@```````$```"D@4:I``!S:W9I+3(P,3,P M.3,P+GAS9%54!0`#[OB#4G5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H" (``"&N``````` ` end XML 28 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK OPTIONS AND WARRANTS - Summary of Options (Details) (USD $)
9 Months Ended

Sep. 30, 2013

Temporary Equity Disclosure [Abstract]

Beginning Balance, number of shares 9,400,000

Beginning Balance, weighted average exercise price $ 0.05

Options granted and assumed, number of shares 300,000

Options granted and assumed, weighted average exercise price $ 0.05

Options expired, number of shares 400,000

Options expired, weighted average exercise price $ 0.05

Options cancelled, number of shares

Options cancelled, weighted average exercise price

Options exercised, number of shares

Options exercised, weighted average exercise price

Ending Balance, number of shares 9,300,000

Ending Balance, weighted average exercise price $ 0.05

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_OptionCancelledPrice

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_OptionExercisedPrice

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_OptionExpiredPrice

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_OptionGrantedPrice

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_OptionIssuedPrice

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_OptionsCancelled

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_OptionsExercised

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_OptionsExpired

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_OptionsGranted

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_OptionsIssued

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_TemporaryEquityDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

UNEARNED REVENUE (Details Narrative) (USD $)
9 Months Ended

Sep. 30, 2013

Notes to Financial Statements

Unearned Revenue $ 19,792

X

- Details

Name: SKVI_NotesToFinancialStatementsAbstract

Namespace Prefix: SKVI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_UnearnedRevenueRecognition

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 30 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8

NOTES PAYABLE (Details Narrative) (USD $)
9 Months Ended

Sep. 30, 2013

Notes to Financial Statements

Date Financing Plan was approved 2013-05-22

Secured Promissory Notes, max amount offered $ 1,000,000

Secured Promissory Notes, interest rate 9.00%

Secured Promissory Notes, proceeds 1,000,000

Secured Promissory Notes, due date 2 years

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_DateFinancingPlanWasApproved

Namespace Prefix: SKVI_

Data Type: xbrli:dateTimeItemType

Balance Type: na

Period Type: instant

X

- Details

Name: SKVI_NotesToFinancialStatementsAbstract

Namespace Prefix: SKVI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_SecuredPromissoryNotesDueDate

Namespace Prefix: SKVI_

Data Type: us-types:durationStringItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_SecuredPromissoryNotesInterestRate

Namespace Prefix: SKVI_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_SecuredPromissoryNotesProceeds

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_SecuredLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 31 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONVERTIBLE NOTES PAYABLE (Details Narrative) (USD $)
9 Months Ended 12 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Convertible Note 1

Sep. 30, 2013

Convertible Note 2

Sep. 30, 2013

Convertible Note 3

Dec. 31, 2012

Convertible Note 3

Convertible Notes Payable, Value $ 52,476 $ 27,000 $ 1,000,000

Unsecured note payable percentage 10.00% 10.00% 9.00%

Shares, fixed price per share $ 0.05 $ 0.05

Shares, exercise price per share $ 0.10 $ 0.07 $ 0.07

Expiration date Jan. 12, 2010

Convertible Notes Payable, Cash Payment 12,000 2,000

Convertible Notes Payable, Principle Converted 15,000 15,000

Convertible Notes Payable, Principle Converted Accrued Interest 1,277 1,277

Convertible Notes Payable, Common Stock Shares Issued 300,000 542,560

Convertible Notes Payable, Warrants Granted 271,280

Convertible Notes Payable, Warrants exercise price $ 0.07

Convertible Notes Payable, Warrants exercise period 2 years

Beneficial conversion feature 326,510 19,385 111,110

Financing expense $ 19,385 $ 40,476 $ 8,910

Due date 2012-10-01 2014-08-01

Price per share of interest converted to warrants $ 0.05 $ 0.05

Percent of common stock discount of current stock price 90.00%

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayableCommonStockSharesIssued

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayablePrincipleConverted

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayablePrincipleConvertedAccruedInterest

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayableValue

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayableWarrantsExercisePeriod

Namespace Prefix: SKVI_

Data Type: us-types:durationStringItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayableWarrantsExercisePrice

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayableWarrantsGranted

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_DueDate

Namespace Prefix: SKVI_

Data Type: xbrli:dateTimeItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ExpirationDate

Namespace Prefix: SKVI_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_IssueDiscountFeatureChargedAsFinancingExpense

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_PercentOfCommonStockDiscountOfCurrentStockPrice

Namespace Prefix: SKVI_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_PricePerShareOfInterestConvertedToWarrants

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_SharesExercisePricePerShare

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_SharesFixedPricePerShare

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_UnsecuredNotePayablePercentage

Namespace Prefix: SKVI_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Beneficial Conversion Feature

-URI http://asc.fasb.org/extlink&oid=6505963

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

+ Details

Name: us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.

+ References

No definition available.

+ Details

Name: us-gaap_RepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 32 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

INTANGIBLE AND OTHER ASSETS (Details Narrative) (USD $)
9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Notes to Financial Statements

Patents and trademarks, Gross $ 584,898

Accumulated Amortization 239,208

Amortization Expense 26,003 43,039

Convertible Notes Payable $ 1,000,000

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_AccumulatedAmortizationPatentsAndTrademarks

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_AmortizationExpensePatentsAndTrademarks

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: SKVI_NotesToFinancialStatementsAbstract

Namespace Prefix: SKVI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 33 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES
9 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES

Description of business – Skinvisible, Inc., (referred to as the “Company”) is focused on the development and manufacture of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations, offer solutions for a broad spectrum of markets women’s health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.

History – Skinvisible, Inc. (referred to as the “Company”) was incorporated in Nevada on March 6, 1998 under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.

Skinvisible, Inc. together with its subsidiary shall herein be collectively referred to as the “Company”.

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $23,601,123 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

Principles of consolidation – The consolidated financial statements include the accounts of the Company and its subsidiary. All significant intercompany balances and transactions have been eliminated.

Use of estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents.

Fair Value of Financial Instruments

The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items.

As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The three levels of the fair value hierarchy are described below:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

Revenue recognition

Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

Royalty sales – The Company also recognizes royalty revenue from licensing its patented product formulations only when earned, when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Distribution and license rights sales – The Company also recognizes revenue from distribution and license rights only when earned (and are amortized over a five year period), when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2013, the Company had not recorded a reserve for doubtful accounts. The Company has $1,000,000 in convertible notes payable which are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®.

Inventory – Substantially all inventory consists of finished goods and are valued based upon first-in first-out ("FIFO") cost, not in excess of market. The determination of whether the carrying amount of inventory requires a write-down is based on an evaluation of inventory.

Goodwill and intangible assets – The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other”. According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.

Income taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Stock-based compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to a Employee Stock Purchase Plan based on the estimated fair values.

Stock based compensation expense recognized under ASC 718-10 for the nine months ended September 30, 2013 and 2012 totaled $21,200 and $0 respectively.

Earnings (loss) per share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.

+ References

No definition available.

+ Details

Name: us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

INTANGIBLE AND OTHER ASSETS
9 Months Ended

Sep. 30, 2013

Notes to Financial Statements

INTANGIBLE AND OTHER ASSETS

Patents and trademarks are capitalized at its historical cost and are amortized over their useful lives. As of September 30, 2013, patents and trademarks total $584,898, net of $239,208 of accumulated amortization. Amortization expense for the nine months ended September 30, 2013 and 2012 was $26,003 and $43,039, respectively. The Company has secured $1,000,000 in notes payable with its US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods".

License and distributor rights (“agreement”) were acquired by the Company in January 1999 and provide exclusive use distribution of polymers and polymer based products. The Company has a non-expiring term on the license and distribution rights. Accordingly, the Company annually assesses this license and distribution rights for impairment and has determined that no impairment write-down is considered necessary as of September 30, 2013.

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_IntangibleAndOtherAssetsDisclosureTextBlock

Namespace Prefix: SKVI_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: SKVI_NotesToFinancialStatementsAbstract

Namespace Prefix: SKVI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

RELATED PARTY TRANSACTIONS
9 Months Ended

Sep. 30, 2013

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

On September 23, 2013, the Company granted stock options for 300,000 shares of its common stock to an employee. See Note 5 for additional information.

During the three months ended September 30, 2013 the Company advanced $40,143 to employees of the Company for business related expenses. The advance is non-interest bearing and due upon demand.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

UNEARNED REVENUE
9 Months Ended

Sep. 30, 2013

Notes to Financial Statements

UNEARNED REVENUE

On January 16, 2013, the company terminated its licensing agreement with Panalab dated January 23, 2008. The agreement provided Panalab the right to distribute, market, sell and promote Skinvisible’s proprietary formulas made with Invisicare and Adapalene through-out Panalabs assigned territory. Panalab had failed to sell or sub-license the products in the territory, thereby not fulfilling the conditions as set forth in the agreement and allowing for immediate termination of the agreement. As a result of this cancelation, unearned revenue of $19,792 has been recognized as revenue during the nine months ended September 30, 2013.

X

- Details

Name: SKVI_NotesToFinancialStatementsAbstract

Namespace Prefix: SKVI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_UnearnedRevenueDisclosureTextBlock

Namespace Prefix: SKVI_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK OPTIONS AND WARRANTS - Summary of Warrants (Details) (USD $)
9 Months Ended

Sep. 30, 2013

Temporary Equity Disclosure [Abstract]

Beginning Balance, number of shares 6,765,200

Beginning Balance, weighted average exercise price $ 0.06

Warrants granted and assumed, number of shares 471,280

Warrants granted and assumed, weighted average exercise price $ 0.06

Warrants expired, number of shares 2,562,500

Warrants expired, weighted average exercise price $ 0.05

Warrants cancelled, number of shares

Warrants cancelled, weighted average exercise price

Warrants exercised, number of shares

Warrants exercised, weighted average exercise price

Ending Balance, number of shares 4,673,980

Ending Balance, weighted average exercise price $ 0.06

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_WarrantsCancelled

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_WarrantsCancelledPrice

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_WarrantsExercised

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_WarrantsExercisedPrice

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_WarrantsExpired

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_WarrantsExpiredPrice

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_WarrantsGranted

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_WarrantsGrantedPrice

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_WarrantsIssued

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_WarrantsIssuedPrice

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_TemporaryEquityDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONVERTIBLE NOTES PAYABLE - Schedule of Conversions of Stock (Details) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Notes to Financial Statements

Convertible Note Payable #1 $ 44,476 $ 52,476

Convertible Note Payable #2 10,000 27,000

Convertible Note Payable #3 1,000,000 1,000,000

Original issue discount 111,110 111,110

Unamortized debt discount (61,724) (102,200)

Convertible Notes Payable $ 1,099,862 $ 1,088,386

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotePayable1

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotePayable2

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotePayable3

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: SKVI_NotesToFinancialStatementsAbstract

Namespace Prefix: SKVI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_OriginalIssueDiscount

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_UnamortizedDebtDiscount

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 22

-Article 5

+ Details

Name: us-gaap_ConvertibleNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

EXCEL 39 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\Y,#4Q-C!F95\X-&8Y7S0V-C%?8F0T,%\U,3$T M8C@X838R8S'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-43T-+7T]05$E/3E-?04Y$7U=! M4E)!3E13/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O M#I7 M;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-43T-+2$],1$524U]$149)0TE4 M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K M#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D1%4T-225!424].7T]&7T)5 M4TE.15-37TA)4U1/4C$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D9)6$5$7T%34T544U]38VAE9'5L95]O9E]0#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D9)6$5$7T%34T544U]$971A M:6QS7TYA#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DE.5$%.1TE"3$5?04Y$7T]42$527T%34T544U]$93PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E5.14%23D5$7U)%5D5. M545?1&5T86EL#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-43T-+7T]05$E/3E-?04Y$7U=!4E)!3E137U-U;3PO>#I. M86UE/@T*("`@(#QX.E=O#I7;W)K#I7;W)K M#I7;W)K#I7 M;W)K#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E M;%=O#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C M=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)V9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)RTM,3(M M,S$\2!A(%9O;'5N=&%R>2!&:6QE2=S(%)E<&]R=&EN9R!3=&%T=7,@0W5R M'0^)SQS<&%N/CPO'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4@86YD(&%C8W)U960@;&EA8FEL:71I97,\+W1D/@T*("`@("`@ M("`\=&0@8VQA6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA6%B M;&4@2P@;F5T(&]F('5N86UOF5D(&1I'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N M/CPOF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L M,#`P+#`P,#QS<&%N/CPOF5D(&1E8G0@ M9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA6%B;&4L(')E;&%T960@ M<&%R='DL(&YE="!O9B!U;F%M;W)T:7IE9"!D:7-C;W5N=#PO=&0^#0H@("`@ M("`@(#QT9"!C;&%SF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#(S.2PR,#@\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPOF%T M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#@R-#QS<&%N M/CPO'!E M;G-E*3PO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M/B@Q,C,L,S(X*3QS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\Y,#4Q-C!F95\X-&8Y7S0V-C%?8F0T,%\U,3$T8C@X M838R8S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3`U,38P9F5? M.#1F.5\T-C8Q7V)D-#!?-3$Q-&(X.&$V,F,W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^)SQS<&%N M/CPOF%T:6]N/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XR-RPP,#8\'0^ M)R9N8G-P.R9N8G-P.SQS<&%N/CPOF%T:6]N(&]F(&1E8G0@9&ES8V]U;G0\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO M'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G1S('1O+"!R96QA=&5D('!A6UE M;G1S(&]N(')E;&%T960@<&%R=&EE'0^)R9N M8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO M#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO6%B;&4@8V]N=F5R=&5D('1O(&-O;G9E'1I;F=U:7-H;65N="!O9B!D96)T'0^)R9N8G-P.R9N8G-P.SQS<&%N M/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0M86QI9VXZ(&IU2!A<'!L:6-A M=&EO;G,@=VET:&EN('1H92!P:&%R;6%C975T:6-A;"P-"F]V97(M=&AE+6-O M=6YT97(L('!E2P@=&AE($-O;7!A;GDF(S$T-CMS(&YO;BUD97)M871O M;&]G:6-A;"!F;W)M=6QA=&EO;G,L(&]F9F5R#0IS;VQU=&EO;G,@9F]R(&$@ M8G)O860@&5C=71I=F4@86YD#0IS86QE6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/'4^2&ES=&]R>3PO=3X@)B,Q M-3`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`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU2!B86QA;F-E6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&IU2!A8V-E<'1E9"!I;B!T:&4@ M56YI=&5D(%-T871E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU'0M86QI9VXZ(&IU M2!C;VYS:61E2!L:7%U M:60@:6YV97-T;65N=',@86YD('-H;W)T+71E'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE2<^ M5&AE(&-A6%B;&4@86YD(&%C8W)U M960@97AP96YS97,@87!P6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IUF5S('1H90T*:6YP=71S('5S960@:6X@;65A6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^)B,Q-C`[/"]P M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M2<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M2!O2!T:&4@9G5L;"!T97)M(&]F('1H92!A'0M86QI9VXZ(&-E M;G1E'0M86QI9VXZ M(&IU6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^3&5V96P@,SH@4')I8V5S(&]R('9A M;'5A=&EO;B!T96-H;FEQ=65S('1H870-"G)E<75I6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/'4^4F5V96YU M92!R96-O9VYI=&EO;CPO=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE'0M86QI9VXZ(&IU2!H879E(&5A M2!A;'-O(')E8V]G;FEZ97,@2!W:&5N(&5AF5D(&]V97(@82!F:79E M('EE87(@<&5R:6]D*2P@=VAE;B!N;R!F=7)T:&5R(&-O;G1I;F=E;F-I97,@ M;W(@;6%T97)I86P@<&5R9F]R;6%N8V4@;V)L:6=A=&EO;G,@87)E('=A2!A6UE;G1S M+CPO<#X-"@T*/'`@3L@;6%R9VEN M+7)I9VAT.B`P.R!M87)G:6XM;&5F=#H@,"XU:6XG/CQU/D-O6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI M9VXZ(&IU6EN9R!A;6]U M;G0@;V8@86-C;W5N=',@2P@86X@86QL;W=A M;F-E('1H870@2P@;V8@=&AE(&)A;&%N8V4@=&AA="!W:6QL(&YO="!B92!C M;VQL96-T960N($%S(&]F(%-E<'1E;6)E0T*=&AE M(&%C8V]U;G1S(')E8V5I=F%B;&4@;V8@82!L:6-E;G-E(&%G2!H87,@=VET:"!7;VUE;B=S($-H;VEC92!0:&%R;6%C975T M:6-A;',L($Q,0R!O;B!I=',@<')O<')I971A6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/'4^26YV96YT M;W)Y/"]U/B`F(S$U,#L@4W5B2!A;&P-"FEN=F5N=&]R>2!C M;VYS:7-T6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/'4^1V]O9'=I;&P@86YD(&EN=&%N M9VEB;&4@87-S971S/"]U/B`F(S$U,#L-"E1H92!#;VUP86YY(&9O;&QO=W,@ M1FEN86YC:6%L($%C8V]U;G1I;F<@4W1A;F1A6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/'4^26YC M;VUE('1A>&5S/"]U/B`F(S$U,#L@5&AE($-O;7!A;GD@86-C;W5N=',-"F9O M&5S(&EN(&%C8V]R9&%N8V4@=VET:"!&05-"($-O M9&EF:6-A=&EO;B!4;W!I8R!!4T,@-S0P+3$P+"`F(S$T-SL\:3Y);F-O;64@ M5&%X97,\+VD^)B,Q-#@[+"!W:&EC:"!R97%U:7)E6EN M9R!A;6]U;G1S(&]F(&5X:7-T:6YG(&%S&%B;&4@:6YC;VUE(&EN('1H92!Y M96%R'!E8W1E9"!T;R!B92!R96-O=F5R960@;W(@'0M86QI9VXZ M(&IU6UE;G0@87=A65E(%-T;V-K(%!U'0M86QI9VXZ(&IUF5D#0IU;F1E6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE2<^/'4^16%R;FEN9W,@*&QO2!R97!O2!T:&4@=V5I9VAT960@ M879E7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA2P@4&QA;G0@86YD($5Q=6EP M;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0M86QI9VXZ(&IU&5D(&%S'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1EF4Z(#$P<'0G/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)A8VMG3L@=VED=&@Z(#4T)2<^36%C:&EN97)Y(&%N9"!E<75I<&UE M;G0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXQ,3,L-C,U/"]T9#X-"B`@("`\=&0@6QE/3-$)V)A M8VMG2<^0V]M M<'5T97)S+"!E<75I<&UE;G0@86YD('-O9G1W87)E/"]T9#X-"B`@("`\=&0^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXS."PQ,#4\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ M(&IU'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI M9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T M6QE/3-$)W1E>'0M M86QI9VXZ(&IU6QE/3-$ M)W!A9&1I;F6QE/3-$)V)O'0M86QI M9VXZ(')I9VAT)SXH,S$X+#4Q.3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O6QE/3-$ M)V)O6QE/3-$)VUA M3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\Y,#4Q-C!F95\X-&8Y7S0V-C%?8F0T,%\U,3$T8C@X838R M8S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3`U,38P9F5?.#1F M.5\T-C8Q7V)D-#!?-3$Q-&(X.&$V,F,W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0M86QI9VXZ(&IU MF5D M(&%T(&ETF5D(&]V M97(@=&AE:7(@=7-E9G5L(&QI=F5S+B!!F%T:6]N+B!! M;6]R=&EZ871I;VX@97AP96YS92!F;W(@=&AE(&YI;F4@;6]N=&AS(&5N9&5D M(%-E<'1E;6)E2X@5&AE($-O;7!A;GD@:&%S('-E8W5R M960@)#$L,#`P+#`P,"!I;B!N;W1E2!A;F0@365T:&]D'0M86QI9VXZ(&IU2`Q.3DY(&%N9"!P2!A;FYU86QL>2!A2!A6QE/3-$)VUA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y,#4Q-C!F95\X M-&8Y7S0V-C%?8F0T,%\U,3$T8C@X838R8S<-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO.3`U,38P9F5?.#1F.5\T-C8Q7V)D-#!?-3$Q-&(X.&$V M,F,W+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQP('-T>6QE/3-$)VUA6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2<^3VX@2F%N=6%R>2`Q-BP@,C`Q,RP@=&AE(&-O;7!A;GD@=&5R M;6EN871E9`T*:71S(&QI8V5N2P@=&AE2!N;W0@9G5L9FEL M;&EN9R!T:&4@8V]N9&ET:6]NF5D(&%S(')E=F5N=64@9'5R:6YG('1H92!N:6YE(&UO;G1H'0M86QI9VXZ(&IU6QE/3-$)VUA3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y,#4Q-C!F95\X-&8Y7S0V-C%? M8F0T,%\U,3$T8C@X838R8S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO.3`U,38P9F5?.#1F.5\T-C8Q7V)D-#!?-3$Q-&(X.&$V,F,W+U=O'0O:'1M;#L@ M8VAA2!$:7-C;&]S=7)E(%M!8G-T2!O9B!O<'1I;VX@86-T:79I='D-"F1U6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)V)O'0M86QI9VXZ(&-E;G1E&5R8VES92!06QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@,C`E)SXY+#0P,"PP,#`\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H="<^,"XP,SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T3L@<&%D9&EN9RUL969T.B`P+C6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXT,#`L,#`P/"]T9#X-"B`@("`\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXP+C`U/"]T9#X-"B`@("`\=&0@6QE/3-$)V)A8VMG3L@<&%D9&EN9RUL M969T.B`P+C6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/"]T3L@<&%D9&EN9RUB M;W1T;VTZ(#%P=#L@<&%D9&EN9RUL969T.B`P+C'0M86QI9VXZ(')I9VAT)SXF(S$U,3L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O M='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D M:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&IU M6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT)SXY+#,P,"PP,#`\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@ M,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE3L@ M=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^07,@;V8@4V5P=&5M8F5R M(#,P+"`R,#$S+"`Y+#,P,"PP,#`@6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^3VX@4V5P=&5M8F5R(#(S+"`R,#$S+"!T M:&4@0V]M<&%N>2!G65A65A M2!R96-O'!E;G-E(&]F("0X+#0P,"!F M;W(@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI M9VXZ(&IU6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T* M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1EF4Z M(#$P<'0G/@T*/'1R('-T>6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$ M)V)A8VMG3L@ M<&%D9&EN9RUL969T.B`P+C6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@ M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H="<^,"XP-CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T3L@<&%D9&EN9RUL969T.B`P+C6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXP+C`U/"]T9#X-"B`@("`\=&0@6QE/3-$)V)A8VMG3L@<&%D9&EN9RUL M969T.B`P+C6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&IU&5R8VES960\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A M9&1I;F6QE M/3-$)V)O6QE/3-$)V)A8VMG3L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!P861D:6YG+6QE9G0Z M(#`N-S5P="<^0F%L86YC92P@4V5P=&5M8F5R(#,P+"`R,#$S/"]T9#X-"B`@ M("`\=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI M9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXP M+C`V/"]T9#X-"B`@("`\=&0@'0M86QI M9VXZ(&IU2!T=V\@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE2<^3VX@36%Y(#(R+"`R,#$S(#(P,"PP,#`@=V%R6QE M/3-$)VUA3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\Y,#4Q-C!F95\X-&8Y7S0V-C%?8F0T,%\U,3$T M8C@X838R8S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3`U,38P M9F5?.#1F.5\T-C8Q7V)D-#!?-3$Q-&(X.&$V,F,W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R2!4 M'0^)SQS<&%N/CPO'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^)B,Q-C`[ M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU6QE/3-$)VUA M3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\Y,#4Q-C!F95\X-&8Y7S0V-C%?8F0T,%\U,3$T8C@X838R M8S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3`U,38P9F5?.#1F M.5\T-C8Q7V)D-#!?-3$Q-&(X.&$V,F,W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO'0^)SQP('-T>6QE/3-$)VUA6QE/3-$)W=I9'1H.B`V,"4[(&)O6QE/3-$)V)A8VMG2<^0V]N=F5R=&EB;&4@3F]T M97,@4&%Y86)L92!C;VYS:7-T6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V)A8VMG6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&IU'!I6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)2<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,C`E)SXT,"PT-S8\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X\ M+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG&5D('!R:6-E(&]F("0P+C`U('!E M2!T=V\@&5R8VES92!P65A6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@ M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SXR-RPP,#`\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI M9VXZ(&IU2!D871E(&]F(&5X96-U=&EO;BX@5&AE(&YO=&5S(&UA='5R92!A M="!V87)I;W5S('1I;65S(&9R;VT@4V5P=&5M8F5R(#(P,30@=&\-"D1E8V5M M8F5R(#(P,30N($%T('1H92!I;G9E6UE;G0@9&%T92P@=&AE(&YO=&4@86YD(')E;&%T960@:6YT M97)E2!T M:&4@86-C;W5N=',@2!P'!E;G-E'!E;G-E(&EN('1H92!A M;6]U;G0@;V8@)#0P+#0W-B!A;F0@)#@L.3$P(&1U'0M86QI9VXZ(')I9VAT)SXQ+#`P,"PP,#`\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D M:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O M6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SXQ+#`W.2PT-S8\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D M:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI M9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ M(&IUF5D(&1E8G0@9&ES8V]U;G0\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SXH,3`R+#(P,#PO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M M86QI9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT M)SXQ+#`Y.2PX-C(\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W!A9&1I;F6QE M/3-$)VUA3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\Y,#4Q-C!F95\X-&8Y7S0V-C%?8F0T,%\U,3$T M8C@X838R8S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3`U,38P M9F5?.#1F.5\T-C8Q7V)D-#!?-3$Q-&(X.&$V,F,W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0M86QI9VXZ(&IU2!R92UN96=O=&EA=&5D#0IA8V-R M=65D('-A;&%R:65S(&%N9"!I;G1E65A2!B92!C M;VYV97)T960@=&\@&5R8VES90T*<')I8V4@;V8@)#`N,#8@<&5R('-H87)E(&9O2!H M87,@9&5T97)M:6YE9"!T:&4@=F%L=64@87-S;V-I871E9"!W:71H('1H92!B M96YE9FEC:6%L#0IC;VYV97)S:6]N(&9E871U6%B;&4@ M87)E("0U-C@L-C,X+"!N970@;V8@=6YA;6]R=&EZ960@8F5N969I8VEA;"!C M;VYV97)S:6]N(&9E871U'0M86QI9VXZ(&IU2!R92UN96=O=&EA=&5D#0IA M8V-R=65D('-A;&%R:65S(&%N9"!I;G1E2`Q+"`R,#$Q(&%N9"!A;&P-"G-A;&%R M:65S(&YO="!P28C,30V.W,@8V]M;6]N M('-T;V-K(&%T(&$@9FEX960@<')I8V4@;V8@)#`N,#0-"G!E2!T=V\@65A MF5D(&)E;F5F:6-I86P@8V]N=F5R6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^3VX@1&5C96UB97(@,S`@86YD(#,Q+"`R M,#$R+"!T:&4@0V]M<&%N>2!R92UN96=O=&EA=&5D#0IA8V-R=65D('-A;&%R M:65S(&%N9"!I;G1E28C,30V.W,@8V]M;6]N('-T M;V-K(&%T(&$-"F9I>&5D('!R:6-E(&]F("0P+C`S('!E2!T=V\@65A'!E;G-E(&EN('1H92!A;6]U;G0@;V8@)#(W+#(R,R!F;W(@ M=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E'0M86QI9VXZ(&IU M2!R92UN96=O=&EA=&5D#0IA8V-R=65D('-A;&%R:65S(&%N9"!I;G1E2!C M;VYV97)T960@=V5R92!C;VYV97)T960@=&\@<')O;6ES2!N;W1E2!N M;W1E6%B;&4@87)E("0S."PY-3`L(&YE="!O9B!U;F%M;W)T M:7IE9"!B96YE9FEC:6%L#0IC;VYV97)S:6]N(&9E871U7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2UF;W5R(#QF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:R<^.24@;F]T97,@ M<&%Y86)L92!T;R!I;G9E2!D871E(&]F(&5X96-U=&EO;BX@/"]F;VYT/E1H92!. M;W1E2!A M;F0@365T:&]D7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2!; M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^)SQP('-T>6QE/3-$)VUA6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE2<^ M5&AE($-O;7!A;GD@:7,@875T:&]R:7IE9"!T;R!I2!H87,@,3$P+#6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^1'5R:6YG('1H92!N:6YE M(&UO;G1H2!I2!R96-O6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^3VX@1F5B6%B;&4@;V8@)#$U+#`P,"!P M;'5S("0Q+#(W-R!A8V-R=65D#0II;G1E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6UE;G1S M('5N9&5R('1H92!O<&5R871I;F<@;&5A65A6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^1FES8V%L('EE87(@96YD:6YG(#(P,30@ M,S,L,34V/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&IU'0M86QI9VXZ(&IU6QE/3-$)VUA3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y,#4Q-C!F95\X-&8Y7S0V-C%? M8F0T,%\U,3$T8C@X838R8S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO.3`U,38P9F5?.#1F.5\T-C8Q7V)D-#!?-3$Q-&(X.&$V,F,W+U=O'0O:'1M;#L@ M8VAA'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y,#4Q-C!F M95\X-&8Y7S0V-C%?8F0T,%\U,3$T8C@X838R8S<-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO.3`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`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IUF5S('1H90T*:6YP=71S('5S960@:6X@;65A6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M2<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI M9VXZ(&IU2!O2!T:&4@9G5L;"!T97)M(&]F('1H92!A'0M86QI M9VXZ(&-E;G1E'0M M86QI9VXZ(&IU6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^3&5V96P@,SH@4')I8V5S M(&]R('9A;'5A=&EO;B!T96-H;FEQ=65S('1H870-"G)E<75I'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^)B,Q-C`[ M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E2!S86QE M2!A;'-O(')E8V]G;FEZ97,@2!R979E;G5E(&9R;VT@;&EC96YS:6YG(&ET2!A6UE;G1S+CPO<#X-"@T*/'`@3L@;6%R9VEN+7)I9VAT.B`P.R!M87)G:6XM;&5F=#H@ M,"XU:6XG/CQU/D1IF5S(')E M=F5N=64@9G)O;2!D:7-T6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE'0M86QI9VXZ(&IU'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2<^/'4^06-C;W5N=',@4F5C96EV86)L93PO=3X@)B,Q-3`[($%C M8V]U;G1S#0IR96-E:79A8FQE(&ES(&-O;7!R:7-E9"!O9B!U;F-O;&QA=&5R M86QI>F5D(&-U6UE;G0@=VET:&EN(#,P(&1A>7,- M"F9R;VT@=&AE(&EN=F]I8V4@9&%T92X@5&AE(&-A2!F;W(@8V]L;&5C=&%B:6QI='DN($EF(&UA;F%G96UE;G0@9&5T97)M:6YE M0T* M:&%D(&YO="!R96-O2!H87,@)#$L,#`P+#`P,"!I;B!C;VYV97)T:6)L M92!N;W1E2!P&5S/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/'`@2!A8V-O=6YT"!C;VYS97%U96YC97,@871T M"!C`T*87-S971S(&%N9"!L:6%B:6QI=&EE0T*9&EF9F5R96YC97,@87)E(&5X<&5C=&5D('1O(&)E(')E8V]V97)E M9"!O"!A"!R871E'0M86QI9VXZ(&IU2!F;VQL;W=S('1H92!G=6ED96QI;F5S(&EN($9!4T(@0V]D:69I8V%T:6]N M(%1O<&EC($%30R`W,3@M,3`@)B,Q-#<[/&D^0V]M<&5N'!E;G-E(&9O65E('-T;V-K(&]P=&EO;G,@86YD(&5M<&QO>65E('-T;V-K('!U6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^)B,Q-C`[ M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'!E;G-E(')E8V]G;FEZ M960-"G5N9&5R($%30R`W,3@M,3`@9F]R('1H92!N:6YE(&UO;G1H'0^)SQP('-T M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/'4^16%R;FEN M9W,@*&QO2!R M97!O2!T:&4@=V5I9VAT960@879E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\Y,#4Q-C!F95\X-&8Y7S0V-C%?8F0T,%\U,3$T8C@X838R8S<-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3`U,38P9F5?.#1F.5\T-C8Q M7V)D-#!?-3$Q-&(X.&$V,F,W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQT86)L92!C96QL M6QE/3-$)W=I9'1H.B`T-24[(&)O6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)2<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@,C`E)SXT-2PR,#@\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/B8C,38P.SPO=&0^/"]T6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ,3,L-C,U/"]T9#X-"B`@("`\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/"]T2<^3&5A6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ,BPU-CD\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,3(L-38Y/"]T9#X-"B`@("`\=&0@ M6QE/3-$)V)A8VMG3L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^3&%B(&5Q=6EP;65N M=#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F2<^5&]T86P\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,S(V M+#,V.#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXS,C(L.36QE/3-$)V)A8VMG'0M86QI9VXZ(')I M9VAT)SXH,S(R+#0W-SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\Y,#4Q-C!F95\X-&8Y7S0V-C%?8F0T,%\U,3$T8C@X M838R8S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3`U,38P9F5? M.#1F.5\T-C8Q7V)D-#!?-3$Q-&(X.&$V,F,W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2!$:7-C;&]S=7)E(%M!8G-T'0^)SQT86)L92!C96QL M6QE/3-$)W=I9'1H.B`T-24[(&)O'0M86QI9VXZ(')I9VAT)SY.=6UB97(@;V8@4VAA6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)2<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@,C`E)SXP+C`U/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H="<^,"XP-3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF M(S$U,3L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W!A9&1I;F6QE/3-$)V)O M'0M86QI9VXZ(')I M9VAT)SXF(S$U,3L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/CPO='(^ M#0H\='(@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)V)O'0M86QI9VXZ(&-E;G1E&5R8VES92!06QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T3L@<&%D9&EN9RUL969T.B`P+C6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M,C`E)SXV+#6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&IU'!I6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^ M,"XP-3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SXF(S$U,3L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3$[/"]T9#X- M"B`@("`\=&0@6QE/3-$)V)A8VMG'0M86QI9VXZ(')I9VAT)SXF(S$U,3L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O M;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT)SXT+#8W,RPY.#`\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU M<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQT86)L92!C96QL6QE/3-$)W=I9'1H.B`V M,"4[(&)O6QE/3-$)V)A M8VMG2<^0V]N M=F5R=&EB;&4@3F]T97,@4&%Y86)L92!C;VYS:7-T6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V)A8VMG6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&IU'!I6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^)#PO=&0^#0H@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,C`E)SXT,"PT M-S8\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W M:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H M.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^ M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG3L@<&%D9&EN9RUL969T.B`U M+C1P="<^)#(W+#`P,"!F86-E('9A;'5E(#$P)2!U;G-E8W5R960@)#(W+#`P M,"!N;W1E&5D('!R:6-E M(&]F("0P+C`U('!E2!T=V\@&5R8VES92!P65A6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR-RPP,#`\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^ M#0H\='(@6QE M/3-$)W1E>'0M86QI9VXZ(&IU2!D871E(&]F(&5X96-U=&EO;BX@5&AE(&YO M=&5S(&UA='5R92!A="!V87)I;W5S('1I;65S(&9R;VT@4V5P=&5M8F5R(#(P M,30@=&\-"D1E8V5M8F5R(#(P,30N($%T('1H92!I;G9E6UE;G0@9&%T92P@=&AE(&YO=&4@86YD M(')E;&%T960@:6YT97)E2!T:&4@86-C;W5N=',@2!P M'!E M;G-E(&EN('1H92!A;6]U;G0@;V8@)#0P+#0W-B!A;F0@)#@L.3$P(&1U'0M86QI9VXZ(')I9VAT M)SXQ+#`P,"PP,#`\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@ M'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)V)O6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT M)SXQ+#`W.2PT-S8\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/CPO='(^ M#0H\='(@6QE M/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/"]T6QE/3-$ M)W1E>'0M86QI9VXZ(&IUF5D(&1E8G0@9&ES8V]U;G0\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`Q<'0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SXH,3`R+#(P,#PO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M M86QI9VXZ(')I9VAT)SXQ+#`Y.2PX-C(\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\Y,#4Q-C!F95\X-&8Y7S0V-C%?8F0T,%\U,3$T8C@X838R8S<-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3`U,38P9F5?.#1F.5\T-C8Q7V)D M-#!?-3$Q-&(X.&$V,F,W+U=O'0O:'1M;#L@8VAA2P@4&QA;G0@ M86YD($5Q=6EP;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO&5D(&%S'1087)T7SDP-3$V,&9E7S@T9CE?-#8V,5]B9#0P7S4Q,31B.#AA-C)C M-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y,#4Q-C!F95\X-&8Y M7S0V-C%?8F0T,%\U,3$T8C@X838R8S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'!R97-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L M,#`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^ M)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!%<75I='D@1&ES8VQO&5R8VES92!P M&5R M8VES92!P&5R8VES92!P'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO&5R8VES92!P'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!O9B!787)R86YT2!%<75I='D@1&ES8VQO&5R8VES92!P&5R8VES92!P&5R8VES92!P'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO&5R8VES M960L('=E:6=H=&5D(&%V97)A9V4@97AE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO&5R8VES86)L93PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S4@>65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!296-O'!E;G-E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO2`R,BP-"@D),C`Q,SQS<&%N/CPO&EM=6T\+W1D M/@T*("`@("`@("`\=&0@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4L(%!R:6YC:7!L92!#;VYV97)T960\+W1D/@T*("`@ M("`@("`\=&0@8VQA'0^)SQS<&%N/CPO M6%B;&4L(%!R:6YC:7!L92!#;VYV97)T960@06-C M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4L($-O M;6UO;B!3=&]C:R!3:&%R97,@27-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4L(%=A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!P97)I;V0\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S(P,3(M,3`M M,#$\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y,#4Q-C!F95\X-&8Y7S0V M-C%?8F0T,%\U,3$T8C@X838R8S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO.3`U,38P9F5?.#1F.5\T-C8Q7V)D-#!?-3$Q-&(X.&$V,F,W+U=O M'0O:'1M M;#L@8VAA'0^)SQS M<&%N/CPOF5D(&1E M8G0@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6%B;&4@4F5L871E9"!087)T>2`Q/&)R/CPO=&@^#0H@("`@("`@(#QT M:"!C;&%S6%B;&4@4F5L871E9"!087)T>2`R/&)R/CPO=&@^#0H@("`@("`@ M(#QT:"!C;&%S6%B;&4@4F5L871E9"!087)T>2`T/&)R/CPO=&@^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO2!$871E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S4@>65A'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!P'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!W M87)R86YT'0^)SQS<&%N/CPO'0^)S,@>65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO6%B;&4L(')E;&%T M960@<&%R='D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2P@;F5T(&]F M('5N86UOF5D(&1I'0^)SQS<&%N/CPO M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)S(P,3,M,#4M,C(\2!.;W1E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4L(%!R:6YC M:7!L92!#;VYV97)T960\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO6%B;&4L(%!R:6YC M:7!L92!#;VYV97)T960@06-C'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC&UL/@T*+2TM+2TM/5].97AT4&%R J=%\Y,#4Q-C!F95\X-&8Y7S0V-C%?8F0T,%\U,3$T8C@X838R8S XML 40 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 24 208 1 false 7 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://SKVI/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 00000002 - Statement - Balance Sheets Sheet http://SKVI/role/BalanceSheets Balance Sheets false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://SKVI/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) false false R4.htm 00000004 - Statement - Statements of Operations Sheet http://SKVI/role/StatementsOfOperations Statements of Operations false false R5.htm 00000005 - Statement - Statements of Cash Flows Sheet http://SKVI/role/StatementsOfCashFlows Statements of Cash Flows false false R6.htm 00000006 - Disclosure - DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES Sheet http://SKVI/role/DescriptionOfBusinessHistoryAndSummaryOfSignificantPolicies DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES false false R7.htm 00000007 - Disclosure - FIXED ASSETS Sheet http://SKVI/role/FixedAssets FIXED ASSETS false false R8.htm 00000008 - Disclosure - INTANGIBLE AND OTHER ASSETS Sheet http://SKVI/role/IntangibleAndOtherAssets INTANGIBLE AND OTHER ASSETS false false R9.htm 00000009 - Disclosure - UNEARNED REVENUE Sheet http://SKVI/role/UnearnedRevenue UNEARNED REVENUE false false R10.htm 00000010 - Disclosure - STOCK OPTIONS AND WARRANTS Sheet http://SKVI/role/StockOptionsAndWarrants STOCK OPTIONS AND WARRANTS false false R11.htm 00000011 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://SKVI/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS false false R12.htm 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE Notes http://SKVI/role/ConvertibleNotesPayable CONVERTIBLE NOTES PAYABLE false false R13.htm 00000013 - Disclosure - CONVERTIBLE NOTES PAYABLE RELATED PARTY Notes http://SKVI/role/ConvertibleNotesPayableRelatedParty CONVERTIBLE NOTES PAYABLE RELATED PARTY false false R14.htm 00000014 - Disclosure - NOTES PAYABLE Notes http://SKVI/role/NotesPayable NOTES PAYABLE false false R15.htm 00000015 - Disclosure - STOCKHOLDERS DEFICIT Sheet http://SKVI/role/StockholdersDeficit STOCKHOLDERS DEFICIT false false R16.htm 00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://SKVI/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES false false R17.htm 00000017 - Disclosure - SUBSEQUENT EVENTS Sheet http://SKVI/role/SubsequentEvents SUBSEQUENT EVENTS false false R18.htm 00000018 - Disclosure - DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES (Policies) Sheet http://SKVI/role/DescriptionOfBusinessHistoryAndSummaryOfSignificantPoliciesPolicies DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES (Policies) false false R19.htm 00000019 - Disclosure - FIXED ASSETS (Tables) Sheet http://SKVI/role/FixedAssetsTables FIXED ASSETS (Tables) false false R20.htm 00000020 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) Sheet http://SKVI/role/StockOptionsAndWarrantsTables STOCK OPTIONS AND WARRANTS (Tables) false false R21.htm 00000021 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables) Notes http://SKVI/role/ConvertibleNotesPayableTables CONVERTIBLE NOTES PAYABLE (Tables) false false R22.htm 00000022 - Disclosure - DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES (Details Narrative) Sheet http://SKVI/role/DescriptionOfBusinessHistoryAndSummaryOfSignificantPoliciesDetailsNarrative DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES (Details Narrative) false false R23.htm 00000023 - Disclosure - FIXED ASSETS - Schedule of Property and Plan Equipment (Details) Sheet http://SKVI/role/FixedAssets-ScheduleOfPropertyAndPlanEquipmentDetails FIXED ASSETS - Schedule of Property and Plan Equipment (Details) false false R24.htm 00000024 - Disclosure - FIXED ASSETS (Details Narrative) Sheet http://SKVI/role/FixedAssetsDetailsNarrative FIXED ASSETS (Details Narrative) false false R25.htm 00000025 - Disclosure - INTANGIBLE AND OTHER ASSETS (Details Narrative) Sheet http://SKVI/role/IntangibleAndOtherAssetsDetailsNarrative INTANGIBLE AND OTHER ASSETS (Details Narrative) false false R26.htm 00000026 - Disclosure - UNEARNED REVENUE (Details Narrative) Sheet http://SKVI/role/UnearnedRevenueDetailsNarrative UNEARNED REVENUE (Details Narrative) false false R27.htm 00000027 - Disclosure - STOCK OPTIONS AND WARRANTS - Summary of Options (Details) Sheet http://SKVI/role/StockOptionsAndWarrants-SummaryOfOptionsDetails STOCK OPTIONS AND WARRANTS - Summary of Options (Details) false false R28.htm 00000028 - Disclosure - STOCK OPTIONS AND WARRANTS - Summary of Warrants (Details) Sheet http://SKVI/role/StockOptionsAndWarrants-SummaryOfWarrantsDetails STOCK OPTIONS AND WARRANTS - Summary of Warrants (Details) false false R29.htm 00000029 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Narrative) Sheet http://SKVI/role/StockOptionsAndWarrantsDetailsNarrative STOCK OPTIONS AND WARRANTS (Details Narrative) false false R30.htm 00000030 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://SKVI/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) false false R31.htm 00000031 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) Notes http://SKVI/role/ConvertibleNotesPayableDetailsNarrative CONVERTIBLE NOTES PAYABLE (Details Narrative) false false R32.htm 00000032 - Disclosure - CONVERTIBLE NOTES PAYABLE - Schedule of Conversions of Stock (Details) Notes http://SKVI/role/ConvertibleNotesPayable-ScheduleOfConversionsOfStockDetails CONVERTIBLE NOTES PAYABLE - Schedule of Conversions of Stock (Details) false false R33.htm 00000033 - Disclosure - CONVERTIBLE NOTES PAYABLE RELATED PARTY (Details Narrative) Notes http://SKVI/role/ConvertibleNotesPayableRelatedPartyDetailsNarrative CONVERTIBLE NOTES PAYABLE RELATED PARTY (Details Narrative) false false R34.htm 00000034 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://SKVI/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) false false R35.htm 00000035 - Disclosure - STOCKHOLDERS DEFICIT (Details Narrative) Sheet http://SKVI/role/StockholdersDeficitDetailsNarrative STOCKHOLDERS DEFICIT (Details Narrative) false false R36.htm 00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://SKVI/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) false false All Reports Book All Reports Process Flow-Through: 00000002 - Statement - Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 00000003 - Statement - Balance Sheets (Parenthetical) Process Flow-Through: 00000004 - Statement - Statements of Operations Process Flow-Through: 00000005 - Statement - Statements of Cash Flows skvi-20130930.xml skvi-20130930.xsd skvi-20130930_cal.xml skvi-20130930_def.xml skvi-20130930_lab.xml skvi-20130930_pre.xml true true XML 41 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Balance Sheets (Parenthetical) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Statement of Financial Position [Abstract]

Common Stock, Par Value $ 0.001 $ 0.001

Common Stock, Shares Authorized 200,000,000 200,000,000

Common Stock, Issued 110,729,969 109,507,409

Accumulated depreciation $ (322,477) $ (318,519)

Convertible Notes Payable, net of unamortized debt discount 61,724 102,200

Convertible Notes Payable, related party, net of unamortized discount 919,956 1,036,956

Accumulated Amortization $ 239,208 $ 213,205

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_DebtInstrumentRelatedPartyUnamortizedDiscountPremiumNet

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land or leased assets).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The amount of debt discount (net of debt premium) that was originally recognized at the issuance of the instrument that has yet to be amortized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28567-108399

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

NOTES PAYABLE
9 Months Ended

Sep. 30, 2013

Notes to Financial Statements

NOTES PAYABLE
On May 22, 2013 the Company approved a financing plan to offer accredited investors up to $1,000,000 in secured promissory notes. During the nine months ended September 30, 2013 the Company entered into twenty-four 9% notes payable to investors and received total proceeds of 1,000,000. The notes are due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods".

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_NotesPayableDisclosureTextBlock

Namespace Prefix: SKVI_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: SKVI_NotesToFinancialStatementsAbstract

Namespace Prefix: SKVI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Statements of Cash Flows (USD $)
9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Cash flows from operating activities:

Net loss $ (1,029,758) $ (1,013,762)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 27,006 43,982

Stock-based compensation 21,200

Amortization of debt discount 228,244 432,602

Accrued expenses converted to notes 223,868

Stock issued for interest expense 422

Debt paid with common stock 78,361

Gain on extinguishment of debt 3,100 (1,691)

Changes in operating assets and liabilities:

(Increase) decrease in inventory (3,668) 8,998

Decrease in accounts receivable 17,299 (8,895)

Increase in prepaid expenses and other current assets (500) (9,691)

Increase in accounts payable and accrued liabilities 69,776 97,283

Increase in accrued interest 105,099 23,174

Decrease in unearned revenue (19,792) (50,000)

Net cash used in operating activities (581,572) (175,771)

Cash flows from investing activities:

Purchase of fixed assets and intangible assets (120,575) (56,023)

Net cash used in investing activities (120,575) (56,023)

Cash flows from financing activities:

Proceeds from, net of payments to, related parties for loans (7,527) (2,681)

Payments on related parties convertible notes payable (12,475)

Proceeds from convertible notes payable 312,900

Advances to related parties (40,043)

Payments on convertible notes payable (14,000) (7,500)

Proceeds from loans payable 1,000,000 (5,000)

Net cash provided by (used in) financing activities 925,955 297,719

Net change in cash 223,808 65,925

Cash, beginning of period 450,507 1,218

Cash, end of period 674,315 67,143

Supplemental disclosure of cash flow information:

Cash paid for interest 97,194

Cash paid for tax

Non-cash investing and financing activities:

Loan payable converted to convertible loan 23,554 (9,719)

Common stock issued on conversion of debts 23,554 78,361

Beneficial conversion feature $ 326,510

Common stock issued for extinguishment of debts 16,100

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_AccruedExpensesConvertedToNotes

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_AdvancesToRelatedParties

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_CommonStockIssuedForExtinguishmentOfDebts

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_DebtPaidWithCommonStock

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_IncreaseDecreaseGainsOnExtinguishmentOfDebt

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_IncreaseDecreaseInUnearnedRevenues

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_LoanPayableConvertedToConvertibleLoan

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_PaymentsOnRelatedPartiesConvertibleNotesPayable

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_PurchaseOfFixedAssetsAndIntangibleAssets

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_StockIssuedForInterestExpense

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Beneficial Conversion Feature

-URI http://asc.fasb.org/extlink&oid=6505963

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

+ Details

Name: us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Increase for accrued, but unpaid interest on the debt instrument for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(f))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph f

-Article 4

+ Details

Name: us-gaap_DebtInstrumentIncreaseAccruedInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Cash received from principal payments made on loans related to operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_ProceedsFromLoans

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_RepaymentOfNotesReceivableFromRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 44 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Balance Sheets (USD $)

Sep. 30, 2013

Dec. 31, 2012

Current assets

Cash $ 674,315 $ 450,507

Accounts receivable 10,000 27,299

Inventory 22,437 18,769

Due from related party 41,188 1,145

Prepaid expense and other current assets 1,015 515

Total current assets 748,955 498,235

Fixed assets, net of accumulated depreciation of $322,477 and $318,519, respectively 3,891 4,459

Intangible and other assets:

Patents and trademarks, net of accumulated amortization of $239,208 and $213,205, respectively 345,690 251,553

Total assets 1,098,536 754,247

Current liabilities

Accounts payable and accrued liabilities 584,536 636,314

Accrued interest payable 131,499 25,264

Loans from related party 134 7,661

Loans payable 1,000,000 1,991

Convertible notes payable, net of unamortized debt discount of $61,724 and $102,200, respectively 1,099,862 1,088,386

Convertible notes payable related party, net of unamortized discount of $919,956 and $1,036,956, respectively 803,905 593,227

Unearned revenue 19,792

Total current liabilities 3,619,936 2,372,635

Total liabilities 3,619,936 2,372,635

Stockholders deficit

Common stock; $0.001 par value; 200,000,000 shares authorized; 110,729,969 and 109,507,409 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively 110,730 109,507

Additional paid-in capital 20,968,993 20,841,670

Stock payable 1,800

Accumulated deficit (23,601,123) (22,571,365)

Total stockholders deficit (2,521,400) (1,618,388)

Total liabilities and stockholders deficit $ 1,098,536 $ 754,247

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayableRelatedParty

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_LoansFromRelatedPartyDebt

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amounts due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 3

-Subparagraph a, b

-Article 5

+ Details

Name: us-gaap_AccountsReceivableGrossCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesSubscribedButUnissued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 22

-Article 5

+ Details

Name: us-gaap_ConvertibleNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).

+ References

No definition available.

+ Details

Name: us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 3

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.3)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.10(3))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_DueFromRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16(a)(2))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_LoansPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK OPTIONS AND WARRANTS (Details Narrative) (USD $)
3 Months Ended 9 Months Ended

Mar. 31, 2013

Sep. 30, 2013

Sep. 23, 2013

Temporary Equity Disclosure [Abstract]

Stock Options, exercisable 9,300,000

Stock Options, shares 300,000

Stock Options, price $ 0.03

Stock Options, expected life 5 years

Stock Options, Value $ 8,400

Stock Options, interest rate 1.33%

Stock Options, dividend 0.00%

Stock Options, volatility rate 443.00%

Company Recorded Expense $ 8,400

Date of Warrant Issuance May 22, 2013

Warrants Issued with Convertible Notes 271,280 200,000

Exercise Price-maximum $ 0.07 $ 0.04

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_CompanyRecordedExpense

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_DateOfWarrantIssuance

Namespace Prefix: SKVI_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ExercisePriceMaximum

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_StockOptionsDividend

Namespace Prefix: SKVI_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_StockOptionsExercisable

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_StockOptionsExpectedLife

Namespace Prefix: SKVI_

Data Type: us-types:durationStringItemType

Balance Type: na

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_StockOptionsInterestRate

Namespace Prefix: SKVI_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_StockOptionsPrice

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_StockOptionsShares

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_StockOptionsValue

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_StockOptionsVolatilityRate

Namespace Prefix: SKVI_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_WarrantsIssuedWithConvertibleNotes

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TemporaryEquityDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

FIXED ASSETS - Schedule of Property and Plan Equipment (Details) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Property, Plant and Equipment [Abstract]

Machinery and equipment $ 48,163 $ 45,208

Furniture and fixtures 113,635 113,635

Computers, equipment and software 38,540 38,105

Leasehold improvements 12,569 12,569

Lab equipment 113,461 113,461

Total 326,368 322,978

Less: accumulated depreciation (322,477) (318,519)

Fixed assets, net of accumulated depreciation $ 3,891 $ 4,459

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ComputersEquipmentAndSoftwareGross

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_LabEquipmentGross

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_FurnitureAndFixturesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 4

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6812-107765

+ Details

Name: us-gaap_LeaseholdImprovementsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 4

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6812-107765

+ Details

Name: us-gaap_MachineryAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 47 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCKHOLDERS DEFICIT (Details Narrative) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Equity [Abstract]

Common Stock, Par Value $ 0.001 $ 0.001 $ 0.001

Common Stock, Shares Authorized 200,000,000 200,000,000 200,000,000

Common Stock, Issued 110,729,969 110,729,969 109,507,409

Common Stock, Shares Issued for Debt Conversion 680,000

Debt Conversion, Fair Value $ 16,100

Debt Conversion, Amount 18,000

Gain on extinguishment of debt 2,400 (36) 3,100 1,691

Convertible Notes Payable, Date of Conversion Feb. 11, 2013

Convertible Notes Payable, Common Stock Shares Issued 300,000

Convertible Notes Payable, Principle Converted 15,000

Convertible Notes Payable, Principle Converted Accrued Interest 1,277

Convertible Notes Payable, Additional Common Stock Shares Issued 242,560

Convertible Notes Payable, Common Stock Shares, Fair Value $ 7,277

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_CommonStockSharesIssuedForDebtConversion

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayableadditionalCommonStockSharesIssued

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayableCommonStockSharesFairValue

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayableCommonStockSharesIssued

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayableDateOfConversion

Namespace Prefix: SKVI_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayablePrincipleConverted

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayablePrincipleConvertedAccruedInterest

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_DebtConversionFairValue

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionOriginalDebtAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12317-112629

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 48 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8

COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)
9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Commitments and Contingencies Disclosure [Abstract]

Operating leases for 2013 $ 14,050

Operating leases for 2014 33,156

Operating leases for 2015 5,526

Rental expense $ 14,942 $ 40,434

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Future rental payments receivable within the fourth year from the balance sheet date under an operating lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6454179&loc=d3e41551-112718

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInFourYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Future rental payments receivable within the third year from the balance sheet date under an operating lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6454179&loc=d3e41551-112718

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Future rental payments receivable within the second year from the balance sheet date under an operating lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6454179&loc=d3e41551-112718

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717

+ Details

Name: us-gaap_OperatingLeasesRentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 49 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONVERTIBLE NOTES PAYABLE RELATED PARTY
9 Months Ended

Sep. 30, 2013

Notes to Financial Statements

CONVERTIBLE NOTES PAYABLE RELATED PARTY

On December 31, 2011, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before December 31, 2010 and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $802,864 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $538,295 for the notes negotiated on December 31, 2010, $45,557 for the notes negotiated on July 1, 2011 and $1,123,078 for the notes negotiated December 31, 2011. The beneficial conversion feature is valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of $124,818 for the nine months ended September 30, 2013. As of September 30, 2013, the aggregate convertible notes payable are $568,638, net of unamortized beneficial conversion feature of $541,965.

On June 30, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before July 1, 2011 and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $325,023 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $209,809. The beneficial conversion feature is valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of $32,161 for the nine months ended September 30, 2013. As of September 30, 2013, the aggregate convertible notes payable are $169,080, net of unamortized beneficial conversion feature of $155,942.

On December 30 and 31, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $182,083 of related party notes accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $182,083 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $182,083. The beneficial conversion feature is valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of $27,223 for the nine months ended September 30, 2013. As of September 30, 2013, the aggregate convertible notes payable are $27,236, net of unamortized beneficial conversion feature of $154,847.

On June 30, 2013, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements, $106,153 of related party notes accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $106,153 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $70,768. The beneficial conversion feature is valued under the intrinsic value method. The aggregate beneficial conversion feature will be accreted and charged to general and administrative expenses as a financing expense As of September 30, 2013, the aggregate convertible notes payable are $38,950, net of unamortized beneficial conversion feature of $67,202.

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayableRelatedPartyTextBlock

Namespace Prefix: SKVI_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: SKVI_NotesToFinancialStatementsAbstract

Namespace Prefix: SKVI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8

RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)
3 Months Ended

Sep. 30, 2013

Sep. 23, 2013

Related Party Transactions [Abstract]

Stock Options, Shares 300,000

Loans from related party $ 40,143

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_LoansFromRelatedParty

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_StockOptionsShares

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

COMMITMENTS AND CONTINGENCIES
9 Months Ended

Sep. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

Lease obligations – The Company has operating leases for its offices. Future minimum lease payments under the operating leases for the facilities as of September 30, 2013 are as follows:

Fiscal year ending 2013 14,050

Fiscal year ending 2014 33,156

Fiscal year ending 2015 5,526

Rental expense, resulting from operating lease agreements, approximated $14,942 and $40,434 for the nine months ended September 30, 2013 and 2012, respectively.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONVERTIBLE NOTES PAYABLE
9 Months Ended

Sep. 30, 2013

Notes to Financial Statements

CONVERTIBLE NOTES PAYABLE

Convertible Notes Payable consists of the following: September 30, December 31,

2013 2012

$52,476 face value,10% unsecured note payable to an investor, note interest and payment are due on demand. The note could be converted to option rights for Skinvisible, Inc. shares at ten cents per share ($0.10), these rights expired January 12, 2010. Note is currently in default, no penalties occur due to default.

During the nine months ended September 30, 2013, the Company made $12,000 in cash payment to reduce the note balance. $ 40,476 $ 52,476

$27,000 face value 10% unsecured $27,000 notes payable to investors, due October, 2012. At the investor’s written request, until the repayment date the note may be converted at the investors option to shares of the Company’s common stock at a fixed price of $0.05 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.07 per share for two years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $19,385. The aggregate beneficial conversion feature has been fully accreted and was charged to general and administrative expenses during the year ended December 31, 2012. The beneficial conversion feature is valued under the intrinsic value method. Interest due to lender can also be converted at a rate of ($0.05) per share into warrants.

During the nine months ended September 30, 2013, the Company made a $2,000 cash payment to reduce the note balance and converted principal of $15,000 plus accrued interest of $1,277 to 542,560 shares of common stock and granted 271,280 warrants with the exercise price of $0.07 per shares for two years. 10,000 27,000

$1,000,000 face value 9% notes payable to investors, due two years from the anniversary date of execution. The notes mature at various times from September 2014 to December 2014. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The Notes are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company has determined the value associated with the beneficial conversion feature in connection with the notes and interest to be $111,110. The aggregate original issue discount feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of $40,476 and $8,910 during the periods ending September 30, 2013 and December 31, 2012, respectively. The original issue discount feature is valued under the intrinsic value method. 1,000,000 1,000,000

1,050,476 1,079,476

Original issue discount 111,110 111,110

Unamortized debt discount (61,724 ) (102,200 )

$ 1,099,862 $ 1,088,386

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayableTextBlock

Namespace Prefix: SKVI_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: SKVI_NotesToFinancialStatementsAbstract

Namespace Prefix: SKVI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 53 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

FIXED ASSETS
9 Months Ended

Sep. 30, 2013

Property, Plant and Equipment [Abstract]

FIXED ASSETS

Fixed assets consist of the following as of September 30, 2013 and December 31, 2012:

September 30, 2013 December 31, 2012

Machinery and equipment 48,163 $ 45,208

Furniture and fixtures 113,635 113,635

Computers, equipment and software 38,540 38,105

Leasehold improvements 12,569 12,569

Lab equipment 113,461 113,461

Total 326,368 322,978

Less: accumulated depreciation (322,477 ) (318,519 )

Fixed assets, net of accumulated depreciation 3,891 $ 4,459

Depreciation expense for the nine months ended September 30, 2013 and 2012 was $1,003 and $943, respectively.

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13-14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONVERTIBLE NOTES PAYABLE RELATED PARTY (Details Narrative) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Jun. 30, 2013

Convertible Note Payable Related Party 1

Dec. 31, 2011

Convertible Note Payable Related Party 1

Jul. 01, 2011

Convertible Note Payable Related Party 1

Dec. 31, 2010

Convertible Note Payable Related Party 1

Jun. 30, 2013

Convertible Note Payable Related Party 2

Jun. 30, 2012

Convertible Note Payable Related Party 2

Jun. 30, 2013

Convertible Note Payable Related Party 3

Dec. 31, 2012

Convertible Note Payable Related Party 3

Jun. 30, 2013

Convertible Note Payable Related Party 4

Promissory Note, Value $ 802,864 $ 325,023 $ 182,083 $ 106,153

Maturity Date 5 years 5 years 5 years 5 years

Interest Rate 10.00% 10.00% 10.00% 10.00%

Conversion Feature, fixed price per share of common stock $ 0.04 $ 0.04 $ 0.03 $ 0.03

Conversion Feature, number of warrants to purchase for every two shares issued 1 1 1 1

Conversion Feature, exercise price per share for warrants purchased $ 0.06 $ 0.06 $ 0.04 $ 0.04

Beneficial Conversion Feature: time allowed to exercise warrants once converted 3 years 3 years 3 years 3 years

Beneficial Conversion Feature 1,123,078 45,557 538,295 209,809 182,083 70,768

Financing Expense 124,818 32,161 27,223

Convertible Notes Payable, related party 803,905 593,227 568,638 169,080 27,236 38,950

Convertible notes payable, related party, net of unamortized discount $ 61,724 $ 102,200 $ 541,965 $ 155,942 $ 154,847 $ 67,202

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_BeneficialConversionFeature

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_BeneficialConversionFeatureTimeAllowedToExerciseWarrantsOnceConverted

Namespace Prefix: SKVI_

Data Type: us-types:durationStringItemType

Balance Type: na

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConversionFeatureExercisePricePerShareForWarrantsPurchased

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConversionFeatureFixedPricePerShareOfCommonStock

Namespace Prefix: SKVI_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConversionFeatureNumberOfWarrantsToPurchaseForEveryTwoSharesIssued

Namespace Prefix: SKVI_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNoteDividendPaymentRate

Namespace Prefix: SKVI_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayableMaturityDate

Namespace Prefix: SKVI_

Data Type: us-types:durationStringItemType

Balance Type: na

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ConvertibleNotesPayableRelatedParty

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_FinancingExpense

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_PromissoryNoteValue

Namespace Prefix: SKVI_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The amount of debt discount (net of debt premium) that was originally recognized at the issuance of the instrument that has yet to be amortized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28567-108399

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 56 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

FIXED ASSETS (Tables)
9 Months Ended

Sep. 30, 2013

Property, Plant and Equipment [Abstract]

Schedule of Property and Plan Equipment

September 30, 2013 December 31, 2012

Machinery and equipment 48,163 $ 45,208

Furniture and fixtures 113,635 113,635

Computers, equipment and software 38,540 38,105

Leasehold improvements 12,569 12,569

Lab equipment 113,461 113,461

Total 326,368 322,978

Less: accumulated depreciation (322,477 ) (318,519 )

Fixed assets, net of accumulated depreciation 3,891 $ 4,459

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 57 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCKHOLDERS DEFICIT
9 Months Ended

Sep. 30, 2013

Equity [Abstract]

STOCKHOLDERS DEFICIT

The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. The Company has 110,729,969 and 109,507,409 issued and outstanding shares of common stock as of September 30, 2013 and December 31, 2012, respectively.

During the nine months ended September 30, 2013, the Company issued a total of 680,000 shares of common stock, with a fair value of $16,100 for the conversion of debts totaling $18,000. The Company recorded a gain of $3,100 on extinguishment of debts.

On February 11, 2013, the Company issued a total of 300,000 shares of common stock for conversion of principal on convertible notes payable of $15,000 plus $1,277 accrued interest. The Company issued an additional 242,560 shares of common stock for this conversion of convertible notes payable, which the shares were fair valued at $7,277.

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 58 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES (Details Narrative) (USD $)
9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Accounting Policies [Abstract]

Date of Incorporation Mar. 06, 1998

Accumulated Deficit $ (23,601,123) $ (22,571,365)

Convertible Notes Payable 1,000,000

Stock based compenstation $ 21,200

X

- Definition

Date when an entity was incorporated

+ References

No definition available.

+ Details

Name: dei_EntityIncorporationDateOfIncorporation

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 59 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK OPTIONS AND WARRANTS (Tables)
9 Months Ended

Sep. 30, 2013

Temporary Equity Disclosure [Abstract]

Summary of Options

Number of Shares Weighted Average Exercise Price

Balance, December 31, 2012 9,400,000 $ 0.05

Options granted and assumed 300,000 $ 0.03

Options expired 400,000 $ 0.05

Options canceled — —

Options exercised — —

Balance, September 30, 2013 9,300,000 $ 0.05

Summary of Warrants

Number of Shares Weighted Average Exercise Price

Balance, December 31, 2012 6,765,200 $ 0.06

Warrants granted and assumed 471,280 $ 0.06

Warrants expired 2,562,500 $ 0.05

Warrants canceled — —

Warrants exercised — —

Balance, September 30, 2013 4,673,980 $ 0.06

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ScheduleOfOptionsTableTextBlock

Namespace Prefix: SKVI_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SKVI_ScheduleOfWarrantsTableTextBlock

Namespace Prefix: SKVI_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TemporaryEquityDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 60 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
9 Months Ended

Sep. 30, 2013

Oct. 01, 2013

Document And Entity Information

Entity Registrant Name SKINVISIBLE INC

Entity Central Index Key 0001085277

Document Type 10-Q

Document Period End Date Sep. 30, 2013

Amendment Flag false

Current Fiscal Year End Date --12-31

Is Entity a Well-known Seasoned Issuer? No

Is Entity a Voluntary Filer? No

Is Entity's Reporting Status Current? Yes

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 110,729,969

Document Fiscal Period Focus Q3

Document Fiscal Year Focus 2013

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Details

Name: SKVI_DocumentAndEntityInformationAbstract

Namespace Prefix: SKVI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 61 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONVERTIBLE NOTES PAYABLE (Tables)
9 Months Ended

Sep. 30, 2013

Notes to Financial Statements

Schedule of Conversions of Stock

Convertible Notes Payable consists of the following: September 30, December 31,

2013 2012

$52,476 face value,10% unsecured note payable to an investor, note interest and payment are due on demand. The note could be converted to option rights for Skinvisible, Inc. shares at ten cents per share ($0.10), these rights expired January 12, 2010. Note is currently in default, no penalties occur due to default.

During the nine months ended September 30, 2013, the Company made $12,000 in cash payment to reduce the note balance. $ 40,476 $ 52,476

$27,000 face value 10% unsecured $27,000 notes payable to investors, due October, 2012. At the investor’s written request, until the repayment date the note may be converted at the investors option to shares of the Company’s common stock at a fixed price of $0.05 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.07 per share for two years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $19,385. The aggregate beneficial conversion feature has been fully accreted and was charged to general and administrative expenses during the year ended December 31, 2012. The beneficial conversion feature is valued under the intrinsic value method. Interest due to lender can also be converted at a rate of ($0.05) per share into warrants.

During the nine months ended September 30, 2013, the Company made a $2,000 cash payment to reduce the note balance and converted principal of $15,000 plus accrued interest of $1,277 to 542,560 shares of common stock and granted 271,280 warrants with the exercise price of $0.07 per shares for two years. 10,000 27,000

$1,000,000 face value 9% notes payable to investors, due two years from the anniversary date of execution. The notes mature at various times from September 2014 to December 2014. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The Notes are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company has determined the value associated with the beneficial conversion feature in connection with the notes and interest to be $111,110. The aggregate original issue discount feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of $40,476 and $8,910 during the periods ending September 30, 2013 and December 31, 2012, respectively. The original issue discount feature is valued under the intrinsic value method. 1,000,000 1,000,000

1,050,476 1,079,476

Original issue discount 111,110 111,110

Unamortized debt discount (61,724 ) (102,200 )

$ 1,099,862 $ 1,088,386

X

- Details

Name: SKVI_NotesToFinancialStatementsAbstract

Namespace Prefix: SKVI_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_ScheduleOfConversionsOfStockTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Statements of Operations (USD $)	3 Months Ended		9 Months Ended
Statements of Operations (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]
Revenues	$ 13,635	$ 22,920	$ 48,370	$ 83,548
Cost of revenues	565		1,754	1,944
Gross profit	13,070	22,920	46,616	81,604
Operating expenses
Depreciation and amortization	9,824	8,068	27,006	43,982
Selling general and administrative	220,021	316,856	616,167	996,189
Total operating expenses	229,845	324,924	643,173	1,040,171
Loss from operations	(216,775)	(302,004)	(596,557)	(958,567)
Other income and (expense)
Other income	97	25,000	97	25,000
Interest expense	(125,825)	(11,866)	(436,398)	(81,886)
Gain on extinguishment of debt	2,400	(36)	3,100	1,691
Total other expense	(123,328)	13,098	(433,201)	(55,195)
Net loss	$ (340,103)	$ (288,906)	$ (1,029,758)	$ (1,013,762)
Basic loss per common share	$ 0.00	$ 0.00	$ (0.01)	$ (0.01)
Basic weighted average common shares outstanding	110,683,012	105,073,960	110,374,484	102,694,597

FIXED ASSETS (Details Narrative) (USD $)	9 Months Ended
FIXED ASSETS (Details Narrative) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Property, Plant and Equipment [Abstract]
Depreciation express	$ 1,003	$ 943

DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]
Description of business	Description of business – Skinvisible, Inc., (referred to as the “Company”) is focused on the development and manufacture of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations, offer solutions for a broad spectrum of markets women’s health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.
History	History – Skinvisible, Inc. (referred to as the “Company”) was incorporated in Nevada on March 6, 1998 under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc. Skinvisible, Inc. together with its subsidiary shall herein be collectively referred to as the “Company”.
Going concern	Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $23,601,123 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.
Principles of consolidation	Principles of consolidation – The consolidated financial statements include the accounts of the Company and its subsidiary. All significant intercompany balances and transactions have been eliminated.
Use of estimates	Use of estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash and cash equivalents	Cash and cash equivalents For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items. As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The three levels of the fair value hierarchy are described below: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
Revenue recognition	Revenue recognition Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered. Royalty sales – The Company also recognizes royalty revenue from licensing its patented product formulations only when earned, when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments. Distribution and license rights sales – The Company also recognizes revenue from distribution and license rights only when earned (and are amortized over a five year period), when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments. Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.
Accounts Receivable	Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2013, the Company had not recorded a reserve for doubtful accounts. The Company has $1,000,000 in convertible notes payable which are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®.
Inventory	Inventory – Substantially all inventory consists of finished goods and are valued based upon first-in first-out ("FIFO") cost, not in excess of market. The determination of whether the carrying amount of inventory requires a write-down is based on an evaluation of inventory.
Goodwill and intangible assets	Goodwill and intangible assets – The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other”. According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.
Income taxes	Income taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
Stock-based compensation	Stock-based compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to a Employee Stock Purchase Plan based on the estimated fair values. Stock based compensation expense recognized under ASC 718-10 for the nine months ended September 30, 2013 and 2012 totaled $21,200 and $0 respectively.
Earnings (loss) per share	Earnings (loss) per share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

STOCK OPTIONS AND WARRANTS - Summary of Options (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Temporary Equity Disclosure [Abstract]
Beginning Balance, number of shares	9,400,000
Beginning Balance, weighted average exercise price	$ 0.05
Options granted and assumed, number of shares	300,000
Options granted and assumed, weighted average exercise price	$ 0.05
Options expired, number of shares	400,000
Options expired, weighted average exercise price	$ 0.05
Options cancelled, number of shares
Options cancelled, weighted average exercise price
Options exercised, number of shares
Options exercised, weighted average exercise price
Ending Balance, number of shares	9,300,000
Ending Balance, weighted average exercise price	$ 0.05

UNEARNED REVENUE (Details Narrative) (USD $)	9 Months Ended
UNEARNED REVENUE (Details Narrative) (USD $)	Sep. 30, 2013
Notes to Financial Statements
Unearned Revenue	$ 19,792

NOTES PAYABLE (Details Narrative) (USD $)	9 Months Ended
NOTES PAYABLE (Details Narrative) (USD $)	Sep. 30, 2013
Notes to Financial Statements
Date Financing Plan was approved	2013-05-22
Secured Promissory Notes, max amount offered	$ 1,000,000
Secured Promissory Notes, interest rate	9.00%
Secured Promissory Notes, proceeds	1,000,000
Secured Promissory Notes, due date	2 years

CONVERTIBLE NOTES PAYABLE (Details Narrative) (USD $)	9 Months Ended					12 Months Ended
CONVERTIBLE NOTES PAYABLE (Details Narrative) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013 Convertible Note 1	Sep. 30, 2013 Convertible Note 2	Sep. 30, 2013 Convertible Note 3	Dec. 31, 2012 Convertible Note 3
Convertible Notes Payable, Value			$ 52,476	$ 27,000	$ 1,000,000
Unsecured note payable percentage			10.00%	10.00%	9.00%
Shares, fixed price per share				$ 0.05	$ 0.05
Shares, exercise price per share			$ 0.10	$ 0.07	$ 0.07
Expiration date			Jan. 12, 2010
Convertible Notes Payable, Cash Payment			12,000	2,000
Convertible Notes Payable, Principle Converted	15,000			15,000
Convertible Notes Payable, Principle Converted Accrued Interest	1,277			1,277
Convertible Notes Payable, Common Stock Shares Issued	300,000			542,560
Convertible Notes Payable, Warrants Granted				271,280
Convertible Notes Payable, Warrants exercise price				$ 0.07
Convertible Notes Payable, Warrants exercise period				2 years
Beneficial conversion feature		326,510		19,385	111,110
Financing expense				$ 19,385	$ 40,476	$ 8,910
Due date				2012-10-01	2014-08-01
Price per share of interest converted to warrants				$ 0.05	$ 0.05
Percent of common stock discount of current stock price					90.00%

INTANGIBLE AND OTHER ASSETS (Details Narrative) (USD $)	9 Months Ended
INTANGIBLE AND OTHER ASSETS (Details Narrative) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Notes to Financial Statements
Patents and trademarks, Gross	$ 584,898
Accumulated Amortization	239,208
Amortization Expense	26,003	43,039
Convertible Notes Payable	$ 1,000,000

CONVERTIBLE NOTES PAYABLE - Schedule of Conversions of Stock (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Notes to Financial Statements
Convertible Note Payable #1	$ 44,476	$ 52,476
Convertible Note Payable #2	10,000	27,000
Convertible Note Payable #3	1,000,000	1,000,000
Original issue discount	111,110	111,110
Unamortized debt discount	(61,724)	(102,200)
Convertible Notes Payable	$ 1,099,862	$ 1,088,386

Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Issued	110,729,969	109,507,409
Accumulated depreciation	$ (322,477)	$ (318,519)
Convertible Notes Payable, net of unamortized debt discount	61,724	102,200
Convertible Notes Payable, related party, net of unamortized discount	919,956	1,036,956
Accumulated Amortization	$ 239,208	$ 213,205

Statements of Cash Flows (USD $)	9 Months Ended
Statements of Cash Flows (USD $)	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net loss	$ (1,029,758)	$ (1,013,762)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	27,006	43,982
Stock-based compensation	21,200
Amortization of debt discount	228,244	432,602
Accrued expenses converted to notes		223,868
Stock issued for interest expense	422
Debt paid with common stock		78,361
Gain on extinguishment of debt	3,100	(1,691)
Changes in operating assets and liabilities:
(Increase) decrease in inventory	(3,668)	8,998
Decrease in accounts receivable	17,299	(8,895)
Increase in prepaid expenses and other current assets	(500)	(9,691)
Increase in accounts payable and accrued liabilities	69,776	97,283
Increase in accrued interest	105,099	23,174
Decrease in unearned revenue	(19,792)	(50,000)
Net cash used in operating activities	(581,572)	(175,771)
Cash flows from investing activities:
Purchase of fixed assets and intangible assets	(120,575)	(56,023)
Net cash used in investing activities	(120,575)	(56,023)
Cash flows from financing activities:
Proceeds from, net of payments to, related parties for loans	(7,527)	(2,681)
Payments on related parties convertible notes payable	(12,475)
Proceeds from convertible notes payable		312,900
Advances to related parties	(40,043)
Payments on convertible notes payable	(14,000)	(7,500)
Proceeds from loans payable	1,000,000	(5,000)
Net cash provided by (used in) financing activities	925,955	297,719
Net change in cash	223,808	65,925
Cash, beginning of period	450,507	1,218
Cash, end of period	674,315	67,143
Supplemental disclosure of cash flow information:
Cash paid for interest	97,194
Cash paid for tax
Non-cash investing and financing activities:
Loan payable converted to convertible loan	23,554	(9,719)
Common stock issued on conversion of debts	23,554	78,361
Beneficial conversion feature		$ 326,510
Common stock issued for extinguishment of debts	16,100

Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets
Cash	$ 674,315	$ 450,507
Accounts receivable	10,000	27,299
Inventory	22,437	18,769
Due from related party	41,188	1,145
Prepaid expense and other current assets	1,015	515
Total current assets	748,955	498,235
Fixed assets, net of accumulated depreciation of $322,477 and $318,519, respectively	3,891	4,459
Intangible and other assets:
Patents and trademarks, net of accumulated amortization of $239,208 and $213,205, respectively	345,690	251,553
Total assets	1,098,536	754,247
Current liabilities
Accounts payable and accrued liabilities	584,536	636,314
Accrued interest payable	131,499	25,264
Loans from related party	134	7,661
Loans payable	1,000,000	1,991
Convertible notes payable, net of unamortized debt discount of $61,724 and $102,200, respectively	1,099,862	1,088,386
Convertible notes payable related party, net of unamortized discount of $919,956 and $1,036,956, respectively	803,905	593,227
Unearned revenue		19,792
Total current liabilities	3,619,936	2,372,635
Total liabilities	3,619,936	2,372,635
Stockholders deficit
Common stock; $0.001 par value; 200,000,000 shares authorized; 110,729,969 and 109,507,409 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	110,730	109,507
Additional paid-in capital	20,968,993	20,841,670
Stock payable		1,800
Accumulated deficit	(23,601,123)	(22,571,365)
Total stockholders deficit	(2,521,400)	(1,618,388)
Total liabilities and stockholders deficit	$ 1,098,536	$ 754,247

STOCK OPTIONS AND WARRANTS (Details Narrative) (USD $)	3 Months Ended	9 Months Ended
STOCK OPTIONS AND WARRANTS (Details Narrative) (USD $)	Mar. 31, 2013	Sep. 30, 2013	Sep. 23, 2013
Temporary Equity Disclosure [Abstract]
Stock Options, exercisable		9,300,000
Stock Options, shares			300,000
Stock Options, price			$ 0.03
Stock Options, expected life			5 years
Stock Options, Value			$ 8,400
Stock Options, interest rate			1.33%
Stock Options, dividend			0.00%
Stock Options, volatility rate			443.00%
Company Recorded Expense		$ 8,400
Date of Warrant Issuance		May 22, 2013
Warrants Issued with Convertible Notes	271,280	200,000
Exercise Price-maximum	$ 0.07	$ 0.04

FIXED ASSETS - Schedule of Property and Plan Equipment (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]
Machinery and equipment	$ 48,163	$ 45,208
Furniture and fixtures	113,635	113,635
Computers, equipment and software	38,540	38,105
Leasehold improvements	12,569	12,569
Lab equipment	113,461	113,461
Total	326,368	322,978
Less: accumulated depreciation	(322,477)	(318,519)
Fixed assets, net of accumulated depreciation	$ 3,891	$ 4,459

STOCKHOLDERS DEFICIT (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
STOCKHOLDERS DEFICIT (Details Narrative) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Equity [Abstract]
Common Stock, Par Value	$ 0.001		$ 0.001		$ 0.001
Common Stock, Shares Authorized	200,000,000		200,000,000		200,000,000
Common Stock, Issued	110,729,969		110,729,969		109,507,409
Common Stock, Shares Issued for Debt Conversion			680,000
Debt Conversion, Fair Value			$ 16,100
Debt Conversion, Amount			18,000
Gain on extinguishment of debt	2,400	(36)	3,100	1,691
Convertible Notes Payable, Date of Conversion			Feb. 11, 2013
Convertible Notes Payable, Common Stock Shares Issued			300,000
Convertible Notes Payable, Principle Converted			15,000
Convertible Notes Payable, Principle Converted Accrued Interest			1,277
Convertible Notes Payable, Additional Common Stock Shares Issued			242,560
Convertible Notes Payable, Common Stock Shares, Fair Value			$ 7,277

COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Commitments and Contingencies Disclosure [Abstract]
Operating leases for 2013	$ 14,050
Operating leases for 2014	33,156
Operating leases for 2015	5,526
Rental expense	$ 14,942	$ 40,434

RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)	3 Months Ended
RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)	Sep. 30, 2013	Sep. 23, 2013
Related Party Transactions [Abstract]
Stock Options, Shares		300,000
Loans from related party	$ 40,143

CONVERTIBLE NOTES PAYABLE RELATED PARTY (Details Narrative) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Jun. 30, 2013 Convertible Note Payable Related Party 1	Dec. 31, 2011 Convertible Note Payable Related Party 1	Jul. 01, 2011 Convertible Note Payable Related Party 1	Dec. 31, 2010 Convertible Note Payable Related Party 1	Jun. 30, 2013 Convertible Note Payable Related Party 2	Jun. 30, 2012 Convertible Note Payable Related Party 2	Jun. 30, 2013 Convertible Note Payable Related Party 3	Dec. 31, 2012 Convertible Note Payable Related Party 3	Jun. 30, 2013 Convertible Note Payable Related Party 4
Promissory Note, Value				$ 802,864				$ 325,023		$ 182,083	$ 106,153
Maturity Date				5 years				5 years		5 years	5 years
Interest Rate				10.00%				10.00%		10.00%	10.00%
Conversion Feature, fixed price per share of common stock				$ 0.04				$ 0.04		$ 0.03	$ 0.03
Conversion Feature, number of warrants to purchase for every two shares issued				1				1		1	1
Conversion Feature, exercise price per share for warrants purchased				$ 0.06				$ 0.06		$ 0.04	$ 0.04
Beneficial Conversion Feature: time allowed to exercise warrants once converted				3 years				3 years		3 years	3 years
Beneficial Conversion Feature				1,123,078	45,557	538,295		209,809		182,083	70,768
Financing Expense			124,818				32,161		27,223
Convertible Notes Payable, related party	803,905	593,227	568,638				169,080		27,236		38,950
Convertible notes payable, related party, net of unamortized discount	$ 61,724	$ 102,200	$ 541,965				$ 155,942		$ 154,847		$ 67,202

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013	Oct. 01, 2013
Document And Entity Information
Entity Registrant Name	SKINVISIBLE INC
Entity Central Index Key	0001085277
Document Type	10-Q
Document Period End Date	Sep. 30, 2013
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		110,729,969
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2013